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Abstract 
 
Plant-expressed virus-like particles (VLPs) could offer an alternative method for the oral 
delivery of vaccines. VLPs' robustness, combined with their compartmentalisation within 
the plant cells, should favour their stability in the harsh gastro-intestinal (GI) environment. 
In the small intestine, intact VLPs should be available for absorption by the Follicle-
associated epithelium (FAE), considered the main portal of entry for antigens in the gut. In 
this work, Hepatitis B core antigen (HBcAg) VLPs, expressed transiently in Nicotiana 
benthamiana leaves, were extracted, purified and characterised. The stability of purified 
HBcAg VLPs in simulated human gastric and intestinal media was investigated. The 
results suggested that the antigen was unstable when subjected to various simulated 
gastric fluids. Upon incubation in simulated human and ex vivo pig intestinal fluids, 
HBcAg maintained higher stability. Leaves expressing HBcAg VLPs could be dried, 
retaining good antigen stability, but the natural encapsulation in the leaves failed to 
protect the antigen from degradation in the simulated GI fluids. However, enteric-coated 
“green” tablets containing dried leaves expressing HBcAg could be produced and were 
shown to confer protection in simulated gastric fluids but allowed the release of intact 
antigen in simulated intestinal fluids. Purified HBcAg VLPs could be formulated into 
spray-dried and spray freeze-dried microparticles using a pH-responsive polymer. 
However, such formulations showed poor gastro-resistance, negating their use for targeted 
intestinal delivery. HBcAg VLPs could be also freeze-dried, suggesting the potential use of 
freeze-drying for further processing of the antigen into an oral formulation. A human cell 
culture model of the small intestinal epithelium indicated selective absorption of HBcAg 
VLPs by the FAE but limited overall absorption. In vivo ligated loop studies in mice 
suggested poor intestinal absorption, mainly relegated to the FAE. This research 
represents an original investigation into the possible applications of plant-expressed 
HBcAg VLPs for oral drug delivery. 
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1 Introduction 
 
The work described in this thesis was aimed to investigate the potential use of a 
recombinant protein expressed in plants for the formulation of an oral candidate vaccine. 
The model antigen used is the recombinant Hepatitis B core antigen (HBcAg).  
 
This Chapter will cover the main background aspects of this research. General concepts of 
immunology, with particular emphasis on the immunophysiology of the gastro-intestinal 
(GI) tract will be initially described. Then after a brief discussion of the most common 
vaccine approaches, the particular features of a relatively new class of vaccine, i.e. virus-
like particles (VLPs), will be described. Subsequently, a general background about 
Hepatitis B virus and about the current vaccination strategies against Hepatitis B will be 
given. Then the structure of HBcAg and its possible use as a model vaccine will be 
examined. Finally, the production of recombinant proteins, including that of HBcAg, in 
plant will be discussed. At the end, the specific objectives of the research will be defined. 
 
1.1 The Immune System - Basic Principles  
1.1.1 Introduction 
The immune system is an extremely complex apparatus whose function is to patrol and 
protect the organism from invasion by pathogens and subsequent infection. The organs of 
the immune system are often referred to as lymphoid and are divided into primary and 
secondary lymphoid organs. The primary lymphoid organs are responsible for the 
production of immune cells (i.e. lymphocytes) from immature progenitor cells and are 
located in the bone marrow and thymus. The secondary lymphoid tissues are constituted by 
organised aggregation of mature lymphocytes, together with other specialised cells of the 
immune system that are distributed all over the body: they include the lymph nodes, the 
spleen and the mucosal- and gut-associated lymphoid tissues (MALT and GALT 
respectively), i.e. tonsils and Peyer’s patches (Hannigan et al., 2009a). Figure 1.1 shows 
the distribution of the main lymphoid sites in the body. 
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Figure 1.1. Organs of the immune system (Moser and Leo, 2010). 
 
The immune system operates at different levels. The first line of defence is constituted by a 
series of non-specific physical and chemical barriers, which aim to prevent pathogen 
invasion. These include the skin's physical barrier, the mucosal membranes and the harsh 
and destructive GI environment. If pathogens do breach the physical and/or physio-
chemical barriers, the innate immune system, considered the second line of defence, is 
usually capable of recognising and “inactivating” the invasive pathogen. As the word 
“innate” indicates, the activity of this apparatus is not based on specific memory patterns, 
but depends on the function of certain receptors to recognise generic molecular structures 
typical of most pathogens. These receptors of the innate immune system are called pattern 
recognition receptors (PRRs) and they recognise pathogen-associated molecular patterns 
(PAMPs), which are distinctive and recurrent molecular moieties present in numerous 
types of micro-organisms. Among other PRRs, toll-like receptors (TLR) seem to have a 
central role in the innate immunity. Such receptors are expressed in a wide range of cells of 
haematopoietic derivation: these include cells located in the tissues, such as dendritic cells 
(DC) and macrophages, but also circulating cells, such as neutrophils, eosinophils and 
monocytes (Doan et al., 2008a). Once the PAMPs present in the pathogens are recognised 
by the PRRs, the immune cells induce a cascade-type of response against the invading 
organism. The most common effector mechanism of the innate immune system is 
constituted by the elimination of the pathogen by phagocytosis (Stuart, 2005). This 
Chapter 1 
 
 
3 
 
phagocytic process does not have memory (i.e. it is innate) and hence, as a standardised 
process, it repeats itself identically upon subsequent infections. 
 
Nevertheless, due to the extreme variability of the pathogens’ molecular structures, many 
pathogens are capable of escaping recognition by the innate system. In this case the main 
line of defence is constituted by the adaptive immune system. The onset of this immune 
response is slower than that of the innate immune system. After recognition of the 
pathogen, the adaptive immune response aims to eliminate the pathogen and generate a sort 
of immune memory, which enables protection of the organisms from re-infections by the 
same pathogen. The cells of the adaptive immune system are called lymphocytes. 
Analogously to the cells of the innate immune system, lymphocytes are cells of 
haematopoietic origin and are present both in lymphoid tissue and as circulating cells in the 
blood and in the lymphatic circulation. Lymphocytes can be divided into B and T cells. B 
cells, upon encountering specific antigens, are stimulated to divide and differentiate into 
different subsets of cells, including plasma cells. Such plasma cells can produce high 
quantities of particular soluble proteins called antibodies. Antibodies are the main 
mediators of B cell immune responses; such immune responses are called “humoral”, 
because the soluble antibodies are released in the blood and other fluids of the organisms. 
The function of antibodies is to bind specific antigenic structures, present in all pathogens. 
The binding of antibodies to the antigen is often sufficient to inactivate the antigen. 
Moreover, antibodies can activate complementary mechanisms to eliminate the pathogen. 
However, antibodies cannot cross the cellular membranes and hence cannot fight 
pathogens located intra-cellularly (Moser and Leo, 2010). Instead, T cells are active 
against intracellular pathogens. All the nucleated cells of the organism have the capability 
to expose partially digested intra-cellular proteins (in form of short peptides) at the surface 
of their plasma membrane. This mechanism enables exposing fragments of pathogens, 
which were present inside the cell, at the cellular surface. Such fragments can be 
recognised by specific receptors exposed by T cells, called T cell antigen receptor (TCR). 
This binding induces anti-pathogenic effects, which are mediated by soluble molecules (i.e. 
cytokines) (Moser and Leo, 2010).  
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1.1.2 Exploitation of the Immune System for Prophylactic Vaccination 
The adaptive immune system is a key component of the immunogenic responses to 
pathogens and vaccines. The effectiveness of the adaptive immune system resides in the 
specificity and memory. These are essential features shared by both T and B cells. 
Specificity is defined as the capability of T and B cells and antibodies to individually 
recognise virtually any known pathogenic (or non-pathogenic) molecular structure. This is 
possible due to the extreme diversity of T and B cells, each expressing a unique receptor, 
bearing a unique configuration. Hence when an antigen enters the body for the first time, a 
specific lymphocyte will bind that given antigen. It has been estimated that the number of 
specific antigen binding sites, produced by the host, is greater than 1011 (Hannigan et al., 
2009b).  
 
Nevertheless, the vast variety of the entire lymphocyte population implies that the relative 
amount of each lymphocyte will be very low. For this reason, in order to mount a strong 
immunogenic response upon contact with the antigen a given lymphocyte starts to 
multiply. Such phenomenon, called “clonal selection”, enables a given lymphocyte type to 
be overproduced (Burnet, 1976). This effect starts upon antigen exposure and can last the 
whole life cycle of the individual host. The overproduction of a specific lymphocyte that 
remains quiescent implies that upon a second exposure to the same antigen, a prompter and 
more potent immunogenic response can be elicited. This sort of “immune memory” is 
regularly exploited in prophylactic vaccination. For instance, exposure to a vaccine is 
supposed to represent the first exposure to one or more antigen belonging to a certain 
pathogen. Following the administration, a potent immunogenic response, characterised by 
T and/or B cell activation, should be elicited. As a consequence, the immunised subject 
will have one or a series of overrepresented lymphocytes. Such “memory cells” should be 
able to protect the immunised individual from harmful re-infection, upon subsequent 
exposure to the (otherwise virulent) pathogen (Gourley et al., 2004).  
 
An ideal vaccine should not stimulate harmful side-effects when inducing the 
immunogenic and inflammatory response. At the same time it should be as good as natural 
pathogens in triggering potent immune responses, which includes the induction of 
“memory cells” (Zepp, 2010).  
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1.1.3 Mucosal Immunity 
Mucosal membranes covering the body are constantly in contact with environmental 
pathogens. Physical and chemical barriers constitute a first line of defence. However, most 
mucosal sites are also well equipped with their own lymphoid tissue. This mucosal- 
associated lymphoid tissue (MALT) is considered separate and independent from the non-
mucosal, so called peripheral or parenteral immune system (i.e. spleen and lymph nodes). 
Nevertheless, the lymphoid structures of the MALT appear similar to the one of the 
parenteral system. However, the two systems are not isolated and seem to constantly 
interact (Doan et al., 2008b).  
 
Considering that many pathogens invade the host through mucosal routes, mucosal 
immune responses are considered strategically important: in fact the induction of immunity 
directly at the site of the entry of the pathogen can offer an excellent means of protection 
by vaccination. Indeed, generally strong mucosal immune responses are induced via 
mucosal immunisation. In contrast, parenteral immunisation often induces poor responses 
at the mucosal site and hence parenteral vaccination often fails in protecting the host from 
mucosal infections. Thus, it is clear how the development of mucosal vaccines could be 
beneficial for protection against pathogens that naturally infects or enter the host via the 
mucosal routes (McGhee et al., 1992; Neutra and Kozlowski, 2006). Furthermore, 
induction of immunity at specific mucosal sites can lead to protective immunity also at 
distal effector mucosal sites. This reflects the notions of a “common mucosal immune 
system”. However, this interplay between distal mucosal sites seems to be selectively 
compartmentalised. For example, nasal immunisation seems to evoke strong vaginal and 
pulmonary immunity; conversely nasal immunisation does not induce strong immunity in 
the gut (Holmgren and Czerkinsky, 2005). On the other hand, induction of potent systemic 
immunity is not only a prerogative of parenteral immunisation: in fact, mucosal 
immunisation can stimulate also strong and protective systemic T cell and B cell responses, 
including the activation of long term memory T and B cells (Lycke, 2012). In summary, 
parenteral vaccination often ensures strong immunogenic responses, but poor 
immunogenicity at mucosal sites; instead mucosal immunity can elicit both mucosal and 
systemic responses.  
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This research will focus on the mucosal delivery of antigens through oral route. Aside from 
the possible immunological advantages just mentioned, a series of other possible 
advantages related to the oral administration of vaccines will be discussed in the next 
Section.  
 
1.2 Oral Vaccination 
1.2.1 Advantages of Oral Vaccination 
Vaccines are broadly regarded as one the major public health successes (Center for Disease 
Control (CDC), 2011). Vaccines are considered worldwide to be a cost-effective medical 
technology that generates broad spectrum benefits among populations of all ages (Poland 
and Jacobson, 2001). Nowadays vaccines are still mainly delivered by injection. However, 
there are several disadvantages and risks related to this route of administration. First of all, 
injections raise safety concerns, as the use of needles carries the risk of contamination with 
infectious diseases leading to transmission between patients and between patients and 
healthcare providers. Moreover, needle-stick injuries represent a further safety issue. These 
problems are particularly concerning in the developing countries, where improper and 
unsafe injection practices are not uncommon (Simonsen et al., 1999). Another concern 
about injectable vaccines is the reduced compliance with the recommended vaccination 
schedules. This is mainly related to the patients’ acceptance of this uncomfortable and 
sometimes painful route of administration (Giudice and Campbell, 2006). Cost is another 
big disadvantage of most injectable vaccines and includes the cost of production of these 
sterile formulations, as well as their storage between 2 to 8 oC from manufacturing to the 
time of administration (“cold chain”). This clearly implies transport and cost-associated 
complications (Giudice and Campbell, 2006; Weir and Hatch, 2004). The need for 
healthcare personnel trained to deliver injections is another problem of this delivery route 
(Giudice and Campbell, 2006). Moreover, in the case of sudden outbreak of infectious 
diseases, the delivery of mass immunisation programme is intrinsically slowed by the 
complex administration route.  
 
In this context, it is clear how the delivery of needle-free vaccine options could be highly 
desirable. Among other routes, the oral delivery of a vaccine could have the potential to 
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overcome all the limitations of the injectable vaccines mentioned above. Oral delivery is 
one of the most desirable routes of administration for patients and would not require the 
need of trained health care workers. Thus, oral vaccines could ensure ease of 
administration and higher compliance worldwide. Moreover, oral vaccines could offer a 
cheap needle-free option, as they would not require to be produced as sterile formulations. 
Additionally, plant-produced oral vaccines could potentially be stable at room temperature, 
eliminating the need for the “cold-chain” [(Daniell et al., 2009), discussed in 1.5.5]. As a 
result, the delivery of mass immunisation programmes worldwide could be more easily 
achieved if oral vaccines became a reality. 
 
Despite all these advantages, the development of oral vaccines has always been limited by 
the presence of several physiological gastro-intestinal (GI) barriers, which often impede 
the delivery of the candidate vaccines to the effector sites that are responsible for the 
induction of protective immunogenic responses. Those gastro-intestinal barriers, which 
constitute a real challenge in oral vaccines design, will be examined in the next Paragraph. 
 
1.2.2 Immunophysiology of the Gastro-Intestinal (GI) Tract - A Barrier to Vaccine 
Delivery 
1.2.2.1 Introduction 
The function of the gastro-intestinal (GI) tract is to digest nutrients into small molecules 
that can be absorbed. For example, in the case of proteins the absorption occurs after their 
digestion into oligo-peptide and amino acids (Jackson and McLaughlin, 2009). This 
mechanism prevents infection from harmful pathogens ingested, while ensuring nutrient 
assimilation. Obviously, such a digestive environment constitutes a barrier also to the 
absorption of protein-based therapeutic molecules. In fact, the harsh gastric and intestinal 
fluids represent severe obstacles to protein stability (Lee, 2002). 
 
Aside from the presence of physiochemical and biochemical barriers, all the mucosal 
surfaces of the body, permanently in contact with the external environment, are patrolled 
by a highly specialised local immune system, the MALT, which constitutes almost 80% of 
the immunocytes of the whole body (Holmgren and Czerkinsky, 2005). The part of the 
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MALT located in the digestive tract is called gut-associated lymphoid tissue (GALT) and it 
represents on its own the largest immune system in the body, with 1012 lymphoid cells per 
metre of human small intestine. In the intestine, 130 to 190 g of dietary proteins are 
normally absorbed daily and there are also 1012 bacteria/g of stool colonising the gut, 
which potentially represents a further antigenic danger for the organism (Weiner et al., 
2011). Therefore, the physiological roles of the GALT include defending the mucosal 
tissue and the body interior from pathogens, impeding intact ingested antigens from being 
absorbed and avoiding the occurrence of potentially damaging immune cascades if the 
antigens were absorbed (Holmgren and Czerkinsky, 2005; Neutra and Kozlowski, 2006).  
 
Thus, to develop an oral protein-based vaccine, the challenge is to circumvent the GI 
barriers, as gastric and intestinal fluids could inactivate the vaccine in a similar way to the 
degradation of food and pathogenic proteins. Furthermore, the features of the GALT could 
prevent the uptake of the antigens. Finally, even though the mucosal tissue is always in a 
permanent condition of alert, it is also used to the presence of external microbiota. 
Therefore, the same vaccine, which induces strong immunogenic response when 
administered into sterile tissues, such as muscles, could be neglected when delivered into a 
tissue permanently subjected to foreign microbiota, such as the gut (Holmgren and 
Czerkinsky, 2005; Neutra and Kozlowski, 2006). 
 
1.2.2.2 Stability of Vaccines in the Fluids of Stomach and Intestine 
The physical and chemical instability typical of proteins in the gastric and intestinal fluids 
constitutes one of the main hurdles towards the effective delivery of vaccines through the 
oral route (Lee, 2002). The first physicochemical barrier encountered in the GI tract is 
constituted by the stomach fluid: the pH in the stomach generally ranges from pH 1 to 2.5 
in normal fasted state condition (Evans et al., 1988). Furthermore, the stomach fluid is rich 
in the enzyme pepsin that constitutes a further biochemical barrier to proteins (Mahato et 
al., 2003). The intestine has a more neutral pH than the stomach, generally ranging from 
pH 6.3 to 7.5 (Evans et al., 1988). However, the intestinal fluid also represents a 
biochemical threat for therapeutic proteins’ stability mainly due to the presence of 
pancreatic enzymes including trypsin and chymotrypsin (Mahato et al., 2003). 
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The stability of a protein must be evaluated both in terms of chemical and physical 
stability. The chemical stability is defined as the integrity of the amino acid sequence 
forming the primary structure of the protein; the physical stability is seen as the integrity of 
the three-dimensional structure, which consists of the secondary, tertiary and quaternary 
structure (Bilati et al., 2005). The acidic pH of the stomach can compromise the physical 
structure of a protein by denaturation, as well as possibly inducing oxidation, deamidation 
or hydrolysis in particularly sensitive proteins. The digestive enzymes present in both the 
stomach and intestine can chemically alter the primary structure by proteolytic degradation 
and as a consequence, also the secondary, tertiary and quaternary structure (Sood and 
Panchagnula, 2001). 
 
1.2.2.3 Permeability of Vaccines in the Intestine 
1.2.2.3.1 GALT Physiology 
The GALT, which contains the machinery to trigger an immunogenic response, represents 
the target tissue for effective oral mucosal vaccine delivery. However, the main barrier in 
oral protein delivery, including vaccines, still remains the low absorption of such 
macromolecules (Park and Kwon, 2011). Therefore, an in depth knowledge about GALT 
structure and function and about the closely related absorptive epithelium of the intestine is 
essential in order to successfully undertake oral vaccine design. The GALT is made of 
isolated and aggregated lymphoid follicles; in the small intestine there are clearly 
distinctive aggregated lymphoid follicles, called Peyer’s Patches (PPs), termed after 
Johann Conrad Peyer, who first described them in 1677. They are major inductive sites for 
immune response in the gut (Neutra et al., 2001). PPs are mostly located in the ileum and 
only a limited number are present in the rest of the small intestine. PP-like structures are 
also found in the colon (Cornes, 1965; Heel, 1997). The number of PPs seems to increase 
through childhood reaching a maximum at puberty, when up to more than 200 PPs in an 
individual have been measured (Cornes, 1965). Similarly to secondary lymphoid tissue, 
they are made of T and B cells: at the side of follicles (FO), which mainly consist of B 
cells, there are T cell-rich interfollicular regions (IFR), as shown in Figure 1.2. However, 
PPs have some unique features of the MALT: they have only efferent and not afferent 
lymphatic vessels. Therefore, the possibility of circulation of antigen from secondary 
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lymphoid tissue to the PPs is reduced (Kunisawa et al., 2008). Furthermore, they contain a 
highly specialised epithelium typical of the MALT, called follicle-associated epithelium 
(FAE). Selective transport of antigen from the gut lumen into the PP take place mainly in 
this region (Owen and Jones, 1974). FAE epithelium will be described more in detail in the 
next Paragraph. Antigens efficiently transported through the epithelium come in contact 
with antigen-presenting cells (APC), mainly present as dendritic cells (DC) inside the PP. 
The processing and presentation of the antigen through the DC can trigger antigen-specific 
immunogenic responses: the position of the DC, mostly located in the subepithelial dome 
region (SED) (Figure 1.2), just under the FAE is strategic for the processing and 
presentation of the antigens to the immune cells (Kunisawa et al., 2012).  
 
 
Figure 1.2. Peyer’s patches compartments and cell distribution. 
(A) 4′, 6-diamidino-2-phenylindole stained PP. The contour of each region is drawn: 
follicle (FO), follicle-associated epithelium (FAE), germinal center (GC), interfollicular 
regions (IFR) and subepithelial dome region (SED); (B) Immunohistological data: staining 
for DC (anti-CD11c); (C) Immunohistological data: staining for T cells (anti-CD4); (D) 
Immunohistological data: staining for B cells (anti-B220). Image adapted from Kunisawa 
et al. (2012). 
 
The mesenteric lymph nodes (MLN) appear also to play a key role in the GALT function 
and activation. They are considered to be an important communication link between the 
mucosal tissue in the gut and the peripheral lymph nodes; however, they have different 
organogenesis than peripheral lymphoid tissue and PP (Mowat, 2003). 
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1.2.2.3.2 FAE and M cells 
Decades of research about the physiology and functions of the intestinal epithelium 
covering the intestinal mucosa has led to clearer understanding of such a complex tissue. 
The intestinal epithelium needs to allow absorption of water, ions and nutrients, but at the 
same time it has to act as a barrier to the large quantities of potential pathogens and 
macromolecules present in the gut. This obstacle to the penetration of macromolecules is 
provided by both physical and chemical mechanisms: first of all the epithelial cells, being 
connected by tight junctions, form a compact, almost impermeable, layer. Moreover, 
locally secreted IgA, the large glycocalix and the thick mucus layer covering the luminal 
side of those cells provide additional impediments to the penetration of pathogens. Despite 
its main function as a barrier, the intestinal epithelium must also allow the immunogenic 
machinery to function; this implies that macromolecules and antigens need to breach the 
barrier in a specific and organised manner in order to reach the intestinal immune system. 
The permeability of an antigen through the intestinal epithelium is considered a necessary 
step for the induction of protective mucosal and systemic immunity. For many years the 
scientific belief was that the transport of microorganism or antigens is a strict prerogative 
of the FAE overlying the PP: within the FAE, this unique function is accomplished by 
antigen-sampling microfold or membranous cells (M cells) (Nicoletti, 2000). Recently, an 
alternative and complementary mechanism of luminal antigen sampling, directly mediated 
by intestinal DC, has been proposed (Rescigno et al., 2001). However, the precise role of 
those DCs has not been fully determined yet and whether they are involved in the 
induction of immune response has not been clarified (Arques et al., 2009; Nicoletti et al., 
2009). Further investigations of this antigen-sampling route are needed and to date M cells 
are still considered the main portal of entry for antigen presentation to the immune system.  
 
M cells constitute 5% of the epithelial cells of the FAE in humans, with variations among 
other animal species (Buda et al., 2005). They have clearly distinctive characteristics 
which differentiate them from conventional epithelial cells: they are covered by only a thin 
layer of mucus and have a reduced glycocalix and short microvilli. On the basolateral side 
they have an invagination, forming a pocket which houses lymphocytes, macrophages and 
DC. M cells have also shown reduced intracellular lysosomal activity (Kraehenbuhl and 
Neutra, 2000). Figure 1.3 shows the main features of FAE, within PP. The function of M 
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cells reflects their morphological structure: M cells' main function is the transport of 
material from the gut lumen. The almost complete lack of mucus and short glycocalix 
allows easy contact with the pathogen or antigen. Thus the antigen could enter into direct 
contact with APCs in the basolateral pocket: the M cells’ pocket provides a “short track” 
for the transport of the antigen to the immune cells. The reduced enzymatic activity 
prevents the digestion of the antigen inside the M cells, during its passage (Corr et al., 
2008; Kunisawa et al., 2012; Nicoletti, 2000).  
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Figure 1.3. Overview of PP compartments with focus on the epithelium.  
The upper illustration shows the structure of the PP: they form a dome-like shape, which is 
embedded within villi. PP contains organised mucosal lymphoid tissue. V = villus. The 
lower illustration is an enlarged representation of the FAE overlying the PP. The FAE is 
constituted by conventional enterocytes and M cells. M cells show unique features: short 
microvilli, basolateral pocket, intimate contact with APC, T cells and B cells. 
 
M cells have shown efficient transport of various types of particulate substances, including 
latex beads, carbon particles, liposomes, bacteria and viruses (Corr et al., 2008). 
Conversely, the specific uptake of soluble antigens or molecules is poor (Awaad et al., 
2011; Mayer et al., 2001). Based on this knowledge it is believed that trans-epithelial 
transport of particles or microbes does not seem strictly specific, as long as the substances 
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to be transported are in particulate form. The transport mechanism as well as the efficiency 
of transport seems to vary based on the nature of the particle transported (Des Rieux et al., 
2007, 2005; Nicoletti, 2000). M cells' particularly intimate contact with APC, B and T cells 
suggest that they might have a greater functional involvement in the gut immunity, than 
just sampling antigens (Nicoletti, 2000). Moreover, the direct release of pro-inflammatory 
cytokines (i.e. IL-1) by M-cells is a further indication of their possible active involvement 
in the induction of immunogenic response in the gut (Pappo and Mahlman, 1993). 
 
1.2.2.3.3 Exploiting the M cells Gateway for Vaccine Delivery 
PPs have been named the “Achilles heel” of the intestinal barrier due to the M cells' 
specific ability to transport various microorganisms. This apparently negative regard given 
to the M cells underlines their capacity to allow the invasion of harmful enteric 
microorganisms into the mucosa leading to infection (Pron et al., 1998; Sansonetti and 
Phalipon, 1999). At the same time, this same feature can also be viewed as positive, 
considering the vital role of M cells in opening the gate of the immune system to 
therapeutics: the antigen-sampling activity can in fact be exploited in vaccine delivery for 
the protection against harmful pathogens (Nicoletti, 2000). 
 
It is worth mentioning that M cell-mediated transport is particularly suitable for oral 
vaccine delivery, more than it is for any other therapeutic proteins. This is due to the fact 
that M cells' function has proved to be much more than simply antigen sampling: the 
housing of immunity cells in the M cell pocket allows fast and direct delivery of the 
candidate vaccine to the machinery capable of inducing immunogenic response. Therefore, 
if for other therapeutics, M cell-mediated delivery approaches can be advantageous, it 
could be indispensable in case of oral vaccines. In the last few years the growing 
understanding about M cells' formation has provided scientists with improved tools to 
study mucosal vaccine delivery. M cell ontogenesis is related to a series of endogenous and 
exogenous factors: exogenous in vivo short-term challenge with a non-intestinal bacterium 
Streptococcus pneumonia R36A has been shown to increase the number of functional M 
cells and to enhance microparticles transport through the FAE in rabbits (Borghesi et al., 
1999; Meynell et al., 1999). Similarly Raji B lymphocytes have been proven to convert 
undifferentiated intestinal epithelial cells into M cells (Kernéis et al., 1997), even when 
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Raji B and epithelial cell are co-cultured, but not in physical contact (Gullberg et al., 
2000). The resulting scenario is that the immune system seems to play a role in the 
induction and regulation of operative M cells: this differentiation into operative M cells is 
induced by the same soluble cytokine produced by the host-bacteria interaction in case of 
bacterial challenge or by Raji B in case of co-culture with epithelial cells (Man et al., 
2008). The co-culture conversion of epithelial cells has also been exploited to develop an 
in vitro model of FAE, useful for the assessment of new candidate vaccines or therapeutic 
proteins (Des Rieux et al., 2005; Kernéis et al., 1997). 
 
Transport and uptake studies with particulate materials allowed the determination of the 
influence of the chemico-physical characteristics of the particles on M cell mediated 
transport: 
 
 Nature of the material: Small molecules, such as dye, did not show PP-specific 
absorption (Awaad et al., 2011); small 2.5 nm dendrimers have also surprisingly 
shown poor absorption in PP, compared to larger size particles (Florence et al., 
2000), but this result could be related to the low stability of those dendrimers in the 
gut (Hussain et al., 2001). Research about the FAE permeability at the interface 
between particles and molecules (as in the case of dendrimers) have not been 
further carried out and could clarify the limit of M cell sampling capacity. 
 
 Size: size is one of the most important parameters that influence the uptake of 
particles by PP. Several studies over the years have demonstrated that particles 
ranging between 50 and 500 nm in diameter are more highly transported than larger 
particles (Des Rieux et al., 2006; Florence et al., 2000; Jung et al., 2000). A recent 
study defined a more precise optimal size: when 95, 130, 200, 340, 695, 1050 nm 
particles were given orally to mice, 95 nm particle showed the greatest transport in 
the PP (Awaad et al., 2011). These results are in accordance with Jani et al. (1990), 
who showed that in mice 50 nm particles were better absorbed in the PP and 
distributed in the body than 100 nm particles (Jani et al., 1990). The optimal range 
of size for PP absorption can be therefore narrowed down to 50 to 100 nm, 
probably with 50 nm better than 100 nm. Unfortunately there are no published data 
for particles smaller than 50 nm. 
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 Surface charge: a positive charge on the particles would seem to favour their uptake 
by M cells, considering the negative charge of the cell membrane. However, the 
mucus and ordinary epithelial cells’ membranes are also negatively charged and 
therefore electrostatic interaction between the positively charged particles and 
negatively charged physiological components would be largely non-specific 
(Kammona and Kiparissides, 2012) and could lead to entrapment of particles by 
enterocytes, by mucus or by the cellular membranes of M cells. Accordingly, 
negative and non-ionic particles have shown better M cell-mediated transport than 
positively charged ones (Florence et al., 2000; Jung et al., 2000). 
 
 Hydrophobicity/hydrophilicity balance: studies with nanoparticles have shown that 
hydrophobic surfaces tend to be more suitable for M cell mediated absorption, 
whereas more hydrophilic particles have better tropism for enterocytes (Des Rieux 
et al., 2006).  
 
 Presence of targeting molecules: decorating the surface of particles with molecules 
targeting M cells can be a more specific way of increasing uptake and transport by 
M cells; increasing the specificity of M cell-mediated transport could 
counterbalance the unfavoured M cells/enterocytes ratio (M cells make only 5% of 
the epithelial cells). Several approaches have been studied: first of all, cellular 
glycosylation pathways have been investigated, so to be able to engineer the 
particles surface with lectin which could target specific sugars on the M cell 
surface. However, surface markers on the M cells have proved to be rather specific 
among animal species, making targeting studies more complicated. Other 
promising approaches have been based on the exploitation of the same M cell 
receptors to which pathogens naturally bind: bacterial surface proteins have been 
attached on the surface of particles in order to target M cells (Azizi et al., 2010; 
Brayden et al., 2005; Des Rieux et al., 2006). Similarly, other specific targets for 
pattern recognition receptors (PRR) of dendritic cells or macrophages have been 
developed (Chadwick et al., 2010). 
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Overall, experimental results are sometimes contradictory and vary between animal species 
and experimental conditions. Nevertheless, there is a general agreement in terms of optimal 
particle size, in the sense that smaller particles always tend to be better absorbed; however, 
in terms of hydrophobicity and surface charge the situation is more complicated (Des 
Rieux et al., 2006). 
 
1.2.2.4 Oral Tolerance vs. Immunogenic Response 
Even in cases in which the undigested vaccine could breach the intestinal barrier, another 
main risk of failure in oral vaccine delivery is the possibility of inducing oral tolerance, 
rather than protective immunogenic responses (Lycke, 2012; Mowat, 2003). This 
Paragraph describes how those two apparently opposite mechanisms can be developed 
within the same mucosal immunity machinery and what are the current approaches adopted 
in drug delivery in order to avoid oral tolerance. 
 
1.2.2.4.1 Mechanisms of Oral Mucosa Responses to Commensal and Foreign 
Microbiota 
Proteins from the diet and commensal bacteria colonising the gut in physiological 
conditions generally show oral tolerance: following exposure to the potential antigen, 
mesenchymal cells and macrophages produce prostaglandin E2 (PGE2) and epithelial cells 
transforming growth factor-β (TGF-β) and possibly interleukin-10 (IL-10), which stimulate 
the maturation of DC. Consequently, those APC become able to present the antigen to 
naïve CD4+ T cells in the MLN or PP. These T cells switch into regulatory T cells, 
characterised by the production of IL-10 and interferon-γ (IFN-γ) and other T helper (Th) 
2-like cytokines, resulting in systemic and local tolerance. Furthermore, differentiation of 
the naïve CD4+ T cells into T helper (Th) 3 cells can also induce secretion of local IgA, 
which has several roles in the mucosal defence from pathogens and favours maintenance of 
the gut immune homeostasis (Mowat, 2003).  
 
Conversely, the interaction with pathogens and their products in the gut tends to produce 
local inflammation: Toll-like receptors (TLRs), expressed by mesenchymal cells, 
macrophages and epithelial cells induce DC maturation. As a result, DCs that have taken 
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up the antigen in the Peyer’s patch or lamina propria mature completely and produce the 
pro-inflammatory cytokine IL-12. Those DCs can also migrate to the MLN, where they 
induce differentiation of naïve CD4+ T cells into gut homing Th1 cells, which produce 
IFN-γ, another pro-inflammatory cytokine (Mowat, 2003). Secretory IgA is also massively 
produced in case of immunogenic response to pathogens, therefore, they have an important 
role both in the case of tolerance and in case of immunogenic response. 
 
Mucosal immunogenic responses and tolerance to antigens can be developed both locally 
and systemically. It has been hypothesised that the interplay of the MLN with PP and 
peripheral immune tissue allows the activation of local and systemic responses; however, 
the physiological mechanism behind these systemic response has not been fully understood 
yet (Mowat, 2003). The fact that mucosal entry routes of vaccine are able to induce not 
only local, but also systemic responses is an essential concept, which is often neglected in 
drug delivery. Oral vaccines research is often confined to vaccines against enteric diseases 
and instead it has also an interesting potential for vaccination against non-enteric 
pathogens (Wang, 2008).  
 
1.2.2.4.2 Vaccine Characteristics for the Development of Robust Immune Responses 
When discussing oral vaccines it is worth remembering that first the GI stability and 
second the entry of the vaccine in the effector sites are necessary prerequisites for inducing 
an immunogenic response: vaccine degradation or lack of absorption would therefore 
reduce contact with the cells of the immune system, decreasing any possible reaction and 
hence protection against the given pathogen. However, even if those first two major 
obstacles were overcome, the interaction of the candidate vaccine with the effector site of 
immunity in the gut would not necessarily lead to the development of strong protective 
immunity, as tolerance could arise (Mowat, 2003). Recently published results in this field 
allow the definition of the general characteristics that a vaccine candidate should have for 
the induction of immunogenic response: 
 
 Antigen dose and schedule: for non-living vaccines, large and multiple doses are 
generally required to induce an immunogenic response (Mayer et al., 2001; Neutra 
and Kozlowski, 2006; Tacket and Mason, 1999); this also takes into account the 
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“upstream” tendency of vaccines to be poorly stable and poorly absorbed in the gut. 
However, it has also been reported that single high doses of antigen might lead to 
tolerance (Garside et al., 1995), whereas smaller, multiple doses could result in an 
immunogenic response (Strobel and Mowat, 1998). In the same manner low 
repeated doses of vaccine should induce tolerance, as may be the case with repeated 
ingestion of drinking water contaminated with potential pathogens, but very low 
doses have been shown to trigger mucosal and systemic immunogenic response 
(Mayer et al., 2001). It is clearly difficult to define general rules, because studies 
are often contradictory even with the same protein antigen: the general consensus is 
that each vaccine candidate should be evaluated independently in terms of dose and 
administration schedule.  
 
 Antigen nature: soluble antigens have proved to be much more prone to tolerance 
than particulate vaccines, that instead tend to produce immunogenic responses: 
even in case of the same candidate antigen, the formulation of the vaccine in 
particulate form can abolish the development of tolerance in favour of strong 
immune responses (Challacombe et al., 1992; Mayer et al., 2001; O’Hagan et al., 
1993). Aside from the great advantages of being taken up by M cells of the PPs, 
particulate vaccines with a repetitive structure can obviously be more efficient in 
presenting the “danger” signal to cells of the immune system (Herbst-Kralovetz, 
2010; Huang, 2005). This is probably due to the similarity of those vaccines with 
the intrinsic nature of pathogens, which is particulate. The influence of particle size 
on induction of either tolerance or immunogenic response has not been directly 
evaluated; however the dependency of antibody production on the particle size has 
been evaluated, but results were different with different antigens, emphasising that 
case by case considerations have to be made (Des Rieux et al., 2006). 
 
Thus, the overall picture suggests that particulate vaccines given orally favour effective 
immunogenic responses over tolerance. The dose and schedule of immunisation must be 
assessed on a case by case basis, but, considering the low bioavailability of oral vaccines, 
high-doses should be the first choice. As previously mentioned, protective immune 
responses through mucosal routes can be achieved by overcoming the three GI barriers: 
environmental instability of the vaccine in gut, reduced absorption and induction of 
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tolerogenic pathways. However, it is often difficult in cases of vaccine candidates which 
fail to induce protective immunity to define which one (or more) of those GI barriers was 
the obstacle that impeded a sufficiently strong immune response. 
 
1.3 Technological Approaches for Oral Vaccine Delivery 
1.3.1 A Unique Class of Vaccines: Virus-like Particles (VLP) 
Vaccines are biological preparations that induce protection of the body against a given 
pathogen. This protection is achieved by stimulation of the immune system. Live 
attenuated vaccines are widely considered the oldest and most effective vaccines. They are 
based on the use of whole viruses or bacteria, whose virulence had been attenuated (WHO, 
2013). They stimulate strong humoral and cellular responses, which often enables 
protection against future infections. However, despite reduced pathogenicity, the 
pathogens, on which these vaccines are based, can still replicate and induce a mild 
infection soon after the vaccination. Furthermore, the good efficacy goes alongside a high 
incidence of side-effects, related to the reversion of the attenuated pathogen to more 
virulent and harmful forms (Martín et al., 2004). 
 
On the other hand, inactivated vaccines, generated by killing the pathogen, are not able to 
replicate and therefore cannot restore virulence. Thus, inactivated vaccines are relatively 
safer, yet less effective than live attenuated vaccines (due to the inability to replicate), and 
several booster injections, as well as addition of adjuvants, are often required to obtain 
protective immunity (Liljeqvist and Ståhl, 1999; Ulmer et al., 2006; Wiedermann et al., 
1990). Furthermore, as in the case of attenuated vaccines, regulatory requirements are 
difficult to meet, due to the fact that they are based on whole organisms (Liljeqvist and 
Ståhl, 1999). Alternatively, subunit vaccines obtained by extraction and purification of 
some of the antigens from the intact micro-organisms have been used as candidate vaccine 
components. Their efficacy was shown to be limited and large scale production is 
expensive and potentially unsafe, due to the risk of inefficient or incomplete purification 
and detoxification of the original pathogen  (Liljeqvist and Ståhl, 1999; Ulmer et al., 2006).  
A promising class of vaccines is that of recombinant subunit vaccines which are composed 
of only some immunogenic portions of the target organism. They are expressed as 
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heterologous proteins in a variety of different hosts including mammalian cells, yeast, 
insect cells and bacteria. Subunit vaccines are safer than vaccines which are generated 
from whole pathogens. However, they bear only parts of the microorganism structure, 
therefore, their efficacy is expected to be lower than that of the whole  pathogen types of 
vaccines and often high doses and multiple administrations are required to obtain 
protective immunity (Liljeqvist and Ståhl, 1999). Nevertheless, in the case of vaccines 
against viral pathogens, a new subclass of recombinant subunit vaccines has been shown to 
be highly effective. Virus-like particles (VLPs) are subunit vaccines that mimic the whole 
organism structure, but they do not contain the genetic material that allows the organism to 
replicate. As with all other subunit vaccines, VLPs are produced as recombinant 
heterologous proteins. However, in the case of VLPs the viral proteins naturally self-
assemble into capsids in the host cell environment where they are produced. Their structure 
resembles the antigenic conformation and repetitive nature of the whole organism. These 
features allow VLPs to be as effective as inactivated vaccines, yet VLPs are also extremely 
safe as they cannot replicate, reverse or recombine to a more virulent form. Overall, VLPs 
combine efficacy of inactivated vaccines and safety of recombinant subunit vaccines 
(Jennings and Bachmann, 2008; Noad and Roy, 2003). The characteristics of each vaccine 
class is summarised in Table 1.1. 
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Table 1.1. Characteristics of different classes of vaccines 
Class of vaccine Ability to 
replicate 
Overall 
safety** 
Microorganism 
structural 
arrangement 
Efficacy*** 
Attenuated Yes + Yes +++ 
Inactivated No ++ Yes ++ 
Non-recombinant 
subunit 
No* ++ No + 
Recombinant 
subunit 
No +++ No + 
Virus-like particle No +++ Yes ++ 
* Unable to replicate, given the effectivity of the purification and detoxification procedure. 
** +, ++ and +++ indicates lowest, intermediate and highest safety profile, respectively. 
*** +, ++ and +++ indicates lowest, intermediate and highest efficacy, respectively. 
 
A relatively new and alternative class of vaccines is constituted by DNA vaccines, which 
are based on the transfection of a plasmid DNA into the cells of the host. The DNA 
containing genes that encode for an immunogenic protein of the pathogen is expressed, 
exploiting the translation machinery directly of the host cell. DNA vaccines could be 
advantageous compared to other classes of vaccines, particularly in those cases where 
antigenic drift of the pathogen strain rendered the more traditional vaccines less effective 
(Donnelly et al., 1995).  
 
A broader description of vaccines for their general use as injectable vaccines goes beyond 
the purpose of the work described in this thesis. However, an examination of vaccines and 
VLPs used in oral delivery research will be given in the next Paragraph. 
 
1.3.2 Oral Vaccine Delivery - State of Art 
Recent literature reveals a rapidly growing interest in needle-free vaccine alternatives: a 
futuristic vision of potentially safe, effective, easily-delivered and cheap therapeutic 
options against many infectious diseases has widely spread among scientists in the last few 
Chapter 1 
 
 
23 
 
years. Oral delivery seems one of the most, if not the most, valued routes towards this 
objective. However, the oral route, as previously mentioned, is associated with three major 
challenges that could hinder effective oral vaccines delivery. Nevertheless, decades of 
research have allowed a deep understanding of those obstacles and have led to the 
development of progressively more valuable methods to overcome them. An overview of 
the current tools in the vaccine delivery arsenal and an analysis of the most promising and 
successful vaccine approaches are an essential step before attempting novel investigations. 
 
Nowadays there are relatively few oral vaccines in the market and they are all attenuated or 
killed vaccines. There are a few examples of both bacterial and viral attenuated vaccines, 
including polio and cholera vaccines. They are known to be highly effective, but are often 
unstable and more importantly could raise safety concerns because the quiescent virulence 
can suddenly revive (Silin et al., 2007). Oral killed (or inactivated) vaccines have been 
shown on the other hand to be safer; however, they can still induce more or less severe side 
effects (Huang, 2004). Furthermore, they are generally less effective than attenuated 
vaccines (Silin et al., 2007). The commonalities of both approaches, relying on actual 
(attenuated or killed) pathogens, are the presence of robust pathogenic structures that can 
resist the GI harsh environment, or that can replicate in the gut (i.e. attenuated vaccines) 
and the presence of surface ligands that the invasive pathogen normally exploit to colonise 
and attack the host organism (Brayden et al., 2005; Lycke, 2012; Silin et al., 2007). All 
other vaccine candidates that are not based on whole (inactivated or killed) pathogens do 
not seem to have passed the phase I clinical trial stage (Amorij et al., 2012).  
 
In the case of recombinant vaccines and DNA vaccines, adjuvants are often required in 
order to induce a strong oral immune response. Adjuvants can be categorised into three 
main classes: particulate adjuvants, targeting adjuvants and/or immunostimulatory 
adjuvants. First of all, the knowledge that the intestine is not a perfect barrier to particles 
has been exploited for the development of particulate carriers: a carrier is considered an 
adjuvant by protecting the antigen or DNA from the harsh GI condition and by enabling 
improved transport in the GALT (Saroja et al., 2011). Bacterial/viral carriers (Silin et al., 
2007), polymeric solid micro- and nanoparticles (Chadwick et al., 2010) and vesicles 
(Wilkhu et al., 2013) have been the most investigated carriers for oral vaccine delivery.  
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Cellular targeting represents another adjuvant mechanism, improving the vaccine transport 
or presentation to the GALT. It can be achieved not only by using whole attenuated 
microorganisms as transporters for foreign vaccines, but also by decorating the carrier with 
targeting sequences for M cells, DC or macrophages [reviewed in Paragraph 1.2.2.3.3].  
 
The third class of adjuvant is comprised of immunostimulatory adjuvants, which work by 
intensifying the immunogenic response. Bacterial-based adjuvants, as well as cytokines, 
chemokines, some plant compounds (.e.g. saponins) and synthetic compounds,  have been 
used for their immunomodulatory properties (Purcell et al., 2007; Silin et al., 2007). These 
adjuvants can often complement the vaccine formulation and sometimes one component 
bears both immunomodulatory and transporter properties: typical examples are 
immunostimulatory complexes (ISCOM), which have been exploited as mucosal adjuvants 
being at the same time carrier and immunostimulatory adjuvants (Cox et al., 2006). 
 
In summary, the oral vaccine formulations available in the market are currently only those 
based on attenuated or killed pathogens. These types of vaccines have raised safety 
concerns over the years, causing the research focus to shift to the development of efficient 
subunit or DNA vaccines. These vaccines are safer and therefore are well regarded by 
pharmaceutical companies: safety is, in fact, a primary issue in vaccine industries, as they 
are the ones legally responsible for the adverse reactions of therapeutics. As a downside, 
they are less effective than attenuated vaccines, because they are less equipped to 
overcome the physiological GI barriers. Therefore, in the last few years carrier- , cell 
targeting- and immunomodulatory adjuvants have been investigated in order to improve 
subunit and DNA vaccine efficacy. It is worth remembering that the three types of 
adjuvants can often overlap, because good adjuvants can bear in the same structure the 
three components: typical examples are the saponin of the ISCOM or VLP, which will be 
discussed in the next Paragraph. 
 
1.3.3 VLPs as Oral Vaccines 
VLPs (Paragraph 1.3.1) are ideal vaccine candidates for oral delivery as they should 
exhibit both the safety of subunit vaccines and the efficacy of inactivated viral vaccines. 
They in fact share the same viral particulate conformation of killed vaccines, but do not 
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carry the viral genome, and they therefore avoid the risk of reversion to virulence (Noad 
and Roy, 2003). They bear in the same structure the four components required for 
induction of potent immunogenic response: 
 
 Antigenicity: the repetitive structure of the VLP is a high-density platform of hundreds 
of identical epitopes. This explains their higher intrinsic immunogenicity when 
compared to traditional subunit (soluble) antigens (Ludwig and Wagner, 2007).  
 
 Carrier: as previously explained in Paragraph 1.3.2, efficient oral vaccines require the 
presence of a carrier that can improve the stability of the labile antigen in the harsh 
gastric environment and improve the intestinal transport. VLPs are self-carriers in the 
sense that the antigenic repetitive structure naturally forms particles. Their highly 
packed structure could be strong enough to survive the harsh GI environment (Herbst-
Kralovetz, 2010; Huang, 2005). For example, Norwalk virus VLPs are stable at low pH 
and are trypsin resistant (Ausar et al., 2006; Jiang et al., 1992; O’Hagan et al., 1993). 
Furthermore, two plant viruses [Cucumber Mosaic Virus and Cowpea Mosaic Virus 
(CPMV)] have been demonstrated to be stable in simulated gastric and intestinal 
conditions (Nuzzaci, 2010; Rae, 2005). This suggests that VLPs of animal viruses may 
also be stable in the gut. 
 
 M cell targeting: VLPs mimic the exact structure of viruses, therefore they use the 
same invasive mechanisms that viral pathogens exploit to infect the host. This is 
particularly true in the case of oral delivery of VLPs of enteric viruses: by exploiting 
the normal route of transmission of the pathogen, VLPs employ a sort of “natural” 
targeting of transporters to intestinal cells (Holmgren, 2005; Huang, 2005). It is also 
expected that the particulate nature of VLPs of non-enteric viruses would favour the M 
cell-mediated absorption. The VLP's average size of circa 50 nm seems the optimum 
for this purpose. In vivo M cell uptake of CPMV, has been recently shown (Gonzalez et 
al., 2009).  
 
 Immunostimulatory: the size of most VLPs favours their uptake by the dendritic cells 
(DC) as the optimal size of nanoparticles to be uptaken by DC is 40 nm (Fifis et al., 
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2004). Furthermore, the highly repetitive organisation of VLPs, which is different from 
the usual structure of the host proteins, exposes the cells of the immune system to 
molecular configurations typical of pathogens, called PAMPs. Those structures are 
recognised by TLRs and other PRRs of the host as a “danger signal” and thus trigger 
innate immune responses. Moreover, the presence of foreign nucleic acid in many 
VLPs candidates constitutes another immunostimulatory PAMP. All those 
characteristics of VLPs aid the development of potent immune responses (Plummer 
and Manchester, 2011). 
 
VLPs have also the potential to be used as vehicles for the presentation of foreign epitopes: 
this adjuvant/carrier function has been also exploited for oral delivery (Niikura et al., 
2002). Furthermore, certain VLPs can act as carriers for DNA vaccines (Takamura et al., 
2004). To date several orally delivered VLPs have been assessed in pre-clinical studies and 
a few VLP candidates have entered phase I clinical trials (such as Norwalk VLP and 
HBsAg) (Kushnir et al., 2012).  
 
1.4 Hepatitis B Core Antigen (HBcAg) 
In this Section background information regarding Hepatitis B and Hepatitis B Core 
Antigen (HBcAg), which is the candidate antigen used in this research, is given. 
 
1.4.1 Hepatitis B Virus (HBV) 
Hepatitis B virus (HBV) is one of the major human pathogens. Chronic infection with 
HBV is associated with cirrhosis and primary liver cancer. It has been estimated that two 
billion people have been infected with HBV and every year HBV causes around 600,000 
deaths world-wide (Center for Disease Control and Prevention (CDC), 2012). HBV has 
been ranked as the 10th leading cause of death in the world (Lavanchy, 2004). Acute HBV 
infection is often not lethal and individuals infected usually fully recover. However, in the 
case of vertical transmission from mother to neonate, there is a 90% risk that the acute 
infection can progress to chronic infection, which is the major cause of premature death 
from cirrhosis or liver cancer in 25% of the infected individuals. Instead, horizontal 
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transmission in adults via body fluids results in chronic infection in only circa 5% of the 
cases (Center for Disease Control and Prevention (CDC), 2012).  
 
Hepatitis B belongs to the family of Hepadnaviridae; the 42 nm HBV virion is formed by 
an external envelope made of a lipid bilayer and three membrane proteins. The envelope 
surrounds an internal nucleocapsid. A 3.2 kB partially double-strand DNA is contained 
inside the nucleocapsid (Seitz et al., 2007). Figure 1.4 shows the structure of the HBV 
virion. 
  
 
 
Figure 1.4. Hepatitis B virus structure. 
Hepatitis B virus bears an external envelope forming a 42 nm shell and an internal 
nucleocapsid, which contains the viral partially double-stand DNA.  
 
HBV replicates preferentially in hepatocytes. Receptor-mediated interaction of the virus 
with the hepatocytes results in internalisation of the virus, with detachment of the envelope 
and nucleocapsid release in the cytosol. Upon nucleocapsid entry into the nucleus, the viral 
genome is used as a template for transcription. The messenger RNAs are then translated 
into viral proteins in the cytoplasm, exploiting the host translational machinery. The viral 
proteins encoded are the envelope proteins, named Hepatitis B surface antigens (HBsAg) 
and the nucleocapsid protein, called Hepatitis B core antigen (HBcAg). Nucleocapsid 
assembly occurs in the cytosol. In the endoplasmic reticulum nucleocapsids are packed 
into the envelopes (Wei et al., 2010). A peculiar characteristic of HBV infection is the 
generation of other viral products aside from the 42 nm virion: a 22 nm subviral empty 
envelope shell as well as a soluble (non-particulate) form of core protein, named E antigen, 
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are also generated in large amounts during the infection (Jean-Jean et al., 1989; Wei et al., 
2010). 
 
1.4.2 Hepatitis B Core Antigen (HBcAg) Structure 
Sequencing of the region of the HBV genome encoding for HBcAg allowed its expression 
in Escherichia coli, opening the possibility for a deeper understanding of this nucleocapsid 
antigen. Full-length HBcAg is 21 kDa monomeric protein (Figure 1.5 A), made of 183 
amino acids (Pasek et al., 1979). Electron cryomicroscopy of recombinant HBcAg revealed 
that HBcAg monomers self-assemble into dimers which present a hammer-like shape with 
the handle being like a protruding spike (Figure 1.5 B). Dimers arrange into icosahedral 
spiky particles of two distinct subtypes (Figure 1.5 C): 34 nm particles, being the majority 
of the total population (circa 85%), are made of 240 HBcAg subunits, arranged as 120 
dimers and with a T = 4 triangulation number. The triangulation number is related to the 
icosahedral geometry. A second class of particles with a diameter of 30 nm was also 
identified: these particles consist of 180 HBcAg monomers, arranged as 90 HBcAg dimers 
and with a T = 3 triangulation number (Birnbaum and Nassal, 1990; Crowther et al., 1994). 
 
Further structural studies revealed two protruding α-helical hairpins are connected by a 
loop within a monomer; the interaction of two hairpins of identical HBcAg monomers 
determines the formation of the spiky dimers, featuring a four-helix bundle (Böttcher et al., 
1997; Wynne et al., 1999). Furthermore, two of the four cysteine residues contained in the 
full-length HBcAg have shown to be important for dimer stabilisation: the two Cys61 
residues of identical monomers have shown to form a disulfide bridge which appears to 
stabilise the interaction of the hairpins of the two dimers (Wynne et al., 1999; Zheng et al., 
1992). Cys183 of a monomer is also involved in a disulfide bond with the Cys183 of the 
other monomer of the dimer (Zheng et al., 1992). Nevertheless, Cys48 (Wynne et al., 
1999) and Cys107 are present as free thiols (Zheng et al., 1992). The formation of disulfide 
bridges is not essential for particle formation. However, it seems to confer stability to the 
dimers (Wynne et al., 1999; Zheng et al., 1992). 
 
The last 34 C-terminal amino acids of HBcAg sequence have been shown to be non-
essential for HBcAg assembly into particles; however, this C-terminal arginine-rich 
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domain, also called protamine-like domain, was demonstrated to bind and encapsidate 
nucleic acids. This arginine-rich tail also confers overall positive charge to the protein 
(Birnbaum and Nassal, 1990; Gallina et al., 1989). A C-terminus truncated version of 
HBcAg, lacking the whole protamine-like domain, has been shown to assemble into 
particles, virtually devoid of nucleic acids and lacking the Cys183 disulfide bridge (Figure 
1.5 A). The fact that the truncated version still forms particle suggests that the C-terminal 
arginine-rich tail is not essential for particle formation (Birnbaum and Nassal, 1990; Zheng 
et al., 1992). However, the C-terminus of the full-length protein seems to have an 
important role in particle stabilisation: in fact full length HBcAg particles subjected to 
different denaturing stress (i.e. high pH and SDS treatment), was shown to be more stable 
than truncated HBcAg versions (Birnbaum and Nassal, 1990; Newman et al., 2003). 
 
HBcAg used in this project is a 176 amino acids deleted version of HBcAg (HBcAgΔ176). 
It is a 20.2 kDa protein (Figure 1.5 A). It contains most of the protamine-like tail amino 
acids and is supposed to bind and encapsidate nucleic acids into its multimeric particles 
(Liu et al., 2010). Figure 1.5  illustrates the structure of HBcAg: the primary structure is 
presented as deleted versions and as full-length protein (Figure 1.5 A); the dimeric 
structure is also shown from two orientations (Figure 1.5 B) and finally the particulate 
structure is displayed in its T = 4 geometric class (Figure 1.5 C). 
  
Chapter 1 
 
 
30 
 
 
Figure 1.5. HBcAg structure. 
(A) represents HBcAg amino acid sequence: HBcAgΔ149 is the C-terminal deleted 
version, lacking the whole protamine-like domain. HBcAgΔ176 is the C-terminal deleted 
version used in this study; HBcAg full-length is the naturally occurring 183 amino acids 
long version. The dash C-terminus indicates the protamine-like region. The four cysteine 
exposing free thiols or forming disulfide bridges are symbolised respectively by –SH or S-
S-. N = N-terminus, C = C-terminus (B) illustrates the dimeric hairpin-like structure, seen 
from two orientations. The green and the yellow spheres symbolise Cys61 and Cys48, 
respectively. (C) represents the surface of a particle bearing T = 4 geometry. The figure 
was adapted from Wynne et al. (1999). 
 
1.4.3 Hepatitis B Core Antigen (HBcAg) as a Vaccine  
Prophylactic vaccination is to date the best prevention strategy against HBV infection in 
humans. The current HBV vaccine is the recombinant surface protein (HBsAg) produced 
in yeast. It has been in the market for more than 20 years and it is produced by Merck (as 
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Recombivax HB) and GlaxoSmithKline Pharmaceuticals (as Engerix-B). HBV vaccine is 
given intramuscularly in a three-dose schedule. It is 80 to 100% effective and less than 5% 
of the people remain unresponsive to vaccine after receiving six doses, as they do not 
develop detectable anti-HBsAg antibody (Center for Disease Control and Prevention 
(CDC), 2012). HBV vaccine is now part of most mass-immunisation programmes 
worldwide: routine infant immunisation with hepatitis B vaccine was carried out in 152 
countries already in 2002 (Lavanchy, 2004). Undoubtedly the current vaccine has proved 
to be overall effective in reducing the incidence of HBV infections worldwide. However, 
aside from the unresponsiveness of a small percentage of the population, this vaccine 
presents other drawbacks including the impracticality of the parenteral administration with 
a schedule of three doses, especially in developing countries (Tiwari and Vyas, 2011).  
 
The core protein, HBcAg, has also been studied as a potential parenteral vaccine candidate. 
HBcAg has been shown to induce potent B and T cell responses (Milich et al., 1997, 
1987a). The very strong immunogenicity of HBcAg could be related to its particulate 
nature. Surprisingly, HBcAg administration can also mediate anti-HBsAg antibody 
production. It was proposed that this capacity of eliciting anti-HBsAg responses could be 
the mechanism underlying the ability of HBcAg to protect against HBV infection (Milich 
et al., 1987b). In fact, it was shown that HBcAg could partially or fully protect 
chimpanzees against HBV infection (Iwarson et al., 1985; Murray et al., 1984). More 
recently, HBcAg has shown an immune-enhancing effect on co-delivered HBsAg upon 
nasal administration in animal studies (Aguilar et al., 2004; Lobaina et al., 2003). 
Furthermore, a phase I clinical trial has demonstrated that seroprotective anti-HBsAg 
antibody levels could be induced in 75% of the subjects to which the HBcAg/HBsAg 
formulation was co-delivered nasally (Betancourt, 2007).  
 
Over the years, HBcAg has also earned the reputation of being an exceptionally promising 
carrier for foreign epitope sequences. The theory behind the use of particles as carriers for 
foreign antigens is based on the fact that, though soluble antigens are safe, they often fail to 
induce strong immunogenic response. Therefore, the conjugation of such antigens to 
particulate carriers can allow high density and repetitive display of the epitopes of interest 
on the surface of particles (Grgacic and Anderson, 2006). HBcAg VLP is considered a 
particularly good candidate for its use as vaccine platform for foreign antigens, because of 
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its extremely high intrinsic immunogenicity. HBcAg's capability of eliciting strong 
antibody production, inducing T cell production and mediating anti-HBsAg responses 
suggested that they could be exceptionally effective carrier vehicles for foreign epitopes 
(Milich et al., 1987b). In addition, HBcAg is non-cytotoxic and well tolerated in humans. 
Moreover, HBcAg has demonstrated flexibility in sustaining chemical and genetic 
insertions without alteration of the particulate integrity. Insertion of the foreign sequences 
is usually obtained by genetic insertion of foreign sequences in the loop region, which is 
the tip that connects the two α-helix of the hairpin-like structure. Insertion of up to 55 
amino acids have shown to be compatible with maintenance of the particle assembly 
(Whitacre et al., 2009). 
 
1.4.4 Hepatitis B Core Antigen (HBcAg) Tandem Technology 
One of the major limitations in using HBcAg as VLP platform for presentation of foreign 
epitopes is that large insertions in the loop region of HBcAg can be incompatible with 
particle assembly. This is mainly due to the fact that, within a dimer, the two loops of each 
monomer are very close and are both sites of insertions. For this reason, the inserted 
epitopes are sterically hindered with respect to each other, impeding initial dimerisation 
and subsequent particle formation (Nassal et al., 2008). 
 
A research group in Leeds developed a technology to reduce this spatial obstruction on the 
site of the insertions (Gehin et al., 2007): genetic fusion of two HBcAg monomers through 
a flexible linker allowed production of a dimer-like protein as a single peptide. In this way, 
the two loops could be modified separately. The tandem HBcAg technologies enable 
having a single insertion within a dimer. This is in contrast with the double insertion, 
which is unavoidable when using wild-type HBcAg, where the dimer is made of two 
identical repeated structures. This tandem technology, by having only half of the tips of 
each monomeric loop bearing a foreign sequence, can significantly reduce the steric 
hindrance, potentially allowing larger sized insertions (Gehin et al., 2007).  
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1.5 Plants as Bioreactors for Recombinant Proteins 
1.5.1 Introduction 
“Molecular farming” is the term given to the production of pharmaceutically and 
commercially valuable proteins in plants (Franken et al., 1997). This description 
emphasises the fact that the production of valuable molecules could be as easy as the 
cultivation of plants. Molecular farming enthusiasts advocate that expression of 
recombinant proteins in plants is both easy to optimise and to scale-up. Thus, molecular 
farming could offer an effective means for the production of pharmaceutical and 
therapeutic proteins, including those whose therapeutic potential has not been evaluated 
due to the lack of a production system (Fischer and Emans, 2000). Historically, 
recombinant protein production has been mainly limited to production in bacteria, yeast, 
insects and mammalian cells. The main advantages for the use of plants for expression of 
heterologous proteins are indicated below: 
 
 Plant ensures a higher eukaryotic synthesis pathway, analogous to those of animals 
cells and compatible with mammalian protein glycosylation (Cabanes-Macheteau et 
al., 1999; Fischer and Emans, 2000); this offers a high chance to produced full-size 
complex recombinant protein.  
 
 Multimeric proteins as complex as antibodies or VLPs can be expressed in plants 
and the expression is often compatible with their correct folding and assembly (Ma 
et al., 1995; Mason et al., 1992; Thuenemann et al., 2013). 
 
 Plant expression systems are cheap and easy to scale-up. In particular, in the case of 
transgenic expression, plant recombinant proteins could be farmed at agricultural 
scales (Fischer and Emans, 2000) 
 
 Plant expression is virtually free from possible contamination or co-purification 
with human or animal pathogens or oncogenic sequences (Fischer and Emans, 
2000; Ulmer et al., 2006). 
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 Plants can be potentially used for the development of oral vaccines [reviewed in 
Paragraph 1.5.5]. 
 
The first pharmaceutically relevant recombinant protein was expressed in plants in 1986. It 
was a form of human growth hormone expressed in transgenic tobacco (Barta et al., 1986). 
Since then, an extremely wide range of recombinant proteins has been produced in plants. 
These include therapeutic proteins such as vaccines, antibodies, cytokines, blood proteins, 
growth factors, therapeutic enzymes and insulin. Furthermore, many enzymes for industrial 
use and some biopolymers have been also produced in plants and some have already 
reached the market (Lico et al., 2012; Xu et al., 2012). However, only very recently, the 
first plant-produced biopharmaceutical has been approved for human use by the US Food 
and Drug Administration: this recombinant protein is taliglucerase alfa, an enzyme used 
for treating type 1 Gaucher’s disease (Fox, 2012). Despite the huge production of 
recombinant proteins for human use, only one has reached the market level so far. This 
clearly suggests that the biggest challenge to be overcome is still the acceptance from 
regulatory bodies. Furthermore, persistent “industrial inertia” does not enable the switch 
from the conventional production systems already in place to the plant-based system, 
because this would require considerable initial investments (Ma et al., 2003; Rybicki, 
2009). 
 
1.5.2 Stable Transformation vs Transient Expression  
Recombinant protein production in plants has been for long, mainly relegated to stable 
integration of constitutively expressed transgenes into the genome of the host plants. This 
production system is very easy to scale-up, because once transgenic lines are produced, the 
scale-up could consist of simply sowing the seeds (Fischer and Emans, 2000). In the case 
of recombinant protein production in transgenic plants, the fact that there is already a 
regulatory framework in place for GM crops and food could potentially reduce the 
regulatory obstacles (Spök et al., 2008). However, the generation of transgenic lines is 
quite a long and troublesome process and it can take up to 9 months before being able to 
analyse the expressed proteins.  
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On the other hand, transient expression of heterologous proteins in plants does not present 
this limitation. As the name suggests, transient expression systems are based on temporary 
transformation: the foreign genes are not integrated with the host chromosomes, but they 
are present in the nucleus where they are transcribed (Fischer and Emans, 2000). Transient 
expression can be used as a means of testing whether a certain protein can be efficiently 
expressed in a plant, as maximum expression levels can be achieved in just seven days, 
thereby allowing fast screening of new constructs (Sainsbury and Lomonossoff, 2008). The 
main disadvantage of the transient expression, compared to the stable transformation, is the 
relatively more difficult scalability than the stable transformation (Daniell et al., 2009)  
 
Transient expression can be achieved in Nicotiana benthamiana by agroinfiltration: a 
simple method based on the use of Agrobacterium tumefaciens. This bacterium contains a 
tumour inducing (Ti) plasmid, in which the disease and virulence causing elements are 
substituted with the foreign genes of interest necessary for the expression of the 
recombinant protein. Agroinfiltration is achieved by simply forcing a suspension of the 
modified Agrobacterium into the intercellular spaces of the leaf lamella. The bacteria can 
then attach to the plant cell and transfer the gene responsible for the foreign protein 
expression into the cell. For small scale experiments, this can be achieved by syringe 
infiltration. However, this process can be easily scaled up using vacuum-agroinfiltration 
(Fischer et al., 2004). Large scale production of foreign proteins in plants by means of 
transient expression is already a reality. In fact, Medicago Inc., (Quebec, Canada) has 
current Good Manufacturing Practice (cGMP) facilities for production of plant-made 
vaccines. Medicago already produce vaccines for Phase I and Phase II clinical trials; 
moreover, this company proved that it was possible to produce 10 million doses of a 
cGMP-grade influenza vaccine in less than 30 calendar days (http://www.medicago.com). 
This achievement highlights that transient expression could be an efficient way to promptly 
achieve industrial scale production of novel vaccines tailored against newly emerging 
pandemic outbreaks. 
 
1.5.3 CPMV-HT and pEAQ Expression Systems 
In the past decades, transient expression of foreign proteins in plants has been mainly 
based on agroinfiltration or alternatively achieved using plant viral vectors. Viral vectors 
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exploit the capacity of plant viruses to infect plants, for the production of the heterologous 
protein of interest. Originally, heterologous gene sequences were included into the full 
viral genome; the capacity of the virus to infect the plant and to replicate was exploited for 
the concomitant production of the foreign protein. However, this method had several 
drawbacks, including the impossibility of producing large and complex heterologous 
proteins and the presence of recombinant, highly infectious viruses poses obvious bio-
containment issues (Gleba et al., 2004). 
 
A remarkable breakthrough in this field consisted of the coupling of agroinfiltration with 
the use of deconstructed viral vectors that cannot replicate (Rybicki, 2010). The use of 
non-replicating viral vectors that can be targeted to the nucleus of the plant cell by 
agroinfiltration overcomes most of the hurdles encountered with full viral vector systems. 
Among other expression systems, the Lomonossoff group at the John Innes centre (JIC), 
Norwich have focused on the development of Cowpea Mosaic Virus (CPMV)-based 
expression systems. CPMV contains two genomic RNAs; over several years of research, it 
was demonstrated that only the so called 5' untranslated regions (5'-UTRs) and 3' 
untranslated regions (3'-UTRs) of CPMV RNA-2, in the presence of RNA-1 and a 
suppressor of silencing, were essential for good levels of expression of inserted 
heterologous proteins. Basically, it was found that only the sequence upstream (5'-UTR) 
and downstream (3'-UTR) to the encoded sequences of RNA-2 were essential for the 
expression of an inserted heterologous genes. Hence removing most of the RNA-2 
sequence, including those encoding for the actual plant virus (i.e. CPMV), was still 
compatible with the expression of the heterologous protein. RNA-1, responsible for the 
RNA-2 replication, had to also be present. The use of this highly deleted version of the 
viral genome did not allow the production of infectious virus, whose sequences were 
substituted with those for the expression of the heterologous genes. Therefore this 
approach solved the biocontainment issues typical of full vectors systems (Cañizares et al., 
2006). 
 
Nevertheless, a huge step forward in this technology came with the finding that the 
expression of the foreign protein could be enhanced by at least 10-fold by further deletions 
of the RNA-2 5'-UTR. The removal of two start codons, which are located upstream to the 
start codon for the heterologous protein, generated this huge increase in the expression 
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level. Furthermore, it was found that the higher expression was not related to increased 
transcription level, but to enhanced translation. From this, the name hypertranslational (-
HT) was given to the expression system. This also obviated the need for replication, so co-
infiltration with RNA-1 was not required (Sainsbury and Lomonossoff, 2008).  
 
Soon after this technology was optimised by the development of a plasmid that could 
combine the high yield achievable with the CPMV-HT, with the possibility of easily 
inserting longer expression sequences and multiple insertion sites. This system, called 
plasmid easy and and quick (pEAQ) enables easy one-step cloning (Sainsbury et al., 2009). 
Figure 1.6 illustrates a schematic representation of the steps required for the preparation of 
pEAQ vectors usable for the transient expression of heterologous proteins by means of 
agroinfiltration.  
 
 
Figure 1.6. Foreign protein expression using pEAQ-expression system. 
The gene encoding for the heterologous protein is initially inserted into the CPMV-HT 
RNA-2 sequences. Then this viral vector is inserted into pEAQ plasmid, which is 
subsequently cloned into Escheirichia coli. Finally, after transformation of the plasmid into 
Agrobacterium tumefaciens, the bacterial suspension can be used for agroinfiltration. 
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Upon infiltration of the intercellular space of the plant leaf with the Agrobacterium 
suspension, the plasmid enables transfer of the encoding sequences to the cellular nuclei. 
Here the CPMV-HT system mediates the expression of the recombinant protein. 
Interestingly, this viral vector system of expression does not rely on enanched replication 
or transcription of the foreign sequences, but on extremely efficient translation (Sainsbury 
and Lomonossoff, 2008).  
 
In only five years from when it was first published, the CPMV-HT system has been used in 
more than 200 universities and institutes for research purposes (Prof Lomonossoff personal 
communication). Furthermore, it has been adopted for industrial-scale production of an 
Influenza hemagglutinin vaccine, which is currently used in clinical trials (D’Aoust et al., 
2010). 
 
1.5.4 Transient Expression of Hepatitis B Core Antigen (HBcAg) in Plant 
HBcAg was expressed for the first time in plants by the Lomonossoff group, using a full 
length viral vector system. The yield achieved was variable, from circa 10 to at least 50 
mg/kg of fresh weight of the leaves, depending on the viral vector used (Mechtcheriakova 
et al., 2006). In the same year it was demonstrated that using another expression system, 
HBcAg could be expressed in plant up to levels of 2.4 g/kg of fresh weight leaf tissue. The 
immuno-equivalence of this plant-produced HBcAg to HBcAg produced in bacteria was 
also demonstrated (Huang, 2006). HBcAg was finally produced also using the CPMV-HT 
system to levels of 1 g/kg of fresh weight tissue (Sainsbury and Lomonossoff, 2008). 
Furthermore, recombinant tandem HBcAg (described in Paragraph 1.4.4) was also 
expressed in plants in a particulate form. Additionally, green fluorescent protein (GFP) 
could be genetically inserted in the tip of the dimeric structure with this insertion being 
compatible with particle formation (Thuenemann, 2010).  
 
HBcAg (HBcAgΔ176) was produced in Nicotiana benthamiana throughout this study, 
using the viral vector CPMV-HT (Sainsbury and Lomonossoff, 2008), inserted into pEAQ 
plasmid (Sainsbury et al., 2009). Moreover, one version of the tandem construct, codifying 
for heterotandem core-GFP, named CoHe7e-GFP, was used in this project. The main 
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reason for its use was that CoHe7e-GFP consists of a fluorescent version of HBcAg and it 
could therefore be used as an investigation tool for bio-imaging. 
 
1.5.5 Plant Oral Vaccines - the History of an Unmet Challenge 
Scientific articles on the use of VLPs for oral delivery are often also articles regarding 
plant oral vaccines. The concept that plant material could act as an adjuvant in the oral 
delivery of VLPs has been growing over the last two decades and has pushed research 
towards the development of plant based VLP oral vaccines. In fact VLP is a very effective 
recombinant vaccine strategy and its expression in plants could constitute an excellent 
delivery system. For instance if the vaccine is expressed in an edible plant or fruit, animals 
or humans could be fed with an un-purified, “ready to use”, low cost edible vaccine. This 
concept was introduced by Charles Arntzen in 1992 when for the first time his research 
group managed to express a recombinant vaccine VLP in plants (Mason et al., 1992). Over 
the subsequent years several important proofs of concept followed that initial intuition: by 
2000 the Arnzten group had demonstrated that both transgenic tobacco and transgenic 
potato expressing recombinant antigens could be immunogenic if fed as oral vaccines 
against bacteria and viruses both in animals and humans. Protection against challenge after 
priming with edible vaccines was subsequently proved in animal models (Haq et al., 1995; 
Mason et al., 1998; Tacket et al., 2000, 1998). After those initially exciting results, several 
further candidate vaccines had shown promising results and at the beginning of the 21st 
century the edible vaccine concept reached the maximum interest, with many reviews 
publicising the great potential of this technology, and new concepts as “vaccine farming” 
became popular slogans in the scientific arena (Rybicki, 2009). 
 
The main presumed advantages of these technologies were the so called “bio-
encapsulation” of the vaccine in the plant cell wall and cellular compartments, which could 
allow supplementary protection to the antigen, and the heat-stable environment of the 
vaccine host (Walmsley and Arntzen, 2000). However, three concomitant circumstances 
induced a sudden regress in the enthusiasm of edible vaccines around 2002 (Rybicki, 
2009): 
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 In 2002, maize and soybean seeds harvest in two US states were found to be 
contaminated with some seeds containing a transmissible gastroenteritis virus 
capsid protein, which a biotech company was producing for research on pig 
vaccines. The case was contained and stricter guidelines were reinforced thereafter 
(USDA, 2013).   
 
 Research in immunology was providing more and more consistent evidence about 
the possibility of developing tolerance following mucosal antigen exposure 
(Rybicki, 2009). 
 The general feeling that the regulatory bodies may not grant a license for plant 
vaccines for animal or human use, due to possible lack of dose and process 
standardisation (Rybicki, 2009). 
 
These factors determined a general drawback after the initial excitement, because it 
suddenly seemed that containment measures for transgenic plants, risks of tolerance and 
regulatory issues could become tough hurdles to overcome. However, research on oral 
vaccines produced in plants continued and scientists had simply to tune their plant oral 
vaccine vision: in a famous interview Arntzen declared "We don't say 'edible' vaccine any 
more - we say 'heat-stable oral vaccines' ". It was explained that for oral vaccine 
development, the use of food that could enter the food chain had been abandoned and that 
previously non-edible plants such as Nicotiana benthamiana would have been used to 
produce vaccines. They could have been minimally processed in order to be filled into 
heat-stable capsule formulations. In this way contamination of the food chain could have 
been avoided. Furthermore, dose standardisation could have possibly led to better 
acceptance by regulatory bodies (Coghlan, 2005).  
 
Over the years plant oral vaccines have often shown good efficacy in terms of antibody 
production: it is feasible that VLPs based on pathogens that normally survive the gut will 
show greater efficacy (Herbst-Kralovetz et al., 2010). Surprisingly, even HBsAg, a VLP of 
a non-enteric pathogen has been proven to induce a strong antibody production in mice 
upon ingestion of transgenic potatoes. In contrast, ingested purified HBsAg did not 
produce any relevant immunogenicity. It is therefore clear that the potatoes' bio-
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encapsulation of the VLP improved the efficacy of the oral vaccine in mice (Kong et al., 
2001). However, not all attempts had been successful, whereby doses of oral vaccines that 
are 10 to 25 times higher than the injectable ones often failed to induce immunogenic 
responses as strong as those induced via injection (Rybicki, 2009). Reduced oral 
immunogenicity can be multi-factorial, but certainly one of the main concerns remains the 
stability in the gut. The plant bio-encapsulation as a mean of antigen protection in the GI 
was shown to be rather convincing for HBsAg expressed in potatoes (Kong et al., 2001), 
but it has not been systematically addressed for different plants and different antigens . 
Recently two articles from the Walmsley group started to address more rigorously this 
crucial point: in this research it was assessed whether the plant material could control the 
release of the antigen in the gut both in mice and sheep and whether this possible delayed 
release could affect the oral immunogenicity of the antigen. They concluded that the choice 
of the plant and of the part of the plant in which the antigen is expressed influences its 
release in the gut, with roots releasing the vaccine more slowly than the leaves in Nicotiana 
benthamiana. However, they used a model antigen stable in the GI tract: thus both studies 
confirmed that there was sustained release of the vaccine in gut, but they failed in 
demonstrating whether the plant material actually protected the antigen (Pelosi et al., 2012, 
2011a).  
 
Not only the plant and the plant tissue chosen, but also the plant cellular compartment of 
expression seems to have an important role in the way the antigen is delivered into the gut: 
chloroplast expression has shown good potential in terms of antigen protection in the gut 
(Kwon, 2013). Looking at this aspect from a drug delivery point of view, the question to be 
answered is whether the plant cell rigid compartments could work as a sort of natural 
gastro-protected formulation or as a simple sustained release system. So far only the latter 
option has been extensively shown. In conclusion, the possible advantages and drawbacks 
of plant oral vaccines can be summarised as follows. 
 
Possible advantages include: 
 
 Heat-stability (Daniell et al., 2009; Hefferon, 2010; Penney et al., 2011). 
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 Cheap vaccine production and minimal formulation processing required (Daniell et 
al., 2009; Hefferon, 2010; Penney et al., 2011).  
 
 Natural bio-encapsulation of the vaccine within the plant cell able to protect the 
vaccine from the harsh conditions of the GI tract (Huang, 2006; Lico, 2012; Paul, 
2010; Zhang, 2006). 
 
 When using agroinflitrated Nicotiana plants as vaccine bioreactors, the presence of 
lipopolysaccharide from Agrobacterium or of plant alkaloid could act as a vaccine 
adjuvant in the GALT (Pelosi et al., 2011a). 
Possible drawbacks involve: 
 
 Dose and formulations standardisation needed for regulatory body approval of 
animal and human vaccines (Huang, 2008; Tiwari, 2009). 
 
 Risk of oral tolerance (Pelosi et al., 2011b; Penney et al., 2011). 
 
 Reduced immunogenicity compared to injectable counterparts (Rybicki, 2009). 
 
 Need for substantial initial investments to support large scale production even for 
clinical trials vs the current conservative tendency of pharmaceutical companies to 
stick to current, well-established technologies (Rybicki, 2009; Tiwari et al., 2009). 
 
The great potential of this revolutionary technology has quickly developed in a few years 
with a series of ground-breaking proofs of concept. However, the impetuous excitement 
and the huge expectation generated by this “trendy” vaccination option probably 
constituted its main setback. There was the feeling that vaccination would have become 
shortly “as easy as eating a banana”. Edible vaccines seemed like the heaven of 
vaccination. Therefore, when a series of more practical issues came out unexpectedly, the 
initial excitement paradoxically risked to turn in a big delusion (Rybicki, 2009). Now a 
more careful and critical approach towards oral plant vaccines has been established and 
scientists are slowly trying to address and give answers to many unsorted questions. Drug 
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delivery could somehow help in understanding the key point of the whole oral plant 
vaccine fundament. In order to prove this technology superior to the existing ones, it has to 
be demonstrated that the plant material can be an effective controlled release aid and that it 
can allow cheap and minimal processing. The plant oral vaccine approach could turn into a 
pioneering branch of drug delivery. 
 
1.6 Plant-expressed Oral Hepatitis B Vaccine - Where Are We? 
Hepatitis B vaccine is one of the major health successes of the last decades. However, 
costs and cold-chain requirements have limited its use in the most poor and remote 
countries in the World (Hayden et al., 2012). Furthermore, circa 5 % of the patients do not 
respond to the vaccine and the multi-dose vaccination regimen often reduces compliance: 
in developing countries the rate of HBV chronic infection still ranges between 8 and 10% 
(Floreani et al., 2004; Makidon et al., 2008). Another problem with systemic immunisation 
is that it elicits very poor mucosal protection: considering that most pathogens usually 
invade the organism through mucosal tissues, protection at the site of entry of the pathogen 
is highly desirable. A safer, cheaper, heat-stable, patient friendly vaccination technology 
could allow the achievement of a more efficient immunisation programme worldwide 
(Lebre et al., 2011). Oral delivery is generally considered the most desired route of 
administration and it could be also exploited for Hepatitis B vaccine (HBV). HBsAg and 
HBcAg have been among the most studied plant-expressed vaccine candidates for oral 
delivery. 
 
When injected, plant-expressed HBsAg proved to be immunologically similar to the yeast 
derived HBsAg, which is marketed (Thanavala and Yang, 1995). However, the proof of 
concept that the plant-expression could favour the development of an oral Hepatitis B 
vaccine came out in 2001: in mice, gavage of raw potatoes containing transgenic expressed 
HBsAg resulted in higher anti-HBsAg antibodies production than yeast expressed HBsAg; 
transgenic potatoes induced anti-HBsAg antibodies exceeding what is considered the 
protective level. The use of an adjuvant proved to be necessary for the development of 
immunity (Kong et al., 2001). Interestingly, they showed also that parenteral priming with 
subimmunogenic doses followed by oral boosts enabled the development of strong 
immunogenicity. Thus, they suggested that the development of an oral Hepatitis B vaccine 
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could serve as a way to improve the efficacy of the current injectable vaccine whereby 
orally delivered HBsAg-expressing potatoes could be used to boost strong immunogenicity 
following priming with a parenteral dose. 
 
A human clinical trial was undertaken using HBsAg expressed in lettuce. Lettuce was 
administered orally in three volunteers, who were not previously immunised or infected by 
HBV. After oral immunisation with two doses, two of the volunteers developed anti-
HBsAg antibodies to a level superior to the established minimum level of protection in 
humans. However, the protection did not seem to last long (Kapusta et al., 1999). 
Subsequent clinical trials in humans have shown interesting results: previously vaccinated 
volunteers, ingesting three separate doses of raw potatoes expressing HBsAg, developed an 
increase in serum anti-HBsAg in 10 cases out of 17, with a maximum antibodies increase 
of 56 fold. The trial was carried out without using any adjuvant (Thanavala et al., 2005). 
The results obtained were encouraging and created the basis to believe that a Hepatitis B 
oral vaccine could be developed. In spite of those promising results, further improvements 
were required. Increasing the expression level in the plant tissue to be eaten and ensuring 
antigen stability in the gut have been proposed to be important future steps towards an 
efficient Hepatitis B oral vaccine (Thanavala and Lugade, 2010).  
 
HBcAg immunogenicity is already demonstrated for parenteral administration (Paragraph 
1.4.3). Furthermore, HBcAg has shown to be potentially effective in protecting against 
HBV when administered systemically by injection (Paragraph 1.4.3). However, its mucosal 
immunogenicity still needs to be established, in order to evaluate its potential as a nasal or 
oral vaccine, delivered on its own or in combination with HBsAg. Nasal delivery of 
HBcAg proved to stimulate strong specific serum IgG production (Lobaina et al., 2003) 
and hence it was successfully co-administered with HBsAg with the aim of developing a 
more potent vaccine formulation against HBV infection (Aguilar et al., 2004; Lobaina et 
al., 2005). Moreover HBcAg could be also used as an immunogenic carrier for foreign 
epitopes and hence used as a sort of adjuvant for heterologous candidate vaccines 
(Whitacre et al., 2009).  
 
In terms of oral delivery, bacterial-expressed HBcAg induced lower serum specific IgG 
when administered orally to mice (Lobaina et al., 2003). Plant-expressed HBcAg was also 
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used for oral immunogenity studies: five mice were primed with partially purified Hepatitis 
B capsids by oral gavage without any adjuvant. Two weeks after, an oral boost with the 
same dose was given. Four weeks after the boost, three mice out of five developed 
detectable specific serum anti-HBc IgG. In the following weeks, anti-HBc antibodies could 
be only detected in two mice out of five. Faecal IgA were detectable at week 16 only in 
one mouse (Huang, 2006). These data showed that partially purified plant-expressed 
HBcAg VLPs were only moderately immunogenic when given by oral gavage to mice. 
However in this study VLP was partially purified before administration: the authors 
speculate that higher immunogenic response could have been obtained by using raw plant 
material expressing HBcAg. These results taken together can raise interesting questions: 
 
 HBcAg shows a poor/moderate oral immunogenicity. Authors consider the gastric 
degradation of the VLP as the main barrier (Huang, 2006). However, this is not the 
only barrier as there could be some intestinal obstacles hindering the oral 
immunogenicity of an antigen, including lack of absorption and stimulation of 
tolerogenic pathways. Further investigation could elucidate the actual impediment 
to a strong oral immunogenicity of HBcAg. 
 
 As many protein vaccines, HBcAg might need protection from the GI instability, 
and plant bio-encapsulation could offer some sort of aid. However, it is not clear to 
which extent this natural protection could function and whether it could substitute a 
more sophisticated artificial pH-dependent formulation. 
 
In conclusion a needle-free vaccine against Hepatitis B could offer a safe, cheap and 
patient friendly option with oral delivery still being the most desirable. HBsAg has been 
extensively studied; alternatively HBcAg could be investigated for mucosal protection 
alone or co-administered with HBsAg for a more potent protection (Lobaina et al., 2005). 
Preliminary results showed reduced oral immunogenicity of HBcAg, when compared to 
the extremely strong immunogenicity of the same antigen administered via other routes of 
administration. The main problem might be the GI instability of the vaccine and further 
studies are essential to define whether the plant bio-encapsulation or some other sort of GI 
protection of HBcAg could promote better survival of the antigen in the gut. 
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1.7 Objectives of the Research 
VLPs are a new generation of recombinant vaccines, which mimic the pathogen structure. 
It has been proposed that such vaccines could be as effective as mucosal oral vaccines, as 
their compact organisation could be strong enough to withstand the harsh-gastrointestinal 
environment (Herbst-Kralovetz, 2010; Huang, 2005). Aside from this intrinsic robustness, 
the expression of VLPs in plant could enable exploitation of the natural bio-encapsulation 
as a sort of adjuvant: if the unpurified plant material is to be delivered orally, the VLP 
internalisation within the plant cell comportments could allow protection of the antigen 
from the extreme gastric pH and from the gastro-intestinal digestive enzymes (Mason et 
al., 2002). Moreover, it is believed that the VLP particulate structure could favour efficient 
absorption in the small intestine by the antigen-sampling epithelial M cells within the PPs 
(Gonzalez et al., 2009). Thus, the expression of VLPs in plant could be an effective way to 
deliver vaccines orally. In this study, HBcAg, as a candidate vaccine, and Nicotiana 
benthamiana, as the host plant, were used to evaluate the potential applicability of this oral 
plant vaccine approach. A previous study on plant-expressed HBcAg elucidated that oral 
administration of plant extracts containing HBcAg elicited only poor immunogenicity in 
mice and it was speculated that this could have been due to the gastric instability of the 
antigen. Hence, the authors suggested that natural plant-bioencapsulation of the antigen 
expressed in plant, administered as raw materials or alternatively the in-vitro 
bioencapsulation could have allowed better immune response upon oral administration 
(Huang, 2006). 
 
In this context, the main objective of this research was that of investigating if and to what 
extent HBcAg VLP could withstand and overcome some of the gastro-intestinal barriers 
and to evaluate whether the compartmentalisation of the antigen in the plant material in 
which it is expressed could offer some aid to the oral delivery of HBcAg. The final 
objective was that of producing an oral formulation of HBcAg, exploiting its expression in 
plant.  
 
Initially, a robust protocol for the routine production, extraction, purification and 
characterisation of plant-expressed HBcAg was established and is described in Chapter 2. 
Then the stability of the plant-expressed antigen in numerous bio-relevant media 
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simulating the GI environment was evaluated. This study was divided into two parts: the 
stability of purified HBcAg in simulated and natural GI fluids was evaluated in Chapter 3. 
Then once the intrinsic susceptibility of the antigen was defined, the aim of Chapter 4 was 
to test whether the raw or dried plant material expressing the VLP could offer protection to 
the antigen against simulated GI fluids. Moreover, the final purpose of this Chapter was to 
produce a dosage form that could enable effective oral delivery of stable antigen to the gut, 
exploiting the expression in plant. In Chapter 5, different drying approaches of the VLPs 
into potentially stable solid dosage forms were attempted, with the final aim of producing 
an oral dosage form, containing purified HBcAg. Finally, as a separate objective, in 
Chapter 6 the permeability of purified HBcAg in the GALT was evaluated in an in vitro 
human cell culture model and in vivo in mice, using a ligated intestinal loop model. The 
overall structure of this thesis is summarised in Figure 1.7. 
 
 
Figure 1.7. Structure of the thesis. 
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2 Production, Purification and Characterisation of Plant-expressed 
HBcAg VLP 
2.1 Introduction 
Hepatitis B core antigen (HBcAg) virus-like particle (VLP) was the main model vaccine 
used in this work. It was expressed in plants, extracted and then purified using a sucrose 
gradient technique. Several characterisation and quantification techniques were used 
including sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
Western blot, dot blot, transmission electron microscopy (TEM), native agarose gel 
electrophoresis, and direct and sandwich enzyme-linked immunosorbent assay (ELISA). 
 
This Chapter will introduce the general materials and techniques used to extract and purify 
HBcAg (i.e. the major raw material in this study), and will show the results of the 
characterisation studies of HBcAg VLPs after harvesting.  
 
Subsequent chapters will include descriptions of the materials and methods specifically 
used at those points (e.g. the formulation preparation techniques will be discussed fully in 
Chapters 3, 4 and 5). 
 
2.2 Materials 
2.2.1 Molecular Biology Media, Buffers and Solutions  
General media, buffers and solution used in this study for bacterial growth, plant agro-
infiltration and protein analysis are catalogued in Table 2.1. 
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Table 2.1 Media, buffers and solutions used for molecular biology experiments. 
Name Recipe 
Luria Bertani (LB) 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium chloride 
(NaCl) adjusted to pH 7.0 
MMA 10 mM 2-[N-morpholino]ethanesulfonic acid (MES) buffer, 
pH 5.6 : 10 mM MgCl2,100 µM acetosyringone 
Extraction buffer 1  50 mM Tris-HCl, pH 7.25 : 150 mM NaCl, 2 mM 
ethylenediaminetetraacetic acid(EDTA), 0.1% (w/v) Triton 
X-100, 1 mM dithiothreitol (DTT) (added fresh), Complete® 
tablet (added fresh) 
Extraction buffer 2 
 
10 mM Tris-HCl, pH 8.4: 120 mM NaCl, 1 mM EDTA, 
0.75% (w/v) sodium deoxycholate, 1 mM dithiothreitol 
(DTT) (added fresh), complete tablet (added fresh) 
Phosphate-buffered saline (PBS) 140 mM NaCl, 15mM monopotassium phosphate (KH2PO4), 
80 mM disodium phosphate (Na2HPO4), 27 mM potassium 
chloride (KCl) 
Dot blot block buffer 5% (w/v) dried milk, 0.1% (v/v) Tween-20, in PBS 
Dot blot washing buffer 0.1% (v/v) Tween-20, in PBS 
Western blot block buffer 1% bovine serum albumin (BSA) (w/v), 1% casein (w/v), 
0.05% (v/v) Tween-20 in PBS 
Western blot transfer buffer 10.8 g/L Tris-HCl, 14.4g/L glycine, 20% (v/v) methanol  
Western blot washing buffer 0.05% (v/v) Tween-20 in PBS 
Tris/Borate/EDTA (TBE) 3.03 g/L Tris-HCl, 5.5g/L boric acid, 2 mM EDTA 
Enzyme-Linked Immunosorbent 
Assay (ELISA) block buffer 
5% (w/v) dried milk, 0.05% (v/v) Tween-20 in PBS 
ELISA washing buffer 0.05% (v/v) Tween-20 in PBS 
 
2.2.2 Antibodies and Antigens  
Antibodies and antigens used for dot blot, Western blot and ELISA are listed in Table 2.2. 
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Table 2.2 Antibodies and antigens used for immunodetection assays. 
Antibody Antigen  Supplier Application 
Monoclonal mouse 
HBcAg antibody-Clone: 
10E11 
HBcAg  Abcam Dot blot: 1:5000 in Dot blot block buffer 
Western blot: 1:5000 in Western blot block 
buffer 
Polyclonal rabbit HBcAg 
antibody 
HBcAg AbD Serotec Dot blot: 1:5000 in Dot blot block buffer 
Western blot: 1:5000 in Western blot block 
buffer 
ELISA direct:1:2000 in 1% (w/v) dried 
milk, 0.05% (v/v) Tween-20 in PBS 
Anti-mouse HRP 
conjugated  
Mouse 
IgG 
Invitrogen or 
Amersham 
Bioscience 
Dot blot: 1:5000 in Dot blot block buffer 
Western blot: 1:5000 in Western blot block 
buffer 
Anti-rabbit HRP 
conjugated 
Rabbit 
IgG 
Promega Dot blot: 1:5000 in Dot blot block buffer 
Western blot: 1:5000 in Western blot block 
buffer 
ELISA direct: 1:4000 in 1% (w/v) dried 
milk, 0.05% (v/v) Tween-20 in PBS  
 HBcAg 
standard  
AbD Serotec ELISA control and standard 
Monoclonal mouse 
HBcAg antibody- Clone: 
H6F5 (7E6) 
HBcAg AbD Serotec ELISA sandwich:1:1000 in 1% (w/v) in 
PBS 
Monoclonal mouse 
HBcAg Antibody HRP 
conjugated- Clone: 
H3A4 (4H5) 
HBcAg 
 
AbD Serotec ELISA sandwich:1:1000 in 1% (w/v) dried 
milk, 0.05% (v/v) Tween-20 in PBS 
 
 
2.2.3 Plasmids  
pEAQ-HT-HBcAgΔ176, pEAQ-HT-CoHe7e-eGFP and pEAQ-HT-empty binary plasmid 
were used (Thuenemann, 2010). Plasmid Easy and Quick (pEAQ) is the denomination 
given to the vector. Hypertranslatable (-HT) is the name given to the expression system. 
HBcAgΔ176 is the construct codifying for the first 176 amino acids from the HBcAg N-
terminus. CoHe7e-eGFP is the construct codifying for heterotandem core-GFP. 
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2.2.4 Other Materials Used in the Molecular Biology Studies  
Complete® Protease inhibitor tablets were purchased from Roche (UK), Miracloth from 
Merck (UK) and dialysis tubes from Spectrum Laboratories (Europe) or from Sigma (UK). 
Amicon 5 and 15 mL ultrafiltration tubes were purchased from Millipore (UK). SDS-
NuPAGE gels bis-tris Mini, NuPAGE MOPS buffer, NuPAGE LDS Sample Buffer and 
SeeBlue Plus 2 marker were purchased from Invitrogen (UK). β-Mercaptoethanol, Brillant 
Blue R Concentrate, 3,3',5,5'-tetramethylbenzidine dihydrochloride (TMB) substrate, 
Rifampicin and Kanamycin  were purchased from Sigma (UK). InstantBlue stain was 
bought from Expedon (UK), SuperSignal West Dura Chemiluminescent Substrate from 
Thermo Scientific (UK) and polyvinylidene fluoride (PVDF) membranes and Hyperfilm 
from Amersham (UK). 
 
2.3 Methods 
This Paragraph will introduce the molecular biology methods used in this Chapter.  
 
2.3.1 Plant Expression of HBcAg and Protein Extraction 
The production process of HBcAg involves three successive steps of agroinfiltration, 
harvesting and protein extraction. Some of the methods described derive from the general 
techniques used in Prof. Lomonossoff's research group [for reference (Sainsbury and 
Lomonossoff, 2008; Sainsbury et al., 2009)] and they were tailored to this particular 
research.  
 
2.3.1.1 Agroinfilitration 
Nicotiana benthamiana plants were grown in a glasshouse at a fixed temperature of 25 ºC. 
During winter time (October to April), 16 hours of daylight were ensured by artificial 
lighting. Plants were watered every afternoon. Valmaine romaine lettuce was grown under 
similar conditions. Nicotiana benthamiana plants were used 3 to 4 weeks after pricking 
out, preferentially before flowering, while Valmaine romaine lettuce was used 4 weeks 
after pricking out. 
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pEAQ-HT-HBcAgΔ176, pEAQ-HT-CoHe7e-eGFP and pEAQ-HT-empty binary plasmid 
were kindly donated by Dr. Eva Thuenemann in the form of glycerol stocks. Cultures were 
grown in Luria-Bertani medium, supplemented with 50 µg/mL Rifampicin and 50 µg/mL 
Kanamycin, and kept in a shaking incubator at 28 ºC for 48 hours. After subculturing and 
further 24 hours incubation, the bacteria were pelleted by centrifugation at 2000 g for 20 
minutes. Pellets were subsequently drained and resuspended in freshly made MMA 
solutions. The suspension was left to stabilize at room temperature for 1 to 4 hours. The 
concentration of the bacterial suspension in MMA was then measured by Optical Density 
at a wavelength of 600 nm (OD600), which was approximately 4 to 5. The culture was 
then appropriately diluted in fresh MMA to a final OD600 of 0.4 to 0.6. This 
agrobacterium suspension was subsequently pressure-inﬁltrated into Nicotiana 
benthamiana leaves. Syringe infiltration was used to infiltrate small batches (up to 15 
plants), whereas vacuum infiltration was chosen for larger batches. Four-week old 
Valmaine romaine lettuce was vacuum-infiltrated using the same agrobacterium 
suspension used for the infiltration of Nicotiana benthamiana. 
 
For reasons of simplicity HBcAgΔ176 will be referred to as HBcAg, hereafter. 
 
2.3.1.2 Harvesting  
Infiltrated leaves were harvested 6 to 7 days post-infiltration. The weight of the batch was 
recorded and the leaves were either extracted immediately or stored at – 80 ºC. In cases of 
small scale experiments, when only a few leaves were infiltrated, leaf disks were prepared 
using a cork borer of 11 mm diameter and the rest of the leaves were discarded. Valmaine 
romaine lettuce leaves, infiltrated with the HBcAg, were harvested at 3, 5, 7 and 9 days 
post-infiltration in order to establish the time of maximum yield. 
 
2.3.1.3 Protein Extraction 
Extraction of the protein from the leaves was performed by homogenisation in three 
volumes of extraction buffer 1 or extraction buffer 2 (See Table 2.1). The recipes for both 
extraction buffers were developed by Dr. Eva Thuenemann (Thuenemann, 2010). For 
batches of Nicotiana benthamiana leaves expressing HBcAg, protein extraction was 
Chapter 2 
 
 
53 
 
performed throughout this study with either extraction buffer 1 or extraction buffer 2. 
Batches of Valmaine romaine leaves expressing HBcAg or Nicotiana benthamiana 
expressing HBcAg tandem-GFP were extracted using extraction buffer 2 only.  
 
In the case of small batches, ceramic beads were added together with the leaf disks and 
three volumes of an extraction buffer in screw-cap tubes and homogenised using a 
FastPrep machine (MP Biomedicals, UK) at a speed setting of 5.0 for 40 seconds. In the 
case of larger scale batches, the leaves and the three volumes of the extraction buffer were 
blended in a Waring blender (UK) for three consecutive times, each for approximately 15 
seconds. The whole extract was then cloth-filtered using a double layer Miracloth and 
subsequently clarified by centrifugation in order to remove most plant cell debris. Crude 
extracts containing HBcAg or CoHe7e-eGFP were centrifuged at 12,000 x g and 9,000 x g, 
respectively, for 15 minutes. In order to control the expressed protein solubility, the pellet 
obtained after the centrifugation was also re-suspended in LDS β-mercaptoethanol, boiled 
and used for SDS-PAGE analysis. 
 
The clarified supernatant was used as a crude extract for further purification through 
sucrose density gradient. Protein extraction was always performed at 4 ºC and the samples 
were kept on ice, before further purification. Figure 2.1 summarises the plant expression 
and protein extraction process. 
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Figure 2.1. HBcAg virus-like particles (VLP) plant expression and protein extraction.  
Agrobacterium containing a genetically modified plasmid was grown in LB culture for 2 
days and subcultured for a further day. Following infiltration either by a syringe for small 
batches or vacuum for large ones, the plants were incubated in the green house for 6-7 
days. After harvesting, the leaves were immediately homogenised in an extraction buffer. 
The crude extract was then clarified by cloth filtration and subsequent centrifugation. 
Orange particles symbolise VLPs. 
 
2.3.2 HBcAg Purification 
2.3.2.1 Sucrose Density Gradient 
Sucrose density gradients have been used as a process for HBcAg purification (Birnbaum 
and Nassal, 1990). Using 10 mM Tris-HCl pH 8.4 containing 120 mM NaCl as a solvent, a 
60% (w/v) sucrose solution was prepared. Subsequently, 50%, 40%, 30%, 20%, 10% (w/v) 
solutions were obtained by dilution of the 60% (w/v) stock solution in increasing volumes 
of 10 mM Tris-HCl pH 8.4 containing 120 mM NaCl. Density gradients were created in 12 
or 36 mL ultra-centrifugation tubes: initially the crude extract was forced to the bottom of 
the tube through a needle and the sucrose solutions of increasing density were then forced 
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to the bottom of the tube. In this manner, the denser layer, pushed to the bottom, will lay 
below the less dense layers, creating a gradient whose density increases from the top to the 
bottom along the tube. The gradients were then centrifuged in a swing-out rotor for 2 hours 
and 30 minutes: a SW41Ti rotor was used at 40,000 rpm for the 12 mL tubes, whereas a 
Surespin 630 rotor was used at 30,000 rpm for the 36 mL tubes. After centrifugation, the 
tubes were pierced at the bottom, so that the sucrose gradient fractions could be collected, 
starting with those of highest densities. Generally, seven fractions were collected with the 
volume of each fraction being approximately correspondent to the volume of each sucrose 
solution layer. Figure 2.2 summarises the steps of the density gradient purification. In some 
specific cases the sucrose gradient procedure was simplified by using only 20%, 30, 40% 
and 50% (w/v) sucrose solutions. 
 
 
Figure 2.2. A schematic representation of sucrose gradient purification. 
Clarified crude extract and sucrose solutions of increasing density were underlained from 
the bottom using a syringe. Then tubes were spun for 2 hours and 30 minutes in an 
ultracentrifuge, allowing VLPs separation from crude extract. Sucrose fractions were 
collected by piercing the bottom of the tube. Percentages represent the concentration (w/v) 
of the sucrose solutions, while orange particles symbolise VLPs. 
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2.3.2.2 Dialysis  
Dialysis was used for the removal of the sucrose from the density gradient fractions and as 
a method for buffer exchange and purification. Dialysis membranes were filled with the 
different sucrose gradient fractions and dialysed against 10 mM Tris-HCl, 120 mM NaCl, 
pH 8.4 or against PBS. Small batches were dialysed using Spectrum Labs tubes with 
molecular cut-off of 100 kDa, while larger batches were dialysed using Sigma membranes 
with a molecular cut-off of 12 kDa. The different cut-off values were used because a 
molecular cut-off of 100 kDa was commercially available for small dialysis tube, but not 
for the larger dialysis membranes. However, in both cases the membrane cut-off would 
have allowed efficient buffer exchange and sucrose removal.  
 
2.3.2.3 Ultrafiltration 
Ultrafiltration was performed to concentrate the purified and dialysed HBcAg solutions: 
diluted HBcAg preparations were added to a 100 kDa molecular weight cut-off membrane, 
specifically built in ultrafiltration tubes. Centrifugation enabled small molecules to pass 
through the filter, while macromolecules larger than 100 kDa (such as HBcAg VLP) were 
concentrated. HBcAg samples were spun at 4,000 x g until the preparation was 
concentrated to the required volume. 
 
2.3.3 Protein Qualitative Analysis 
Protein qualitative analysis was carried out on purified and crude extract samples. The 
techniques used were sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), Western western blot and dot blot. 
 
2.3.3.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) - 
Coomassie Blue Staining 
SDS-PAGE-Coomassie Blue Staining was used to assess the protein content of different 
preparations. This electrophoretic technique allows the fractionating and distinguishing of 
deliberately denatured proteins on the basis of their molecular weight. SDS-PAGE is a 
simple protein analysis method. However, it has a high detection limit (i.e. low sensitivity) 
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and it does not furnish information about the chemical identity of the proteins bands 
visualised, merely the molecular weight range (Sambrook and Russel, 2001a). 
 
Ten, twelve and fifteen well gels were used throughout this study. Proteins were reduced 
and denatured by adding one volume of 3X LDS β-mercaptoethanol to two volumes of the 
samples. Samples were then boiled at 100 ºC for 5 minutes. NuPAGE gels were run in 3-
(N-morpholino)propanesulfonic acid (MOPS) buffer following the manufacturer’s 
instructions. After electrophoresis, the protein bands were visualised by addition of 
Coomassie blue-protein stain for at least 1 hour. Then gels were de-stained in water for at 
least 2 hours before imaging. In each gel one well was always allocated to the protein 
marker. 
 
2.3.3.2 Dot Blot 
Dot blot allows identification of un-denatured proteins by interaction with specific 
antibodies. The sample is bound directly to the nitrocellulose (or PDVF) membrane for 
immunochemical recognition (Harlow and Lane, 1988). Compared to SDS-PAGE gel, it 
allows recognition of specific sequences of interest; however, it does not give information 
about the molecular weight of the protein. 
 
Three µL of each sample were spotted onto PDVF membranes, using 10 µL tips. 
Membranes were left to dry for 30 minutes and then blocked with the blocking buffer at 4 
ºC overnight. On the following day, membranes were washed once with the washing buffer 
in a shaker at room temperature for 15 minutes, before being incubated with the primary 
antibody for 2 hours. After three 15 minutes washes with the washing buffer at room 
temperature, the membranes were then probed with the secondary antibody for a further 2 
hours. Following three subsequent washes with the washing buffer, chemiluminescent 
HRP substrate was used for the detection of the secondary antibody. The 
chemiluminescence was detected with Hyperfilm. 
 
The blocking and washing buffers used are listed in Table 2.1, while the antibodies are 
listed in Table 2.2. 
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2.3.3.3 Western Blot 
Western blot is a technique that allows the identification of an electrophoretically separated 
denatured protein band by its interaction with specific antibodies. Therefore, it combines 
the convenience of both SDS-PAGE and dot blot: Western blot supports immunochemical 
recognition of a specific antigen protein and also gives information about its molecular 
weight. Furthermore, Western blot offers higher sensitivity (i.e. lower detection limit) than 
SDS-PAGE Coomassie stained gels (Sambrook and Russel, 2001b). 
 
SDS-PAGE gels were run as in 2.3.3.1. However, gels were not stained and were 
transferred to PVDF membranes immediately after the electrophoresis: the cassettes were 
assembled with the gel and the membrane layered between a sandwich of filter papers and 
sponges. Each layer was pre-wetted in transfer buffer. The electroblotting was performed 
at 100 V for 1 hour at 4 ºC. The membranes were blocked with the blocking buffer at 4 ºC 
overnight and were then washed once with the washing buffer in a shaker at room 
temperature for 15 minutes, before being incubated with the primary antibody for 2 hours. 
After three 15 minutes washes with the washing buffer at room temperature, the 
membranes were probed with the secondary antibody for a further 2 hours. Following three 
subsequent washes with the washing buffer, chemiluminescent HRP substrate was used for 
the detection of the secondary antibody bound to the membrane. The chemiluminescence 
was detected with Hyperfilm. 
 
The blocking and washing buffers used are listed in Table 2.1, while the antibodies are 
listed in Table 2.2. 
 
2.3.3.4 Fluorescence Microscopy 
Fluorescence microscopy was used in order to effectively visualise the fluorescence of 
CoHe7e-eGFP. A 3 µL drop of circa 50 µg/mL purified CoHe7e-eGFP was dotted on a 
microscopy slide and directly observed on a Zeiss Axioplan microscope. 
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2.3.4 HBcAg Physical Characterisation  
HBcAg assembles into virus like particles (VLPs). The physical stability of VLPs was 
assessed by transmission electron microscopy (TEM), native agarose gel electrophoresis 
and sucrose density gradient followed by qualitative or quantitative techniques.  
 
2.3.4.1 Transmission Electron Microscopy (TEM) 
Samples diluted to an approximate concentration of 0.1 mg/mL were adsorbed onto 
hexagonal, plastic and carbon-coated copper grids, which were then washed three times by 
dripping of three consecutive water droplets. Then grids were negatively stained with 2% 
w/v uranyl acetate for 20 seconds and the stain was removed using filter paper. VLPs were 
imaged using a FEI Tecnal G2 20 Twin TEM with a build-in digital camera at the bottom. 
 
TEM imaging was kindly carried out by Mrs. Elaine Barclay or by Dr. Alaa Aljabali in my 
presence. 
 
2.3.4.2 Native Agarose Gel Electrophoresis 
Native agarose gels are protein gels that run in non-denaturing conditions; they allow the 
detection of intact HBcAg VLPs (Birnbaum and Nassal, 1990) and they were therefore 
used to determine particle integrity.  
 
Agarose gels (1.2% (w/v)) were usually run in duplicate at 60 V for 90 minutes. One gel 
was stained in a bath containing a 0.5 µg/mL solution of ethidium bromide for 30 minutes 
and then visualised under UV light (wavelength = 302 nm). The other gel was stained with 
Brillant Blue R Concentrate (Coomassie stain) for 30 minutes. The gel was then de-stained 
for 1 to 2 days with 20% methanol, 10% acetic acid solution. Foam bags were added in the 
floating solution in order to absorb the excess of the stain.  
 
Ethidium bromide binds to nucleic acid, while Coomassie stains proteins. Therefore gels 
stained with ethidium bromide were used for the detection of encapsidated nucleic acid, 
while Coomassie stained gels were used to detect protein. Overlapping of the two stains is 
an indication of the presence of nucleic acid encapsidated in a protein core. 
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2.3.4.3 Sucrose Density Gradient 
Sucrose density gradients were used as a purification method (Paragraph 2.3.2.1). 
However, sucrose density gradients coupled with other detection techniques were also used 
for the evaluation of the physical integrity of HBcAg VLPs. Intact particles were shown to 
sediment in the 30% and 40% sucrose gradient bands (Birnbaum and Nassal, 1990), 
therefore, analysis of these sucrose fractions using qualitative or quantitative techniques 
can reveal the stability of the VLPs. 
 
In this Chapter, density gradients were followed by SDS-PAGE Coomassie stained, dot 
blot, Western blot or ELISA. 
 
2.3.5 Protein Quantitative Analysis 
One of the most commonly used techniques for the quantification of antigenic proteins is 
the enzyme-linked immunosorbent assay (ELISA). This method is based on the 
exploitation of enzyme-conjugated antibodies for the quantification of given antigens. 
Direct and sandwich ELISA methods have been carried out throughout this work. Direct 
ELISAs are usually used to quantify purified or semi-purified samples containing the 
antigen. Instead there is generally no requirement for antigen purity in sandwich ELISAs 
and this can be three to five times more sensitive than direct ELISAs (Khan, 2009). 
 
2.3.5.1 Direct Enzyme-Linked Immunosorbent Assay (ELISA) 
Direct ELISA was carried out following the protocol developed by Thuenemann (2010). 
 
ELISA plates of 96-wells were coated in replicates with 50 µL of different sample 
dilutions in PBS. Two-fold dilution series of known concentrations of HBcAg were used as 
standard references. Plates were incubated at 4 ºC overnight. Preceded by three washes, the 
remaining protein-binding sites were blocked with the blocking buffer at 37 °C for 1 hour 
and 30 minutes. Following three subsequent washes with the washing buffer, each well 
was incubated with 50 µL of a dilution of primary rabbit polyclonal antibody at 37 °C for 1 
hour and 30 minutes. After further three washes with the washing buffer, 50 µL dilutions 
of rabbit secondary antibody were added to each well and incubated at 37 °C for 1 hour 
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and 30 minutes. Following three subsequent washes with the washing buffer, 3,3',5,5'- 
tetramethylbenzidine dihydrochloride (TMB) substrate solutions, prepared as per the 
manufacturer's instructions, were used to elicit a colour reaction that was stopped with 1 M 
sulphuric acid upon visualised saturation of the standard curve (approximately 2 minutes 
and 30 seconds). Absorbance of the whole plate was then determined at 450 nm using a 
multi-well plate reader. HBcAg was quantified by reference to the emission values of the 
standard dilutions: the negative control emission values were subtracted from all the 
samples and a linear regression of the standard curve was calculated by plotting the 
resulting values of the known concentrations of the standard dilutions. Using the equation 
of the linear regression, the dilutions of the original samples were back-calculated.  
 
The blocking and washing buffers used are listed in Table 2.1, while the antibodies and the 
HBcAg standard are listed in Table 2.2.  
 
2.3.5.2 Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
A specific sandwich ELISA has been developed for this study. After several trials, the 
following protocol was established. 
 
ELISA plates of 96-wells were coated with 50 µL of mouse monoclonal antibody [Clone: 
H6F5(7E6)] dilutions. Plates were incubated at 4 °C overnight. Preceded by three washes 
with the washing buffer, the remaining protein-binding sites were blocked with the 
blocking buffer at 37 °C for 2 hours. Following three subsequent washes with the washing 
buffer, each well was coated in replicates with 50 µL of different sample dilutions in 1% 
dried milk and 0.05% (v/v) Tween-20 in PBS. Two-fold dilution series of known 
concentrations of HBcAg were used as standard references. The plates were then incubated 
at 37 °C for 2 hours. After further three washes with the washing buffer, 50 µL dilutions of 
mouse monoclonal antibody [Clone: H3A4(4H5)] were added to each well and incubated 
at 37 °C for 2 hours. Following three subsequent washes with the washing buffer, TMB 
substrate solutions, prepared as per the manufacturer's instructions, were used to elicit a 
colour reaction that was stopped with 1 M sulphuric acid upon visualised saturation of the 
standard curve (approximately 12 minutes). Absorbance of the whole plate was then 
determined at 450 nm using a multi-well plate reader. HBcAg was quantified by reference 
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to the emission values of the standard dilutions: the negative control emission values were 
subtracted from all the samples and a linear regression of the standard curve was calculated 
by plotting the resulting values of the known concentrations of the standard dilutions. 
Using the equation of the linear regression, the dilutions of the original samples were back-
calculated.  
 
2.4 Results and Discussion 
Over the last years, Prof. Lomonossoff’s research group has been working on the 
expression of recombinant proteins in plant, using a Cowpea Mosaic Virus (CPMV)-based 
gene expression system (Sainsbury et al., 2010). Extremely high yields of foreign protein 
expression were demonstrated by the CPMV-HT system, which is based on the use of a 
deleted version of CPMV RNA-2. Among other proteins, HBcAg was also expressed using 
the CPMV-HT system up to yields of approximately 1 g/kg fresh weight (FW) tissue 
(Sainsbury and Lomonossoff, 2008). Such high levels of expression have opened the 
possibility of using this plant-based expression system for medical and pharmaceutical 
research purposes.  
 
2.4.1 Expression of HBcAg and CoHe7e-eGFP in Plant 
As described in Paragraph 2.3.1, pEAQ-HT-HBcAgΔ176, pEAQ-HT-CoHe7e-eGFP and 
pEAQ-HT-empty binary constructs were infiltrated in Nicotiana benthamiana and the 
infiltrated leaves were harvested after 6 or 7 days. The leaf material was then weighed and 
blended in three volumes of the extraction buffer 2. Following cloth filtration, the crude 
extract was clarified by centrifugation and the resulting supernatant was separated from the 
precipitated pellet (insoluble fraction). The pellet was re-suspended in LDS β-
mercaptoethanol, boiled and clarified again. Both the supernatant and the insoluble 
fractions were examined by SDS-PAGE, as shown in Figure 2.3. Identical SDS-PAGE gels 
were either Coomassie stained (Figure 2.3 A) or used for anti-HBcAg Western blot 
detection (Figure 2.3 B).  
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Figure 2.3. HBcAg and CoHe7e-eGFP identification in Nicotiana benthamiana protein 
extracts.  
SDS-PAGE analysis of supernatant and insoluble fractions of crude extracts of leaves 
infiltrated with different constructs: (A) Coomassie stained SDS-PAGE; (B) Western blot 
(mouse antibody). Both gels were run identically: crude extracts of leaves infiltrated with 
pEAQ-HT-empty (lane 1); pEAQ-HT-HBcAgΔ176 (lane 2); pEAQ-HT-CoHe7e-eGFP 
(lane 3); insoluble fractions of leaves infiltrated with the aforementioned constructs (lanes 
4, 5 and 6), respectively. Arrows indicate the location of the expected bands for HBcAg 
(red) and for CoHe7e-eGFP (green). 
 
Coomassie stained gel (Figure 2.3 A) illustrates the protein bands contained in the clarified 
crude extracts and in the insoluble fractions of plant material infiltrated with different 
constructs: crude extracts of leaves infiltrated with pEAQ-HT-empty (control), pEAQ-HT-
HBcAgΔ176 and pEAQ-HT-CoHe7e-eGFP are separated in lanes 1, 2 and 3, respectively; 
insoluble fractions of the plant material infiltrated with the aforementioned constructs are 
separated in lanes 4, 5 and 6, respectively. Comparing the protein bands of crude extracts 
of leaves infiltrated with HBcAg-based construct (lane 2) to those of the control (lane 1), it 
could be noted that evident bands corresponding to the HBcAg-based protein were present 
in lane 2, but missing in the control. This comparison offers good evidence for the 
expression of the recombinant protein in plant material. However, various plant protein 
bands, possibly having a similar size to HBcAgΔ176 and CoHe7e-eGFP, could be seen in 
the control. It was therefore not possible to prove the expression of the foreign proteins 
solely by simple observation of this gel.  
 
Therefore, anti-HBcAg Western blot of an identical gel (Figure 2.3 B) was examined in 
parallel. As expected, crude extracts of leaves infiltrated with the control pEAQ-HT-empty 
vector did not show any anti-HBcAg reactivity (lane 1). Instead, HBcAg was detected in 
the crude extract of leaves infiltrated with pEAQ-HT-HBcAgΔ176 (lane 2, as indicated by 
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red arrows), as well as in the crude extract of those infiltrated with pEAQ-HT-CoHe7e-
eGFP (lane 3, as indicated by green arrows). HBcAgΔ176 was detected at circa 20 kDa 
protein band, while CoHe7e-eGFP showed a much higher anti-HBcAg band at circa 68 
kDa. In conclusion, the use of Coomassie stained SDS-PAGE along with the Western blot 
confirmed the presence of the HBcAg and CoHe7e-eGFP in the protein extract of the 
infiltrated leaves. 
 
However, insoluble fractions of crude extracts of leaves infiltrated with pEAQ-HT-
HBcAgΔ176 (lane 5) and pEAQ-HT-CoHe7e-eGFP (lane 6), showed that some of the 
HBcAg-based protein remained trapped in the solid pellet that formed upon centrifugation. 
In the case of HBcAgΔ176, the intensity of the anti-HBcAg signal was however clearly 
stronger in the supernatant (lane 2), rather than in the insoluble fraction (lane 5) of the 
crude extract. These findings can be related to the extraction buffer in use. 
 
When expressing a recombinant protein in plant, the buffer chosen for the homogenisation 
of the leaf material must be able to efficiently extract this protein into the extract solution. 
In contrast, incomplete extraction would result in most of the recombinant protein getting 
trapped in the insoluble fraction, which is pelleted upon centrifugation. A recombinant 
protein “stuck” in the insoluble fraction is virtually un-retrievable and it is not therefore 
effectively viable for further processing. Thus the choice of the extraction buffer is 
obviously crucial. Under the conditions of this experiment, HBcAgΔ176 could be highly 
“solubilised” and only a minor fraction remained in the insoluble pellet. Instead, the 
amount of HBcAg-based protein in the insoluble fraction of plant material infiltrated with 
CoHe7e-eGFP was almost as high as the amount of the same protein “solubilised” in the 
extraction buffer. The efficiency of this extraction buffer, developed by Dr. Eva 
Thuenemann, seemed good enough to allow the use of this extraction protocol as a 
standard for systematic plant-production of HBcAg-based proteins used in the course of 
this research.  
 
2.4.2 Purification and Characterisation of Plant-expressed HBcAg VLPs 
HBcAg is a circa 20 kDa immunogenic protein, whose monomers self-assemble into a 
virus-like particle (Birnbaum and Nassal, 1990). The purification of VLPs from the crude 
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extract was carried out by sucrose density gradient, exploiting the properties of HBcAg 
VLP structure. HBcAg tertiary structures arrange into monomers, the monomers assemble 
into dimers and the dimers form a VLP, which constitutes the quaternary structure 
(Chapter 1). Upon ultracentrifugation, these VLPs are expected to sediment in the density 
fractions of 30, 40, and 50% (w/v) sucrose (Birnbaum and Nassal, 1990; Broos et al., 2007; 
Huang et al., 2006). Most plant proteins, as well as disassembled HBcAg, are expected to 
remain in the supernatant, whereas aggregated particles or other agglomerates of 
monomers tend to migrate to the bottom of the sucrose gradient. Therefore this technique 
was used as a primary method for the purification of VLPs from the crude extracts. 
Furthermore, the knowledge that morphologically intact cores can be specifically separated 
by density gradient centrifugation was also used throughout this study as a systematic 
quality control method to assess the yield, purity, morphological integrity and antigenicity 
of the VLP cores. For the fraction analysis, the sucrose gradient centrifugation was coupled 
with different detection methods, such as Coomassie stained SDS-PAGE gel, dot blot, 
Western blot or native agarose gel electrophoresis. Alongside with the qualitative 
characterisation methods, two different quantification methods for HBcAg were assessed.  
 
2.4.2.1 HBcAg Assembly in Plant Crude Extracts - A Qualitative Approach 
Figure 2.4 illustrates the distribution of HBcAg VLPs, contained in the plant crude extract, 
along the density fractions of a 10 to 60% discontinuous sucrose gradient upon 
ultracentrifugation. After ultracentrifugation, seven fractions, each approximately 
corresponding to the density layers of sucrose and to the supernatant, were collected from 
the bottom side of the tube (Figure 2.4 A) and analysed by SDS-PAGE. Three identical 
gels were run in parallel using the following set up (Figure 2.4 B, C and D): lane 1 
corresponds to the original crude extract; lanes 2 to 8 contains density fractions of the 
sucrose gradient starting from the supernatant (lane 2) to the 60% sucrose fraction (lane 8); 
and lanes 9, 10 and 11 were loaded with diluted samples of the commercially available 
HBcAg standard with HBcAg content of 20, 100 and 500 ng/well, respectively. Figure 2.4 
E and F show the dot blot immunoreactivity using the monoclonal and the polyclonal 
antibody, respectively. 
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Figure 2.4. Qualitative sucrose gradient analysis of plant crude extract. 
Crude extract of leaves of plant expressing HBcAg were layered onto 10 to 60% sucrose 
step gradient: (A) sucrose gradient (7 fractions from the supernatant to 60% sucrose); (B) 
Coomassie stained SDS-PAGE of the fractions; (C) Western blot using monoclonal 
antibody; (D) Western blot using polyclonal antibody. The lanes arrangement was as 
follows: crude extract (lane 1); supernatant (lane 2), 10 to 60% w/v sucrose fractions (lane 
3 to lane 8); 20, 100 and 500 ng / well HBcAg standards (lanes 9, 10 and 11, respectively). 
E and F show the dot blot immunoreactivity using the monoclonal and the polyclonal 
antibody, respectively. The dots were spotted as follows: crude extract (dot 1); supernatant 
(dot 2); 10 - 60% (w/v) sucrose fractions (dot 3 to dot 8). 
 
Coomassie stained gel (Figure 2.4 B) showed a 20 kDa band, corresponding to the size of 
monomeric HBcAg, in the 30, 40 and 50% (w/v) sucrose gradient fractions. The same 
band was, however, absent in the 60% (w/v) sucrose fraction. Most plant proteins bands 
remained in the supernatant and in the first two density fractions, i.e. 10 and 20% (w/v). 
The standard was probably too diluted and could not be detected. Proteins from the other 
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two gels, separated by gel electrophoresis, were transferred in PVDF membranes and 
probed with either anti-mouse monoclonal antibody (Figure 2.4 C) or anti-rabbit 
polyclonal antibody (Figure 2.4 D). The anti-HBcAg Western blots confirmed that the 20 
kDa band, detected in lanes 5, 6 and 7 of Coomassie stained SDS-PAGE gel, actually 
corresponded to HBcAg. As expected, HBcAg was also detected in the original crude 
extract (lane 1) and in the most concentrated sample of HBcAg standard used as a control 
(lane 11). In the HBcAg-rich lanes, it is also possible to notice a persistent 40 kDa band. 
This band very likely denotes HBcAg dimers, which were resistant to the denaturing and 
reducing condition of the assay. The presence of this band corresponding to the dimer was 
also observed by others (Huang et al., 2006; Mechtcheriakova et al., 2006). Even larger 
size HBcAg multimeric structures have been detected in denaturing gel electrophoresis 
(Broos et al., 2007). Weaker bands of circa 15 kDa monomeric HBcAg and its dimer of 30 
kDa can also be seen and they are possibly the result of partial enzymatic digestion of 
HBcAg by plant proteins. In the remaining samples HBcAg was not detected or only a 
weak signal could be detected under the experimental conditions employed. 
 
Furthermore, the collected fractions from the sucrose gradient were also spotted onto two 
identical PVDF membranes, which were subsequently probed with either anti-mouse 
monoclonal primary antibody (Figure 2.4 E) or anti-rabbit polyclonal primary antibody 
(Figure 2.4 F). Dot 1 corresponds to the crude extract, while dots 2 to 8 contain density 
fractions of the sucrose gradient starting from the supernatant (dot 2) to the 60% (w/v) 
sucrose fraction (dot 8). HBcAg signal was detected in all the samples in both membranes. 
However, the anti-mouse monoclonal antibodies detected higher HBcAg content in the 30, 
40 and 50% (w/v) sucrose fractions as compared to the other samples, whereas the rabbit 
polyclonal antibody seemed to detect high amounts of HBcAg in all the sucrose fractions 
as well as in the supernatant.  The dots corresponding to the HBcAg immunoreactivity 
were of similar intensity in all the sucrose gradient fractions upon shorter exposure to the 
polyclonal antibody, suggesting that the high HBcAg concentration might have saturated 
the immunodetection. 
 
A complete qualitative analysis of the sucrose gradient of the crude extract containing 
plant-expressed HBcAg was carried out by comparing denaturing gels either stained for 
protein or probed with two different specific monoclonal and polyclonal anti-HBcAg 
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antibodies, and with dot blots carried out in non-denaturing conditions. The first evidence 
is that most of the HBcAg was accumulated in the density fraction corresponding to 40% 
(w/v) sucrose and to a lower extent in 30 and 50% (w/v) sucrose gradient bands. This 
migration of the HBcAg to these high density fractions is compatible with the assembly of 
HBcAg into VLP (Birnbaum and Nassal, 1990; Broos et al., 2007; Huang et al., 2006). A 
close comparison between the monoclonal and polyclonal antibodies shows a very similar 
affinity of the two antibodies for HBcAg when this protein is denatured (Western blot). 
However, in the case of native undenatured samples as in the dot blot, the polyclonal 
antibody demonstrated much greater affinity for HBcAg than the monoclonal, particularly 
in those fraction of the sucrose gradient where partially disassembled HBcAg structures 
(10 to 20% (w/v) sucrose) or aggregated HBcAg (60% (w/v) sucrose) are expected. It is 
possible that the polyclonal antibody might have a particular affinity for a conformational 
epitope which is hindered by the properly assembled VLP structure and it is exposed in 
case of incomplete particulate formation or in case of protein aggregation. Moreover, this 
study allowed a first evaluation of the efficiency of the purification method: the Coomassie 
stained SDS-PAGE shows excellent purification and concentration of the VLPs using this 
sucrose gradient protocol. The crude extract (lane 1) appeared to be highly rich in plant 
proteins, to an extent that HBcAg, either as VLP or disassembled was not clearly 
detectable, possibly overlapping with the pool of plant proteins. In contrast, HBcAg VLP 
purified by density gradient centrifugation (lanes 5, 6 and 7) appeared well separated from 
the protein impurities and constituted the predominant protein band in each of these lanes. 
Approximately, a purity of > 90% could be estimated by visualisation of the gel. 
 
2.4.2.2 HBcAg Assembly in Plant Crude Extracts - A Quantitative Approach 
The distribution of plant-expressed HBcAg in the sucrose density gradient was also 
quantitatively examined. Two different ELISA approaches were carried out for this 
purpose. This study also allowed the estimation of the total HBcAg yield. Furthermore it 
was possible to investigate the morphological integrity of HBcAg expressed in plant and 
therefore to evaluate the effective yield of VLP that can be recovered from the sucrose 
gradient and be used for further processing. Finally it was possible to compare the 
specificity of the two different ELISA methods. 
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Figure 2.5 illustrates a quantitative analysis of the density gradient: plant crude extracts 
containing HBcAg were loaded onto 20 to 50% (w/v) sucrose density gradients. After 
ultracentrifugation, five fractions approximately corresponding to each density layer as 
well as the supernatant were collected from the bottom side of the tubes and analysed by 
either direct (Figure 2.5 A) or sandwich ELISA (Figure 2.5 B). The amount of HBcAg in 
the density gradient fractions or in the supernatant was presented as mg HBcAg/kg of fresh 
weight (FW) of the original leaf tissue. Quantification by direct ELISA (Figure 2.5 A) 
revealed a total yield of the soluble HBcAg of 561 mg/kg FW, of which 44.1% was present 
in the 30 and 40% (w/v) sucrose density fractions and expected to correspond to intact 
HBcAg VLPs (Birnbaum and Nassal, 1990). HBcAg seemed predominantly detected in the 
supernatant of the sucrose gradient constituting 37.7% of the total HBcAg detected. 
Quantification of another density gradient by sandwich ELISA (Figure 2.5 B) 
demonstrated a total yield of the soluble HBcAg of 569 mg/kg FW, of which 75.4% was 
present in the 30 and 40% (w/v) sucrose density fractions. The supernatant contained only 
1.9 % HBcAg of the total HBcAg detected.  
 
 
Figure 2.5. Quantitative analysis of sucrose gradient density fractions of plant crude 
extract.  
Crude extracts of leaves of plant expressing HBcAg was layered onto 20 to 50% (w/v) 
sucrose step gradients. After ultracentrifugation, five fractions were collected from the 
bottom and further analysed by ELISA to quantify HBcAg distribution in these fractions: 
(A) direct ELISA (n = 3); (B) sandwich ELISA (n = 3). Error bars indicates standard 
deviation (SD). The amount of HBcAg is presented as mg of HBcAg/kg FW of the original 
tissue (y-axis) and plotted against concentration (in %) of the sucrose fractions (x-axis). 
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Although the total yield values obtained by the direct and sandwich ELISA were almost 
the same, the quantitative distribution of HBcAg through the sucrose gradient was clearly 
different between the two methods. This can be explained by the fact that different 
antibody sets were used for the two ELISAs and therefore the specificity of the two 
protocols could differ, potentially significantly. This hypothesis was confirmed by a simple 
experiment whereby purified samples of HBcAg, dialysed to remove the sucrose, were 
boiled for 10 minutes and analysed either by direct ELISA or by sandwich ELISA. The 
direct ELISA showed that boiled HBcAg maintained 75% residual anti-HBcAg 
immunoreactivity, when compared to the original sample. This finding together with the 
fact that the same polyclonal antibody used for the ELISA was also successfully used for 
detection in Western blot analysis of denaturing gels (Figure 2.4 D), confirmed that the 
polyclonal antibody has some affinity not only for conformational epitopes, but also for 
linearised and denatured epitopes. On the other hand, the sandwich ELISA analysis 
showed that boiled HBcAg lost all the anti-HBcAg immunoreactivity when compared to 
the native undenatured sample. This result clearly demonstrates that the use of a 
combination of two antibodies in the sandwich ELISA assay allowed the detection of 
conformationally intact particles only and it is therefore specific for VLPs.  
 
In the light of this finding, the results of the quantification of HBcAg distribution obtained 
in Figure 2.4 can be re-examined and clarified: the most evident difference is that direct 
ELISA detected high amounts of HBcAg in the supernatant, while the sandwich ELISA, 
specific for VLP, did not. This suggests that the HBcAg detected in the supernatant was 
very likely monomeric, dimeric or a disassembled form; for this reason this HBcAg was 
unable to migrate down the gradient. The fact that a consistent amount of disassembled 
HBcAg was present in the supernatant is probably due to the incomplete formation or to 
the partial degradation of some of the HBcAg present in the leaf material or in the crude 
extract. 
 
2.4.2.3 Purified HBcAg VLP Characterisation 
Using different qualitative and quantitative methods, thus far it was shown that plant-
expressed HBcAg can assemble into VLP and can be separated from the more “soluble” 
proteins of the crude extract by sucrose gradient centrifugation. In this Paragraph, HBcAg 
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VLPs purified from plant-material were pooled together and further analysed, in order to 
characterise the integrity of the particles and to further explore the detection methods. 
 
Plant crude extract containing HBcAg was layered onto sucrose gradient fractions for 
subsequent ultracentrifugation as described in the previous Paragraph. Based on the results 
previously shown and the knowledge that 30 and 40% (w/v) sucrose fractions should 
contain HBcAg VLPs (Birnbaum and Nassal, 1990; Huang et al., 2006), the purified 30 
and 40% (w/v) immunoreactive fractions were pooled together and dialysed against 10 
mM Tris-HCl, 120 mM NaCl buffer, in order to remove the sucrose. The sample was then 
examined by native agarose gel: equal amounts of HBcAg were separated by 
electrophoresis at 60 V for 90 minutes into 1.2% (w/v) agarose gel (Figure 2.6 A) and 
either stained with Coomassie stain (lane 1) or with ethidium bromide (lane 2). Coomassie 
is a stain for proteins, while ethidium bromide indicates the presence of nucleic acids. A 
clear band could be seen in the Coomassie stained native agarose gel, as well as in the 
ethidium bromide stained gel. The two signals appeared at equal electrophoretic mobility, 
strongly suggesting that the protein core, stained by the Coomassie, encapsidated nucleic 
acids. This is not surprising as it has been demonstrated that HBcAg contains an arginine-
rich C-terminus domain, which binds non-specifically host nucleic acids (Birnbaum and 
Nassal, 1990; Gallina et al., 1989). The knowledge that HBcAg VLP binds nucleic acids 
has been exploited in the past to extensively characterise the stability and morphology of 
HBcAg by Coomassie or ethidium bromide stained native agarose gels (Newman et al., 
2003).  
 
The presence of VLPs was further confirmed by TEM images (Figure 2.6 B) of the 
dialysed 30 and 40% (w/v) sucrose gradient fractions: intact VLPs were clearly visible and 
their diameter (circa 30 to 35 nm) matches the size documented in the literature (Lee and 
Tan, 2008; Wingfield et al., 1995). From the TEM images, it was also possible to note the 
lack of evident agglomerates or nano-sized impurities in the sample.  
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Figure 2.6. Purified HBcAg assembled into VLP.  
Purified HBcAg samples, dialysed from 30 and 40% (w/v) sucrose gradient fractions were 
pooled together and analysed by: (A) native agarose gel electrophoresis, either stained with 
Coomassie stain (lane 1) or with ethidium bromide (lane 2), and (B) TEM images. Black 
scale bars and their relative dimensions are reported at the bottom of the image.  
 
To further characterise HBcAg VLPs, purified and dialysed sucrose fractions were layered 
on a sucrose gradient, in order to establish the migration of purified VLPs following 
ultracentrifugation. The sucrose gradient fractions were analysed by sandwich and direct 
ELISA. Figure 2.7 A shows the distribution of the anti-HBcAg reactivity throughout the 
collected fractions of the sucrose gradient, detected by sandwich ELISA or direct ELISA. 
The data are reported as a percentage of immunoreactivity of the single density fraction as 
compared to the total reactivity of the sample. The sandwich ELISA, specific for VLPs, 
showed that 93.2% of the HBcAg particles migrated to the 30 and 40% (w/v) sucrose 
fractions. The fact that the purified intact VLPs migrated efficiently to the middle fractions 
of the sucrose gradient has been exploited in the subsequent chapters as a standard 
quantitative method to determine the stability of VLPs to particular conditions or 
manufacturing processes. In contrast, the direct ELISA detected only 73.1% of HBcAg in 
the 30 and 40% (w/v) sucrose fractions, and also showed certain immunoreactivity in the 
supernatant and the 10 and 20% (w/v) sucrose fractions. This latter signal possibly 
corresponded to partially degraded or breakdown forms of HBcAg. The lower specificity 
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of the direct ELISA for morphologically intact particles makes the use of this technique as 
a method to assess VLP stability complicated; for this reason the sandwich ELISA was 
always the technique of choice for future experiments. 
 
 
Figure 2.7. Sucrose gradient analysis of purified VLPs.  
Purified HBcAg, obtained from pooling together the dialysed 30 and 40% (w/v) sucrose 
gradient fractions, were layered onto 10 to 60% (w/v) sucrose step gradients. After 
ultracentrifugation, seven fractions were collected from the bottom and further analysed. 
(A) shows the distribution of the anti-HBcAg reactivity throughout the collected fractions 
of the sucrose gradient, detected by sandwich ELISA or direct ELISA. The data are 
reported as a percentage of immunoreactivity of the single density fraction as compared to 
the total reactivity of the sample. (B) and (C) show the dot blot immunoreactivity using the 
monoclonal and the polyclonal antibody, respectively. S = supernatant; percentages 
indicate the respective sucrose concentration of each fraction. 
 
The sucrose gradient was further analysed by dot blot, probing the membranes with anti-
HBcAg monoclonal antibody (Figure 2.7 B) or with anti-HBcAg polyclonal antibody 
(Figure 2.7 C). The monoclonal antibody detected HBcAg mainly in the 30 and 40% (w/v) 
sucrose fractions, whereas the polyclonal antibody detected HBcAg in all fractions under 
study except in the supernatant and the 60% (w/v) sucrose fraction. This result reflects a 
similar experiment carried out on the crude extract (Figure 2.4 E and F), whereby the 
polyclonal antibody seemed to have a higher tropism than the monoclonal for disassembled 
HBcAg, present in the lighter fractions of the sucrose gradient. This result is a 
confirmation that the binding of VLPs to antibodies can be quite complicated. Thus, a 
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careful selection of the right antibody, depending on the specific application for which it is 
chosen, as well as a careful interpretation of the experimental results should be carried out. 
 
2.4.2.4 Preparation of Purified VLP Batches 
Batches of purified HBcAg VLPs were routinely prepared during the course of this 
research to be used for further processing or testing. For this purpose plant leaves were 
infiltrated with pEAQ-HT-HBcAgΔ176, harvested after 6 to 7 days and homogenised with 
extraction buffer 2. The resulting crude extract was clarified and the supernatant was 
placed on the top of the sucrose density gradient. After ultracentrifugation, fractions 
corresponding to each density layer were collected from the bottom. Sucrose density 
fractions of 30 and 40% (w/v) were pooled together and dialysed against PBS or 10 mM 
Tris-HCl, 120 mM NaCl buffer, depending on the application. VLP preparations were then 
concentrated by ultrafiltration carried out at 4,000 x g for the time required. The 
preparation was then centrifuged at 4,000 x g for 20 minutes, in order to spin down 
residual impurities. After final quantification by ELISA, the purified HBcAg batches were 
stored in the fridge until use. Generally the purified VLPs were used within 4 to 6 weeks 
from production. Immediately before use, VLP preparations were appropriately diluted, 
depending on the application. Figure 2.8 A summarises the VLP production and 
purification steps described above. Samples indicated by numbers 1, 2, 3, 4, 5 were 
collected at different steps of the purification and further analysed. 
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Figure 2.8. VLP purification and concentration efficiency.  
(A) is a diagram that illustrates the VLPs production and purification steps. Samples 
indicated by numbers 1, 2, 3, 4, 5 were collected at different steps of the purification and 
further analysed. (B) shows the Coomassie stained SDS-PAGE. Lanes correspond to 
samples as numbered in the diagram above. (C) shows the native agarose gel 
electrophoresis: the images relative to the ethidium bromide stain and to the Coomassie 
stain are presented in the left side and in the right side, respectively. Lanes correspond to 
samples as numbered in the diagram above. 
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Figure 2.8 B illustrates a Coomassie stained SDS-PAGE relative to the different 
purifications steps. The 20 kDa protein band, corresponding to HBcAg, can be constantly 
observed in samples 1, 2, 3 and 5, indicating that HBcAg was not significantly lost during 
the process. Dialysis was carried out using membranes up to 100 kDa cut-off. This size of 
the cut-off would allow monomeric HBcAg, but not HBcAg VLP, to leak out from the 
membrane, proving that most HBcAg was present as VLPs. However, the sample became 
quite dilute upon dialysis, due to the osmotic force exercised by the sucrose solution 
loaded into the dialysis membrane. For this reason, the sample was subsequently 
concentrated by ultrafiltration. HBcAg VLP did not pass through the 100 kDa cut-off 
membrane as demonstrated by the fact that the HBcAg protein band was absent in the 
filtrate (sample 4). Furthermore, VLP did not stick to the ultrafiltration membrane: in fact 
it could be recovered and concentrated, as shown in sample 5.  
 
The same samples were also separated by native agarose gel electrophoresis (Figure 2.8 
C). Two identical gels were stained either by ethidium bromide (Figure 2.8 C, left side) or 
by Coomassie (Figure 2.8 C, right side). A discrete band can be also visualised in both 
native agarose gels: the band of protein staining (Coomassie-stain) and that of nucleic acid 
(ethidium bromide-stain) showed identical electrophoretic migration. This strongly 
suggests that the capsid-like structure, encapsidating nucleic acid, was stable throughout 
the purification. The dilution of the VLPs during the dialysis and the subsequent 
concentration of the sample during the concentration step are evident in the native agarose 
gel, as in the SDS-PAGE gel. 
 
Overall, the downstream yield of plant-expressed intact HBcAg VLPs, extracted and 
purified through sucrose gradient was circa 400 mg/kg FW, as determined by sandwich 
ELISA. During the course of the current research, 15 plants were generally infiltrated each 
time and were then pooled together, extracted and purified in a single batch of six identical 
sucrose gradients: 15 plants correspond to circa 50 g of leaf tissue, which, after dialysis 
and concentration, could allow the recovery of approximately 10 mg of purified VLPs, 
usable for pharmaceutical research purposes. Initially, the amount of HBcAg VLPs can 
seem quite low, when compared to the kilograms of bulk stocks of other active ingredients 
available for drug delivery research purposes. However, VLP proteins are very complex 
and expensive macromolecules. For comparison, the price of the cheapest recombinant 
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HBcAg standard, sold by a global manufacturer, costs at the present day £234 for only 0.1 
mg of product. It is therefore evident that the production of tens of mg of the same 
recombinant protein in plant, inexpensively and in less than 2 weeks starting from 
culturing the glycerol stock to the final protein purification, constituted a unique 
opportunity for this project: each 10 mg batch of purified VLPs was potentially worth 
about £20.000! Overall, subsequent drug delivery oriented research could have not been 
carried out on these proteins if such an effective expression system was not available. 
 
2.4.3 Plant-expressed CoHe7e-eGFP Characterisation 
In Paragraph 2.4.1, the expression of CoHe7e-eGFP in plant was shown in parallel to 
HBcAg expression. CoHe7e-eGFP is a construct in which the original HBcAg expression 
sequence was modified to allow the expression of a GFP molecule on the loop of each 
HBcAg dimer. Therefore, the assembly of dimers into particles generates VLPs decorated 
by fluorescent proteins all around its structure. The possibility of using fluorescent HBcAg 
particles could provide a useful investigation tool for the drug-delivery studies and bio-
imaging purposes of this research. 
 
Plant-expression and assembly of HBcAg-derived VLP, such as CoHe7e-eGFP, is not as 
efficient as for HBcAg wild-type (Dr. Eva Thuenemann, personal communication). Thus, 
before further use of CoHe7e-eGFP in the current research, it was essential to evaluate 
whether adequate yields of purified, properly formed CoHe7e-eGFP VLP could be 
achieved. For this purpose, leaves expressing CoHe7e-eGFP were homogenised in the 
extraction buffer 2 and the resulting crude extract was layered on the top of a 10 to 60% 
(w/v) discontinuous sucrose gradient. After centrifugation, fractions were collected from 
the bottom and analysed by Coomassie stained SDS-PAGE, as illustrated in Figure 2.9 A: 
lanes 1 and 2 represent the crude extract and the supernatant, respectively, while lanes 3 to 
8 correspond to density fractions of sucrose concentration increasing from 10 to 60% 
(w/v). As indicated by the green arrow, a protein band of circa 65 to 70 kDa, matching 
CoHe7e-eGFP size, could be seen in lanes 1 to 7 and more markedly in lanes 5, 6 and 7. 
The same density gradient fractions were also spotted on two PVDF membranes, which 
were then probed with anti-HBcAg antibody, in order to assess HBcAg immunoreactivity 
along the density gradient. Figure 2.9 B and C illustrate the anti-HBcAg dot blots using 
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monoclonal and polyclonal antibody, respectively: dots 1 and 2 represent the crude extract 
and the supernatant, respectively, while dots 3 to 8 correspond to density fractions of 
sucrose concentration increasing from 10 to 60% (w/v). Both images confirmed that 
HBcAg immunodetection was observed in the supernatant and along all fractions of the 
sucrose gradient, except for the 60% (w/v) sucrose density layer. Most anti-HBcAg 
reactivity can be seen in the dots corresponding to 30, 40 and 50% (w/v) sucrose fractions. 
This result matches the one obtained with the SDS-PAGE gel: CoHe7e-eGFP showed good 
expression levels in plant, however, it was detected in most layers of the sucrose gradient. 
This latter observation suggested that a significant amount of CoHe7e-eGFP was not 
properly assembled into VLP and it was present in a variety of multimeric intermediate 
forms, which migrated all along the gradient. However, the almost complete lack of 
CoHe7e-eGFP detection in the 60% sucrose fraction implies that probably the protein did 
not form agglomerates.  
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Figure 2.9 CoHe7e-eGFP purification and characterisation.  
Crude extract of leaves of plant expressing CoHe7e-eGFP were layered onto 10 to 60% 
(w/v) sucrose step gradients. After ultracentrifugation, seven fractions were collected from 
the bottom and further analysed. (A) illustrates the Coomassie stained SDS-PAGE: crude 
extract (lane 1); supernatant (lane 2); sucrose density fractions of increasing concentrations 
of 10 to 60% w/v (lanes 3 to 8). (B) and (C) show the dot blot immunoreactivity using the 
monoclonal and the polyclonal anti-HBcAg antibody, respectively: crude extract (dot 1); 
supernatant (dot 2); 10 to 60% (w/v) sucrose (dots 3 to 8). Purified HBcAg, dialysed from 
30 and 40% w/v sucrose gradient fractions were pooled together and subsequently 
concentrated by ultracentrifugation. Finally, the sample was clarified by centrifugation at 
4,000 x g for 20 minutes before use. (D) shows the native agarose gel electrophoresis: 
ethidium bromide stained (left side) and Coomassie stained (right side). Pooled together 30 
and 40% (w/v) sucrose density fractions, dialysed sample, concentrated sample, and final 
product after the last centrifugation are illustrated in lanes 1, 2, 3 and 4, respectively. (E) 
illustrates the fluorescence of purified CoHe7e-eGFP drops as seen using the fluorescent 
microscope (10x magnification).  
 
Based on the knowledge that wild type HBcAg VLPs tend to migrate to the 30 and 40% 
w/v sucrose gradient fractions, CoHe7e-eGFP collected from those two fractions were 
pooled together, dialysed and concentrated by ultrafiltration, before a final centrifugation 
at 4,000 x g for 20 minutes. The presence of VLPs and their stability during each step were 
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assessed by native agarose gel electrophoresis: two identical gels were stained either by 
ethidium bromide (Figure 2.9 D, left side) or by Coomassie-stain (Figure 2.9 D, right side): 
lane 1 corresponds to the VLP-rich 30 to 40% (w/v) sucrose fractions collected after 
ultracentrifugation; lane 2 represents the same sample, after dialysis of the 30 to 40% (w/v) 
sucrose fractions; lane 3 relates to the dialysed sample, after being concentrated by 
ultrafiltration; lane 4 corresponds to the sample after the last centrifugation at 4,000 x g for 
20 minutes. The ethidium bromide stained native agarose gel seemed free from nucleic 
acid bands, while the Coomassie-stain gels showed the presence of a very faint band in 
lanes 1 and 2, which seemed more marked in lanes 3 and 4. The lack of evident nucleic 
acid bands suggests that the particles were either too diluted or that they did not 
encapsidate consistent amounts of nucleic acid. Instead, in the Coomassie stained gel, the 
presence of a protein band whose intensity increased upon concentration by ultrafiltration, 
suggests that CoHe7e-eGFP did not pass through the filter being in a particulate state. 
Furthermore, despite its complex protein structure, CoHe7e-eGFP VLP resisted the 
ultrafiltration stress and could be re-suspended without getting agglomerated or stuck to 
the filter membrane. However, the protein band was less concentrated and more diffused 
compared to the ones obtained for HBcAg (Figure 2.8 B), suggesting that external charge 
and/or size of CoHe7e-eGFP VLP are more variable, compared to HBcAg VLP. 
Additionally, the yield of VLP seemed significantly lower than that of HBcAg. 
Furthermore, purified CoHe7e-eGFP VLP was quantified by direct ELISA (data not 
shown). Finally, CoHe7e-eGFP VLP drops were also observed using the fluorescent 
microscope. Figure 2.9 E shows the green-fluorescence of CoHe7e-eGFP VLP drop. The 
presence of visible fluorescence is compatible with the correct folding of the GFP portions 
of the VLP.  
 
Taken together, the above results suggest that CoHe7e-eGFP was expressed in plant less 
efficiently than HBcAg, both in terms of yield and morphological integrity of the particles. 
This finding together with the fact that the CoHe7e-eGFP engineered structure differed 
from the naturally occurring HBcAg structure, set back the use of CoHe7e-eGFP as the 
first candidate VLP for further drug delivery experiments of this research, when compared 
to wild type HBcAg. However, despite these limitations, CoHe7e-eGFP VLP could be 
purified and concentrated; therefore its use was attempted for bio-imaging investigations. 
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2.4.4 HBcAg Expression in Lettuce 
The main focus of this research was the investigation of plant-expressed HBcAg VLP for 
the development of oral vaccines. One of the most recognised benefits of the expression of 
candidate vaccines in plant is the possibility of using edible plants (Walmsley and Arntzen, 
2000): the prospect of producing effective edible vaccines in fruits or vegetables is 
extremely fascinating and has driven extensive biotechnological research in the past two 
decades. However, the risks of contamination of the food chain with attendant safety 
issues, as well as the likely difficulties in dose and formulation standardisation and 
possible lack of efficacy have decreased interest in edible vaccines. These aspects were 
discussed in Chapter 1. Aware of these limitations, the expression of HBcAgΔ176 in an 
edible plant was attempted: Valmaine romaine lettuce was vacuum-infiltrated with an 
Agrobacterium suspension containing pEAQ-HT-HBcAgΔ176. The infiltrated leaves were 
then harvested at 3, 5, 7 and 9 days post-infiltration (DPI). The leaf material was then 
snap-frozen and stored at - 80 ºC until use. For the extraction of VLPs, the leaf material 
was weighed and blended in three volumes of the extraction buffer 2. Following cloth 
filtration, the crude extract was clarified by centrifugation: the resulting supernatant was 
separated from the precipitated pellet (insoluble fraction). The pellet was re-suspended in 
LDS β-mercaptoethanol, boiled and clarified again. Both the supernatant and the insoluble 
fraction were separated by SDS-PAGE. The gel was then used for anti-HBcAg Western 
blot detection. The soluble fraction was also used for sandwich ELISA quantification of 
HBcAg VLP.  
 
Figure 2.10 illustrates the presence of the HBcAg in the protein extracts of the infiltrated 
lettuce leaves. Figure 2.10 A presents the anti-HBcAg Western blot: purified HBcAg 
expressed in Nicotiana benthamiana (lane 1); the supernatant of the crude extract of 
infiltrated lettuce leaves harvested at 3, 5, 7 and 9 days post-infiltration (DPI) (lanes 2, 3, 4 
and 5, respectively); empty lanes (lanes 6 and 7); insoluble fraction of the crude extract of 
infiltrated lettuce leaves harvested respectively at 3, 5, 7 and 9 DPI (lanes 8, 9, 10 and 11). 
Anti-HBcAg immunoreactivity can be seen from 5 to 9 DPI in the soluble fraction. 
Furthermore, the quantification of HBcAg VLP by sandwich ELISA (Figure 2.10 B) 
showed that a maximum yield of 8.75 mg/kg of FW of the tissue was reached at 7 DPI. 
This result represents a proof of concept that HBcAg could be expressed in edible lettuce 
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using the unmodified pEAQ-HT- system. However, the level of expression was 
approximately 50-fold lower than the expression level achieved in Nicotiana bethamiana. 
For this reason the expression of HBcAg in lettuce was not carried forward for the 
production of bulk quantities of HBcAg throughout this project. Nevertheless it is possible 
to hypothesise that optimisation of the plasmid sequence for Valmaine romaine could boost 
expression to considerably higher levels. 
 
         
Figure 2.10. HBcAg expression in lettuce. 
pEAQ-HT-HBcAgΔ176 was vacuum infiltrated in Valmaine romaine. The infiltrated 
leaves were harvested at 3, 5, 7 and 9 days post-infiltration. Following extraction of the 
leaves’ protein, the supernatant and the insoluble fraction of the crude extract were 
separated by SDS-PAGE. (A) illustrates the anti-HBcAg Western blot (monoclonal 
antibody) of the crude extracts: purified HBcAg expressed in Nicotiana benthamiana (lane 
1); the supernatant of the crude extract of infiltrated lettuce leaves harvested at 3, 5, 7 and 
9 DPI (lanes 2, 3, 4 and 5, respectively); empty lanes (lanes 6 and 7); insoluble fraction of 
the crude extract of infiltrated lettuce leaves harvested respectively at 3, 5, 7 and 9 DPI 
(lanes 8, 9, 10 and 11). (B) shows the sandwich ELISA quantification (n = 2) of the 
supernatant of the crude extracts at different DPI. Results are presented as mg of 
HBcAg/kg FW of the original tissue. DPI= days post-infiltration.  
 
2.4.5 Conclusions 
In this research, plant-expressed HBcAg VLP was studied as a potentially orally active 
macromolecule. In this Chapter, HBcAg-based VLP, expressed in plant using the pEAQ-
HT-system, were extensively characterised. The physical structure and immunogenicity of 
HBcAg in the plant crude extract were evaluated; in parallel purified HBcAg VLPs were 
further characterised. Additionally, the extraction, purification and concentration methods 
were assessed in terms of yield, purity, morphological integrity and antigenicity.  
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Plant-expressed HBcAg could be immunodetected. Purification of the crude extract by 
density gradient ultracentrifugation demonstrated that part of the expressed HBcAg could 
penetrate the lower density fractions of the gradient, which is compatible with the 
formation of VLP. HBcAg VLP could in fact be detected in the 30, 40 and 50% (w/v) 
fractions by Coomassie stained SDS-PAGE, Western blot and dot blot. However, a 
moderate amount of HBcAg, present in the less dense fractions of the sucrose gradient, did 
not seem to have correctly assembled into particles. The distribution of the HBcAg from 
the crude extract through the sucrose gradient was also quantified using two different 
ELISA methods. Furthermore, analysis of purified VLPs showed highly selective 
migration to the 30 and 40% (w/v) sucrose density fractions upon ultracentrifugation. 
Moreover, purified HBcAg VLPs could be detected by native agarose gel electrophoresis 
and could be visualised by TEM. Thus, native agarose gel, TEM, as wells as sucrose 
gradient centrifugation coupled to Coomassie stained SDS-PAGE, Western blot and/or dot 
blot proved to be effective tools for investigation of the physical stability of the VLP. 
These techniques would therefore be essential for the assessment of VLPs’ physical 
stability in the following Chapters. 
 
Moreover, the specificity and limitations of the detection methods were defined: 
monoclonal and polyclonal anti-HBcAg antibody could be both used for immunodetection 
of denatured or native samples; however, the polyclonal antibody appeared to have a better 
affinity for the disassembled form of HBcAg. Furthermore, sandwich ELISA was 
demonstrated to specifically detect intact HBcAg VLP only, whereas direct ELISA was 
shown to detect both undenatured and disassembled HBcAg forms. Knowing the 
specificities of the methods used is important for a better interpretation of the results. 
Finally, the purification and concentration technique proved to be effective in terms of 
yield and VLP stability. Overall, for standard batches of 15 plants, corresponding to 50 g 
of leaves, approximately 10 mg of purified HBcAg could be produced.  
 
In parallel, CoHe7e-eGFP expression in plant was also examined. This recombinant 
protein is a fluorescent alternative to the wild type HBcAg, potentially usable for bio-
imaging purposes. The expression of CoHe7e-eGFP proved to be significantly inferior to 
HBcAg in terms of yield and morphological integrity. It was demonstrated also that 
HBcAg could also be expressed in Valmaine romaine lettuce, which is, unlike Nicotiana 
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benthamiana, an edible plant. However, the yield achieved was very low, discouraging the 
use of this method for further studies in the present research.  
 
Overall, this Chapter described the efficiency and limitations of the production and 
purification of HBcAg constructs from plant. Furthermore, the usability and specificity of 
the characterisation techniques were investigated. In the following Chapters, the 
expression, purification and characterisation techniques described here will be utilised in 
the investigation of the potential of HBcAg VLPs as orally vaccines.  
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3 Stability of HBcAg VLP in Bio-relevant Gastro-Intestinal (GI) Media  
3.1 Introduction 
The harsh environment present in the stomach and intestine is the first barrier to the oral 
delivery of vaccines and constitutes a real challenge to the stability of therapeutic proteins, 
including vaccines.  
 
The gastric fluid in the human stomach is an extremely harsh environment for physically- 
and chemically-labile molecules, due to the highly acidic pH and the presence of digestive 
enzymes. In vitro models of simulated gastric fluids are often used for the determination of 
the behaviour of therapeutic molecules and formulations under these conditions. The first 
systematic application of simulated gastric fluid digestion was developed to establish the 
digestibility of food allergens (Astwood et al., 1996). Since then such in vitro models have 
been used for the evaluation of the stability and release of different therapeutic 
formulations, including those of nucleic acids and therapeutic proteins (Gamboa and 
Leong, 2013; O’Neill et al., 2011). Several protocols have been established, in order to 
achieve good correlation between in vitro models and human gastric conditions [reviewed 
by (O’Neill et al., 2011)]. Three commonly used recipes are summarised in Table 3.1.  
 
Table 3.1. In vitro models of gastric fluids [adapted from(O’Neill et al., 2011)] 
Model media Description  Reference 
Simulated gastric fluid (SGF)  pH 1.2 (with and without 
pepsin), NaCl 
(British Pharmacopeia, 2012) 
Fasted State Simulated Gastric 
Fluid (FaSSGF) 
pH 1.6, pepsin and low levels 
of bile salt and lecithin, NaCl 
(Vertzoni et al., 2005) 
Fed State Simulated Gastric 
Fluid (FeSSGF) 
Variable pH , full-fat milk, 
acid and pepsin 
(Fotaki et al., 2005) 
 
Simulated gastric fluid (SGF) as described in the British Pharmacopeia is the standard 
model mimicking fasting conditions in the stomach and can be supplemented also with 
porcine pepsin (British Pharmacopeia, 2012). However, Vertzoni et al. (2005) proposed a 
media which should more accurately simulate the fasting gastric contents; this bio-relevant 
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media was called Fasted State Simulated Gastric Fluid (FaSSGF): compared to the original 
SGF formula, in FaSSGF, the pH was increased to 1.6 and physiologically appropriate 
small amounts of bile salts and phospholipids were introduced. Furthermore, a different 
pepsin than that used in SGF was employed in FaSSGF and its concentration in the media 
was fixed as 0.1 mg/mL. This concentration should relate to the reported in vivo 
concentration of pepsin, after ingestion of a glass of water (Kalantzi et al., 2006; Vertzoni 
et al., 2005). Later in the same year, a model of gastric fluid simulating the fed condition of 
the stomach was also developed. The Fed State Simulated Gastric Fluid (FeSSGF) is based 
on the knowledge that there are postprandial pulsatile acid and pepsin secretions in 
humans. The initial medium is constituted by full-fat UHT milk, which contains protein, 
carbohydrates and fat, mimicking the composition of a complete meal. At predetermined 
time intervals, aliquots of HCl and pepsin are added, in order to closely simulate the in vivo 
pulsatile secretion of these two components after a meal: in this model the pH declines 
from pH 6.5 to circa pH 2.8 over the first 90 minutes (Fotaki et al., 2005), reflecting the 
physiological values observed in vivo after the ingestion of a meal substitute (Kalantzi et 
al., 2006). 
 
Despite the improved bio-relevance of these simulated gastric fluid models, it is still 
difficult to completely simulate the extremely variable physiological conditions. For 
example, human gastric acidity was reported to range between pH 1 and 6 in fasted 
conditions (Efentakis and Dressman, 1990). It has been also stated that the pepsin activity 
in human gastric fluid can vary over 10,000 fold (Gomes et al., 2003). In this perspective, 
it is clear that a single standard protocol cannot fully represent this huge variability 
observed in vivo.  
 
The small intestinal environment is, after the stomach, the second physico-chemical barrier 
that a candidate vaccine has to withstand upon oral administration. The intestinal fluids 
bear a more neutral pH compared to the gastric fluids, generally ranging between pH 6.3 
and pH 7.4 (Evans et al., 1988). However, it was more recently reported that the pH can be 
as low as 5.5 in the duodenum (the first section of the small intestine). Moreover, even in 
the small intestine the variability of pH between different people can be very high (over 
two pH units) (McConnell et al., 2008b). Nevertheless, due to its relative neutrality, the pH 
of the intestine is not expected to be such an important barrier as that of the stomach for 
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most orally delivered vaccine formulations. However, the intestine also contains several 
enzymes, including trypsin and chymotrypsin, which could digest antigens. Moreover, 
many novel nanoparticulate protein formulations, in particular those based on vesciular 
carriers, such as liposomes, can also be degraded by the detergent effect of physiological 
levels of intestinal bile salts (Parmentier et al. 2011). Several in vitro models of intestinal 
fluids containing bile salts are available (O’Neill et al., 2011). A disadvantage of these 
model fluids is that they do not contain enzymes, which are likely to cause degradation of 
therapeutic proteins.  Therefore, media containing the digestive enzymes are often used in 
the study of therapeutic proteins. Simulated Intestinal Fluid (SIF) described in the British 
Pharmacopeia (2012) is a bio-relevant medium of pH 6.8 containing porcine pancreatin, 
which is composed of pancreatic digestive enzymes, including most intestinal proteases 
(British Pharmacopeia, 2012). This model fluid is not based on the use of a single enzyme, 
but contains the whole pancreatic enzyme complex, and is therefore expected to be more 
relevant for digestion studies than those which contain a single protease (Reuter et al. 
2009). Yet, it has been reported that even a pool of pancreatic endopeptidases accounts for 
only 1/3 of the total proteolytic activity of the intestinal fluids. Therefore, it has been 
suggested that ex-vivo studies should also be considered when assessing the stability of a 
protein, as the proteolytic activity of natural intestinal fluids represents the closest possible 
simulation of the in vivo scenario (Reuter et al. 2009). 
 
In this Chapter, the GI stability of plant-expressed Hepatitis B core antigen (HBcAg) VLP, 
as a model candidate vaccine, was investigated. In vitro stability studies were carried out 
using bio-relevant media that simulate the different environmental conditions of the human 
GI tract. Furthermore ex vivo evaluation of the antigen stability was carried out in pig 
luminal intestinal fluids. The integrity of the HBcAg was investigated in terms of chemical 
stability of the primary structure. For this purpose the main characterisation techniques 
used were SDS-PAGE and Western blot. The physical stability of the capsids under gastro-
intestinal conditions was also evaluated using native agarose gel electrophoresis, TEM, as 
well as sucrose density gradient ultracentrifugation coupled with immunodetection 
techniques.  
 
The overall objective was to determine the extent to which purified HBcAg VLPs are 
stable under conditions simulating the gastric and intestinal environments. 
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3.2 Materials  
3.2.1 Molecular Biology Media, Buffers and Solutions  
General media, buffers and solutions used in this study for bacterial growth, plant agro-
infiltration and protein analysis are catalogued in Table 2.1 of Chapter 2. 
 
3.2.2 Antibodies and Antigens  
Antibodies and antigen standards used for Western blot, dot blot and ELISA are listed in 
Table 2.2 of Chapter 2. 
 
3.2.3 Enzymes and Other Materials Used for Stability Studies 
The materials used for the preparation of bio-relevant media used for the incubation of 
HBcAg are indicated below in Table 3.2. 
 
Table 3.2. Components of incubation media. 
Name Supplier 
HCl Fisher Scientific, UK 
NaOH Fisher Scientific, UK 
KH2PO4 VWR (AnalaR), UK 
Pepsin (Ph Eur) from porcine gastric mucosa Sigma, UK 
Pepsin (≥ 400 units/mg) from porcine gastric mucosa Sigma, UK 
Pancreatin (≥ 3× USP) from porcine pancreas Sigma, UK 
Taurocholic acid, sodium salt hydrate, 98% Fisher Scientific (Acros Organics), UK 
Lecithin (L-α-phosphatidylcholine) Sigma (Biochemika), UK 
Complete Protease Inhibitor Roche, UK 
NaHCO3 Sigma (Riedel-de Haën), UK 
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3.2.4 Pig Small Intestinal Fluids 
A full-length intestine was obtained from a freshly killed pig at a local abattoir (H G Blake 
Costessey Ltd, Norwich, UK). The animal was processed under standard UK legislation 
for food-producing animals, the intestine extracted within a few hours of slaughter, 
transported intact to the laboratory on ice and the intestinal fluids extracted within a short 
time. 
 
3.2.5 Other Materials Used in the Molecular Biology Studies  
Materials used for SDS-PAGE, Western blot, dot blot, native agarose gel electrophoresis 
and ELISA are indicated in Chapter 2. Western blot and dot blot were carried out using the 
mouse monoclonal antibody indicated in Chapter 2, unless otherwise stated. 
 
3.3 Methods 
The stability of plant-expressed HBcAg VLPs in gastric and intestinal conditions was 
investigated by the following protocols. Each experiment consisted of incubation of VLPs 
in the bio-relevant media, followed by a post-incubation assessment of their physical and 
chemical stability using several characterisation techniques. The production and 
purification of HBcAg from the plant, as well as the methods used for the VLPs 
characterisation were described in detail in Chapter 2. Unless otherwise specified these 
techniques were carried out using the same protocols described in Chapter 2.  
 
3.3.1 HBcAg Stability in Simulated Gastric Conditions 
Simulated gastric fluid models which mimic the harsh gastric environment have been 
developed (British Pharmacopeia, 2012; Fotaki et al., 2005; Vertzoni et al., 2005). Despite 
their good bio-relevance, it is still difficult to fully simulate the conditions of the stomach 
fluids using a single standard protocol, as this would not be representative of the extreme 
variability in acid and pepsin concentrations observed in vivo (Efentakis and Dressman, 
1990; Gomes et al., 2003). For this reason, in the current research the relative stability of 
HBcAg in gastro-intestinal (GI) bio-relevant media was determined not only under the 
standard conditions of the in vitro models, but also under a range of different pH values 
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and pepsin concentrations. This was carried out in order to obtain a better and more 
relevant understanding of HBcAg susceptibility to the gastric degradation.   
 
Moreover, protein stability is often evaluated by SDS-PAGE gel, which allows the 
determination of the stability of the primary structure. However, it should be remembered 
that HBcAg is a VLP, with a complex multimeric quaternary structure. Therefore, its 
stability was evaluated not only in terms of chemical stability, but also in terms of physical 
integrity of the three-dimensional structure.  
 
3.3.1.1 HBcAg Stability in Simulated Gastric Fluid (SGF) without Pepsin 
HBcAg VLPs were incubated in SGF (pH 1.2) without pepsin (British Pharmacopeia, 
2012) for two hours. Following the incubation, both physical and chemical stability were 
investigated.  
 
Plant-expressed HBcAg was extracted using extraction buffer 1 (Chapter 2) and purified 
through sucrose density gradient ultracentrifugation. VLP-rich fractions corresponding to 
30 and 40 % (w/v) sucrose density bands were pooled together and were then diluted 1:5 
with a solution of 80 mM HCl and 34 mM NaCl, resulting in a final pH of 1.2, matching 
SGF (British Pharmacopeia, 2012). The 1:5 volume ratio of HBcAg solution to SGF was 
chosen in order to avoid detection problems associated with highly diluted concentrations. 
However, at this dilution ratio the purified HBcAg solution would slightly increase the pH 
of the SGF. For this reason, SGF was prepared at a slightly lower pH, so that the final pH 
was 1.2 upon dilution, matching that of British Pharmacopoeia recipe (2012). 
 
The HBcAg solution in SGF was incubated at 37 °C for two hours. After incubation, it was 
layered on the top of a pH 1.2, 10 to 45% (w/v) sucrose density step gradient. The gradient 
was made by preparing five concentrations of sucrose solution in HCl (pH 1.2) ranging 
from 10 to 45% (w/v). The migration of stable VLPs through sucrose density gradients at a 
more neutral pH was used as a control; for this purpose HBcAg particles from the same 
stock used for the SGF incubation were employed. In this case, the purified HBcAg 
particles were diluted 1:5 in a 10 mM Tris-HCl pH 8.4, 120 mM NaCl solution.  After two 
hours incubation, the control sample was layered on the top of a 10 mM Tris-HCl pH 8.4, 
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10 to 45% sucrose density gradient. After ultracentrifugation, fractions from the sample 
that had been incubated at pH 1.2, as well as fractions from the control were collected. All 
fractions were then analysed by Coomassie stained SDS-PAGE.  
 
In a different experiment, VLPs were incubated both at pH 1.2 and under control 
conditions in an identical way to the aforementioned method. Density gradient 
ultracentrifugation was carried out, and fractions from the sample incubated at pH 1.2 and 
fractions from the control were collected. These fractions were analysed by Western blot 
and dot blot. 
  
3.3.1.2 HBcAg Stability in Simulated Gastric Fluid (SGF) without Pepsin, Followed 
by pH Neutralisation 
During the GI transit, a hypothetical therapeutic is subjected first to the stomach acidity 
and then to the more neutral pH of the intestinal environment. Therefore, it was considered 
important to evaluate the VLPs stability upon incubation in acid, followed by pH 
neutralisation to simulate the normal biological process: for instance, in case of partial or 
total physical instability of the VLPs in acids, the pH neutralisation might have allowed re-
assembly of the VLPs structure. Therefore, in the following experiments HBcAg was first 
incubated in SGF without pepsin. After the incubation, the samples at pH 1.2 were 
neutralised and the physical and chemical stability were investigated by Coomassie stained 
SDS-PAGE, Western blot, dot blot and TEM.  
 
Purified VLP preparations were incubated at pH 1.2 for two hours as described in the 
previous section. At the end of the two hour-incubation, the pH of the sample was 
neutralised by initial addition of 1 M NaOH in a drop wise manner. The neutralising agent 
was then switched to 0.1 M NaOH once the pH became closer to neutrality. The sample 
was layered on the top of 10 mM Tris-HCl, 120 mM NaCl pH 8.4, 10 to 45% (w/v) 
sucrose step gradient. After ultracentrifugation, fractions were collected and examined by 
dot blot. Moreover, a precipitate was formed at the bottom of the tube upon 
ultracentrifugation: it was re-suspended in 10 mM Tris-HCl, 120 mM NaCl pH 8.4 and 
then analysed, together with the other sucrose gradient fractions, by Coomassie stained 
SDS-PAGE and Western blot.  
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A similar experiment was performed for the assessment of the VLP physical integrity upon 
incubation in SGF without pepsin, followed by pH neutralisation, using transmission 
electron microscopy (TEM). Purified HBcAg in water was diluted 1:6 with a solution of 73 
mM HCl to a final pH of 1.2. After two hours incubation at 37 °C, the pH was neutralised 
using aliquots of 400 mM NaHCO3. The resulting sample was used for TEM imaging.  
 
3.3.1.3 HBcAg Physical Stability in Acid Without Pepsin 
Considering the extreme variability in the pH of the human gastric fluid, it was considered 
important to evaluate the physical stability of HBcAg not only at the standard pH of SGF 
(British Pharmacopeia, 2012), but at a wider range of pH values likely to be encountered in 
the human stomach. Native agarose gel electrophoresis had been used before to assess the 
stability of bacterially expressed HBcAg incubated under a wide range of conditions, 
including different pH (Newman et al., 2003). In that research the authors also suggest that 
sucrose density gradient assays, measuring changes in the hydrodynamic properties, can be 
more sensitive for conformational changes; in contrast native agarose gel electrophoresis 
and TEM can constitute a more direct way to assess the particle integrity (Newman et al., 
2003). For this reason, in order to define a net threshold of stability upon incubation of 
HBcAg at a series of different pH, the native agarose gel electrophoresis assay was 
considered best. This technique has a high detection limit for HBcAg compared to other 
techniques; hence concentrated dilutions of the antigen in the incubation media were used. 
In a preliminary experiment, two solutions of 100 mM HCl (pH 1) with 34 mM NaCl and 
10 mM HCl (pH 2) with 34 mM NaCl were prepared. As a control, a solution of PBS was 
used. Purified HBcAg, dialysed in water was diluted 2:3 in each of the aforementioned 
acidic solutions and in PBS. After two hours incubation, each solution containing HBcAg 
at a different pH was loaded on the wells of an agarose gel for gel electrophoresis. The gel 
was then ethidium bromide stained.  
 
In another experiment, four solutions of 10 mM HCl (pH 2) with 34 mM NaCl, 3.2 mM 
HCl (pH 2.5) with 34 mM NaCl, 1 mM HCl (pH 3) with 34 mM NaCl and 0.32mM HCl 
(pH 3.5) with 34 mM NaCl were prepared. Purified HBcAg, dialysed in water, was diluted 
1:4 in each of the four acidic solutions. After two hours incubation, each solution 
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containing HBcAg at a different pH was loaded on the wells of an agarose gel for 
electrophoresis. The gel was then ethidium bromide stained and Coomassie stained. 
 
3.3.1.4 HBcAg Chemical Stability in Simulated Gastric Fluid (SGF) with Different 
Pepsin Concentrations 
The relative chemical stability of HBcAg in SGF in the presence of pepsin was evaluated. 
Pepsin is a protease and it can, therefore, biochemically digest the primary structure of a 
protein, i.e. the protein amino acid sequence. SGF with pepsin, based on the British 
Pharmacopeia (2012) contains 3.2 mg/mL pepsin (Ph Eur) and 34 mM NaCl at pH 1.2. 
However, given the extremely high variability of pepsin activity found in the human 
stomach (Gomes et al., 2003), it was decided to assess the stability over a wider range of 
pepsin concentrations, keeping the pH constant at pH 1.2. The stability of HBcAg after 
incubation in SGF with pepsin was evaluated by separating the residual HBcAg by SDS-
PAGE. The SDS-PAGE gel was then used for immunodetection by Western blot. 
  
A 50 mg/mL stock solution of pepsin (Ph Eur) from porcine gastric mucosa in 63 mM HCl 
with 34mM NaCl was prepared and the final pH was adjusted to pH 1.2. In parallel, 
purified HBcAg in water was diluted 1:4 in a 67 mM HCl solution, giving a final pH of 
1.2. Different aliquots from the pepsin stock (pH 1.2) were added to the VLP solution of 
the same pH, in order to obtain VLP samples incubated with four different concentrations 
of pepsin and a control with no pepsin (10, 3.2, 1, 0.5 and 0 mg/mL). After two hours 
incubation at 37 ºC, the samples were boiled to stop the enzymatic reaction and analysed 
by Western blot. 
 
For samples at lower concentrations of pepsin, a 10 mg/mL stock solution of pepsin (Ph 
Eur) from porcine gastric mucosa in 63 mM HCl was prepared and the pH was then 
adjusted to 1.2. In parallel, purified HBcAg VLP in water was added at a volume ratio 1:4 
to a 67 mM HCl solution, giving a final pH of 1.2. Different aliquots from the pepsin stock 
at pH 1.2 were added to the VLP solution of the same pH, in order to obtain VLP samples 
incubated with four different concentrations of pepsin and a control (0.2, 0.1, 0.05, 0.01 
and 0 mg/mL). After two hours incubation at 37 ºC, the samples were boiled and analysed 
by Western blot. 
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3.3.1.5 HBcAg Chemical Stability in Fasted State Simulated Gastric Fluid (FaSSGF) 
and in Fed State Simulated Gastric Fluid (FeSSGF) 
Fasted State Simulated Gastric Fluid (FaSSGF) and Fed State Simulated Gastric Fluid 
(FeSSGF) have been developed as bio-relevant media that can mimic closely the pre- and 
post-prandial conditions of the human stomach, respectively. HBcAg was tested in these 
two media, in order to obtain a clearer understanding of its potential use as an orally 
delivered therapeutic. A different source of pepsin from the one used in the previous 
experiments was used to prepare both FaSSGF and FeSSGF, in accordance with the 
original recipes described by Vertzoni et al. (2005) and Fotaki et al. (2005): pepsin (≥ 400 
units/mg) from porcine gastric mucosa, a raw material that contains 60 to 70 µg of pepsin 
protein per mg of solid product, was used. Therefore, the calculation of pepsin 
concentration in the media should be performed considering not just the total solid weight, 
but the actual pepsin content in the solid (Diakidou et al., 2009; Fotaki et al., 2005; 
Vertzoni et al., 2005). 
 
Initially, FaSSGF, containing 0.1 mg/mL pepsin, 80 µM taurocholic acid (sodium salt), 20 
µM lecithin and 34 mM NaCl at pH 1.6 was prepared according to Vertzoni et al. (2005). 
FeSSGF was prepared according to Fotaki et al. (2005): full-fat UHT milk is the main 
component. In parallel, a pepsin stock solution of 1.83 M HCl containing 1.1 mg/mL 
pepsin was prepared. Aliquots of this pepsin stock were subsequently added to the milk 
during the incubation of HBcAg in FeSSGF, so as to mimic the pulsatile release of acid 
and pepsin during normal human digestion (Fotaki et al., 2005). Fifty (50) µL of purified 
HBcAg were added to 950 µL of FaSSGF medium. Similarly another sample of 50 µL of 
purified HBcAg was added to 950 µL of full-fat milk, which was the FeSSGF starting 
component. The samples were then incubated at 37 ºC for three hours. During the 
incubation the FeSSGF was supplemented with 8 µL of the 1.83 M HCl stock solution 
containing 1.1 mg/mL pepsin. These additions were performed after 0, 15, 30, 45, 60, 75 
and 90 minutes from the beginning of the incubation, resulting in pH and enzymatic 
changes over time, closely mimicking the postprandial changes observed in vivo (Fotaki et 
al., 2005). Aliquots from both the FaSSGF and FeSSGF incubations were sampled after 
30, 60, 120, 180 minutes from the beginning of the incubation. The enzymatic reaction was 
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immediately stopped in each sample by adding one volume of 3X LDS β-mercaptoethanol 
to two volumes of the sample and subsequent boiling.  
 
Identical samples incubated in FaSSGF in absence of pepsin and in full-fat milk in the case 
of FeSSGF were used as enzyme-free controls. At the end of the experiment, all the 
samples corresponding to different incubation time points for FaSSGF and FeSSGF were 
separated by SDS-PAGE gel electrophoresis, followed by Western blot using the anti-
HBcAg polyclonal rabbit antibody, described in Chapter 2. 
 
3.3.2 HBcAg Stability in Simulated Intestinal Conditions and Pig Intestinal Fluids 
The intestine contains several enzymes, including trypsin and chymotrypsin, which could 
digest an antigen. Moreover, many novel nanoparticulate protein formulations, in 
particular those based on vesciular carriers, such as liposomes, can also be degraded by the 
detergent effect of physiological levels of intestinal bile salts (Parmentier et al., 2011). 
However, VLPs are protein-based particles and not vesicles and the conditions employed 
for the extraction of plant-expressed HBcAg from the leaves of Nicotiana benthamiana, 
suggest that HBcAg were stable in bile salts: in fact, the extraction buffer (described in 
Chapter 2) used for the extraction of VLPs from leaves, contained 0.75% sodium 
deoxycholate, corresponding to a concentration greater than 18 mM. Nevertheless, VLPs 
were intact when extracted using this extraction buffer (Figure 2.4 in Chapter 2). For a 
comparison the concentration of bile salts in the gut is considered to range between 0.5 
mM and circa 11 mM, depending on the fasted/fed condition and on the section of intestine 
(i.e. duodenum, jejunum, ileum) (McConnell et al., 2008b). Thus the concentration used in 
extraction buffer is well above that found in the human gut.  
 
Based on this, it was considered that the main parameter that could influence the stability 
of HBcAg in the intestine is the presence of digestive enzymes. For this reason, a model 
intestinal fluid containing digestive enzymes was required: hence Simulated Intestinal 
Fluid (SIF) containing pancreatin was used (British Pharmacopeia, 2012). An ex vivo study 
using pig intestinal fluids was also carried out, in order to more closely resemble the in 
vivo conditions. All digestion studies were performed over 4 hours duration, as it has been 
established that the small intestinal transit time in humans is almost invariably 3 to 4 hours 
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in most individuals, and is also not considerably influenced by the presence or absence of 
food (McConnell et al., 2008b).  
 
3.3.2.1 HBcAg Chemical Stability in Simulated Intestinal Fluid (SIF) 
Simulated intestinal fluid (SIF) with pancreatin was prepared by mixing 7.7 mL of 0.2 M 
NaOH with 25 mL of a solution containing 6.8 g of K2PO4 and 50 mL of water. Porcine 
pancreatin (≥ 3× USP), 333 mg, was then added. The pH was then adjusted to 6.8 and the 
volume diluted to 100 mL with water (British Pharmacopeia, 2012). SIF without 
pancreatin was prepared identically, but omitting the pancreatin. Before the stability 
experiment, a protease inhibitor tablet was diluted in 5 mL SIF without pancreatin. This 
concentrated solution is 10 x more concentrated than the recommended dilution suggested 
by the manufacturer to ensure effective enzymatic inibition. 
 
For Coomassie stained SDS-PAGE and Western blot, five identical samples were prepared 
by dilution of purified HBcAg 1:19 in SIF. Each sample represented a different time point 
of HBcAg digestion in SIF: samples 1, 2, 3, 4 and 5 were incubated for 240, 180, 120, 60 
and 30 minutes, respectively. A 1:19 dilution of HBcAg in SIF without pancreatin was 
used as a positive control. A 1:19 dilution of water in SIF was used as a negative control. 
The incubation temperature was set at 37 ºC. Back-preparation of the five samples in 
reverse order (i.e. starting the reaction at different times) allowed stopping the enzymatic 
reaction at the same time in all the samples, immediately before processing of all samples 
together. For this purpose the (10 x) protease inhibitor solution was diluted 1:9 in each 
digestion sample.  
 
The samples corresponding to each time point were separated in two SDS-PAGE gels. One 
was subsequently Coomassie stained and the other was used for Western blot. 
 
3.3.2.2 HBcAg Physical Stability in Simulated Intestinal Fluid (SIF) 
For dot blot, an identical digestion experiment to the aformentioned one was carried out. 
The resulting digestion products at each time point and the positive control were loaded 
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onto six different sucrose density gradients. After ultracentrifugation, fractions from the 
sucrose gradients were collected and analysed by dot blot.  
 
For detection of HBcAg by native agarose gel, higher concentrations of HBcAg were 
required. Therefore, HBcAg was diluted 1:9 in SIF in five samples. Each sample 
represented a different time point of HBcAg digestion in SIF: samples 1, 2, 3, 4 and 5 were 
incubated for 240, 180, 120, 60 and 30 minutes, respectively. The incubation temperature 
was set at 37 ºC. Samples were also prepared in reverse order so that the the enzymatic 
reaction could be stopped at the same time in all samples. For this purpose the (10 x) 
protease inhibitor solution was diluted 1:9 in each digestion sample and the samples were 
immediately cooled on ice. A 1:9 dilution of HBcAg in SIF without pancreatin was used as 
positive control and a 1:9 dilution of water in SIF was used as a negative control. The 5 
samples and the controls were then loaded on two native agarose gels. After 
electrophoresis, one gel was ethidium bromide stained and the other was Coomassie 
stained.  
 
For TEM imaging, HBcAg was diluted 1:6 in SIF and the sample was incubated for 120 
minutes. The enymatic reaction was then stopped by 1:9 dilution of (10 x) Protease 
inhibitor solution in the digestion sample. The sample was kept cool on ice. TEM imaging 
was carried out within two hours of the end of the incubation. 
  
3.3.2.3 Ex Vivo HBcAg Stability in Natural Intestinal Fluid (natIF) 
Pig intestinal fluids were chosen as natural intestinal fluids (natIFs). The full-length 
intestine collected from the freshly killed animal was immediately transported to the 
laboratory and used for the collection of the luminal fluids. Firstly, the intestine was laid 
inside a fume-hood. The small intestine is circa 4 to 4.5 fold longer than the large intestine. 
Furthermore, the small intestine is considerably thinner then the colon and the luminal 
content is generally less viscous (Kararli, 1995; Merchant et al., 2011). After localisation 
of the small intestine and large intestine, the two parts were separated and the large 
intestine was discarded. Then, four segments of approximately the same size from the 
proximal to the distal small intestine were divided and luminal fluid content was collected 
from each of the four segments separately. Small aliquots were made and frozen at – 80 ºC 
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until use. Digestion experiments were conducted within ten weeks of collection of the 
fluids. 
 
For the SDS-PAGE analysis, aliquots from the four different segments of the small 
intestine were thawed and the solid content was pelleted by centrifugation at 9300 g for 10 
minutes. Aliquots from the most proximal part of the intestine (i.e. duodenum) were 
centrifuged twice to separate the more viscous phase. The supernatants constituted the 
natural intestinal fluid (natIF) of this study. The four natIFs from the proximal to the distal 
small intestine are referred to as natIF 1, natIF 2, natIF 3 and natIF 4 for the studies 
detailed below. Purified HBcAg aliquots were diluted 1:19 in each of the four natIFs and 
incubated at 37 ºC for 4 hours. At the end of the incubation, 1:3 dilutions of the four 
samples in water where made and then boiled to stop the enzymatic reaction. The four 
samples were then run on two SDS-PAGE gels. One gel was used for Coomassie staining 
and the other for Western blot. For a positive control, HBcAg aliquots were diluted 1: 19 in 
PBS. In parallel, further positive controls were created: 1:3 dilutions of the natIFs in water 
and LDS β-mercaptoethanol were boiled for 10 minutes and then cooled. Purified HBcAg 
was then added in the same ratio as in the digestion samples. This control allowed 
enzymatically inactive natIFs media to be compared to the active ones. Negative controls 
were also created by diluting the PBS in natIFs.  
 
For dot blot, on the day of the experiment, purified HBcAg aliquots were diluted 1:19 in 
the four natIFs and incubated at 37 ºC for four hours. Then, the proteolysis was stopped by 
the addition of 1:9 dilution of (10 x) protease inhibitor solutions in each digestion sample. 
For a positive control, HBcAg was dilued 1:19 in PBS. The control and the digestion 
samples were loaded onto five identical sucrose density gradients. After ultra-
centrifugation, fractions from the sucrose gradients were collected and analysed by dot blot 
using anti-HBcAg mouse monoclonal antibody.  
 
3.4 Results and Discussion 
The development of oral vaccines, which can effectively protect humans from infectious 
diseases, is one of the greatest challenges of today’s drug delivery research. However, the 
natural physiology of the GI tract presents a series of obstacles to the oral delivery of 
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vaccines. The first barrier that a vaccine encounters subsequent to oral administration is the 
harsh environment in the stomach and intestine. Gastric and intestinal fluids, designed for 
the digestion of food, could induce chemical and physical instability of protein-based 
antigenic vaccines (Lee, 2002). Plant-expressed HBcAg was used in this study as a model 
candidate vaccine and its potential stability in the GI tract was assessed in various media 
simulating the GI conditions, as well as in pig intestinal fluids. The main reason for which 
this delivery approach could be considered particularly promising is related to the dense 
and compact structure of the VLPs: their morphology, in fact, is similar to that of the main 
component of viruses that naturally invade, survive and proliferate inside various fluids of 
animals or plants. Therefore, they could be resistant to relatively harsh GI environmental 
conditions (Huang et al., 2005).  
 
3.4.1 HBcAg Stability in Simulated Gastric Fluid (SGF) 
HBcAg is a complex protein structure assembled as a VLP. The gastric fluid could 
interfere with the stability of HBcAg VLPs, due to the effect of pH and the presence of 
pepsin. These two conditions could degrade HBcAg by different mechanisms: the pH 
could physically denature the particles’ three-dimensional structure, while the pepsin could 
digest the protein's primary structure. For this reason, the effect of these two different 
environmental factors was investigated separately. Firstly, HBcAg VLP stability was 
studied evaluating the denaturing effect of the SGF in absence of pepsin, i.e. the pH effect; 
then the enzymatic digestion of HBcAg VLP was investigated using SGF in the presence 
of pepsin.  
 
3.4.1.1 HBcAg Stability in Simulated Gastric Fluid (SGF) without Pepsin 
Initially the stability of plant-expressed HBcAg VLPs was investigated at the acidic pH of 
the SGF (1.2).  
 
The results of these experiments are illustrated in Figure 3.1. It is worth noticing that the 
sucrose gradient was set up in a way to maintain its pH consistent with the incubation pH 
(Figure 3.1 A). This was done in order to prevent pH neutralisation of the test samples 
during the analysis, which could possibly have caused further conformational change of 
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the protein chains, thus affecting the assessment of protein stability and not giving a 
faithful representation of the sole effect of the acid on the VLP stability. Coomassie stained 
SDS-PAGE electrophoresis of the collected fractions, from the sucrose gradients at pH 8.4 
(control) and at pH 1.2, shows that the acidic pH of the SGF did not cause any disruption 
of the primary structure of the HBcAg, which was present throughout the gel as a circa 20 
kDa protein band (Figure 3.1 B). Therefore, HBcAg seems chemically stable under acidic 
conditions. HBcAg appeared to migrate to the bottom of the density gradient in the control 
sample, as indicated by the presence of the 20 kDa band only in the lanes corresponding to 
circa 30 and 40% (w/v) sucrose fractions (lanes 6 to 8), suggesting intact VLPs. However, 
in the sample incubated in SGF, part of the 20 kDa band could be seen diffused in most 
fractions of the sucrose density gradient (lanes 9 to 16), although the highest concentration 
of the protein was seen in the circa 40% (w/v) sucrose fraction (lanes 14 to 16). This result 
clearly suggests that the capsid structure of HBcAg VLP exhibits a certain degree of 
physical instability on exposure to the acidic conditions. This is based on the fact that 
intact particles are expected to be found almost exclusively in the 30 and 40% sucrose 
density fractions, as seen in the control, whereas partially disassembled VLPs may appear 
in the less dense gradient fractions.  
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Figure 3.1. HBcAg stability in simulated gastric fluid (without pepsin).  
(A) illustrates the setting of the experiment: purified HBcAg, dialysed from 30 and 40% 
sucrose gradient fractions, was incubated either in SGF (pH 1.2) or in the control, Tris 
buffer (pH 8.4). The content of both samples was then separated by density gradient 
ultracentrifugation, carried out at the respective pH. (B) shows the Coomassie stained 
SDS-PAGE of the fractions collected from the sucrose gradients of both the control sample 
and the sample incubated in SGF: supernatant (lanes 1 to 3); 10 to 45% sucrose fractions 
for the control (lanes 4 to 8); supernatant (lanes 9 to 11); 10 to 45% sucrose fractions for 
SGF (lanes 12 to 16). (C) illustrates the dot blot (polyclonal antibody) of a similar 
experiment: supernatant (dot 1); 10 to 45% (w/v) sucrose fractions for both control and 
SGF (dots 2 to 7). (D) represents the Western blot (monoclonal antibody) of the SGF 
fractions: supernatant (lane 1); 10 to 45% sucrose fractions (lanes 2 to 7). 
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The same samples were also analysed by dot blot (Figure 3.1C). In the dot blot of the 
control sample, most of the anti-HBcAg signal was visible in the circa 30 and 40% (w/v) 
sucrose fractions (dots 5 and 6). Instead, in the sample incubated in SGF, most of the 
HBcAg was detected in the less dense sucrose fractions (supernatant and dots 1 to 4) and at 
the bottom fraction of the gradient (dot 7), with a very weak signal in the circa 30 and 40% 
(w/v) sucrose (dots 5 and 6). This result suggests that HBcAg VLP was not physically 
stable in the SGF without pepsin (pH 1.2). However, the degree of instability was much 
more remarkable in the dot blot than in the Coomassie stained SDS-PAGE, where the 
HBcAg band intensity seemed most intense in the 30 and 40% (w/v) sucrose bands. 
Therefore, the same fractions collected from the sucrose gradient were also examined by 
Western blot analysis for a better understanding of this issue (Figure 3.1 D). This 
immunodetection technique confirmed the results of the corresponding Coomassie stained 
SDS-PAGE gel, where a circa 20 kDa anti-HBcAg signal could be detected mainly in 30 
and 40% (w/v) sucrose fractions (dots 4, 5 and 6). In addition, weaker bands were also 
present in the supernatant and in the other fractions of the gradient, indicating partial 
disassembly of VLPs.  
 
Taken together, these results suggest that HBcAg VLP is chemically stable in SGF in the 
absence of digestive enzymes, but the quaternary structure that forms the VLP shows a 
certain degree of physical disassembly. However, there is a discrepancy in the results 
depending on the technique used: the SDS-gel assays (Coomassie stained gel and Western 
blot) show that most of HBcAg VLPs sedimented in the 30 and 40% sucrose fractions as 
expected for intact VLPs, with only a moderate amount of HBcAg present in the other 
fractions of the gradient. This is compatible with relatively modest instability of the 
capsids. The instability, however, seemed much more accentuated based on the outcome of 
the dot blot. This difference may be attributed to the fact that HBcAg VLP is not 
deliberately denatured in the dot blot process as it would be in the SDS-PAGE process, 
therefore the antibody might have bound differently to the denatured HBcAg (in the SDS-
PAGE gels) compared to the native HBcAg (in the dot blot). The different specificity of 
antibodies to denatured and native samples was also discussed extensively in Chapter 2. It 
can be speculated that the Coomassie stained SDS-PAGE gel, where the band intensity is 
merely proportional to the amount of protein present, and does not depend also on the 
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antibody affinity to the antigen, can probably be considered the most reliable method to 
estimate the extent of distribution of HBcAg throughout the sucrose density gradient.  
The physical stability of HBcAg in SGF in the absence of pepsin was also analysed by 
evaluating the fate of purified HBcAg VLPs after an initial incubation at pH 1.2 and 37 ºC 
for two hours, followed by neutralisation of the pH. The neutralised sample was layered on 
the top of a sucrose density gradient at pH 8.4 (Figure 3.2 A). After ultracentrifugation, the 
fractions from the gradient were collected and analysed. The dot blot shows that HBcAg 
could not be detected in any of the fractions of the sucrose gradient (Figure 3.2 B). 
However, a precipitate was visible at the bottom of the tube used for the ultracentrifugation 
of the sample. This precipitate was re-suspended and analysed by SDS-PAGE together 
with the other fractions from the gradient. The Coomassie stained gel (Figure 3.2 C) shows 
that a 20 kDa protein band corresponding to HBcAg was not present in any of the gradient 
fractions; however, a protein band, of a similar size to HBcAg, was visible in the re-
suspended precipitate sample (lane 8). A Western blot of the same sample (Figure 3.2 C, 
right side) revealed anti-HBcAg immunoreactivity at a protein size of 20 kDa, confirming 
that the precipitate contained HBcAg monomers. The fact that HBcAg was not found in 
any of the fractions of the gradient indicate that HBcAg was not present as intact VLP, nor 
as a disassembled monomeric or multimeric form. Furthermore, HBcAg sedimentation at 
the bottom of the gradient suggests that possibly the monomers or dimers aggregated in 
some sort of cluster that could migrate through all fractions of the gradient. For a final 
characterisation of HBcAg in SGF without pepsin, purified HBcAg particles were 
incubated in SGF at pH 1.2 for two hours and then the acidity was neutralised with 
NaHCO3. This sample was used for TEM imaging. The TEM image (Figure 3.2 D) shows 
that the typical HBcAg VLP structure detected in the control sample could not be found in 
the acidified and neutralised sample. Instead clusters of materials could be diffusely seen in 
the latter. It can be hypothesised that these clusters are agglomerates of HBcAg protein.  
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Figure 3.2.  HBcAg stability upon incubation in simulated gastric fluid (without 
pepsin) and subsequent neutralisation.  
(A) illustrates the setting of the experiment: purified HBcAg, dialysed from 30 and 40% 
sucrose gradient fractions was incubated at pH 1.2 and 37 ºC for two hours and the pH was 
subsequently neutralised. The resulting sample was separated by density gradient 
ultracentrifugation. Seven fractions were collected and analysed by dot blot and SDS-
PAGE. (B) shows the dot blot of the collected fractions; in the upper lane: supernatant (dot 
1); 10 to 45% sucrose fractions (dots 2 to 7) and in the bottom lane P = positive HBcAg 
control. (C) illustrates the Coomassie stained SDS-PAGE of the sucrose gradient fractions 
and of the re-suspended precipitate resulting from the ultracentrifugation: supernatant (lane 
1); 10 to 45% sucrose fractions (lanes 2 to 7); precipitate (lane 8). At the right side of the 
image the same precipitate was examined by Western blot (monoclonal antibody).  (D) 
illustrates two TEM images: a control HBcAg sample can be seen in the top image; an 
HBcAg sample upon acidification in SGF and subsequent neutralisation is shown in the 
bottom image.  
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The observation that HBcAg VLPs were unstable upon acidification in SGF and 
subsequent neutralisation was confirmed by a similar experiment using native agarose gel 
electrophoresis. In this experiment, samples of HBcAg were incubated in HCl solutions of 
pH 1 and pH 2 and in Tris buffer (pH 8.4, control) for two hours. Then, the three samples 
were directly loaded on the wells of an agarose gel in Tris/Borate/EDTA (TBE) buffer. 
After the electrophoresis, the gel was ethidium bromide stained. It is worth remembering 
from Chapter 2, that HBcAg VLPs contain nucleic acids and can be separated by 
electrophoresis in agarose gels. Therefore, HBcAg can be identified by the presence of 
ethidium bromide stained nucleic acid, which is encapsidated in its VLP. The image of the 
agarose gel (Figure 3.3 A) reveals that in the samples incubated at pH 1 (lane 2) and pH 2 
(lane 3) the band corresponding to the VLP was not present, whereas a clear band was seen 
in the control (lane 1). However, a strong signal was visible in the wells at pH 1 and pH 2. 
These results suggested that while intact VLPs in the control sample could migrate through 
the agarose gel, HBcAg agglomerated and remained blocked in the wells of samples 
incubated under acidic pH. Considering the previous finding that HBcAg seemed to 
agglomerate upon acidification and subsequent neutralisation, it is possible to hypothesise 
that HBcAg clustered when loaded in the gel, upon neutralisation by the 
Tris/Borate/EDTA (TBE) buffer present. This result is in accordance with Newman et al. 
(2003), who used native agarose gel electrophoresis to study the stability of HBcAg 
expressed in bacteria: it was shown that HBcAg, when incubated at pH 2 for only 30 
minutes, was unstable and it remained blocked in the well (Newman et al., 2003).  
 
A second experiment was conducted in order to establish the threshold pH for HBcAg VLP 
stability (Figure 3.3 B). The image of the ethidium bromide stained agarose gel (Figure 3.3 
B - left side) shows the presence of nucleic acids trapped in the wells of samples incubated 
at pH 2 (lane 1) and pH 2.5 (lane 2), while a nucleic acid smear was visible in the sample 
incubated at pH 3 (lane 3). Finally a discrete band was visible in the sample incubated at 
pH 3.5 (lane 4). The Coomassie stained gel (Figure 3.3 B - right side) confirmed the 
presence of a protein smear in the sample incubated at pH 3 (lane 3); furthermore a protein 
band could be seen in the sample incubated at pH 3.5 (lane 4): this band showed an 
identical electrophoretic migration to the respective lane in the ethidium bromide gel. As 
seen in Chapter 2, overlapping Coomassie stained and ethidium bromide stained bands is 
compatible with the presence of VLP that encapsidated nucleic acids. These results suggest 
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that HBcAg VLP quaternary structure is physically stable upon incubation in acid at pH 
3.5 for two hours. The VLP appeared only partially stable when incubated at pH 3 and 
totally unstable at lower pH. At pH 2 and 2.5, HBcAg seemed to agglomerate as revealed 
by the presence of trapped nucleic acids in the wells.  
 
 
Figure 3.3. HBcAg VLP stability in different acidic conditions.  
(A) represents an ethidium bromide stained native agarose gel where HBcAg is incubated 
at different pH: positive HBcAg control (lane 1); pH 1 (lane 2) and pH 2 (lane 3). (B) 
represents an ethidium bromide stained native agarose gel (left) and an identical 
Coomassie stained gel (right) where HBcAg is incubated at different pH: pH 2 (lane 1); pH 
2.5 (lane 2); pH 3 (lane 3) and pH 3.5 (lane 4). 
 
Based on these results, it is possible to think that HBcAg tends to disassemble rather than 
agglomerate upon incubation in acids (Figure 3.1), however, it completely agglomerates 
when the neutral pH is restored (Figure 3.2 and Figure 3.3). It is well known that 
hydrophobic interactions are responsible for the dimerization of monomers and that the 
residues between the amino acid 120 and 143 stabilise the dimer-dimer assembly into 
capsids (Metzger and Bringas, 1998; Pumpens and Grens, 1999; Wynne et al., 1999). 
Therefore, it can be suggested that the denaturing effect of the acid pH induces partial 
disruption (i.e. disassembly) of the monomer-to-monomer or dimer-to-dimer interactions 
responsible for proper assembly. Then, once the denaturing effect of the pH is removed by 
neutralisation of the pH, the same interactions, which usually keep the monomer and 
dimers assembled into well-defined capsids, could not be restored. Instead the subunits 
were driven into agglomeration. This behaviour is similar to HBcAg thermal instability: 
Newman et al. (2003) showed that native agarose gel electrophoresis of heat-denatured 
HBcAg results in nucleic acid stuck on the wells, when the gel is run at room conditions. 
This suggests that when HBcAg is subject to a denaturing shock (i.e. acidic pH or 
temperature) and then the denaturing agent is removed, the protein tends to aggregate. It 
can hence be suggested that as the thermal denaturation is irreversible (Wingfield et al., 
1995) so is the acid-mediated denaturation.  
Chapter 3 
 
 
107 
 
Finally native agarose gel electrophoresis revealed that this complete loss of the physical 
stability upon incubation of HBcAg for two hours in acid and further neutralisation occurs 
at pH < 3 to 3.5.  
 
The in vitro model of simulated gastric fluid adapted from British Pharmacopeia (2012) is 
based on two hours incubation at pH 1.2. However, the actual pH of human gastric fluid in 
fed state has been reported to range between 1.0 and 2.5 (Evans et al., 1988), although in 
some individuals the pH values can be as high as pH 5 to 6 (Efentakis and Dressman, 
1990). On the base of the experiments carried out in this research, it was possible to 
hypothesise that HBcAg VLPs are likely to be unstable in the stomach environment of 
humans. More specifically, it is possible that the pH would not cause a complete 
disassembly of the capsid three-dimensional structure; however, the subsequent passage to 
a more neutral pH in the intestine could induce complete VLP disassembly and 
agglomeration. This would reflect the VLP particular behaviour observed here. The fact 
that the VLP particulate structure was lost upon incubation in media at pH values lower 
than pH 3 to 3.5, suggests that even though the gastric pH in the fasting state can have 
individual variability, HBcAg would be unstable in the fasted gastric environment in most 
cases. In fact this experimentally-found pH 3 to 3.5 threshold, though useful to know as an 
absolute stability value, is well above the usual range of pH found in the empty stomach.  
 
3.4.1.2 HBcAg Chemical Stability in Simulated Gastric Fluid (SGF) with Pepsin 
The stability of purified plant-expressed HBcAg was evaluated after 2 hours incubation in 
SGF in the presence of pepsin, in order to model the digestive environment of the stomach. 
The British Pharmacopoeia (2012) formula of SGF has a fixed 3.2 g/L pepsin (Ph.Eur.) 
concentration; however variations of pepsin activity up to 4 orders of magnitude have been 
reported in humans (Gomes et al., 2003). For this reason it was decided to use other 
concentrations of pepsin as well as the pharmacopoeial concentration. Specifically, several 
aliquots of HBcAg were incubated in SGF at pH 1.2 containing pepsin at concentrations 
ranging from 10 g/L to 0.01 g/L. After two hours incubation, the samples were run on two 
SDS-PAGE gels that were subsequently used for anti-HBcAg Western blots (Figure 3.4). 
The Western blot shows that the 20 kDa band, present in the control and corresponding to 
HBcAg, was absent in the sample of HBcAg incubated in SGF containing 3.2 g pepsin/L, 
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i.e. the concentration specified in the British Pharmacopoiea (2012). Furthermore, some 
digestion of HBcAg occurred at all concentrations of pepsin. For concentrations of pepsin 
≥ 0.5 g/L (lanes 2 to 5), no anti-HBcAg signal was clearly detected; however, for 
concentrations of pepsin ≤ 0.2 g/L (lanes 6 to 10) a circa 14 kDa band of anti-HBcAg 
immunoreactivity could be visualised. Only when the concentration of pepsin was as low 
as 0.01 g/L (lane 10) was a detectable amount of 20 kDa HBcAg present.  
  
 
Figure 3.4. HBcAg digestion in SGF (with pepsin). 
HBcAg was incubated for two hours in SGF containing different concentrations of pepsin. 
The digested samples were then analysed by Western blot (monoclonal antibody): SGF 
without pepsin (lane 1 and lane 6); 10 g/L pepsin (lane 2); 3.2 g/L pepsin (lane 3); 1 g/L 
pepsin (lane 4); 0.5 g/L pepsin (lane 5); 0.2 g/L pepsin (lane 7); 0.1 g/L pepsin (lane 8); 
0.05g/L pepsin (lane 9) and 0.01 g/L pepsin (lane 10). 
 
This result suggests that HBcAg is extremely sensitive to chemical digestion by pepsin, not 
only at the pharmacopoeial pepsin concentration of SGF, but at thousands-fold lower 
concentrations. According to these data, it is likely that HBcAg would also be highly 
digested in the gastric fluid in vivo. 
 
3.4.1.3 HBcAg Chemical Stability in Fasted State Simulated Gastric Fluid (FaSSGF) 
and in Fed State Simulated Gastric Fluid (FeSSGF) 
The stability of purified plant-expressed HBcAg was then evaluated using the 
FaSSGF/FeSSGF models. The Western blot image (Figure 3.5) shows the results of 
HBcAg digestion in FaSSGF (Figure 3.5 - left side) and FeSSGF (Figure 3.5 - right side). 
On the left side of the image, it can be seen that the 20 kDa band, present in the control 
(lane 1), was absent after only 30 minutes of incubation in FaSSGF (lane 2). This suggests 
that HBcAg had been promptly digested in this medium. On the right side of the image, it 
can be visualised that the 20 kDa band, present in the control (lane 1), was consistently 
present for the first 60 minutes of incubation (lanes 2 to 3). At longer incubation times, i.e. 
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120 (lane 4) and 180 (lane 5) minutes, a faint anti-HBcAg signal could be detected at a 
protein size of circa 15 kDa. This is consistent with partial digestion of HBcAg over time. 
In all the lanes clear anti-HBcAg immunoreactivity corresponding to the presence of 
HBcAg dimers could be visualised. Dimers were visible at circa 40 kDa band for the intact 
protein over the first 60 minutes and circa 30 kDa for the partially digested HBcAg at 120 
and 180 minutes. Samples in FeSSGF did not show a perfect electrophoretic migration due 
to the presence of milk in the media. The results obtained indicate that HBcAg was 
strongly and quickly digested in FaSSGF. However, it was digested much more slowly in 
FeSSGF, where incubation times as long as 180 minutes could result in a digested form of 
HBcAg that was still immunoreactive. 
 
 
Figure 3.5. HBcAg digestion in FaSSGF and FeSSGF. 
HBcAg was incubated in FaSSGF and FeSSGF for 180 minutes. Samples were drawn at 
30, 60, 120 and 180 minutes. The digested samples were then analysed by Western blot 
(polyclonal antibody): positive control (lane 1), 30 minutes (lane 2), 60 minutes (lane 3), 
120 minutes (lane 4) and 180 minutes (lane 5). 
 
FaSSGF is definitely a harsher media than FeSSGF in terms of acidity; however the final 
concentration of pepsin in both media is comparable. Therefore, it is surprising that 
HBcAg was highly susceptible to digestion in FaSSGF, but it appeared to be partially 
stable in FeSSGF over the first 180 minutes of incubation. This result can be possibly 
explained by the presence of nutrient components of the milk reducing the enzymatic 
degradation of this candidate vaccine by being digested themselves. Intriguingly, it has 
already been reported that bystander proteins can protect candidate oral vaccine-ligands 
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against intestinal enzymatic proteolysis. Reuter et al. (2009) found that three vaccine-
ligands which were normally susceptible to enzymatic degradation in simulated intestinal 
fluids could withstand the enzymatic digestion for at least three hours when they were co-
incubated with Bovine Serum Albumin or Ovalbumin. The authors speculated that it would 
be advisable to administer oral vaccines, not on an empty stomach, but together with easily 
digestible irrelevant bystander proteins from foods. Moreover, a more recent study 
suggested that the formulation of an antigen in peanut butter favoured slower release and 
higher immunogenic responses than when the same candidate vaccine was delivered with 
honey and apple juice upon oral administration in mice. It was hypothesised that the 
protein and fat present in large quantities in the peanut butter could function as a 
“defensive coating” and act as a “decoy for digestive enzymes” (Pelosi et al., 2011a). The 
preliminary data presented here seems to support this hypothesis. Furthermore, it is 
reasonable to think that the presence of food in the stomach could buffer the harsh pH 
towards more neutral levels, allowing certain proteins to withstand the denaturation. It has 
been reported that after the administration of a complete nutrient drink, the neutralising 
effect of the meal on the pH was still apparent three and a half hours after intake (Kalantzi 
et al., 2006). Thus, a vaccine might possibly bypass the stomach barrier if “delivered” 
together with a meal, which is expected to act as a decoy for enzymes and simultaneously 
buffer and dilute the gastric fluid for hours.  
 
3.4.2 HBcAg in Intestinal Fluids: An In Vitro and Ex Vivo Stability Approach 
The second barrier that HBcAg could encounter upon oral administration is the harsh 
environment of the small intestine. In the following experiments the ability of HBcAg to 
withstand the intestinal digestive environment was investigated from two angles: firstly 
HBcAg was incubated in an in vitro model of intestinal fluid containing pancreactic 
enzymes. Then a more bio-relevant study was carried out using natural small intestinal 
fluids from pig, in order to closely mimic the in vivo scenario. It is worth remembering that 
HBcAg is a complex protein bearing an organised particulate quaternary structure. 
Therefore, in these stability experiments not only the chemical digestion was investigated, 
but also the influence of digestion on the maintance of the VLP’s particulate structure, i.e. 
the physical stability was evaluated.   
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3.4.2.1 HBcAg Stability in Simulated Intestinal Fluid (SIF) 
The two gels relative to the chemical stability of HBcAg incubated in SIF are shown in 
Figure 3.6. The Coomassie stained gel (Figure 3.6 A) shows that the circa 20 kDa band, 
seen in the positive control (lane 1) and corresponding to HBcAg, slightly overlaps with a 
much fainter band of the same size in the negative control (lane 2). For this reason, careful 
consideration is required when interpreting these results. At all incubation times, it appears 
that HBcAg was partially digested into slightly shorter proteins. In particular the more 
prominent digestion residual appeared at a circa 17 kDa protein band. The intensity of this 
band seems to increase proportionally with the incubation time in SIF. These results were 
confirmed by the Western blot, which shows that the strongest anti-HBcAg signal in the 
samples incubated in SIF (lanes 3 to 7) was the circa 17 kDa band. However, a series of 
anti-HBcAg bands of intermediate sizes between the full-length and the 17 kDa version 
were present in smaller quantities. As expected a circa 20 kDa band, corresponding to 
indigested HBcAg is seen in the positive control (lane 1) and no bands are present in the 
negative control (lane 2).  
 
Figure 3.6. HBcAg Chemical Stability in SIF. 
Aliquots of purified HBcAg were incubated in SIF with pancreatin for different time 
intervals. All the resulting digestion samples were analysed by SDS-PAGE. HBcAg was 
also incubated in SIF without pancreatin as a positive control; whereas a dilution of water 
in SIF with pancreatin was used as a negative control. (A) shows the Coomassie stained 
SDS-PAGE and (B) shows the Western blot (monoclonal antibody): positive control (lane 
1); negative control (lane 2); 30 minutes (lane 3); 60 minutes (lane 4); 120 minutes (lane 
5); 180 minutes (lane 6); 240 minutes (lane 7). 
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These results suggested that HBcAg was highly digested by the pancreatic enzymes of SIF. 
However, the main detectable product of this digestion was not smaller than circa 17 kDa. 
Considering that the anti-HBcAg mouse monoclonal primary antibody used has specificity 
for the first N-terminal 10 amino acids, it is evident that the digestion is expected to have 
only occurred at the C-terminus. In contrast, digestion of the N-terminal would have 
resulted in loss of affinity of HBcAg to this given antibody, resulting in a lack of 
immunoreactivity. 
 
The above results demonstrated that HBcAg was digested to a smaller protein after 
exposure to SIF. However, SDS-PAGE gels are carried out on denatured proteins (the 
denaturation being part of the processing for the gel electrophoresis), thus they can give 
information only about the stability of the primary structure. It was therefore necessary to 
define whether this chemical digestion maintained or disrupted the physical three-
dimensional structure of the VLP.  
 
Figure 3.7 illustrates the effect of the incubation of HBcAg in SIF with pancreatin on its 
physical stability. The dot blot (Figure 3.7 A) represents the HBcAg sedimentation upon 
ultracentrifugation of the samples undergoing the proteolytic treatment. Irrespective of the 
incubation time in SIF with pancreatin, most HBcAg immunoreactivity could be visualised 
in dots corresponding to the 30 and 40% (w/v) sucrose fractions, as in the undigested VLP 
positive control. This result suggests that HBcAg maintained its particulate form after 
digestion. This result was confirmed by native agarose gel electrophoresis (Figure 3.7 B). 
HBcAg incubated in SIF (lanes 2 to 7) showed electrophoretic migration almost identical 
to that of the untreated VLP of the control sample (lane 1). Finally TEM imaging (Figure 
3.7 C) indicates that VLPs were still present after incubation of HBcAg in SIF with 
pancreatin for 120 minutes. These results taken together strongly suggest that HBcAg was 
partially digested upon treatment in SIF; however the digestion did not seem to interfere 
with physical stability of the VLPs.  
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Figure 3.7 HBcAg Physical Stability in SIF. 
Aliquots of purified HBcAg were incubated in SIF with pancreatin for different time 
intervals. All the resulting digestion samples were either separated by density gradient 
centrifugation and analysed by dot blot, or directly examined by native agarose gel 
electrophoresis or TEM imaging. HBcAg was also incubated in SIF without pancreatin as a 
positive control; whereas a dilution of water in SIF with pancreatin was used as a negative 
control. (A) shows the dot blot (monoclonal antibody): percentages indicate the 
approximate concentration of the sucrose density fraction (S = Supernatant), while 
incubation times are listed vertically (P = Positive). (B) shows the native agarose gel: 
positive control (lane 1); negative control (lane 2); 30 minutes (lane 3); 60 minutes (lane 
4); 120 minutes (lane 5); 180 minutes (lane 6); 240 minutes (lane 7). (C) shows a TEM 
image of HBcAg incubated in SIF with pancreatin for two hours.  
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The pancreatin present in the SIF contains several pancreatic proteases, including trypsin, 
chymotrypsin and elastase, which could potentially digest antigens. Interestingly, it was 
reported in a virology study, that HBcAg, expressed in Xenopus oocytes, was partially 
digested into smaller proteins upon incubation in trypsin: the main residue was a circa 17 
kDa protein, but several intermediate forms ranging between 17 and 21 kDa were also 
detected, corresponding to different cleavage sites for trypsin at the C-terminus. However, 
the most striking finding was that intact capsids were digested only at the C-terminus and 
that this digestion did not affect the particle assembly (Seifer and Standring, 1994). It is 
worth remembering that HBcAg bears in its monomeric structure a C-terminal tail 
arginine-rich domain. This domain is not essential for the assembly and stabilisation of the 
monomers into a VLP (Chapter 1). Intriguingly, it was demonstrated that the trypsin 
digests only these C-terminus sequences, which were “non-essential” for the particle 
assembly. The authors suggested that these C-terminal regions are accessible to the 
enzymatic attack, while the other possible cleavage sites are relatively sequestered inside 
the VLP structure. Another important finding of the aforementioned research is that the 
maximal trypsin cleavage was achieved after only 8 minutes of incubation and that the 
addition of fresh protease or longer incubation times up to 8 hours did not increase the 
extent of specific digestion (Seifer and Standring, 1994). The results obtained in the 
current research in SIF with pancreatin strongly suggest that the main pancreatic enzyme 
involved in the digestion of HBcAg is trypsin. In fact the intestinal bio-relevant media used 
determined a similar pattern of digestion to that suggested in the study, described by Saifer 
and Standring (1994).  
 
Putting all these results into the wider context of oral delivery strongly suggest that HBcAg 
VLPs, though partially digested, could still withstand the harsh intestinal environment 
maintaining the particulate morphology and immunogenicity. In fact it was found that all 
the major epitopes mediating T- and B-cell responses are not found in the C-terminal 
arginine rich region (Vanlandschoot et al., 2003), which is digested by the trypsin. It is 
fascinating to ascertain that once again structures, whose design is the result of thousands 
years of evolution, have been naturally equipped to resist extreme environmental 
conditions. For instance, in this case only sequences that are non-essential for the stability 
and immunogenicity were digested, while the particle “scaffold” remained intact.  
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3.4.2.2 Ex Vivo HBcAg Stability in Natural Intestinal Fluids (natIFs) 
Despite the fact that pancreatic enzymes are the main proteases in the intestine, it has been 
recently reported that pancreatic proteases only partially contribute to the total intestinal 
enzymatic activity in animal models (Reuter et al., 2009). Therefore, the stability of 
HBcAg in natural intestinal fluid (natIF) of pig was investigated, in order to complement 
the in vitro model. 
 
The whole pig small intestine was execised in four parts of approximately same length and 
natIFs were collected from the resulting four sections and named natIF 1, natIF 2, natIF 3 
and natIF4 from the proximal to the distal regions.  For evaluating the extent of digestion, 
HBcAg was incubated in each of these natural media at 37 ºC for 4 hours and the fate of 
HBcAg was subsequently evaluated. Figure 3.8 shows the Coomassie stained SDS-PAGE, 
Western blot and the dot blot of the density gradient ultracentrifugation relative to this 
study. After the 4 hours incubation, the samples were diluted in water, boiled and loaded 
on gels for SDS-PAGE. The dilution step of samples in water was required, based on a 
preliminary experiment that showed that the very high protein content of the natIF did not 
result in good electrophoretic separation of bands when undiluted. As a negative control, 
natIF diluted in water was used. Positive controls, including a dilution of HBcAg in PBS 
and a dilution in previously boiled, and thus enzymatically inactive, natIFs were used. 
After electrophoresis one of the two gels was Coomassie stained while the other was used 
for Western blot. The Coomassie stained gel showed a faint 20 kDa band corresponding to 
HBcAg in the positive control in PBS (lane 1). However, it was difficult to identify 
HBcAg in the other samples containing natIFs due to the very high content of proteins of 
various sizes. Nevertheless, the Western blot of the same samples showed that anti-HBcAg 
immunoreactivity was detected at circa 20 kDa in all positive controls where natIFs had 
been previously inactivated (lanes 2 to 5). In contrast, for the actual digestion samples 
where active natIFs were present (lanes 6 to 9), HBcAg was mainly visible at circa 16-17 
kDa band. The intensity of the band was the highest in natIF 1 (lane 6) and reached a 
minimum in natIF 2 (lane 7), then it gradually increased in natIF 3 (lane 8) and natIF 4 
(lane 9). In natIF 4 a weak 20 kDa band was also present, probably corresponding to intact 
HBcAg. As expected, no bands were seen in the negative controls (lanes 11 to 14).  
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Figure 3.8. Ex vivo HBcAg Stability in pig intestinal fluids.  
Stability studies were carried out in four NatIFs collected from pig, named natIF 1, natIF 2, 
natIF 3, natIF 4 from the proximal to the distal small intestine, respectively. HBcAg was 
incubated in each of the aforementioned media at 37 ºC for four hours. (A) and (B) 
represent the Coomassie stained SDS-PAGE and Western blot (monoclonal antibody), 
respectively. The two gels were run identically: HBcAg in PBS (lane 1); HBcAg in 
inactive natIF 1 to natIF 4 (lanes 2 to 5, respectively); HBcAg in natIF 1 to natIF 4 (lanes 6 
to 9); empty lane (lane 10); PBS in natIF 1 to natIF 4 (lanes 11 to 14). (C) shows the dot 
blot (monoclonal antibody) of fractions collected from sucrose density gradient 
ultracentrifugation of different HBcAg samples incubated in each of the aforementioned 
natIFs. The sucrose concentrations corresponding to density fractions collected are 
indicated horizontally; the incubation samples analysed are indicated vertically. P = 
positive (HBcAg in PBS); S = Supernatant.  
 
In a similar experiment samples were not boiled, so they could maintain their native 
physical structure. However, the enzymatic reaction was stopped at the end of the digestion 
study by adding a protease inhibitor solution. Sucrose density gradient ultracentrifugation 
was then carried out in parallel for the four samples, corresponding to the digestion of 
HBcAg in the four natIFs, and for the control sample of HBcAg in PBS. After 
ultracentrifugation, fractions approximately corresponding to the original sucrose solutions 
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loaded were collected and analysed by dot blot. Figure 3.8 C shows that anti-HBcAg 
immunoreactive dots were found mainly in the 30 and 40 % (w/v) sucrose fractions, 
typical for intact HBcAg VLP, in the positive control. For samples digested in the natIFs, 
HBcAg was still detected mainly in the 30 and 40% (w/v) sucrose density fractions; 
however, some immunoreactivity was also present in the less dense fractions of the 
gradient.  
 
In the light of these results, the stability of HBcAg in natIFs can be discussed both in terms 
of chemical and physical stability. HBcAg incubated ex vivo in pig intestinal fluids was 
chemically digested mainly to the shorter, circa 16 to 17 kDa, form that matched the size of 
HBcAg resulting from the in vitro digestion in the SIF with pancreatin. This suggests that 
despite the fact that the intestinal natural fluids have a much wider pool of proteases than 
just the pancreatic proteases used in vitro (Reuter et al., 2009), the main product of HBcAg 
digestion appears to be the same.  
 
However, comparing the anti-HBcAg signal between the positive control and the HBcAg 
sample incubated in the enzymatically active natIFs, a decrease in the overall band 
intensity can be observed for the ex vivo samples, especially those samples incubated in 
natIF 2 and natIF 3. Such remarkable loss of HBcAg was not observed upon incubation in 
SIF with pancreatin, suggesting that a more aggressive chemical digestion occurred in the 
natural fluids than in SIF. Furthermore, differences in HBcAg digestion in the different 
natIFs collected from different parts of the small intestine could be possibly explained by 
the fact that the enzymatic activity is higher in the duodenum (proximal segment), where 
the pancreatic juice is released, than in the ileum (distal segment). A decrease in enzymatic 
activity on moving from the duodenum to the ileum has been demonstrated in humans, 
with only 22% of trypsin activity being preserved in the ileum compared to the duodenum 
(Whitcomb and Lowe, 2007). The increase in HBcAg stability on moving from natIF 2 to 
natIF 3 and then natIF 4 is therefore consistent with the intrinsic enzymatic activity of each 
intestinal segment. However, the fact that HBcAg is much more stable in natIF 1 than in 
natIF 2 was surprising. This result could be related to the ductal pancreatic physiology in 
pigs. It has been reported that the pancreatic duct in pigs enters the duodenum in the 
second, descending part of the duodenum. Furthermore it was found that pigs can have an 
accessory pancreatic duct that opens into the third part of the duodenum (Ferrer et al., 
Chapter 3 
 
 
118 
 
2008). In the current experiment the natIF 1 is constituted by the very proximal luminal 
fluid of the duodenum, possibly upstream from the pancreatic ducts, which discharge the 
pancreatic load in the second and third part of the duodenum. This could explain the lower 
degradation of HBcAg in natIF 1 compared to natIF 2. Moreover, it could be observed that 
natIF 1 fluid was remarkably thicker and more viscous than the other three natIFs fluids. 
The viscous content might have partially sheltered HBcAg from enzymatic digestion. 
 
In terms of physical stability of HBcAg in pig small intestinal fluids, the dot blot detected 
some minor anti-HBcAg signal in the less dense fraction of the gradient and thus suggested 
that partial disassembly took place upon incubation of HBcAg natIFs. However most of the 
immunoreactivity was still detected in the 30 and 40% fractions of the gradient, where 
usually intact VLPs are found. It is also worth noticing that the intensity of dots’ signal 
was moderately weaker in the natIFs than in the control, indicating partial HBcAg loss. 
This latter consideration is in accordance with what was seen in the Western blot.  
 
It can be concluded that HBcAg appeared chemically unstable upon incubation in pig 
intestinal fluids. However, these data also suggest that the principal digestion products 
were still immunoreactive and that HBcAg was still mainly present as a VLP. 
 
3.4.3 Contextualisation and Relevance of the Findings 
The aim of this Chapter was to gain a better understanding of the stability of purified plant-
expressed HBcAg in the gastro-intestinal (GI) tract. For this purpose, several in vitro bio-
relevant models simulating the GI conditions, as well as pig intestinal fluids, were used as 
incubation media for HBcAg. The stability of the antigen was investigated in terms of 
chemical digestion of HBcAg primary structure and physical stability and integrity of the 
VLP structure. The outcomes suggested that HBcAg was generally unstable in conditions 
simulating the human stomach in the fasting state, as a result of both physical instability in 
the harsh acidic pH and prompt enzymatic digestion by pepsin. However, improved 
chemical stability of HBcAg upon incubation in gastric fed state conditions was also 
suggested. Moreover, it was reported that the average stomach pH can remain > 3.5 for the 
first three hours after a meal (Kalantzi et al., 2006). Therefore, based on the finding that 
HBcAg was found to be physically stable upon two hours incubation at pH 3.5, it can be 
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expected that the VLP structure could be potentially physically stable at the pH of the fed 
stomach.  
 
Furthermore, it was found that HBcAg was promptly digested in the in vivo and ex vivo 
simulations of the intestinal condition. However, it remained physically stable upon 
digestion and maintained its most immune-relevant antigenic determinant. Therefore, it is 
possible to hypothesise that if these results were closely correlated to the in vivo scenario, 
HBcAg could circulate through the human small intestine withstanding major degradation. 
These findings can help interpret previous findings: previous research showed that HBcAg 
could elicit only weak immunogenicity upon oral administration in mice and it was 
speculated that exposure to the gastric environment could have resulted in either major 
chemical degradation or particulate disassembly (or both) before the VLP could enter into 
contact with the mucosal surfaces of the intestine (Huang et al., 2006). This assumption is 
supported by the current work and strongly suggests that HBcAg gastric instability, both in 
terms of chemical digestion and physical disassembly, can constitute a major obstacle to 
HBcAg oral delivery. The oral immunogenicity of a candidate vaccine is the result of the 
intrinsic ability of the antigen to efficiently cross the several GI barriers on its way down 
through the gut, including pH and enzymes. The current findings can be an important step 
towards understanding the complex oral immunogenicity of HBcAg. 
 
Investigations into the chemical stability of two plant viruses in simulated gastric 
conditions have been previously carried out. However, in these studies, the physical 
stability of the virus was not evaluated (Nuzzaci et al., 2010; Rae et al., 2005). In the 
current research a more systematic approach was adopted: the gastro-intestinal barriers 
were evaluated separately, analysing firstly the pH influence and then the enzymatic 
degradation. Furthermore, the fate of the VLP was evaluated not only in terms of chemical 
digestion of the primary structure, but also in terms of the stability of the three-dimensional 
quaternary structure. In addition, a wide range of different conditions of the gastric fluids 
was employed to account for the extremely high variations of pH and pepsin activity in the 
human stomach (Efentakis and Dressman, 1990; Gomes et al., 2003), so that more 
representative conclusions regarding the fate of HBcAg VLPs in the stomach could be 
drawn. Finally, it was recently reported that the use of simulated intestinal fluids to assess 
antigen stability is not the most efficient means to simulate the in vivo conditions. 
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Therefore, it was proposed that the use of intestinal fluids from animals could be a more 
efficient way to simulate the in vivo scenario in humans (Reuter et al., 2009). Based on this 
knowledge, it was decided to flank the results of HBcAg stability in the routinely used 
simulated intestinal fluids, with the evaluation of its stability upon incubation in natural 
intestinal fluids of pig.  
 
Overall, this Chapter presents a deep investigation into HBcAg stability in GI bio-relevant 
conditions. In addition a systematic method for the effective assessment of VLP stability 
was developed, possibly adaptable to other VLP candidates for oral use.  
   
3.5 Conclusions 
HBcAg gastric stability was investigated using in vitro models of gastric fluids. HBcAg 
was demonstrated to be physically unstable at gastric pH, showing a peculiar behaviour 
where it appeared only slightly unstable upon acidification, but showed major aggregation 
upon subsequent neutralisation. Furthermore, HBcAg could be highly digested by 
biologically relevant concentrations of pepsin at the simulated gastric pH. However, 
HBcAg appeared to be relatively more stable at pH > 3.5 and under conditions mimicking 
the fed state of the stomach. In simulated intestinal fluids, HBcAg was shown to be highly 
digested, selectively at the C-terminal arginine-rich tail, which is not essential for the 
maintenance of the particulate structure, nor essential for HBcAg immunogenicity. Finally, 
more bio-relevant studies relative to the intestinal stability were carried out by incubating 
HBcAg ex vivo in pig intestinal fluids. HBcAg seemed to be subjected to a similar 
digestion pattern to that seen in simulated intestinal fluids; however, slightly harsher 
digestion occurred, leading to partial antigen recovery. Furthermore, a minor amount of the 
VLP seemed to have been physically disassembled.  
 
Taken together, these findings suggest that HBcAg would be very likely unstable in the 
stomach, but fairly stable in the intestine upon oral administration. Therefore, it can be 
suggested that oral delivery of HBcAg VLPs to the mucosal absorption sites could possibly 
be achieved if the antigen could be protected from the gastric environment. In the 
following two Chapters different approaches towards the development of oral formulations 
of HBcAg have been investigated. 
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4  Exploitation of the Expression in Plant for Oral HBcAg Delivery 
4.1 Introduction 
One of the most claimed advantages of the expression of recombinant vaccines in plant is 
the potential use of this technology for the development of oral vaccines. In other words, 
the use of plants as green bioreactors for the production of vaccines might allow an oral 
administration of raw plant material or more probably minimally processed plant 
formulations (Mason et al., 2002). This could result in a huge reduction in purification and 
formulation costs. Moreover, the expression of the vaccine within the plant cellular 
compartments could act as a sort of bio-encapsulation: it is in fact thought that such 
entrapment within the plant cell wall could confer protection of the vaccine from gastro-
intestinal (GI) degradation, if administered orally (Pelosi et al., 2011a; Walmsley and 
Arntzen, 2000).  
 
In Chapter 3 the intrinsic stability of HBcAg exposed to bio-relevant GI media was 
investigated and the results are summarised in Table 4.1. 
 
Table 4.1. HBcAg stability in bio-relevant GI fluids (summary of Chapter 3) 
Media  Chemical 
Stability 
Physical Stability Impact on 
immunogenicity 
Simulated Gastric 
Fluids 
   
Gastric pH Stable Partially denatured - 
agglomeration upon pH 
neutralisation (i.e. intestinal 
passage) 
VLP chemically and 
physically unstable and 
hence loss of 
immunogenicity 
Enzymatic digestion Degraded Chemical digestion 
incompatible with VLP 
stability 
Simulated and Natural 
Intestinal Fluids 
   
Enzymatic digestion Selectively 
digested at the C-
terminus 
Chemical digestion 
compatible with VLP 
stability 
VLP physically stable 
and immunogenicity 
maintained 
 
Based on this knowledge, HBcAg could represent a suitable candidate to study the effect 
of the plant bio-encapsulation on the oral delivery of the antigen: the leaves-mediated 
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delivery of the antigen in simulated gastric and intestinal media could be evaluated. 
Moreover, given the intrinsic antigen instability in the bio-relevant gastric media, it could 
be assessed whether HBcAg entrapment within plant leaves could somehow protect it from 
degradation and denaturation. 
 
In this research project, Nicotiana benthamiana was used as a platform for HBcAg 
expression. This plant is one of the most extensively used in molecular farming: it is 
particularly suited for transient expression, because it can be easily agroinfiltrated and it 
grows quickly (Conley et al., 2011). Nevertheless its potential use for oral administration is 
somehow contradictory. In some cases Nicotiana benthamiana leaves are regarded as the 
most promising candidate for the production of oral vaccines (Clark and Pazdernik, 2011; 
Coghlan, 2005): this plant is non-edible, offering a considerable advantage for its 
exploitation as a recombinant protein expression host, as there is no risk of contamination 
of the food chain. In contrast, other authors believe that the presence of alkaloids within 
Nicotiana benthamiana makes it unsuitable for oral delivery. For this reason, a bio-
engineered alternative version of Nicotiana tabacuum (a closely related species to 
Nicotiana benthamiana), containing very low amounts of alkaloids has been developed. 
This low-alkaloids tobacco was fed for 30 days to mice at concentrations as high as 20% 
(w/w) of the diet and it was perfectly tolerated (Menassa et al., 2007). More recently, 
alkaloids-free Nicotiana hybrid species were created: in this case even the subcutaneous 
administration to mice of crude extract from the leaves did not induce any toxicity (Ling et 
al., 2012). These low or free alkaloids Nicotiana versions could certainly constitute a good 
alternative for the possible production of oral vaccines in plants. Nevertheless, it is 
reasonable to think that even wild-type Nicotiana benthamiana could be sufficiently 
tolerable upon oral administration: the simple observation that Nicotiana tabacuum leaves 
are chewed regularly without apparent acute toxicity suggests that the ingestion of only 
few tens of milligrams of Nicotiana benthamiana plant material, for one-off oral vaccine 
administrations, should not lead to any acute side effect.  
 
The aim of this Chapter was to exploit the leaf material for the oral delivery of HBcAg. 
Several aspects had to be addressed. First of all the fresh plant material containing the 
antigen had to be efficiently processed into an unpurified pre-formulation, which could 
retain stable HBcAg VLP. The second objective was to evaluate the effect of the plant bio-
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encapsulation on the delivery of the antigen in simulated GI fluids, so to understand 
whether this natural delivery system could allow release of the entrapped antigen and 
whether it could offer some protection against the antigen degradation in the GI. The last 
objective of this Chapter was to exploit the antigen expression in plants to produce a 
simple and potentially cheap oral formulation that could effectively protect HBcAg from 
the GI degradation.  
 
4.2 Materials  
4.2.1 Molecular Biology Media, Buffers and Solutions  
General media, buffers and solutions used in this study for bacterial growth, plant agro-
infiltration and protein analysis are catalogued in Table 2.1 of Chapter 2. 
 
4.2.2 Antibodies and Antigens  
Antibodies and antigens standards used for Western blot, dot blot and ELISA are listed in 
Table 2.2 of Chapter 2. 
 
4.2.3 Enzymes and Other Materials Used for Stability and Release Studies 
The materials used for the preparation of bio-relevant media used for the incubation of 
HBcAg are indicated in Chapter 3. 
 
4.2.4 Other Materials Used in Molecular Biology Studies  
Materials used for SDS-PAGE, Western blot, dot blot, native agarose gel and ELISA are 
indicated in Chapter 2.  
 
4.2.5 Excipients Used for the Formulation of Tablets  
Alpha-lactose monohydrate (α-lactose monohydrate) is the most widely used filler 
excipient for tablets. Its main characteristics are good compactability, solubility in water, 
lack of hygroscopicity and a fairly non-reactive character (Alderborn, 2007). α-Lactose 
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monohydrate imparts mechanical strength to tablet formulations. It was purchased from 
Sigma-Aldrich (UK) in a reagent grade and used as received. 
 
Microcrystalline cellulose (MCC) is considered a good tablet former and it is extensively 
used as a filler in solid pharmaceutical formulations (Alderborn, 2007). The type of MCC 
used in this study is Avicel PH 101 and it was obtained from FMC BioPolymer (UK) and 
used as received.  
 
Partially gelatinized starch bears swelling properties that causes the tablet to rupture when 
in contact with a liquid. It was therefore used here as a disintegrant. Moreover partially 
gelatinized starch also functions as a binder in wet granulation formulations. It was 
purchased from Colorcon (UK) as the grade Starch 1500 and used as received. 
 
Magnesium stearate is usually used to reduce friction between the tablet and the punches 
during the formation and ejection of the tablet. It was therefore used as a lubricant. It was 
purchased from Aldrich (UK) and used as received. 
 
4.2.6 Excipients Used for the Coating of Tablets  
Eudragit L 100 is a polymer that dissolves at pH > 6. It is a copolymer of methacrylic acid 
and methyl methacrylate. It is commonly used for enteric coating of oral formulations with 
fast dissolution in the small intestine (Eudragit, 2011). Eudragit L 100 was kindly donated 
by George-William Smith (Evonik Industries, UK) and used as received.  
 
PlasACRYLT20 is a blend of anti-tacking agent and plasticiser added to the coating 
suspension (Evonik Industries, 2013). It was also kindly donated by George-William Smith 
(Evonik Industries, UK) and used as received. 
 
Triethyl citrate (TEC) is a commonly used plasticiser added to the coating suspension. It 
was purchased from Sigma Aldrich (UK) and used as received. 
 
Ammonia (NH3) used for the partial alkaline-neutralisation of the Eudragit L 100 was 
bought from Fisher Scientific (UK) as 35% solution in water and diluted to 1 M before use.  
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4.3 Methods 
In this Paragraph, different methods of processing of the plant material expressing HBcAg 
are described. Furthermore, the characterisation of the formulated plant material will be 
defined. Finally, the protocols used to assess the stability of HBcAg, as well as its release 
from the formulation are also explained. Molecular Biology techniques were carried out as 
described in Chapter 2, unless otherwise stated.  
 
4.3.1 Oven-drying 
Oven-drying is a simple desiccation method commonly used in food and pharmaceutical 
industry. It has been used in the past for the drying of plant-expressed vaccine candidates 
(Lee et al., 2003). 
 
Nicotiana benthamiana leaves were infiltrated with pEAQ-HT-HBcAgΔ176 as described 
in Chapter 2. Infiltrated leaves were harvested 6 to 7 days post-infiltration, weighed and 
spread on a tray. The tray was then incubated in oven at 40 ºC or 50 ºC for 5 days to dry 
the leaves before being collected. Alternatively when smaller batches were needed, after 
harvesting, leaf disks were prepared using a cork borer of 11 mm diameter and they were 
also oven dried at 40 ºC or 50 ºC for 5 days. After drying, the leaves or the leaf disks were 
kept in glass vials sealed with parafilm and stored in fridge (2-8 ºC).  
  
4.3.1.1 In Process Dehydration of Oven-dried Leaves 
Gravimetric analysis (GA) was used as a method to assess the water loss from the leaves 
due to dehydration during oven-drying. Circa three grams of wild type (wt) Nicotiana 
benthamiana fresh leaves were cut into approximately 1 to 2 cm pieces, which were 
equally distributed into three identical glass bottles. The total weight of the glass bottles as 
well as their empty weight was recorded immediately. Then the bottles were incubated in 
an oven at 40 ºC for 6 days. During the drying process, the total weight of the bottles was 
measured at different time intervals, in order to assess the water loss over time. The weight 
loss during the drying corresponds to water evaporation.  
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4.3.2 Freeze-drying 
Freeze-drying is a commonly used drying technique for the preparation of parenteral 
formulations. It is extensively used for the formulation of proteins and other bio actives, as 
it usually ensures high stability of the active ingredient. It has also been used for the 
production of fast-dissolving tablets; furthermore, it is widely used in the food industry. 
Freeze-drying is based on the sublimation, i.e. conversion from ice into vapour without 
passing through the liquid state. This phase transition is possible only at very low pressure 
conditions (Abdul-Fattah et al., 2007). In this Chapter, freeze-drying was used as a drying 
method for the leaves expressing HBcAg. 
 
Nicotiana benthamiana leaves were infiltrated with pEAQ-HT-HBcAgΔ176 as described 
in Chapter 2. Infiltrated leaves were harvested 6 to 7 days post-infiltration, weighed and 
laid on a tray for subsequent freeze-drying in a Wizard 2.0 freeze drier (VirTis, USA). For 
the thermal treatment step, the shelf temperature was initially set at – 60 C for 360 
minutes and was then reduced to the lowest possible temperature (maximum freezing 
mode) for 240 minutes to achieve maximum freezing. After this phase, the primary drying 
was carried out at a chamber pressure of 180 millitorr with sequential temperature steps of 
180 minutes, using the following order: - 45, - 35, - 25 and - 15 °C; this was followed by 
further drying steps at a chamber pressure of 180 millitorr with sequential temperature 
steps of 240 minutes: 5, 15, 20 and 25 °C.  
 
After freeze-drying, the leaf material was usually ground into powder using a Waring 
blender (UK). Alternatively disks from leaves expressing HBcAg were prepared using a 
cork borer of 11 mm diameter. The leaf disks were freeze-dried using the aforementioned 
protocol. Freeze-dried leaves or leaf disks were stored in glass vials sealed with parafilm 
and stored in fridge (2-8 ºC). Freeze-dried samples were generally used within 4 weeks 
from production. 
 
4.3.3 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) measures changes in mass, resulting from chemical or, 
sometimes, physical processes, as a function of temperature or isothermally as a function 
of time (Galwey and Craig, 2007). It is a simple and quick technique used for the 
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measurement of weight loss. Among other uses in drug delivery, TGA is commonly used 
for the measurement of the water content of a given drug or excipient. TGA was performed 
using a Hi-Res TGA 2950 (TA Instruments, Newcastle, USA). 
 
The residual water content of the oven-dried and freeze-dried wild type (wt) Nicotiana 
benthamiana leaf material was measured by weight loss due to sample dehydration. Dried 
leaves were ground into powder using a Waring blender (UK) and the resulting powder 
was used. Samples (n = 3) were loaded into open aluminium pans and heated from 30 ºC to 
110 ºC at a heating rate of 10 ºC/minute, and then were held (isothermally) at 110 ºC for 30 
minutes. The weight change was calculated as a measure of residual moisture content. 
Statistical differences in residual moisture content between the different drying techniques 
were calculated using a 2-tailed T-test.  
 
4.3.4 HBcAg VLP Stability upon Oven- and Freeze-drying of Leaves 
The stability of HBcAg within the leaf material upon oven-drying and freeze-drying was 
evaluated using the commonly used detection methods already described throughout this 
thesis. The chemical stability was evaluated by Coomassie stained SDS-PAGE and 
Western blot, while the physical stability of the VLP was assessed by density gradient 
ultra-centrifugation, followed by collection of fractions and dot blot analysis. Finally, 
HBcAg VLP overall stability was also quantified by sandwich ELISA. 
 
4.3.4.1 HBcAg VLP Chemical and Physical Stability: A Qualitative Investigation 
Nicotiana benthamiana leaves were infiltrated with pEAQ-HT-HBcAgΔ176. Three leaves 
from the same plant were harvested 7 days post-infiltration. Four leaf disks were prepared 
from each of the three leaves using a cork borer of 11 mm diameter. Three disks, one from 
each of the three leaves, were pooled together. This was done to minimise differences in 
expression levels. Each of the four collected samples was subject to a different treatment 
protocol: the first was frozen at – 80 ºC, the second was freeze-dried, the third was oven 
dried at 40 ºC for 5 days and the fourth was oven dried at 50 ºC for 5 days. The preparation 
protocol is summarised in Figure 4.1. 
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Figure 4.1. Preparation of leaf disks for different treatments. 
Four disks from each of three leaves expressing HBcAg were prepared. Three disks, one 
from each of the three leaves, were pooled together and either frozen, freeze-dried, oven 
dried at 40 °C or 50 °C.  
 
The oven-drying and freeze-drying were carried out as mentioned in the previous 
Paragraph. At the end of the 5 days the freeze-dried disks, the disks oven-dried at 40 ºC 
and those oven-dried at 50 ºC were used for protein extraction. Frozen disks (stored in the 
freezer at - 80 ºC) were thawed and used as a positive control. After extraction, small 
aliquots from the four crude extracts were run on two SDS-PAGE gels; then one was 
Coomassie stained, while the other was used for Western blot. The physical stability of the 
VLP was evaluated by layering the same four crude extracts on the top of different 10 to 
60% (w/v) sucrose step gradients. After ultracentrifugation seven density fractions were 
collected from the four gradients and analysed by dot blot. The gradient containing the 
crude extract from the leaf material previously stored at - 80 ºC was used as a control.  
 
4.3.4.2 HBcAg VLP Stability: A Quantitative Measurement 
The four crude extracts obtained from samples stored at - 80 ºC, from freeze-dried and 
oven-dried (both at 40 and 50 ºC) samples were also quantified by sandwich ELISA. The 
amount of HBcAg resulting from the extraction of the frozen sample was considered as the 
total extractable HBcAg. Therefore, the quantified HBcAg resulting from the extraction of 
the oven-dried and freeze-dried samples was calculated as a percentage ratio to the total 
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HBcAg extracted from the frozen material. Statistical significance was calculated using a 
2-tailed T-test. 
 
4.3.5 Delivery of Bio-encapsulated HBcAg in Simulated GI fluids  
In this Paragraph, the methods used for the investigation of the effect of the plant bio-
encapsulation on the protection and release of HBcAg in simulated GI fluids are described. 
 
4.3.5.1 Freeze-dried Bio-encapsulated HBcAg in Simulated Gastric and Intestinal 
Fluids 
In this study the delivery of HBcAg from freeze-dried leaves in SGF and SIF fluids in 
presence and absence of enzymes was evaluated. Simulated gastric fluid (SGF) was 
prepared according to the British Pharmacopeia (2012): SGF without pepsin was prepared 
as a pH 1.2 HCl, 34 mM NaCl solution; in parallel SGF with pepsin was prepared 
similarly, yet 3.2 g/L pepsin was added. SIF with and without pancreatin were prepared as 
in Chapter 3. One mL aliquots from SGF with and without pepsin and SIF with and 
without pancreatin were used for the stability-release study. Fifteen (15) mg of freeze-dried 
material were added to each of the four 1 mL media aliquots. The samples were then 
incubated at 37 °C for 2 hours and frequently vortexed. At the end of the incubation the 
solid material was separated from the supernatant by centrifugation of the sample at 12,000 
g for 5 minutes. The supernatant was immediately boiled to stop the enzymatic reaction, 
while the pellet was re-suspended in LDS β-mercaptoethanol, boiled and clarified again. 
Both the supernatant and the re-suspended precipitate of samples incubated in SGF with 
and without pepsin and in SIF with and without pancreatin were separated by SDS-PAGE 
gel for subsequent anti-HBcAg Western blot detection. 
 
4.3.5.2 Delivery of Bio-encapsulated HBcAg in Intestinal Fluids, after Pre-
incubation in Gastric Fluids 
The delivery of HBcAg from differently processed plant material was evaluated by 
incubating leaf disks in SGF, followed by subsequent incubation of the same plant material 
in SIF. This experiment was performed in order to see if the plant material could protect or 
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not the labile HBcAg against SGF and to evaluate if the antigen could be released in either 
SGF or SIF. 
 
Three leaves expressing HBcAg were collected and three disks were prepared from each 
leaf. Then three disks, one from each of the three leaves, were pooled together and freeze-
dried, oven-dried at 40 °C or frozen at – 80 °C. On the day of the experiment, fresh SGF 
with pepsin and SIF with pancreatin were prepared. The freeze-dried, oven-dried and 
frozen samples were incubated in 5 mL of SGF at 37 °C for 2 hours and were frequently 
vortexed. After this initial pre-incubation, SGF was carefully drained and the leaf material 
was collected with tweezers and incubated in 0.75 mL SIF for further 4 hours. Twenty five 
(25) µL aliquots were collected after 30 minutes, 2 hours and at the end of the 4 hours 
incubation. The residual leaf material was pelleted by centrifugation, re-suspended in LDS 
β-mercaptoethanol, boiled and clarified again. A control was prepared by incubating a 
fourth group of frozen leaf disks in SIF, without pre-incubation in SGF. Aliquots of 25 µL 
were also collected at the same predetermined time points. Finally, the 30 minutes, 2 hours 
and 4 hours incubation and re-suspended pellet samples collected from the frozen, freeze-
dried, oven dried and control disks were loaded on two SDS-PAGE gels, separated by 
electrophoresis and the gels were used for anti-HBcAg Western blot.  
 
A similar experiment was carried out for sandwich ELISA quantification. Freeze-dried, 
oven-dried and frozen leaf disks were incubated in 1 mL SGF with pepsin at 37 °C for 2 
hours and were frequently vortexed. After this initial pre-incubation, SGF was carefully 
drained and the leaf material was collected with tweezers and incubated in 1 mL SIF 
without pancreatin for further 4 hours. One hundred (100) µL aliquots were collected after 
30 minutes, 2 hours and at the end of the 4 hours. The residual leaf material was re-
suspended, homogenised in extraction buffer and clarified again. Finally, the collected 
samples were quantified by sandwich ELISA. For control, identical batches of frozen, 
freeze-dried and oven-dried disks from the same leaves used for the experiment were 
homogenised in extraction buffer and the total HBcAg content was calculated from these 
crude extracts. In this way the amount of HBcAg present in the supernatant and in the re-
suspended pellets upon incubation of leaf disks in SGF/SIF could be calculated as a ratio to 
the total HBcAg content of disks, made from the same leaves. 
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4.3.6 Formulation of Tablets 
Tablets are by far the most commonly used pharmaceutical dosage form. They are solid 
unit dosage forms obtained by the compression of powder: the coherence of the powder 
into compact form is promoted by bond formation during the compression. There are three 
main stages during the tableting: die filling, tablet formation and tablet ejection. Such a 
sequence, also called the compaction cycle, results in formation of tablet units. Two types 
of tablet presses are available: single-punch presses and multi-station (rotary) presses. In 
the case of single-punches presses one die and an upper and lower punch are present. The 
powder is generally filled in a feeding shoe, which is positioned over the die; movement of 
the feeding shoe allows the powder to flow into the die. The lower punch position 
determines the quantity of powder filled into the die; therefore the lower the punch is 
positioned the higher will be the weight of the final dosage form. The tablet is generated by 
the compression of the powder in the die due to the descent of the upper punch. The lower 
punch which is stationary during the compression moves upwards at the end of cycle, 
determining the ejection of the tablet. Tablets can be obtained either by direct compression 
of powder, or via wet granulation. Granules have usually better flowability and mixing 
homogeneity properties than powders used for direct compression. Furthermore, they 
generally elicit good compactibility. On the other side, direct compression is a faster and 
cheaper production method and it is more suitable for moisture sensitive actives 
(Alderborn, 2007). 
 
In this research, tablets were produced by direct compression of freeze-dried plant 
material, together with other excipients for compression. The freeze-dried leaves 
expressing HBcAg were carefully ground into powder and used as a natural matrix 
containing the active ingredient. The tablet formulation consisted of 69% (w/w) lactose 
monohydrate, 10% (w/w) ground freeze-dried leaf material, 10% (w/w) microcrystalline 
cellulose, 10% (w/w) pre-gelatinised starch and 1% (w/w) magnesium stearate. All 
ingredients except the magnesium stearate were blended together using a mortar and 
pestle, and then the lubricant was added. Given the small scale nature of the experiments 
(5-10 g of powder), tablets were produced using manual cycles; the powder mix was 
loaded into a Manesty E-2 single station tablet press (Manesty Machines Ltd., Liverpool, 
UK) and was compressed using round 7 mm diameter, plain, normal concave punches. The 
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powder was loaded for each single tablet using a spatula. Each batch of tablets consisted 
usually of 25 to 40 single dosage forms. The weight target for each dosage form was circa 
175 mg.  
 
4.3.7 Physical Characterisation of Tablets 
4.3.7.1 Weight Uniformity and Hardness Tests 
An essential parameter in the characterisation of tablets is the evaluation of the mass 
uniformity of tablets within a batch. To test uniformity, 20 tablets from the same batch, 
were weighed individually. After calculation of the mean weight, compliance with the 
British Pharmacopeia specifications was checked: for tablets with mean weights between 
80 and 250 mg, no more than two units can deviate by more than 7.5% and none by more 
than 15% from the average weight (British Pharmacopeia, 2012).  
 
Another important characteristic of tablets is the hardness: sufficient hardness is essential 
so that the tablets can bear handling and further processing, i.e. coating, packaging and 
transport, without being damaged. The hardness generally influences the disintegration and 
hence the dissolution profile of the dosage form; for a given powder mix, normally, 
enhanced hardness coincides with slower disintegration and dissolution. It should be 
noticed that the term “hardness”, commonly used in pharmaceutical industry and hence 
used here, should be more correctly defined as “resistance to crushing”. The hardness of 
the tablets was assessed using an Erweka TBH 28 apparatus (Erweka GmbH, Germany). 
The hardness of 3 tablets from each batch was measured in kilo-ponds (kp) and the mean 
value was calculated.  
 
4.3.7.2 Disintegration Time Test 
The disintegration of tablets is important to ensure reproducibility of the therapeutic effect, 
therefore, it should be as consistent as possible within a batch. The disintegration test was 
carried out by placing one single tablet in one of the tubes of the basket of a Copley DTG 
2000 apparatus with disks (Copley Scientific Ltd., Nottingham, UK). The basket was then 
immersed in water at 37 °C. The time required for the disintegration of each tablet was 
recorded and the mean value for three tablets was measured. The disintegration of 
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uncoated tablets should occur within 15 minutes according to British Pharmacopeia (2012). 
However, generally most immediate-release conventional tablets disintegrate within 5 
minutes or less. 
 
4.3.8 Coating of Tablets 
Oral dosage forms are often coated for different purposes: the coating can protect the 
active ingredient from environmental conditions, i.e. moisture and light, or it can mask the 
taste of certain active ingredients, or it can simply give a better appearance to tablets. 
However, one of the most important reasons for coating tablets is to modify the release of 
the active drug from the dosage form. Modified release formulations can be classified as 
prolonged released dosage forms and delayed release dosage form (British Pharmacopeia, 
2012). Delayed release of the active is often achieved using enteric coated dosage forms. 
Such formulations are used for the protection of the gastric mucosa from an irritant active 
ingredient and for the targeted release in a pre-determined area of the intestine. However, 
one of the main aims of enteric coating is the stabilisation of gastro-labile drugs 
(Balamuralidhara et al., 2011). Film coating is usually performed by spraying a polymeric 
dispersion or solution onto a tablet surface. The formation of a single layer of coating on 
the surface of an oral dosage form is the result of multiple repeated sequences, starting 
with droplet formation, contact, spreading, coalescence and evaporation (Dewettinck and 
Huyghebaert, 1998). In this research, tablets were film coated using an aqueous dispersion 
of Eudragit L 100, a commercially available polymer that is soluble at ≥ pH 6 (Eudragit, 
2011). 
 
4.3.8.1 Preparation of Coating Dispersion 
The preparation of the coating dispersion is based on the available guidelines of the 
company producing the polymer for the enteric coating. Eudragit L 100 is a co-polymer of 
methacrylic acid and methyl methacrylate, hence it is highly rich in carboxylic groups. 
Suspensions of such polymers in water can be re-dispersed to form a nano-sized latex. This 
is obtained by the addition of small quantities of NH3 or other alkali that partially neutralise 
the carboxylic groups, enabling the formation of latex-like dispersions. Creation of such a 
colloidal dispersion is essential for the subsequent film formation. Furthermore plasticisers 
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have to be added to the aqueous dispersion in order to enable the formation of a flexible 
film at relatively low temperatures. However, the addition of a plasticiser can lead to 
formation of sticky or rubbery coating. Thus, anti-tacking agents are also added in the 
aqueous dispersion, to counteract this tendency (Eudragit, 2011). 
 
The preparation of the coating dispersion was carried out in a beaker under continuous 
stirring; the excipients were added in the order indicated in Table 4.2. Two protocols with 
different stirring times were carried out and named protocol 1 and protocol 2, respectively. 
The respective stirring time in each phase of the formulation re-dispersion are specified in 
Table 4.2. 
 
Table 4.2. Formulation of the coating dispersion. 
Ingredient Function  Weight Stirring time 
Water  53 g  
Eudragit L 100 Polymer 10 g 15 minutes   
1M NH3 Alkali 5.6 mL 2 hours (1) 
Overnight (2) 
TEC Plasticiser 4.5 g 90 minutes (1) 
Overnight (2) 
PlasACRYL T20 Anti-
tacking/Plasticiser 
5 g 15 minutes (1) 
2 hours (2) 
 
4.3.8.2 Fluid-bed Coating  
A laboratory scale, top spray fluidised bed coater (Mini Coater/Drier 2, Caleva Process 
Solutions Ltd, UK) was used for coating the tablets. In this fluid-bed processing, pre-
heated air is forced into the bottom of the coating chamber, where the unit dosage forms 
are placed. This warm stream of air keeps the substrate fluidised and enables the applied 
coating to be dried. The coating dispersion mixed with atomised air is sprayed from the top 
via a nozzle. The main parameters that can be controlled are fan speed, bed temperature, 
pump speed and atomised air pressure of the nozzle. Figure 4.2 summarises the coating 
process carried out with the fluid-bed coater used in this study. 
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Figure 4.2. Fluid-bed coating. 
A warm airstream from the bottom, keeps the substrate (i.e. tablets) fluidised in the coating 
chamber. A nozzle, located above the tablets sprays atomised droplets of coating liquid 
onto the tablets surface. The airstream enables the coating to dry.  
 
Tablets were coated with the Eudragit L 100 dispersion. The air stream from the bottom of 
the chamber was set at a temperature of 30 ˚C. Nine to twelve (9 to 12) tablets per batch 
were placed in the coating chamber. The coating process was performed at a pump rate of 
1% (1.03 rpm), with an atomization pressure set at 0.6 bar and the fan speed was kept at 
80%. After coating, the tablets were left in the coater (bed temperature = 30 °C) for 10 
minutes to dry. Post-drying (curing) was performed by placing the coated tablets in a hot 
air oven at 40 °C for 2 hours. The final coating thickness is expressed in terms of 
percentage total weight gain (TWG), which is the difference in the weight of tablets prior 
to and at the end of the coating process divided by the initial weight of tablets. 
 
4.3.9 Dissolution-Stability Test of the Enteric-coated Tablets 
Dissolution tests are routinely used in the pharmaceutical field for the determination of the 
dissolution profile of solid dosage forms in GI bio-relevant media; such tests provide 
important information regarding the likely biological activity of the drug and can predict 
the in vivo performance of oral formulations (Wang et al., 2009).   
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The British Pharmacopeia (2012) specifications for delayed-release formulations indicate 
that the dosage form should be pre-incubated for 1 or 2 hours in an acidic medium, 
followed by incubation in buffer solution, preferentially at pH 6.8. At least two 
specification time points should be used: one at the end of the incubation in acid and the 
other after a pre-set time in the second media (British Pharmacopeia, 2012). For the current 
study, it was chosen to pre-incubate the samples in SGF with pepsin (pH 1.2), followed by 
incubation in SIF without pancreatin (pH 6.8). Samples were drawn only from the second 
medium and quantified by ELISA. Samples were not drawn from the SGF because HBcAg 
is a gastro-labile active, and hence any given amount of antigen, released from the 
formulation into SGF, would be promptly denatured and digested, becoming undetectable 
(Chapter 3). SIF without pancreatin was used, as pancreatin could have degraded the 
antibodies used in the ELISA assay and it was not well known whether the short version of 
HBcAg resulting from enzymatic digestion could be correctly measured by the ELISA 
assay. 
 
4.3.9.1 Preparation of the Dissolution Media 
Dissolution media were prepared in 1 L volumetric flasks according to British 
Pharmacopeia (2012). The single components were weighed, transferred into the flask and 
dissolved in distilled water under continuous stirring. The final pH was calculated using a 
calibrated pH meter and was adjusted using HCl or NaOH when needed.  
 
SGF was prepared by dissolving 2 g of NaCl and 3.2 g of pepsin (Ph. Eur.) in distilled 
water. Then circa 80 mL of 1M HCl was added, the pH was adjusted to pH 1.2 and the 
volume was diluted to 1 L. 
 
SIF was prepared by mixing of 77 mL of 0.2 M NaOH with a solution of 250 mL KH2PO4 
under continuous stirring and the volume was brought to 250 mL. Then the pH was 
adjusted to pH 6.8 by further addition of 0.2 M NaOH aliquots. Finally, the volume was 
diluted to 1 L.  
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4.3.9.2 Dissolution Method 
Dissolution tests were performed using a BP Apparatus I (Copley Scientific Ltd., 
Nottingham, UK). Three vessels were used and each was filled with 300 mL of SGF. The 
bath temperature was fixed at 37 ± 0.5 ˚C and the paddle rotation speed was maintained at 
50 rpm. Three coated tablets were weighed separately and one tablet was added into each 
vessel. After 2 hours incubation, the paddles were stopped, the media were discarded and 
the tablets were preserved by passing the content of vessels through a sieve. Tablets were 
then added to vessels containing 300 mL of SIF and incubated for further 6 hours. One (1) 
mL samples were collected after 30 minutes, 1, 2, 4 and 6 hours from the beginning of the 
incubation in SIF. Samples were filtered through 0.2 μm membrane filters and kept on ice 
until the end of the dissolution test. Finally, the samples were quantified by indirect and 
sandwich ELISA. The dissolution studies were conducted in triplicate and the average drug 
release ± SD was calculated. The results are expressed as cumulative percentage drug 
release versus time profiles. 
 
For control purposes, the total HBcAg content in the tablets was evaluated by adding three 
coated tablets in three different vessels of the dissolution bath containing 300 mL SIF 
without pancreatin. After 6 hours incubation, 1 mL samples were collected and filtered. 
The HBcAg content of these samples was also quantified by direct and sandwich ELISA. 
 
The release of HBcAg in SIF without pancreatin, after pre-incubation in SGF, was 
measured as a percentage ratio to the total HBcAg released in the control vessels where the 
tablets were incubated in SIF without pancreatin only.   
 
4.3.10 Imaging of Uncoated and Coated Tablets 
Coated and uncoated tablets were imaged by optical light microscopy and Scanning 
Electron Microscopy (SEM). 
 
4.3.10.1 Light Microscopy  
Light microscopy was used for the visual examination of coated and uncoated tablets. A 
microscope (Leica DM LS2, Leica Microsystems UK Ltd) connected to a digital camera 
Chapter 4 
 
 
138 
 
(JVC colour video camera, TK-C1481BEG, Victor company of Japan Limited, Thailand) 
were used. 
  
4.3.10.2 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) is a microscopy technique that allows three 
dimensional imaging of surfaces at high resolution (Kaminskyj and Dahms, 2008). In this 
work the surface morphology of tablets was examined. Using double-sided tape, the tablets 
were mounted onto stubs and coated with gold using a Polaron SC7640 sputter gold coater 
manufactured by Quorum Technologies. The gold coating was generally 15 nm thick. The 
imaging was carried out in a high vacuum environment. Images were taken using a JEOL 
JSM5900 LV SEM (Japan), mounted with a tungsten filament with an acceleration voltage 
of 5–20 kV. Images were taken with the kind assistance of Bertrand Leze, the laboratory 
chief technician in School of Environmental Sciences at the University of East Anglia.  
 
4.4 Results and Discussion 
The expression of antigens in plant has the potential to provide the candidate vaccine with 
a natural adjuvant: it is in fact hypothesised that the bio-encapsulation of the antigen within 
the plant cell could protect the antigen from GI degradation (Mason et al., 2002). 
Furthermore, the plant material containing the vaccine could be exploited to produce 
minimally processed, non-sterile pharmaceutical oral formulations, potentially cheap to be 
produced (Penney et al., 2011; Walmsley and Arntzen, 2000). In this Chapter, the 
processing of Nicotiana benthamiana leaves into a dry solid form, as well as the evaluation 
of the stability of HBcAg upon drying were evaluated. Furthermore the effect of the plant 
bio-encapsulation on the stability and release of HBcAg in simulated GI fluid was 
investigated. Finally, an oral formulation of plant vaccine, potentially stable in the GI 
environment was developed. 
 
4.4.1 Drying of Nicotiana benthamiana Leaves Expressing HBcAg 
The drying of Nicotiana benthamiana leaves expressing HBcAg using different drying 
methods was examined in this Paragraph. Initially the dehydration and the residual 
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moisture content were checked, and then the stability of the antigen upon drying was 
investigated.  
 
4.4.1.1 Drying of Nicotiana benthamiana Leaves: Dehydration and Residual 
Moisture Content 
The first step toward the development of a plant-based oral candidate vaccine was to 
process the leaf material expressing the vaccine into a dry form that could be possibly 
ground into powder. For this purpose freeze-drying and oven-drying were chosen as 
desiccation techniques. Initially the drying time in oven was evaluated. Then the different 
drying methods were compared in terms of water content remained after the process, so to 
define the most suitable drying method in terms of residual moisture content. 
 
In a preliminary study the water loss from Nicotiana benthamiana leaves was evaluated 
during the oven-drying process at 40 ºC, over 6 days incubation. Figure 4.3 illustrates the 
weight loss accounted as water loss during this process as a function of time in days. This 
figure shows that rapid water loss seemed to have occurred in the first day and then it 
slowly levelled up till the third day. Only circa 0.2% water was further removed from the 
third to the sixth day.  
 
 
Figure 4.3. In process Gravimetric Analysis (GA) of oven-dried leaves.  
Cut pieces of Nicotiana benthamiana leaves were oven-dried at 40 ºC. During the drying 
the weight loss (n = 3) was measured and then it was plotted against time (days). Error bars 
indicates SD.  
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Based on this result 3 to 4 days of oven-drying at 40 ºC is expected to be sufficient to 
achieve maximum water removal under the experimental conditions used. This relatively 
short drying time might have been due to the small sized batch (3 g) used in this 
experiment. Nevertheless, it is reported that tomato fruit expressing VLPs and transgenic 
clover expressing an antigen had been previously oven-dried: the tomato fruit was dried for 
2 weeks in a chemical hood with a final drying step in oven at 37 ºC for 24 hours (Zhang et 
al., 2006); the transgenic clover was oven-dried in oven at 50 ºC for 5 to 7 days (Lee et al., 
2003). Based on the previous references and considering that batches larger than 3 g might 
be used in future experiments, it was thought that a longer drying period of 5 days at 40 ºC 
might be needed and was therefore always carried out.  
 
Then three different drying methods were compared in terms of residual moisture of the 
leaf material. For this purpose Nicotiana benthamiana leaves were either oven-dried at 40 
ºC for 5 days, oven-dried at 50 ºC for 5 days, or freeze-dried. At the end the dried leaves 
were ground into powder using a blender (Waring, UK) and the residual moisture content 
of these leaf powders was measured by TGA. The results obtained are shown in Table 4.3.  
 
Table 4.3. A summary of the residual moisture content (%) of oven- and freeze-dried 
leaf material (mean ± SD) as measured by TGA. 
Drying method  
Oven-drying at 40 ºC 
for 5 days 
Oven-drying at 50 ºC 
for 5 days 
Freeze-drying 
Moisture content 
(%) (n = 3) 
6.21 ± 0.69 6.80 ± 0.42 6.24 ± 1.59 
 
The residual moisture content in the desiccated leaf samples was very similar for the three 
drying methods. As expected, the T-test revealed no significant difference between the 
values obtained. It can therefore be concluded that oven-drying at 40 ºC, oven-drying at 50 
ºC and freeze-drying were comparable in terms of their drying efficiency. However another 
essential parameter in the processing of plant-expressed vaccines is the physio-chemical 
stability of the labile antigen upon drying. Therefore, the three drying protocols were 
compared in terms of stability of the HBcAg VLP next. 
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4.4.1.2 Stability of HBcAg VLP upon Oven- and Freeze-drying of Leaves 
The evaluation of the stability of proteins upon drying can be quite complex: in fact 
different processing conditions can influence both chemical and physical integrity of the 
active ingredient (Abdul-Fattah et al., 2007). HBcAg VLP is a multimeric protein, where 
the effectiveness as an immunogen is dependent both on the chemical stability of the 
primary structure and on the physical stability of the particle in terms of tertiary and 
quaternary structure. In Chapter 2 it was shown that both chemical and physical integrity 
could be investigated using molecular biology techniques. In this Paragraph, these 
techniques were used for the assessment of the stability of HBcAg within the leaf material 
upon oven- and freeze-drying of the leaves. Frozen disks containing HBcAg were used as a 
positive control: it was in fact demonstrated that HBcAg VLP could withstand at least 
three freeze-thawing cycles, without significant stability loss (Nath et al., 1992). Therefore 
HBcAg can be considered totally stable when frozen. 
 
Frozen, freeze-dried or oven dried at 40 and 50 °C leaf disks containing HBcAg were 
homogenised with the extraction buffer and the crude extracts were used for Coomassie 
stained SDS-PAGE, Western blot and sucrose density gradient ultracentrifugation followed 
by analysis of the fractions by dot blot. The results are shown in Figure 4.4. In the 
Coomassie stained denatured gel (Figure 4.4 A), it was not possible to obtain clear 
information about HBcAg, as the bands due to the plant proteins did not allow selective 
recognition of HBcAg in all the lanes. However, it could be noticed that the intensity of the 
bands due to the plant proteins was the strongest for the frozen (lane 1), followed by the 
freeze-dried (lane 2), oven-dried at 40 °C (lane 3) and then oven-dried at 50 °C (lane 4) 
leaves. This suggests that generally the plant proteins were more stable when freeze-drying 
was used and less stable when the leaves were oven-dried, especially at the higher 
temperature. The Western blot (Figure 4.4 B) revealed that the 20 kDa immunoreactive 
band corresponding to HBcAg was present in all samples stored at the different conditions. 
Furthermore, major degradation products were not visible. This indicates that HBcAg was 
chemically stable within the plant material processed by freeze-drying (lane 2) and oven-
drying (lanes 3 and 4). However, the HBcAg signal intensity seemed lower for the oven-
dried samples, in particular for the one dried at higher temperature, suggesting moderate 
HBcAg loss during this process.  
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Figure 4.4. Stability of unpurified plant-expressed HBcAg upon drying of leaves. 
Leaf disks from fresh leaves expressing HBcAg were stored either at -80 °C (control) or 
freeze-dried, oven-dried at 40 °C for 5 days, or oven-dried at 50°C for 5 days. Then the 
crude extract from the control and from the differently desiccated leaf material was 
analysed by Coomassie stained SDS-PAGE, Western blot and sucrose density gradient 
ultracentrifugation followed by dot blot. (A) illustrates the Coomassie stained SDS-PAGE 
and (B) the Western blot (monoclonal antibody); in both cases: frozen (lane 1), freeze-
dried (lane 2), oven dried at 40°C for 5 days (lane 3), oven dried at 50 °C for 5 days (lane 
4) leaf material. (C) shows the dot blot (monoclonal antibody) of the density gradient 
fractions. The different drying processes are indicated vertically, while approximate 
sucrose fraction concentrations are indicated horizontally. S = supernatant 
 
Then the same crude extracts were separated by density gradient ultracentrifugation and 
seven fractions corresponding to different sucrose concentrations were collected. Analysis 
of these fractions by dot blot (Figure 4.4 C) shows that most of the anti-HBcAg 
immunoreactivity was present in fractions corresponding to 30 and 40% (w/v) sucrose both 
in the case of oven- and freeze-dried samples, as well as in the frozen control sample. 
Based on the fact that intact VLPs tend to sediment in the 30 and 40% (w/v) sucrose 
fractions, it can be suggested that the drying process did not interfere with the stability of 
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VLPs within the leaves. All together these results indicated that unpurified plant-expressed 
HBcAg was chemically and physically stable upon freeze- and oven-drying, even though a 
moderate HBcAg loss could be observed in the case of oven-drying. This latter observation 
was more pronounced at higher drying temperatures, i.e. greater loss occurred at 50 °C 
than at 40 °C.  
 
For a more quantitative investigation, the stability of HBcAg within the leaves upon drying 
using different methods was also evaluated by sandwich ELISA. Figure 4.5 illustrates the 
results of the ELISA: in the case of the freeze-dried leaf material 87.7% of HBcAg could 
be recovered compared to the frozen sample; instead only 56.5% and 43.9% HBcAg could 
be retrieved after the oven-drying at 40 and 50 °C for 5 days, respectively. The values 
obtained with the oven-drying at different temperatures were not statistically different (p > 
0.05- 2-tailed T-test). The sandwich ELISA developed in this research (Chapter 2) was 
specific for intact VLP, hence the quantified HBcAg in this assay should correspond to 
intact HBcAg only. The ELISA results therefore suggest that the most efficient drying 
method in terms of stability of the active ingredient was the freeze-drying, followed by 
oven-drying at 40 and 50 °C.  
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Figure 4.5. Quantitative evaluation of HBcAg stability upon drying of leaves.  
Four 11 mm leaf disks were prepared from each of three leaves expressing HBcAg. Four 
sets each of three disks, pooled from different leaves, were either frozen, freeze-dried, 
oven-dried at 40 °C or oven-dried at 50 °C. After the drying, the samples were used for 
protein extraction and the content of HBcAg in these extracts was measured by sandwich 
ELISA (n = 3). Error bars indicates SD. The frozen sample was used as a control and the 
stability of HBcAg is presented as a percentage ratio to the control. 
 
In this Paragraph, it was evaluated whether plant material expressing HBcAg could be 
exploited to produce a dry material usable for further pharmaceutical processing. Drying of 
the leaf material was achieved by freeze-drying and oven-drying. The two methods did not 
show any relevant difference in residual moisture content of the dried leaves, suggesting 
similar efficiency in terms of desiccation. However, freeze-drying was proven to offer 
better protection of HBcAg than oven-drying did. 
  
Nevertheless, the level of HBcAg VLP stability measured upon drying of leaves using the 
three drying methods is quite impressive. For comparison a similar study can be mentioned 
(Pniewski et al., 2011), where lettuce leaves containing Hepatitis B surface antigen 
(HBsAg) were freeze-dried and the stability of HBsAg after freeze-drying was evaluated. 
In that case most of the VLPs were lost upon drying, with less than 0.3% of the total 
HBsAg content being left in the lyophilised sample. A comparison of the HBsAg content 
in the freeze-dried sample to that present in the crude extract of fresh leaves (more than 
50% VLP/total HBsAg content) suggests almost complete physical instability of the VLPs 
upon freeze-drying (Pniewski et al., 2011). In another similar study, the stability of two 
other HBsAg proteins upon freeze-drying of the leaves was also evaluated: in this case the 
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VLPs content ranged between 13.2 and 95.9%, depending on the expression group of 
transgenic plants used (Pniewski et al., 2012). In the light of these comparisons, the results 
obtained in the current research on HBcAg are remarkable: in fact after drying most 
HBcAg seemed to be still present as VLPs, as indicated by the fact that most of the antigen 
banded in the 30 and 40% (w/v) fractions of the density gradient. Furthermore, the 
sandwich ELISA specific for intact VLPs confirmed high levels of stability of the VLPs 
upon drying of leaves.  
 
A final consideration can also be made by comparing the gravimetric analysis with the 
HBcAg quantification. The weight loss upon drying was > 90% of the original weight; in 
the HBcAg stability experiment it was found that 87.7% and 56.5% of the VLP were stable 
upon freeze-drying and upon oven-drying at 40 °C, respectively. This more than 10-fold 
reduction in the weight of leaf material, combined with the considerable stability of VLPs 
suggests that the concentration (w/w) of the antigen in the leaf sample could be increased 
up to 10-fold with drying. This antigen concentration in the leaf tissue could offer evident 
advantages in terms of dosing of the oral formulation. Furthermore, it could also be an 
advantage for storage of the leaf material for production scaling-up purposes.  
 
4.4.2 Delivery of Bio-encapsulated HBcAg in Simulated GI fluids 
One of the main advantages of vaccine expression in plant is the potential oral 
administration of raw or minimally processed plant material containing the antigen, as the 
inclusion of the antigen within the plant cell wall holds the promise of protecting the 
vaccine against digestion in the gut (Walmsley and Arntzen, 2000). Despite the great 
potential and some initial encouraging results (Pelosi et al., 2012, 2011a), it is still unclear 
if, and to what extent, plant bio-encapsulation can effectively protect the antigen against 
digestion and then release the antigenic cargo in the target area of the intestine, where it 
can be absorbed. Therefore, the fate of plant bio-encapsulated HBcAg in SGF and SIF was 
investigated in this work, in order to assess the effect of the plant material on the stability 
and delivery of the antigen into the bio-relevant media.  
 
Initially, samples of freeze-dried plant material containing HBcAg were incubated in SGF 
with or without pepsin and in SIF with or without pancreatin at 37 ºC for 2 hours. The 
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supernatant was collected at the end of the two-hour incubation of the samples in the four 
different media. Furthermore, the residual solid plant material was precipitated by 
centrifugation and the pellet obtained was re-suspended in LDS β-mercaptoethanol. This 
protocol allowed a separate evaluation of release and stability aspects of the plant 
expressed antigen in different media. The supernatant of samples incubated in SGF and 
SIF without enzymes gave information about HBcAg release. Conversely, the HBcAg 
detected in the supernatant of samples incubated in SGF and SIF with enzymes was that 
remaining after both release and digestion, as for any given amount of HBcAg released 
into the medium, at least some digestion would have occurred. On the other hand, the 
analysis of the pellets could explain whether some unreleased antigens were segregated in 
the plant material and whether this possible segregation could allow antigen protection 
against digestion in the presence of enzymes. The four supernatants and the four re-
suspended pellets, resulting from incubation in the SGF with and without pepsin, and SIF 
with and without pancreatin were run on SDS-PAGE gel. The gel was then used for anti-
HBcAg Western blot immunodetection. This image, illustrated in Figure 4.6, shows that a 
20kDa anti-HBcAg signal was present in the supernatant of samples incubated in SGF 
(lane 1) and SIF (lane 3) in absence of enzymes. However, upon incubation in SGF with 
pepsin (lane 2) and SIF with pancreatin (lane 4), HBcAg was undetectable. No protein was 
detected in lane 2, but a circa 16 to17 kDa immunoreactive band could be visualised in SIF 
with pancreatin (lane 4). In the re-suspended pellets it was possible to observe similar 
results to those obtained with the supernatants (lanes 1 to 4). However, the bands did not 
look as sharp, due to the high concentration of plant material that impeded good 
electrophoretic migration and band resolution.  
  
Chapter 4 
 
 
147 
 
 
Figure 4.6. Delivery of HBcAg from freeze-dried plant material into SGF and SIF. 
Freeze-dried plant material containing HBcAg was incubated in different bio-relevant 
media. The fate of HBcAg upon incubation was evaluated by examination of the 
supernatant and of the re-suspended residual solid leaf material by anti-HBcAg Western 
blot (poyclonal antibody). The left part of the image shows the supernatants, while the 
right part relates to the re-suspended pellets. In both cases: SGF without pepsin (lane 1), 
SGF with pepsin (lane 2), SIF without pancreatin (lane 3) and SIF with pancreatin (lane 4).  
 
Taken together these results suggest that HBcAg was not completely trapped in the plant 
cell and was partially released into the media during the two hours of incubation, as 
indicated by the detection of “soluble” HBcAg in the supernatant of samples incubated in 
SGF and SIF without enzymes. However, such premature release implies a lack of 
protection; in fact free antigens in the media were digested when pepsin and pancreatin 
were present in SGF and SIF, respectively. The pattern of digestion was the same as seen 
with purified HBcAg in Chapter 3, where HBcAg was digested to an undetectable product 
in SGF; while it was only digested to a shorter 17 kDa protein in SIF. Examination of the 
results obtained with the pellets revealed that part of the HBcAg remained entrapped in the 
plant material, as indicated by the fact that some HBcAg could be detected in the pellets of 
samples incubated in SGF and SIF without enzymes. However, the fact that even the 
HBcAg contained in the pellet was digested in presence of enzymes, suggests that although 
the leaf matrix retained some HBcAg, it could not prevent the enzymes from coming into 
contact with the antigen, determining partial or complete digestion in the case of 
incubation in SIF and SGF, respectively. Overall, these results indicate that freeze-dried 
unpurified HBcAg within the leaf material was partially released in the simulated gastric 
and intestinal media; moreover, part of the antigen remained in the solid residual leaf 
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material. However, this segregation in the leaf cellular compartments did not prevent the 
enzymatic degradation.  
 
In another experiment, the leaf material containing HBcAg, previously frozen at – 80 ºC, 
freeze-dried or oven-dried, was pre-incubated in SGF with pepsin at 37 ºC for 2 hours. 
Then the solid leaf content was carefully removed and incubated in SIF with pancreatin for 
a further 4 hours. Aliquots of the supernatant during the SIF incubation were drawn and the 
final solid content was centrifuged forming pellets, which were re-suspended. This in vitro 
model of incubation in SGF and subsequently in SIF mimics the gastric transit and the 
passage to the intestinal fluids. The sampling from SIF incubation medium would be 
indicative of the antigen release in target areas of the gut, i.e. small intestine, where 
absorption is expected to take place. The supernatant aliquots and the pellets were then 
examined by Western blot. Moreover the influence of processing on the delivery of antigen 
in the bio-relevant media simulating both gastric and intestinal conditions could be also 
evaluated. As a control, frozen leaf material containing HBcAg was incubated in SIF with 
pancreatin, without pre-incubation in SGF. This enabled the examination of the release in 
the simulated small intestinal environment, devoid from the parameter of the gastric 
instability.  
 
The image of the Western blot, shown in Figure 4.7, revealed that HBcAg was always 
undetectable in the supernatant of SIF incubated with frozen, freeze-dried or oven dried 
samples (lanes 1 to 3 of each sample) when the leaf material was pre-incubated in SGF. 
However, a circa 16 to 17 KDa version of HBcAg was present in the re-suspended pellets 
of frozen, freeze-dried and oven dried samples (lane 4 of each sample). The intensity of 
this band seemed higher for the frozen, followed by the oven-dried and then the freeze-
dried leaf material. The result obtained in the control, where the plant material was not pre-
incubated in SGF, revealed that HBcAg was present in the supernatant as a 17 kDa band 
(control lanes 1 to 3). Furthermore a strong HBcAg signal was also present in the pellet 
(control lane 4).  
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Figure 4.7. Delivery of HBcAg from processed plant material upon incubation in GI 
simulating media. 
Frozen, freeze-dried and oven-dried leaf disks containing HBcAg were pre-incubated in 
SGF with pepsin for 2 hours and were subsequently incubated in SIF with pancreatin for 
further 2 hours. Aliquots from the supernatant in SIF were drawn after 30 minutes (lane 1), 
1 hour (lane 2) and 2 hours (lane 3) for examination by anti-HBcAg Western blot 
(monoclonal antibody). The residual leaf solid content was pelleted and then re-suspended 
at the end of the incubation (lane 4). As a control, frozen leaf disks were incubated in SIF, 
without a pre-incubation in SGF. P = positive control of HBcAg in PBS. 
 
The comparison of the control sample with all the other samples that were pre-incubated in 
SGF indicates that the pre-incubation resulted in premature release and subsequent 
instability of HBcAg and hence determined the apparent absence of HBcAg in SIF. 
Furthermore the re-suspended solid leaf pellets contained only small amount of HBcAg. In 
contrast, a considerable amount of HBcAg was released in SIF of the control sample that 
was not pre-incubated in SGF and was also present in the re-suspended pellet. These 
results taken together suggest that the up-stream passage of leaf material containing the 
antigen in the gastric environment could determine HBcAg degradation. In Chapter 3, it 
was shown that HBcAg was highly unstable in SGF, and the results of this study suggest 
that the entrapment of HBcAg in the plant material could not protect this antigen that was 
intrinsically unstable in SGF.  
 
A similar experimental design was carried out for ELISA quantification. Frozen, freeze-
dried and oven-dried leaf disks were pre-incubated in SGF with pepsin for 2 hours and 
then the leaf material was incubated in SIF without pancreatin for a further 4 hours. 
Samples were drawn during the SIF incubation. At the end of incubation period, the 
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residual leaf material (pellet) was re-suspended in the extraction buffer, without adding 
reducing or denaturing agent and without boiling the sample. Furthermore another batch of 
frozen, freeze-dried and oven-dried disks, made from the same leaves as the incubation 
samples, was used for protein extraction and total HBcAg quantification. This was done in 
order to compare the residual amount of HBcAg after SGF-SIF incubation, with the total 
amount of HBcAg present in the leaf tissue. At the end of the in vitro assay, the HBcAg 
content in the frozen, freeze-dried and oven-dried samples collected during the SIF 
incubation as well as the re-suspended pellets was measured by sandwich ELISA. Two 
differences in the assay design can be noticed as compared to the last experiment. First, 
SIF without pancreatin was used, as pancreatin could have degraded the antibodies used in 
the ELISA assay and it was not well known whether the short version of HBcAg resulting 
from enzymatic digestion could be correctly measured by the ELISA assay. Second, the re-
suspended pellets from the residual leaf material was kept in the native, undenatured state, 
because sandwich ELISA is specific for native HBcAg VLP preparation, as shown in 
Chapter 2 (page 68-70) .  
 
The ELISA suggested that HBcAg was undetectable in the SIF supernatant of frozen, 
freeze-dried and oven-dried leaf samples pre-incubated in SGF. However, a weak HBcAg 
immunoreactivity could be measured only in the leaf material (pellet), re-suspended after 
the incubation in SIF. The comparison of the total HBcAg content in untreated leaf 
material with the residual amount of HBcAg contained in the pellets of disk pre-incubated 
in SGF and then in SIF, revealed that circa 0.2% of the total HBcAg could be recovered in 
case of oven-drying and less than 0.05% (practically undetectable) in frozen and freeze-
dried leaf material. In this experiment a precise quantification would have been difficult: in 
fact, even though the re-suspended samples were used undiluted for the ELISA assay, only 
a weak immunoreactivity, close to that of the background, could be measured. Essentially, 
HBcAg was digested during the pre-incubation of the leaf in SGF, regardless of the drying 
method.  
 
Bio-encapsulated plant-vaccine systems designed for oral delivery should ideally protect 
the vaccine in the stomach and release it in the small intestine, where absorption takes 
place. Overall, the three assays carried out in this Paragraph consistently suggest that the 
leaf tissue does not constitute a perfect barrier for HBcAg from the external bio-relevant 
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media in which the material is incubated. Generally, HBcAg showed to be partially 
released from the plant material where it was expressed and once released the antigen was 
completely exposed to the medium, resulting in complete digestion of HBcAg in SGF and 
partial digestion in SIF. However, despite this undesired prompt release of the antigen 
from the plant material, if the residual HBcAg entrapped in the plant cell compartments 
could have remained protected from the harsh gastric environment, it could be possible that 
this small amount of HBcAg could be slowly released from the leaf tissue in distal 
segments of the upper GI. Nevertheless, the Western assays (Figure 4.6 and Figure 4.7) 
revealed that the HBcAg entrapped in the leaf material had been digested upon incubation 
just as the HBcAg already released. This suggests that the digestive enzymes could get into 
and attack the HBcAg entrapped inside the leaf tissue. Moreover, the use of differently 
processed plant material, i.e. frozen, freeze-dried or oven-dried, did not result in substantial 
differences. In conclusion, it can be hypothesised that the bio-encapsulation of HBcAg in 
Nicotiana benthamiana leaves would not be able to efficiently protect such a labile antigen 
from enzymatic degradation.  
 
Interestingly, it was recently suggested that upon oral administration of an antigen 
expressed in the leaves of Nicotiana bethamiana in mice and sheep, the antigen was 
mainly released in the stomach. In contrast, it was found that the expression of the same 
antigen in the roots of the plant resulted in a slower release of the antigen in the intestine 
(Pelosi et al., 2012, 2011a). Therefore, it was hypothesised that in case of labile antigens 
the expression in leaf might have not been the most-suitable approach (Pelosi et al., 
2011a), as prompt release of the antigen in stomach could have caused premature 
degradation. Indeed, data from the current research suggest that the bio-encapsulation of 
HBcAg, which is a gastric-labile antigen, did not prevent its release in the simulated gastric 
media and did not allow protection of the antigen. It is possible to speculate, as suggested 
by Pelosi et al. (2011a), that the expression of gastric-labile antigens in more fibrous plant 
parts, such as roots, could allow better gastric protection upon oral administration of the 
plant material. However, doubts remain about whether a tightly protected antigen within 
fibrous plant material could be released in the small intestine at all: if premature release 
negates any benefit of antigen incorporation within the plant, too efficient entrapment of 
the antigen within plant material could imply that the antigen does not get released at all in 
the gut. Therefore a balance between protection and release should be established on a case 
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by case approach, finely tuning the choice of the plant material to the antigen used (Pelosi 
et al., 2012). Nevertheless, it appears somewhat implausible that naturally occurring plant 
parts could act as an impermeable coat that protects a candidate vaccine till a certain area 
of the gut (i.e. stomach or upper small intestine), and then allow sudden and complete 
release of the same antigen in distal absorption areas, therefore enabling some sort of 
targeted delivery.  
 
In this study it was also evaluated whether differently processed plant material could show 
different outcomes in terms of antigen protection against harsh simulated GI media. The 
fact that HBcAg was mainly either prematurely released or digested, in all cases, did not 
allow an optimal comparison. However examination of the residual pellets based on both 
the Western blot (Figure 4.7) and the ELISA suggests that oven-dried plant material 
seemed to better protect the antigen from the GI media than freeze-dried plant material. 
This agrees with previously established results, where air-dried tomato fruit expressing 
Norwalk virus VLP could induce higher antibodies production than freeze-dried fruit upon 
oral administration in mice (Zhang et al., 2006). It was suggested that the air-drying could 
have better preserved the fruit cellular structure, therefore enabling greater protection of 
the antigen. This could explain the slightly higher residual content of HBcAg in the oven-
dried leaf material which remained after the incubation in simulated GI media, compared 
to the content in freeze-dried leaf material. Nevertheless, the relative amount of this 
residual HBcAg in the plant tissue was minimal in both cases, suggesting that the use of 
processed Nicotiana benthamiana leaves for oral protection of HBcAg would be 
inconvenient regardless of the drying process employed. 
 
4.4.3 Development of an HBcAg VLP Enteric-coated Tablet Formulation  
Previous findings of this work showed that HBcAg was highly unstable at gastric pH and 
was digested in bio-relevant gastric media containing pepsin. This strongly suggested that 
the harsh gastric environment would provide a major limitation to the oral delivery of 
HBcAg. Furthermore, it was also found that bio-encapsulation in leaf tissue did not protect 
the antigen against gastric degradation. Therefore, it was decided to develop a gastro-
protected formulation that could shelter the sensitive antigen from the highly denaturing 
and digestive environment of the stomach. In the following Paragraph the development of 
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a plant-based film coated tablet formulation of HBcAg VLP and the testing of such a 
formulation are described.  
 
4.4.3.1 Preparation of Tablets 
One of the main aims of this work was to exploit the expression of HBcAg in plant to 
produce an oral formulation of the VLP that could protect the antigen from the harsh GI 
environment. The expression in plants could be used as a simple approach for producing 
reasonably large quantities of minimally processed plant material formulations containing 
the antigen. Plant-expressed HBcAg VLP was demonstrated to be highly stable upon 
freeze-drying of the leaves. It was decided to use such processed plant material as the raw 
active material in the development of the tablet formulation, rather than to extract the 
antigen from the plant and then to formulate it directly. The primary function of the leaf 
tissue in this approach was to protect the VLP upon drying. Moreover, the homogeneous 
distribution of a very low dose active in oral formulations can be difficult to achieve: a 
suggested dose of HBcAg could be in the range of tens of micrograms and an easily 
handleable tablet will be at least 100 mg in weight, giving an active content of less than 
0.1%. The direct use of the relatively bulky freeze-dried plant material, where HBcAg is 
already naturally distributed, could help to reduce these homogeneity issues. 
 
Nicotiana benthamiana leaves expressing HBcAg were freeze-dried and ground into 
powder. Then a blend of the leaf powder with other excipients (the formulation is 
described above in Paragraph 4.3.4) was compressed into tablets. Figure 4.8 shows light 
microscopy images of the intact tablets (Figure 4.8 A) and a cross-section of a tablet 
(Figure 4.8 B). 
 
 
Figure 4.8. Images of uncoated tablets.  
Light microscopy images of uncoated tablets (x 0.63 magnification). (A) illustrates an 
image of two intact uncoated tablets. (B) shows an image of a section of an uncoated 
tablet. 
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Tablets were characterised in terms of weight uniformity, hardness and disintegration time: 
the data are shown in Table 4.4. The weight uniformity and the disintegration time values 
were well within the limits of British Pharmacopeia (2012). Overall, the blend of powder 
containing the freeze-dried leaf material could be efficiently used for direct compression of 
tablets. Neither capping nor lamination occurred during the process and the physical 
characteristics of the tablets were within typical ranges.  
 
Table 4.4. Physical characterisation data for plant-based tablets (mean ± SD) 
Parameter 
Weight uniformity 
(mg, n = 20) 
Hardness 
(kp, n = 3) 
Disintegration time 
(minutes, n = 3) 
 164.8 ± 4.47 8.6 ± 0.73 4.26 ± 0.08 
 
4.4.3.2 Enteric Coating of Tablets 
It was previously suggested that the freeze-dried leaf tissue containing HBcAg, would not 
be able to protect the antigen against the harsh gastric condition. For this reason it was 
decided that the tablets containing the VLP, naturally bio-encapsulated in the freeze-dried 
plant material, required to be coated with a gastro-resistant polymer. Eudragit L 100, a co-
polymer of methacrylic acid and methyl methacrylate, is a commonly used excipient for 
the formulation of gastro-resistant coating for tablets. This polymer is rich in carboxylic 
groups, which are unionised at acidic pH, making the polymer water-insoluble. However, 
neutralization of the pH induces deprotonation of the carboxylic acid groups and formation 
of carboxylate anions. The formation of these carboxylate salts at neutral pH renders the 
polymer water-soluble. This pH-dependent solubility of Eudragit L 100 can be exploited 
for preparation of enteric coated oral formulations, which are soluble only at ≥ pH 6 
(Eudragit, 2011) and thus for targeting the delivery to a specific part of the gut. Film coats 
of Eudragit L 100 are impermeable at the gastric pH and dissolve in the small intestine, 
where the pH ranges from pH 5.5 to pH 7.5 (McConnell et al., 2008b).  
 
The preparation of the coating dispersion was performed according to the manufacturer's 
guidelines. Briefly, the Eudragit L 100 powder was mixed with water, then small aliquots 
of NH3 were added in order to partially neutralise the carboxylic groups of the polymer. 
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The mixture was stirred for 2 hours to enable the re-dispersion of Eudragit L 100 into a 
nano-size latex-like form. Then triethyl acetate (TEC), a plasticiser, was added and the 
mixture was stirred for further 1 hour and a half. Finally, PlasACRYLT20, an anti-tacking 
agent, was included in order to reduce the stickiness of films in the final product. This re-
dispersion method was named protocol 1. The resulting coating dispersion was used to coat 
the tablets made of the freeze-dried leaf tissue expressing HBcAg. The coating was 
performed up to a final 15% total weight gain (TWG). During the coating process, some 
dust developed in the coater chamber. After the coating, optical microscopy and SEM 
imaging were performed to examine the film formation: Figure 4.9 shows images of the 
coated tablets and of a tablet surface. The optical microscopy image shows the section of a 
coated tablet (Figure 4.9 A). SEM images of the surface revealed the presence of evident 
cracking on the surface of the coating (Figure 4.9 B and C). Ultimately the deposition of 
the polymer on the tablets seemed to have formed a brittle and cracked coating rather than 
a homogeneous and flexible film as expected.  
 
 
Figure 4.9. Imaging of tablets coated using the short re-dispersion protocol.  
Eudragit L 100 dispersions were prepared according to protocol 1 and were used to coat 
tablets made of freeze-dried material expressing HBcAg VLP. The surface of the coated 
tablets was examined by microscopy. (A) illustrates an optical microscopy image of a 
section of a coated tablet (0.63x). (B) and (C) show SEM images of the surface of another 
coated tablet (100 and 1000x, respectively). White arrows indicate the major sites of 
cracking. 
 
Pseudo-latex formation and plasticisation are considered essential for the formation of a 
flexible film (Eudragit, 2011). In this case the poor film formation, indicated by the 
presence of a dusty and cracked coating, suggested that the Eudragit L 100 re-dispersion 
into a latex-like form had not been efficient and that the plasticisation was not effective. 
Thus, the re-dispersion protocol was modified (protocol 2), increasing the stirring time 
post-addition of NH3 and TEC from circa 2 hours to overnight. This was done to ensure 
enough time for complete re-dispersion of the pseudo-latex and to allow homogeneous 
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distribution of the plasticiser within the supposedly nano-size particles of the polymer 
latex. The resulting dispersion of the polymer was then used to coat another batch of 
tablets up to 14% TWG. Figure 4.10 illustrates different images of the coating. An optical 
microscopy image of a section of a coated tablet (Figure 4.10 A) shows the formation of a 
more transparent film than the one produced using the coating protocol 1 (Figure 4.9 A), 
hence suggesting better re-dispersion of the polymer particles into a colloidal state. A 
closer examination of the coating in the SEM images revealed the presence of a smooth 
surface, without evident cracking (Figure 4.10 B and C). It can be suggested that the longer 
time allowed for pseudo-latex dispersion and for plasticisation in protocol 2 favoured the 
formation of a much more flexible and plasticised film coating, than when protocol 1 was 
used. 
 
 
 
Figure 4.10. Imaging of tablets coated using the long re-dispersion protocol. 
Eudragit L 100 dispersions were prepared according to protocol 2 and were used to coat 
tablets made of freeze-dried material expressing HBcAg VLP. The surface of the coated 
tablets was examined by microscopy. (A) illustrates an optical microscopy image of a 
section of a coated tablet (0.63x). (B) and (C) show SEM images of the surface of another 
coated tablet (100 and 1000x, respectively). The surface appears free from crackings.  
 
The functionality of the film obtained with both protocols was investigated by assessing 
the gastro-resistance of such formulations in dissolution tests. To test the formulation, 
freshly prepared SGF with pepsin was used as the dissolution medium for the first 2 hours 
and was then replaced by freshly prepared SIF without pancreatin for an additional 6 
hours. Three tablets coated using the re-dispersion protocol 1 formed evident cracking and 
the tablet cores swelled upon imbibition of the SGF with pepsin medium. This dissolution 
test was therefore interrupted, because it was evident that the coating was permeable to the 
acidic media and allowed penetration of SGF inside the tablet core. In conclusion, this 
coating formula failed to provide protection to the formulation against the gastric 
conditions. The lack of functionality of this coating matches with the brittle and cracked 
Chapter 4 
 
 
157 
 
appearance seen in the previous images (Figure 4.9). It is therefore possible to hypothesise 
that the poor film formation and the already present cracks on the dry coating favoured the 
penetration of medium and swelling of the tablets, resulting in further cracking of the 
coating.  
 
The tablets coated using protocol 2 were also evaluated by dissolution test. Each of three 
coated tablets were added to one vessel containing SGF with pepsin and incubated for 2 
hours at 37 °C. During this phase the coating appeared intact and the tablets did not show 
any sign of swelling. Then the tablets were drained using a sieve and carefully swapped 
into SIF without pancreatin. Aliquots were drawn after 30 minutes, 1, 2, 4 and 6 hours 
during the incubation in SIF without pancreatin. In parallel three tablets from the same 
batch were also incubated in three vessels containing SIF without pancreatin, without 
previous incubation in SGF with pepsin. These tablets were used as a control to calculate 
the total HBcAg content within the dosage form, assuming that complete stability would be 
observed in SIF without pancreatin, due to almost neutral pH and to the absence of 
enzymes. For this purpose an aliquot from each vessel was drawn after 6 hours incubation. 
At the end of the dissolution test the content of HBcAg in all the aliquots collected was 
measured by sandwich and direct ELISA.  
 
Figure 4.11 illustrates the result from the dissolution test: HBcAg release is presented as 
percentage ratio from the total HBcAg content measured for the control tablets. During the 
first 2 hours incubation in SGF with pepsin samples were not collected, because any 
antigen released would have been undetectable, due to the instability of the antigen in SGF 
with pepsin, as demonstrated in Paragraph 4.4.2. Quantification by direct ELISA revealed 
that most of HBcAg was released within the first hour of incubation in SIF without 
pancreatin and then the presence of HBcAg in the media seemed to reach a plateau, 
corresponding to circa 90% release. A maximum of 91.4% (± 4.3%) HBcAg release was 
measured after 6 hours of total incubation (corresponding to 4 hours in SIF without 
pancreatin). Moreover, quantification by sandwich ELISA showed a similar release profile: 
87.1% (± 9.6%) HBcAg VLPs were released after 6 hours of total incubation. The 
difference in results between the maximum release obtained with the two methods is not 
statistically different (p > 0.05- 2-tailed T-test) and might be related to the different 
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specificity of the two assays: the sandwich ELISA detects only native VLP, while the 
direct ELISA measures the native as well as the denatured forms of HBcAg.  
 
Figure 4.11. Gastro-resistance of the enteric coated formulation. 
Tablets were coated with a dispersion of Eudragit L 100 up to 14% TWG. The release of 
HBcAg from tablets (n = 3) was tested by pre-incubating the formulations for 2 hours in 
SGF with pepsin (red), followed by a further 6 hours in SIF without pancreatin (blue). 
Samples from SIF without pancreatin were collected at different times. The total HBcAg 
content within the formulation was evaluated by a control dissolution test of tablets (n = 3) 
from the same batch in SIF without pancreatin. Quantification was carried out by sandwich 
and direct ELISA. Error bars indicates SD. The release is presented as percentage ratio 
between the measured HBcAg and total HBcAg content in the formulation. 
 
The fact that HBcAg could be detected by sandwich ELISA suggests that the HBcAg was 
present as intact VLP. It was shown in Chapter 2 that the sandwich ELISA used in this 
work is specific for undenatured HBcAg VLPs. The total content of HBcAg VLP for the 
control tablet incubated only in SIF without pancreatin was 24.4 (± 2.3) µg per tablet (n = 
3). Although comparisons between two different antigens are difficult to make, it can 
however be mentioned that the current Hepatitis B vaccine, based on Hepatitis B surface 
antigen (HBsAg) is given by injection in 5 to 20 µg doses, depending on the formulation 
(Center for Disease Control and Prevention (CDC), 2012). Hence, the HBcAg content in 
the tablets produced here is in the same range as that used in current Hepatitis B injectable 
vaccines, containing HBsAg. 
 
These results taken together demonstrate that the enteric coated formulation was effective 
in protecting the particulate antigen against the simulated gastric media and allowing the 
release of HBcAg VLPs in SIF. It is worth remembering that this assay is not a typical 
dissolution test, as the quantified release of HBcAg is not resulting only from the 
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dissolution of the formulation, but also from the possible digestion and denaturation of 
HBcAg during the pre-incubation in SGF. Therefore, it is likely that the while circa 90% 
HBcAg was protected within the enteric formulation, the remaining 10% was degraded by 
the pre-incubation in SGF. Overall, taking into account the complexity of the HBcAg 
macromolecular structure and the extremely high intrinsic instability of HBcAg VLP in 
SGF (Chapter 2), the level of protection obtained with this enteric coated formulation was 
remarkable.  
 
4.4.4 Contextualisation and Relevance of the Findings 
The overall aim of this Chapter was to define how and in which way the expression of a 
candidate vaccine in plant could be an advantage for the development of an oral 
formulation. One of the presumed advantages of the expression of antigen vaccines in plant 
is the potential protection against the harsh GI environment offered by the plant bio-
encapsulation (Walmsley and Arntzen, 2000). In contrast, the results from this work 
suggest that the expression of HBcAg in Nicotiana benthamiana leaves neither protect 
HBcAg VLPs, nor prevent their release upon incubation in simulated GI media. However, 
these findings cannot be generalised, as the use of more stable antigens or the use of 
different plant parts for the antigen expression could generate different results, as 
suggested by Pelosi et al. (2011a, 2012). In that case, it was found that upon oral 
administration of Nicotiana benthamiana leaves containing a candidate antigen in animal 
models the antigens were prematurely released in the stomach, compared to other plant 
parts that allowed slower release and protection in the gut (Pelosi et al., 2012, 2011a). 
However, from a drug delivery point of view, it appears improbable that a plant tissue, able 
to tightly seal the antigen within its cellular compartments during the gastric transit and 
then promptly release it in the target area to be absorbed, could be found.  
 
Once the instability of the HBcAg within plant material to the gastric media was 
established, a tablet formulation was produced using the plant material as the source of the 
antigen, i.e. without any further antigen purification. The formulation was coated, in order 
to protect the labile antigen from gastric degradation. This formulation was shown to be 
functional in protecting HBcAg against SGF incubation, yet allowed the release of HBcAg 
in SIF. Given the fact that dissolution tests are usually predictive of the in vivo behaviour, 
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it is possible to hypothesise that such a formulation would be able to protect HBcAg from 
the harsh gastric environment and then release the antigen in the small intestine, where the 
absorption could take place.  
 
Although the leaf material did not directly confer gastric-protection to the antigen, the use 
of freeze-dried plant material expressing the candidate vaccine did however offer other 
advantages. First, the minimal processing, involving mainly the freeze-drying step of the 
raw plant material expressing the antigen, is potentially simple and extremely economical. 
Furthermore, the leaf tissue acted as a sort of natural lyoprotectant, conferring stabilisation 
to HBcAg VLP upon freeze-drying. This eliminated a series of technological hurdles 
generally encountered in the drying of many purified labile proteins (Abdul-Fattah et al., 
2007). Finally, the reproducibility in yield of recombinant protein within different crude 
extracts, typical of this expression system in plant (Sainsbury and Lomonossoff, 2008), 
indicate that the protein is uniformly dispersed within the leaf tissue. Moreover the 
homogeneity of HBcAg content within tablets, measured in the dissolution test in this 
study, suggests even distribution also in the final formulation. Hence the plant material 
could act as a sort of natural bulking excipient, reducing the dose homogeneity issue, 
typical of low dose active oral formulations.  
 
Despite the aforementioned advantages of preparing oral vaccines formulations from 
minimally processed plant material, a few issues still remain to be solved, including the 
standardisation of the dose and dose homogeneity within large batches of plant material, as 
well as the study of the long-term stability of the dry formulations (Pelosi et al., 2011b; 
Tiwari et al., 2009).  
 
The main in vitro models used to assess HBcAg VLP stability in this Chapter and in 
Chapter 3 are the standard British Pharmacopeia models of gastric and intestinal fluids. 
These models are standard receipes commonly used to mimick the far more complex GI 
fluids composition. In the last few years, state of art models, that are supposed to better 
simulate the gastric (i.e. model gut-Institute of Food Research Norwich) and small 
intestinal (i.e. TNO Pharma, Netherlands) physiology, have been developed. However, 
these models are very costly and have very low throughoutput. Moreover it is questionable 
whether such standardised in vitro protocols could be ever able to closely mimick the 
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extremely variable GI environment (McConnell et al., 2008b). On this basis it can be 
proposed that the biological relevance of the current studies about the GI stability of plant-
expresseed HBcAg VLP could be only enhance with ex vivo studies using animal GI fluids 
or even better with in vivo experiments.  
 
4.5 Conclusions 
In this Chapter the expression of HBcAg in plants was exploited for the development of 
stable dry oral formulations. Firstly, it was shown that Nicotiana benthamiana leaves 
expressing HBcAg can be dried using different methods, including freeze-drying and oven 
drying at different temperatures. The different drying methods showed the same drying 
efficiency in terms of residual moisture content. Moreover, HBcAg VLP showed to be 
physically and chemically stable upon freeze- and oven-drying, using qualitative 
techniques. A more quantitative investigation showed that better preservation of HBcAg 
VLP could be achieved by freeze-drying, followed by oven-drying at 40 °C and then by 
oven-drying at 50 °C.  
 
Then it was examined whether the natural bio-encapsulation of HBcAg in the leaf material 
could offer protection against digestion in simulated GI media. The results obtained 
strongly suggest that the Nicotiana benthamiana leaves did not protect HBcAg against the 
degradation in SGF and SIF. Furthermore the different processing of the plant material, 
either freeze- or oven-dried, did not seem to improve the protection of the antigen from the 
external media. Finally, given the fact that freeze-drying of the leaves expressing HBcAg 
favoured higher antigen stability compared to oven-drying, freeze-dried leaves were used 
for the production of a prototype “green” tablet formulation. Tablets could be prepared by 
direct compression of a blend of freeze-dried leaf expressing the VLP, mixed with other 
excipient for compression. These tablets were characterised in terms of weight uniformity, 
hardness and disintegration time, showing values typical of standard immediate release 
dosage forms. Then the tablets were coated using Eudragit L 100, which is a polymer used 
for the formulation of gastro-resistant dosage form. Optimisation of the latex-like re-
dispersion time and the plasticisation time enabled the formation of a flexible and 
homogeneous film coating that proved to be functional in protecting the formulation in 
SGF in presence of pepsin. The coated tablets were tested for 2 hours in SGF with pepsin 
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and then for further 6 hours in SIF with pancreatin. Approximately 90% of the total 
HBcAg VLP present in the formulation could be released undigested and undenatured 
within the first 4 hours of incubation in SIF.  
 
Overall the key message of this Chapter is that even though Nicotiana benthamiana leaves 
expressing HBcAg did not offer protection against the degradation in simulated GI fluids, 
the expression in plant could overcome a series of technological obstacles towards the 
formulation of an effective oral dosage form. Firstly, the challenge of drying a 
pharmaceutical protein could be simply overcome by directly drying the leaf material 
expressing HBcAg. In addition, the expression in plants can solve the dose homogeneity 
issue and this plant tissue could function as natural tablet filler. Finally, a potentially cheap 
and simple prototype oral formulation of HBcAg VLP that is able to protect the antigen 
from the gastric degradation was produced, exploiting the expression of the antigen in 
plant.
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5 Formulation Development of Purified HBcAg VLPs Potentially 
Usable for Oral Delivery  
5.1 Introduction 
In Chapter 3 it was shown that purified HBcAg VLP could not withstand incubation in 
simulated gastric fluids. However, HBcAg maintained its particulate structure and 
immunogenicity upon incubation in simulated and animal intestinal fluids. Chapter 4 
showed that the natural bio-encapsulation of HBcAg in the leaves of Nicotiana 
benthamiana could not protect the antigen from gastric degradation, but that the plant 
material could be exploited to develop a “green” tablet formulation. This solid oral dosage 
form was then film coated with a pH-dependent polymer. The coated tablets demonstrated 
gastro-protective properties, enabling the protection of HBcAg in simulated gastric 
conditions and the release of the antigen in simulated intestinal media. In this Chapter, the 
development of a dry solid dosage form of purified HBcAg as an alternative to the “green” 
formulation is described. 
 
The drying of pharmaceutical proteins is considered particularly challenging, due to their 
complex macromolecular structure, which can render them susceptible to chemical and 
more frequently physical instability upon drying. Typical drying methods for proteins are 
based on solvent evaporation or sublimation, with freeze-drying and spray drying being the 
most widely used among other techniques (Abdul-Fattah et al., 2007). However, only 
liquid sterile formulations of VLP-based vaccines for parenteral use are commercially 
produced (Vicente et al., 2011). Therefore to date, extremely limited literature on the 
formulation of purified VLPs in solid dosage forms is available. Nevertheless, only very 
recently, the growing interest in the new generation of vaccines is pushing research 
towards the development of stable dry formulations for parenteral and non-parenteral use 
(Lang et al., 2009; Shenoy and Robinson, 2009; Watts and Smith, 2011). Interestingly, 
Chen et al. (2010) showed that dry formulations of Hepatitis B surface antigen (HBsAg) 
could be produced by spray drying; the formulations produced showed good in-process and 
long-term stability. Moreover, they elicited comparable antibody production to that of a 
commercially available liquid HBsAg formulation upon reconstitution of the powder and 
intra-peritoneal injection in mice. Furthermore, in another study it was also shown that the 
Norwalk VLPs could be formulated into spray dried forms for intranasal delivery: sucrose 
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gradient sedimentation studies suggested that VLPs were fairly stable upon spray drying. 
Immunisation studies in mice proved that the spray dried formulation was at least as potent 
as an alternative liquid formulation (Velasquez et al., 2011).  
 
In this Chapter, different approaches for the drying of purified HBcAg VLPs, including 
desiccation, oven drying, spray drying, spray-freeze-drying and freeze-drying were 
studied. The final aim of this study was producing a solid formulation potentially usable 
for oral delivery.  
 
5.1.1 Granulation  
The process of granulation consists of producing granules, generally usable for the 
compression of tablets. In wet granulation, powders are processed into multiparticulate 
granules by mixing the dry powder with a binder (or granulation) solution. A wet mass is 
created by mixing the dry components with the binder solution and once the granules are 
formed, the solvent is removed by drying, generally in an oven (Summers and Aulton, 
2007).  
 
In the current study, preliminary trials of producing granules containing HBcAg VLP was 
carried out, drying the granules by desiccation. The desiccation process is a very low cost 
drying process; however, the desiccation of biopharmaceuticals carries a higher risk of 
denaturation of the active compared to the drying obtained by spray drying and freeze-
drying. This is mainly related to the nature of the desiccation process relying on slow heat 
induced water evaporation (Amorij et al., 2008). 
 
5.1.2 Spray Drying and Spray Freeze-Drying of pH Responsive Microparticles 
Microencapsulation is considered to be the inclusion of an active within particles ranging 
from 50 nm to 2 mm. One of the applications of this technique is the production of 
polymeric controlled release dosage forms for oral delivery (Singh et al., 2010). The 
production of enteric microparticles, which are supposed to prevent premature drug release 
in the gastric environment and allow selective release in the intestine, has been attempted 
by means of solvent evaporation, coacervation and spray drying. (Alhnan et al., 2011; 
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Dong and Bodmeier, 2006; Kendall et al., 2009). Typically, solvent evaporation and 
coacervation methods rely on the use of high concentrations of organic solvents. However, 
organic solvents in prolonged direct contact with the antigen could not be used for the 
fabrication of microparticles in this study. In fact purified HBcAg VLPs were shown to be 
unstable upon incubation in high concentrations of organic solvent, i.e. methanol, ethanol 
or acetone (data not shown). Spray drying of microparticles compared to other 
microencapsulation techniques allows the production of formulations in a quick single step 
process, without using or with only minimal concentration of organic solvents (Alhnan et 
al., 2011; Año et al., 2011; Pastor et al., 2013); hence spray drying was the technique of 
choice.  
 
Spray drying consists of the atomisation of a feed liquid into a hot air-stream, which 
induces prompt drying of the atomised droplets into dry powder. This technique is 
relatively cheap and easy to scale-up (Abdul-Fattah et al., 2007). Año et al. (2011) have 
shown that killed Vibrio cholerae used as a vaccine candidate could be effectively 
formulated within Eudragit microparticles by spray drying. This microparticles production 
method simply relies on the spray drying of an Eudragit suspension, containing the vaccine 
candidate. This process is carried out at a relatively low temperature; it might therefore be 
potentially applicable to heat-labile ingredients, such as VLPs. A more complex technique 
for microparticles production was described by Alhnan et al. (2011). This method relies on 
the solubilisation of the Eudragit aqueous suspension, where the active ingredient (i.e. 
prednisolone in their studies) could be intimately mixed within the polymer solution, 
resulting in the formation of spray dried microparticles, in which the active is finely 
dispersed and incorporated in the polymeric matrix. This novel method enabled the 
production of particles of good spherical morphology compared to previous attempts. 
Moreover, the microparticles showed remarkable gastro-resistant properties and targeted 
gastro-intestinal delivery of prednisolone, used as a model drug (Alhnan et al., 2011).  
 
Spray freeze-drying is a recently developed method for production of particles, which 
combines spray- and freeze-drying. Generally, in this technique a feed solution containing 
the active ingredient and pharmaceutical excipients is sprayed into a bed of liquid nitrogen; 
upon contact with the liquid nitrogen the atomised droplets freeze. Finally, freeze-drying of 
the frozen droplets in a conventional freeze-drier allows complete ice-water removal from 
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the particles. Among other applications, spray freeze-drying has been used recently as a 
method for enteric microsphere production (Niwa et al., 2009).  
 
Both techniques, i.e. spray drying and spray freeze-drying, have been previously used for 
the formulation of enteric microparticles for oral targeted delivery (Alhnan et al., 2011; 
Año et al., 2011; Niwa et al., 2009). However, the formulation of VLPs into enteric coated 
microspheres produced either by spray drying or by spray freeze-drying had never been 
attempted. The observation that HBcAg VLPs are totally unstable in acidic media 
simulating the gastric fluids (Chapter 3) makes them a challenging candidate for the 
development of enteric microparticles. 
 
5.1.2.1 Stability of Proteins within Microparticles - Encapsulation Efficiency 
Drying of proteins with complex physical three-dimensional structure is one of the main 
challenges in drug delivery. During spray drying, a protein is exposed to heat and 
atomisation stress (Abdul-Fattah et al., 2007). Several proteins have been shown to be 
vulnerable to this process, while others could withstand spray drying, maintaining good 
native structure (Amorij et al., 2008; Chen et al., 2010). The process parameters, the choice 
of stabilisers and the intrinsic physicochemical properties of the protein, influence protein 
instability upon spray drying. Spray freeze-drying could be more expensive and difficult to 
scale-up than spray drying. However, spray freeze-drying is considered a safer drying 
method for particularly labile proteins; compared to the heat evaporation typical of the 
spray drying, the ice removal by sublimation upon spray freeze-drying might favour 
protein stability (Abdul-Fattah et al., 2007; Niwa et al., 2009). Nevertheless, in spray 
freeze-drying the freezing stress and the liquid atomisation could also induce protein 
instability (Abdul-Fattah et al., 2007; Amorij et al., 2008). 
 
Encapsulation efficiency is defined as the active entrapment within a particulate carrier 
formulation. However, in the case of spray dried proteins this parameter is not merely 
related to the amount of protein that remains confined within the microparticles, but it is 
also associated with the maintenance of the protein's native structure. Therefore, the 
encapsulation efficiency of a protein should be effectively considered as the percentage 
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ratio of physiochemically stable protein that remained entrapped within the microparticles 
(Li et al., 2000).  
 
5.1.3 Freeze-drying of Biopharmaceutical Proteins 
A general overview of freeze-drying was given in Chapter 4. Freeze-drying is the most 
widely used technique for the preparation of dry parenteral formulations (Abdul-Fattah et 
al., 2007). Furthermore, it is also considered the most common method for production of 
solid forms of pharmaceutical proteins. Preparation of freeze-dried solid formulations of a 
protein can result in much longer stability than the liquid counterpart (Wang, 2000). One of 
the main obstacles in the freeze-drying of proteins is the possibility of in-process protein 
instability, due to the freezing or to the subsequent dehydration process (Abdul-Fattah et 
al., 2007; Amorij et al., 2008). The de-hydration process removes water from the system 
that can possibly lead to loss of water-protein hydrogen bonds, resulting in instability of 
the native structure of the protein. The protein instability during the freezing and/or 
dehydration can often be avoided by using stabilisers that prevent protein denaturation. 
Those stabilisers whose function is that of protecting the protein from freezing are called 
cryoprotectant, while those that protect the protein during the dehydration are called 
lyoprotectant (Wang, 2000). However, such stabilisers when freeze-dried can confer high 
hygroscopicity to the final product. In particular, excipients, such as many sugars, that are 
in the amorphous state at the end of the freeze-drying process are often extremely 
hygroscopic and they can crystallise into more thermodynamically stable forms upon 
absorption of water. This physical state instability is dependent on the storage condition 
and it is not desired as it usually compromises protein stability (Wang, 2000). Therefore, a 
good compromise between in-process protein stabilisation and maintenance of the physical 
state is sought when developing a novel solid formulation of a biopharmaceutical protein.  
 
Freeze-drying of HBcAg VLP was attempted with the aim to produce a solid formulation 
that could be potentially processed into an oral dosage form (i.e. filled into capsules).  
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5.2 Materials 
5.2.1 Excipients Used for Wet Granulation 
Polyvinyl pyrrolidone (PVP) is an inert, synthetic polymer consisting of a linear chain of 
1-vinyl-2-pyrrolidinone groups. It is generally used as bulking and stabilising agent in 
parenteral formulations and as a granulation binder in oral dosage forms (Akers, 2002; Cutt 
et al., 1986). PVP K 30 was bought from Sigma (UK) and used as received. The K-value is 
an index of the mean molecular weight (Folttmann and Quadir, 2008): PVP K 30  
corresponds to a molecular weight of 40,000. The chemical structure of this polymer is 
shown in Figure 5.1. 
 
 
Figure 5.1. Chemical structure of PVP. 
 
Hydroxypropyl methylcellulose (HPMC), also called hypromellose, is a semi-synthetic 
polymer of cellulose. HPMC's structure can be seen in Figure 5.2. It is a polymer widely 
used as excipient for oral formulations. Low viscosity grades are generally employed as 
binders for wet granulation (Akers, 2002). HPMC E15 LV was obtained from Colorcon 
(UK). In the HPMC classification, the initial letter identifies the ratios of hydroxypropyl 
and methyl substitution of the cellulose. The number in the middle indicates the viscosity. 
The last suffix indicates the specificity of the product. Therefore in the case of HPMC E15 
LV “E” indicates a 28 to 30% methoxy-substitution and 7 to 12% hydroxypropoxy-
substitution (see Figure 5.2); “15” indicates the viscosity in milliPascal-seconds, measured 
at 2% (w/v) concentration of the polymer in water at 20 °C; “LV” indicates the low 
viscosity type of the product.  
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Figure 5.2. Chemical structure of HPMC. 
 
5.2.2 Excipients Used for the Microencapsulation Studies 
Eudragit L30 D55, Eudragit L 100 (introduced in Chapter 4) and Eudragit S 100 are 
copolymers of methacrylic acid and methyl methacrylate. They are commonly used for 
enteric coating of oral formulations for targeting dissolution in the small intestine 
(Eudragit, 2011). Table 5.1 describes the main characteristics of the Eudragit polymer 
used, including molecular structure, molecular weight, solubility and acid value. The acid 
value is the amount of alkali required for the complete neutralisation of the acid groups 
contained in 1 g of the polymer (Eudragit, 2011).  
 
Table 5.1. Eudragit polymers characteristics 
Polymer  Molecular structure Molecular 
Weight 
(g/mol) 
Solubility Acid value  
(mg KOH/g) 
L 30 D55 
 
320,000  > pH 5.5 315  
L 100 
 
125,000  > pH 6 315  
S 100 
 
125,000  
 
 
> pH 7 190  
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The three polymers differ in their intrinsic solubility: Eudragit L 30 D55, Eudragit L 100 
and S 100 are soluble at pH > 5.5, > 6 and > 7, respectively. Therefore, such polymers are 
commercialised to direct the delivery of encapsulated actives to different areas of the gut: 
L30 D55, L 100 and S 100 are supposed to target the release of the active in the duodenum, 
in the jejunum and in the ileum/colon, respectively (Eudragit, 2011). 
 
Eudragit L 30 D55 (liquid dispersion), L 100 (powder) and S 100 (powder) were kindly 
donated by George-William Smith (Evonik Industries, UK).  
 
Other materials used for the microencapsulation studies are described in Chapter 3.  
 
5.2.3 Excipients Used for the Freeze-drying Studies 
Different stabilisers and bulking excipients were used in the freeze-drying. The function of 
this class of excipients is to provide structure and to possibly stabilise proteins upon freeze-
drying (Wang, 2000). Glycine was purchased from Fisher (UK), α-lactose monohydrate 
and α-trehalose dihydrate from Sigma (UK) and D-mannitol from Sigma (Germany).  
 
5.3 Methods 
5.3.1 Wet Granulation  
Preliminary trials for producing granules containing HBcAg VLP were carried out. Given 
the small scale of the experiments, the wet granulation was performed manually mixing the 
dry powder and the binder solution using a mortar and pestle. HBcAg was added in the 
binder solution and, after sieving of the wet mass, the granules were dried in an oven or in 
a desiccator.  
 
Before the granulation experiment, plant-expressed HBcAg was purified and quantified by 
sandwich ELISA, according to Chapter 2. Six granulation protocols were carried out, in 
order to compare the stability of HBcAg upon granulation, using lactose-based or lactose-
free dry powder formulations, PVP or HPMC as the binder in the granulation solution and 
drying either in an oven or in a desiccator. Table 5.2 summarises the granulation protocols. 
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Table 5.2. Granulation protocols. 
 Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5 Protocol 6 
Dry 
powder 
Lactose 
formula 
Lactose-free 
formula 
Lactose 
formula 
Lactose-free 
formula 
Lactose 
formula 
Lactose 
formula 
Binding 
solution* 
PVP PVP PVP PVP HPMC HPMC 
Drying 
method 
Oven Oven  Desiccator Desiccator Oven Desiccator 
*Added as aqueous solution during granulation. 
 
Two formulations of dry powders were prepared: one containing 7.9 g of α-lactose 
monohydrate mixed with 1 g of microcrystalline cellulose and 1 g of pre-gelatinised starch. 
The other was a lactose-free formula prepared by mixing 7.5 g of microcrystalline 
cellulose with 2.4 g of pre-gelatinised starch. Two different binding solutions were used: 
one solution contained 8.5% (w/v) PVP and 26 µg/mL HBcAg in PBS; the second solution 
was made of 5% (w/v) HPMC and 85 µg/mL HBcAg in PBS. Wet massing was carried out 
using a small mortar and pestle and by gradually mixing 2 g of the dry powder with 0.56 
mL of PVP solution or 0.29 mL of HPMC solution. After complete mixing, the wet 
granules were sieved through a 2 mm sieve. The granules were then dried overnight in an 
oven at 45 °C or at room temperature in a closed container pre-equilibrated with P2O5, to 
give an atmosphere of almost 0% RH.   
 
After overnight drying, 100 mg aliquots of the granules produced according to the six 
different protocols were weighed and dispersed in 10 mL PBS. The residual HBcAg VLP 
content in the dispersion was measured by sandwich ELISA and calculated as a percentage 
ratio to the total HBcAg VLP added to the binder solution, prior to the granulation. The 
calculated residual HBcAg VLP content represents a measure of HBcAg stability upon the 
granulation process. 
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5.3.2 Formulation of HBcAg Containing Microparticles 
In this Paragraph the production of HBcAg VLP pH-responsive microparticles, by spray 
drying and spray-freeze drying, and the characterisation and tests performed on these 
macroparticles are described.  
5.3.2.1 Stability Pre-formulation Assessment 
Both methods used for microparticles production, described by Año et al. (2011) and by 
Alhnan et al. (2011), were initially taken as a reference in this study for the production of 
gastro-resistant formulations of HBcAg VLP microparticles.  
 
The feed solution to be spray dried had to contain a Eudragit polymer, either in solution [as 
in Alhnan et al. (2011)] or dispersed as a suspension [as in Año et al. (2011)], and HBcAg 
VLP; however, it was unknown whether the antigen could remain intact upon incubation 
with the polymer mixtures. Therefore, a preliminary screening was conducted, where the 
antigen and the polymer solutions (or dispersions) were co-incubated for 2 hours. Four 
aqueous Eudragit formulations were created: Eudragit L 30 D55 was prepared as a 
dispersion, while Eudragit L 100 and S 100 were solubilised by addition of alkali, allowing 
neutralisation (i.e. ionisation of the carboxylic groups of the polymer), thus increasing its 
aqueous solubility. The preparation methods for the three Eudragit polymers are illustrated 
in Table 5.3. 
 
Table 5.3. Eudragit re-dispersion.  
Polymer  Weight/Volume Dilution Final Polymer 
concentration 
-COOH 
neutralisation  
Physical 
state 
L 30 D55 0.1 mL dispersion 
(30% w/v) 
Undiluted 30% Circa 0% 
(circa pH 3) 
Dispersion 
L 30 D55 0.33 mL 
dispersion (30% 
w/v) 
Water to 3.33 mL 3% Circa 0% 
(circa pH 3) 
Dispersion 
L 100 100 mg powder Water + 0.65 mL 1M 
NH3 to 5 mL  
2% 100%  
(to pH 8.5) 
Solution 
S 100 100 mg powder Water + 0.4 mL 1 M 
NH3 to 5 mL 
2% 100%  
(to pH 8.5) 
Solution 
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Then 2 µL of 0.5 mg/mL purified HBcAg was diluted in 198 µL Eudragit L 30 D55 
dispersion or Eudragit L 100 and S 100 solutions and incubated for two hours at room 
temperature (25 °C). Finally, the residual HBcAg in the incubation samples was measured 
by sandwich ELISA and calculated as ratio to an identical dilution of HBcAg in PBS used 
as a control.  
 
5.3.2.2 Spray Drying Process 
Spray drying was carried out using a Büchi 191 Mini Spray Dryer (Büchi, Labortechnik 
AG, Flawil, Germany) with a standard 0.7 mm nozzle.  
 
In the case of Eudragit L 100, 800 mg Eudragit were re-dispersed in 20 mL of water under 
stirring, then 5.2 mL of 1M NH3 and 3.2 mL of ethanol were added and the volume was 
brought to circa 39 mL with water. Finally, 150 µL of a solution of 1.5 mg/mL HBcAg 
was added and the volume adjusted to 40 mL with water. This was done in order to 
minimise the contact of HBcAg with the diluted ethanol. For Eudragit S 100, 800 mg of 
polymer were re-dispersed in 20 mL of water under stirring, then 3.2 mL of 1M NH3 and 
3.2 mL of ethanol were added and the volume was brought to circa 39 mL with water. 
Finally, 150 µL of a solution of 1.5 mg/mL HBcAg was added and the volume adjusted to 
40 mL with water. The two mixtures of Eudragit L 100 and S 100 containing HBcAg were 
spray dried separately. Each feed solution was pumped continuously at a rate of 5% (circa 
2 mL/min) and 360 L/h of compressed air for atomization. The inlet air temperature was 
set at 88 °C.  
 
At the end of the spray drying process, the harvested microparticles were weighed. The 
yield of the spray drying process was calculated as a percentage ratio between the mass of 
harvested microparticles and the mass of solid content in the feed solution.  
 
The removal of residual ammonia was carried out by vacuum evaporation: half of the 
harvested batch of microparticles produced with Eudragit L 100 and S 100 were loaded in 
a Wizard 2.0 freeze drier (USA). The shelf temperature was then set at 40 °C and a 
vacuum of 200 millitorr was applied for 12 hours.  
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5.3.2.3 Spray Freeze-drying Process 
Feed solutions of 2% (w/v) Eudragit were obtained by dispersion of the polymer in water 
and addition of alkali. To prepare Eudragit L 100 dispersion, 400 mg Eudragit were re-
dispersed in 10 mL of water under stirring; then 2.6 mL of 1M NH3 were added; finally 60 
µL of 2.4 mg/mL HBcAg solution were added and the volume was brought to 20 mL with 
water. For Eudragit S 100, 400 mg of polymer were re-dispersed in 10 mL of water under 
stirring; then 1.6 mL of 1M NH3 were added, followed by 60 µL of 2.4 mg/mL HBcAg 
solution. Finally, the volume was brought to 20 mL with water. Spraying was performed 
using the Büchi 191 Mini Spray with a standard 0.7 mm nozzle with the drying chamber 
removed. The feed solutions were pumped continuously at a rate of 25% and 250 L/h of 
compressed air for atomization into a tray containing a bed of liquid nitrogen, positioned 
horizontally circa 25 cm beneath the nozzle opening. Then the tray was immediately 
loaded in the Wizard 2.0 freeze drier, the shelf of which had been pre-cooled. For the 
thermal treatment step the shelf temperature was set at – 60C for 180 minutes. After this 
phase, the primary drying was carried out at a chamber pressure of 200 millitorr with 
sequential temperature steps of 120 minutes, using the following order: − 45,− 35,− 25,− 
15,− 5, 5, 15 and 20 °C. For the final drying and ammonia removal the shelf temperature 
was set at 35 °C and a vacuum of 200 millitorr was applied for 6 hours.  
 
5.3.2.4 Characterisation of the Eudragit Particles 
Eudragit particles containing HBcAg were characterised by SEM and FT-IR. The 
encapsulation efficiency and the gastro-protection were also evaluated. Four formulations, 
consisting of Eudragit L 100 and S 100 particles produced by spray drying and spray 
freeze-drying were used for the characterisation. 
 
5.3.2.4.1 SEM 
Examination of the morphology of the Eudragit L 100 and S 100 particles was carried out 
by SEM imaging. This technique was performed as described in Chapter 4.  
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5.3.2.4.2 Fourier Transform Infra-Red (FTIR) Spectroscopy 
Fourier Transform Infra-Red (FTIR) spectroscopy is a technique used for the detection of 
functional groups in molecular structures. It is based on the absorption of infra-red (IR) 
radiation of specific wavelengths by different functional groups. It can therefore be used to 
identify structural changes of certain materials upon processing. FTIR can be used to 
determine the residual ammonium content in the Eudragit microparticle (Alhnan et al., 
2011). An IFS-60/S Fourier transform infrared (Bruker Optics, UK) was used. For each 
sample a total of 16 scans were determined at a resolution of 4 cm-1. Spectra were analysed 
using OPUS software (version 6.0). The IR spectrum was plotted as percentage of 
transmittance rather than absorbance. Wavenumbers are the reciprocal of the wavelength 
and have the units of cm-1. The stretching of the N–H bond corresponded to a wavelength 
of 1525–1550 cm-1. 
 
5.3.2.4.3 Encapsulation Efficiency 
The encapsulation efficiency of the spray dried and spray freeze-dried microparticles was 
calculated as the percentage ratio between the actual content of stable HBcAg VLP present 
in the Eudragit microparticles and the theoretical content of HBcAg VLP in the 
microparticles. For the calculation of the HBcAg present in the formulation, 10 mg of 
microparticles were dissolved in 10 mL of 50 mM Tris buffer (pH 8.0) and the HBcAg 
content in the solution was then measured by sandwich ELISA. The theoretical content 
corresponded to the amount of quantified HBcAg VLP added to the feed solutions before 
spray drying and spray freeze-drying.  
 
5.3.2.4.4 Gastro-protective Properties of Particles  
The protection of HBcAg formulated within the Eudragit particles was assessed by pre- 
incubation of the particles in simulated gastric fluids (SGF), followed by evaluation of the 
HBcAg release in alkaline conditions. The pre-incubation in SGF was intended to mimic 
the gastric passage in humans.  
 
For this assay 5 mg of each Eudragit particulate formulation was incubated in 5 ml of SGF 
with pepsin (preparation as described in Chapter 4) at 37 °C for 2 hours with frequent 
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vortexing. Then 1.025 mL of 160 mM Na2CO3 were added to neutralise the acidity (final 
pH 8.5), allowing complete dissolution of the pH-responsive particles. In parallel, control 
samples were made by dissolution of identical Eudragit formulations in 3.025 mL of 50 
mM Tris buffer (pH 8.0). Upon complete dissolution of the particles the content of HBcAg 
was measured by sandwich ELISA. HBcAg protection was calculated as percentage ratio 
between the HBcAg content in the samples pre-incubated in SGF and the HBcAg 
measured in the control samples. 
 
5.3.3 Freeze-drying  
Freeze-drying was also investigated as a drying method for purfied HBcAg. 
5.3.3.1 Stability of HBcAg upon Freeze-drying with Different Excipients 
In this Paragraph HBcAg was freeze-dried together with different stabilisers and the 
physical stability of HBcAg VLP in the re-suspended freeze-dried material was 
investigated by density gradient sedimentation and by native agarose gel electrophoresis.  
 
5.3.3.1.1 Freeze-Drying  
Separate aliquots of fifty (50) µL of 3 mg/mL purified HBcAg in PBS were mixed with 2 
mL of 4% solutions of glycine, lactose, mannitol and trehalose in PBS. The four resulting 
solutions were freeze-dried in a Wizard 2.0 freeze drier (VirTis, USA). For the thermal 
treatment step, the shelf temperature was set at – 60 C for 360 minutes, followed by 240 
minutes of maximum freezing, a phase through which the shelf temperature was reduced to 
the lowest possible temperature. After this phase, the primary drying was carried out at a 
chamber pressure of 180 millitorr with sequential temperature steps of 180 minutes, using 
the following order: – 45, – 35, – 25 and – 15 °C; this was followed by further drying steps  
at a chamber pressure of 180 millitorr with sequential temperature steps of 240 minutes:  5, 
15, 20 and 25 °C. Secondary drying was set at 25 °C for 60 minutes.  
 
5.3.3.1.2 Density Gradient Sedimentation of Re-suspended Freeze-dried HBcAg 
Immediately after freeze-drying, 25 mg from each of the four dry formulations were re-
suspended in 2.5 mL PBS. A positive control was created by diluting 15.6 µL of 3 mg/mL 
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purified HBcAg in 2.5 mL PBS. The four re-suspended solutions and the control were 
loaded on the top of five 10 to 60% (w/v) sucrose density gradients. After 2 hours and 30 
minutes ultracentrifugation at 41,000 rpm in a SW41-Ti rotor, the five sucrose gradients 
were fractioned and the collected density fractions were examined by either sandwich 
ELISA or dot blot using the monoclonal antibody. The sucrose density gradient method 
and the detection techniques are described in Chapter 2.  
 
5.3.3.1.3 Native Agarose Gel Electrophoresis of Re-suspended Freeze-dried HBcAg 
Given the lower sensitivity of the native agarose gel method, more concentrated HBcAg 
freeze-dried formulations had to be prepared, compared to those used for the ELISA and 
dot blot. Separate aliquots of 150 µL of 3 mg/mL purified HBcAg in PBS were mixed with 
1 mL of 4% solutions of glycine, lactose, mannitol and trehalose in PBS. The four resulting 
solutions were freeze-dried as in 5.3.3.1.1. Then 10 mg of each freeze-dried product was 
re-suspended in 250 µL PBS. The resulting solutions were loaded on the wells of two 
agarose gels. After electrophoretic separation, one of the gels was stained with ethidium 
bromide, while the other was Coomassie stained. The method used for native agarose gel 
electrophoresis is described in detail in Chapter 2. 
 
5.3.3.2 Thermal Analysis of Freeze-dried Excipients 
The thermal properties of the excipients used as potential stabilisers during the freeze-
drying were examined by modulated temperature differential scanning calorimetry 
(MTDSC) and by thermogravimetrical analysis (TGA). HBcAg VLP was not present in the 
formulations studied. However, as in the antigen stability studies (Paragraph 5.3.3.1), 
HBcAg was present at an excipient: protein ratio of only 535:1, the antigen effect on the 
thermal behaviour of the excipients was considered marginal. 
 
5.3.3.2.1 Modulated Temperature Differential Scanning Calorimetry (MTDSC) 
Differential Scanning Calorimetry (DSC) is the most widely used thermo-analytical 
technique employed in the study of pharmaceutical products. Generally, the process is 
based on heating or cooling a sample and then calculating the temperature and energy 
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associated with significant endothermic or exothermic thermal events and heat capacity 
changes of the material investigated (Craig and Reading, 2007). Heat flux DSC 
instruments are based on applying identical linear heating signals to the sample and to a 
reference (usually an empty pan) present in the same crucible. In this type of DSC the 
temperature difference between the sample and the reference changes during thermal 
events and it is recorded as a difference in heat flow between them. The heat flow changes 
are generally expressed as a function of time. Modulated Temperature Differential 
Scanning Calorimetry (MTDSC) is a type of heat flux DSC, in which a sinusoidal heating 
signal is applied on top of the linear heating signal. This method enables the separation of 
kinetic and thermodynamic events, which is sometimes difficult to achieve with 
conventional DSC, and overlapping or weak thermal events may be more easily 
distinguished.   
 
In this study, four separate 4% (w/v) solutions of glycine, lactose, mannitol and trehalose 
in PBS were prepared and then 2 mL samples of each formulation were loaded into a glass 
vial and freeze-dried, using the same process parameters indicated in Paragraph 5.3.3.1. 
After freeze-drying, one vial of each of the glycine, lactose, mannitol and trehalose 
formulations was stored for 5 days in a pre-equilibrated desiccator over P2O5 (in an 
environment with virtually 0% RH). Four identical vials were stored for 5 days in a pre-
equilibrated desiccator over NaCl (giving an environment of 75% RH). After the 
incubation at the different storage conditions, the thermal behaviour of the eight samples 
was assessed using a Differential Scanning Calorimeter (2920, TA Instruments, Newcastle, 
USA) in MTDSC mode. Samples were carefully weighed (2 to 5 mg) into pinhole 
aluminium pans then scanned between – 30 °C and 250 °C, with modulation temperature 
amplitude of ± 0.212 °C, modulation time of 60 s and an underlying temperature ramp rate 
of 2 °C/minute. Before the experiments, the temperature and cell constant of the DSC 
instrument were calibrated with indium, n-octadecane and tin, while the calibration of the 
heat capacity was performed with aluminium oxide in modulated mode. Three analyses 
were performed for each sample. The thermograms were plotted as total heat flow, 
reversed heat flow and non-reversed heat flow.  
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5.3.3.2.2 Thermo Gravimetric Analysis (TGA) 
Thermo Gravimetric Analysis (TGA) was carried out for the same samples analysed by 
DSC, in order to evaluate water loss and possible sample degradation. The samples were 
loaded onto aluminium pans and were heated from 25 ºC to 200 ºC at a heating rate of 10 
ºC/minute. The sample dehydration was calculated as the weight loss between 30 °C and 
110 °C. Each sample was assessed in triplicate and the water loss was calculated as an 
average of the three measurements  
 
5.4 Results and Discussion 
In the vaccine development process, along with the discovery of new antigens, the design 
of suitable formulations is another extremely challenging task (Borde et al., 2012). For oral 
administration of vaccines, the gastro-intestinal instability is one of the major issues to be 
overcome and another is the development of a suitable oral dosage form. In fact for the 
development of a solid oral dosage form, the antigen has to remain stable throughout the 
formulation and manufacturing process, which includes protein drying. It is well 
documented that the preservation of the physiochemical stability of pharmaceutical 
proteins upon drying represents another challenging area of today’s drug delivery research 
(Abdul-Fattah et al., 2007). In the case of VLPs this task is complicated by its complex 
quaternary structure: it is in fact reasonable to think that the physical stability issue would 
be greater with complex macromolecules made of hundreds of monomers, such as VLPs, 
than with smaller biopharmaceutical macromolecules, such as monomeric proteins or 
peptides. In this study, different approaches for developing solid dosage forms of purified 
HBcAg were investigated.  
 
5.4.1 HBcAg Stability upon Granulation – Preliminary Study  
When considering the development of an oral dosage form, tablets represent the most 
typical and widely used type of formulation. Furthermore, tablets represent a suitable 
substrate for coating with gastro-protective films when gastro-protection is required, as for 
HBcAg VLPs. A potential formulation of HBcAg into tablets would probably contain a 
few tens of µg of active ingredient, which would constitute < 0.1% of the weight of the 
whole tablet. This formulation falls into the category of very low-dose active ingredient 
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and thus in this case the dose homogeneity in the oral dosage forms becomes a formulation 
development hurdle. Wet granulation is often used to overcome this issue of oral dosage 
forms and prevent the segregation often seen in direct compression powder mixtures. In 
wet granulation, granules are prepared by mixing the dry ingredients (drug and excipients) 
of the formulation with a binder solution and then the solvent (generally water) is removed 
to produce roughly spherical granules, containing a roughly homogenous mixture of the 
ingredients. For very low dose actives, the drug may be dissolved in the binder solution, 
promoting homogeneity within the granule. The dried granules can then be compressed 
into tablets. In this way segregation and inefficient mixing of the low-dose actives can be 
limited (Wan et al., 1992). Based on this knowledge, a preliminary study was carried out, 
in which HBcAg VLP was dissolved in the binder solution used for the formulation of 
granules.  
 
Table 5.4 summarises the six granulation protocols and illustrates the residual HBcAg 
stability upon granulation measured for each protocol. The antigen stability is presented as 
a percentage ratio to the total HBcAg VLP added to the binder solution used for the 
granulation. Less than 25% HBcAg could be recovered in all six formulations, suggesting 
high HBcAg VLP instability. As an exact quantification was not intended for this 
preliminary screening, the tests were not carried out in triplicate; therefore these data are 
only indicative of a trend. Comparing the relative stability of the specific protocols it 
appears evident that the presence of HPMC (protocols 5 and 6) in the binder solution 
seems to stabilise the VLP more than PVP (protocols 1 to 4) did. Furthermore, the 
presence of α-lactose monohydrate in the formulation of the granules seemed to favour 
antigen stability (protocols 1 and 3), compared to the lactose-free formulation (protocols 2 
and 4). Finally, drying in a desiccator seemed to have allowed higher VLP stability than 
oven-drying in all cases.  
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Table 5.4. HBcAg stability upon granulation.  
 Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5 Protocol 6 
Dry powder Lactose  Lactose-free  Lactose Lactose-
free  
Lactose Lactose 
Binding solution PVP PVP PVP PVP HPMC HPMC 
Drying method Oven Oven  Desiccator Desiccator Oven Desiccator 
HBcAg VLP 
stability (n = 1) 
5.1% 2.3% 5.6% 3.9% 14.2% 20.4% 
 
The greatly reduced stability observed upon granulation is probably related to the drying 
method. Despite the fact that PVP and HPMC, often used as protein stabilisers (Wang, 
2000), were dissolved in the binder solution together with the VLP, the final stability of the 
antigen was remarkably low. An analysis of the drying process suggests that the long 
drying time, typical of the desiccation process, often generates phase separation between 
stabilisers and active ingredient, resulting in low stability of biopharmaceutical protein 
(Amorij et al., 2008). In addition, the fact that the liquid containing the VLP was not 
directly dried from liquid into solid, but the liquid was present as moisture adsorbed to the 
dry components of the granules, probably further slowed the drying process, resulting in 
further instability. Finally, as the HBcAg was spread within the wet mass of excipient 
during the granulation, this resulted in an extremely large air-liquid interface area: it is well 
documented that a large air-liquid interface area is one of the main causes of protein 
instability upon drying (Abdul-Fattah et al., 2007). However, drying pharmaceutical 
proteins in an oven or in a desiccator would be much cheaper than using spray drying or 
freeze-drying (sublimation) methods, therefore, the risks of instability could be 
counterbalanced by the low cost of this application (Amorij et al., 2008). Nevertheless, the 
high HBcAg instability observed in this experiment discouraged taking this approach any 
further. An alternative approach would be to produce the wet mass of granules as described 
in this section and then perform the drying by means of vacuum desiccation or by freeze-
drying. In this case, the overall process would become more expensive, losing the 
advantage of using such an alternative approach. It was instead considered wiser to try a 
completely different approach, potentially able to warrant higher stability of the antigen 
upon drying. 
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5.4.2 Preparation of Eudragit Particles by Spray Drying and Spray Freeze-Drying 
This Paragraph describes the production of HBcAg VLP enteric microparticles by spray 
drying and spray freeze-drying. The challenges presented by these processes were two-
fold: the first hurdle would have been to ensure the stabilisation of the physical, three-
dimensional stability of protein in the dry state (i.e. in the microparticles). Second, the 
microparticles had to provide efficient gastro-protection.  
 
5.4.2.1 Spray Drying Process 
Both methods of production, described by Año et al. (2011) and by Alhnan et al. (2011), 
were initially taken as a reference for the production of gastro-resistant formulations of 
HBcAg VLP microparticles. Año et al. (2011) prepared the formulations mixing their 
active (i.e. inactivated Vibrio cholerae) in Eudragit dispersions, while Alhnan et al. (2011) 
mixed the active (i.e. prednisolone) in neutralised Eudragit solutions. Hence, a preliminary 
assessment was made as to whether the antigen would remain intact upon incubation with 
either of the polymer mixtures (i.e. dispersion or solution).  
 
Table 5.5 describes the re-dispersion protocol and the stability of HBcAg in the dispersion 
or solution of the polymer. Measurements of HBcAg VLP stability by sandwich ELISA 
indicated that the antigen was not stable in the dispersion of Eudragit L 30 D55, even when 
the polymer was diluted to 3 % (w/v). However, HBcAg was more stable in 2% polymer 
solution of Eudragit L 100 and S 100, obtained from the neutralisation with alkali of the 
carboxylic group of the polymers.  
 
Table 5.5. HBcAg stability in Eudragit.  
Polymer Polymer 
concentration 
-COOH 
neutralisation  
Physical state HBcAg stability 
(n = 2) 
L 30 D55 30% Circa 0% 
(circa pH 3) 
Dispersion Undetectable 
L 30 D55 3% Circa 0% 
(circa pH 3) 
Dispersion Undetectable 
L 100 2% 100%  
(to pH 8.5) 
Solution 82.6% 
S 100 2% 100%  
(to pH 8.5) 
Solution 56.3% 
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This result strongly suggests that the highly acidic environment of the Eudragit L30 D55 
dispersion was not compatible with VLP stability. This is in accordance with Chapter 3, 
where it was shown that HBcAg is unstable at pH lower than 3-3.5. However, the increase 
in pH, resulting from the addition of ammonia solutions to solubilise the polymer, also 
enabled higher antigen stability.  
 
As HBcAg VLPs were unstable in the polymeric dispersion, the approach described by 
Año et al. (2011) was obviously not carried forward. Instead, as aforementioned, the 
enteric microparticles produced by Alhnan et al. (2011) were produced by spray drying of 
Eudragit solution, obtained by neutralisation of the carboxylic groups. This was supposed 
to improve particle morphology and functionality (Alhnan et al., 2011); however, in the 
current study, this formulation approach offered another advantage. The more neutral pH 
of the final polymer solution could allow mixing the labile antigen with Eudragit, while 
maintaining adequate VLP stability (Table 5.5).     
 
Thus, the feed solution to be spray dried was formulated by dissolving 2% (w/v) Eudragit 
L 100 and S 100 in neutralising alkali, containing 8% ethanol. Purified HBcAg VLPs were 
added to the solution just before the experiment. At the end of the process the powder was 
collected and weighed. The yield of the processes corresponded to 25.3% and 21.6% of 
recovered solid product for Eudragit L 100 and S 100 microparticles, respectively. The 
relatively low yield obtained was related to the very low batch size of the experiments.  
 
Alhnan et al. (2011) suggested that enteric microparticles can elicit better GI targeting 
properties if a post-spray drying heat treatment is performed. Spray drying of Eudragit, 
where the carboxylic acid groups are present in their ammonium salt form, would result in 
the formation of microparticles in which the polymer is still present in the salt form. 
Therefore, such an ionised polymeric matrix would promote water uptake in acidic gastric 
fluids, basically allowing contact of the acidic media with the active dispersed in the 
polymer matrix. This would induce premature drug release and possible instability in the 
acidic media. This problem was overcome by post-spray drying heating of the 
microparticles: the heat treatment at 70 °C favours ammonia evaporation and therefore 
restoration of the carboxylic acid as shown in the Eq. (5.1) (Alhnan et al., 2011). 
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 𝑅— 𝐶𝑂𝑂− +  𝑁𝐻4
+
∆
↔ 𝑅 − 𝐶𝑂𝑂𝐻 + 𝑁𝐻3
 Eq. (5.1) 
 
Such heat treatment was shown to improve the gastro-resistant properties of the 
microparticles upon incubation at pH 1.2 (Alhnan et al., 2011). In the current work, the 
restoration of the unionised carboxylic groups in the microparticles was not carried out by 
heating at 70 °C as this could have affected the VLP stability; instead, the microparticles 
were incubated in the freeze-drier at 40 °C for 12 hours at a pressure of 200 millitorr. Then 
the microparticles were analysed by FTIR, in order to determine the residual ammonium 
content in the Eudragit microparticles. In Figure 5.3, FTIR spectra of Eudragit L 100 
microparticles (Figure 5.3 A) and of Eudragit S 100 microparticles (Figure 5.3 B) before 
and after the post-spray drying treatment are shown. In both cases the spectrum reveals that 
the heat and vacuum treatment in the freeze-drier enabled effective removal of the 
ammonia, visible as a peak at circa 1550 cm-1, corresponding to N–H bond stretching.  
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Figure 5.3. FTIR spectra of Eudragit microparticles.  
Eudragit L 100 and S 100 microparticles containing HBcAg VLP were produced by spray 
drying. The collected particles were incubated at 40 °C and a pressure of 200 millitorr for 
12 hours in order to remove ammonia. (A) illustrates the FTIR Spectra of Eudragit L 100 
microparticles before and after the post-drying treatment, while (B) shows the FTIR 
Spectra of Eudragit S 100 microparticles before and after the post-drying treatment. The 
ammonium peak is indicated by an arrow at circa 1550 cm-1. 
 
The regeneration of the unionised carboxylic acids of the polymer upon the heat and 
vacuum treatment (Figure 5.4) is thought to make the microparticles less hydrophilic, as 
compared to the ammonium salt form present in the untreated microparticles. This should 
reduce the water uptake of the polymer in the acidic gastric fluids, therefore enabling better 
protection of the HBcAg VLP present within the polymer matrix.  
 
 
Figure 5.4. Schematic representation of the effect of heat and/or vacuum treatment on 
Eudragit microparticles. 
Eudragit microparticles were highly rich in carboxylate salts when collected from the spray 
drier. Post-processing heat and vacuum treatment allowed ammonia removal and 
restoration of carboxylic acid moieties within the polymer. This final unionised form of the 
polymer is less hydrophilic than the ionised one. HBcAg VLPs are represented as orange 
particles dispersed in the grey-coloured polymeric matrix.  
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Further characterisation of the microparticles was performed together with that of particles 
produced by spray freeze-drying in Paragraphs 5.4.2.3 and 5.4.2.4.  
 
5.4.2.2 Spray Freeze-drying Process 
Spray freeze-drying has been demonstrated to be particularly suitable for heat labile 
proteins (Rogers et al., 2002). Considering the extremely complex physical architecture of 
VLPs and also given the high instability of HBcAg upon desiccation seen when 
granulation was attempted, the spray freeze-drying of enteric particles could represent a 
judicious choice for maintaining the native protein structure of the particles. For 
comparison purposes the Eudragit L 100 and S 100 feed solution formulas were 
maintained similar to those used for the spray drying. The feed solutions were sprayed 
through the nozzle of a conventional spray drier and the atomised droplets were directly 
frozen into liquid nitrogen. The drying was completed in the freeze drier. At the end of the 
process, a post-drying step consisting of a further 6 hours incubation at 35 °C and 200 
millitorr pressure was added in order to remove the residual ammonia from the Eudragit 
polymer and restore the unionised carboxylic groups, similarly to the procedure followed 
for the spray drying of the microparticles. At the end of the process, the dry polymeric 
particles were collected; however such particles showed high electrostatic forces, rendering 
the collection very difficult. Therefore, only part of the material could be recovered; for 
this reason the yield could not be calculated. 
 
The spray freeze-dried particles were then characterised together with the spray dried 
microparticles.  
 
5.4.2.3 SEM Imaging of Eudragit Particles 
The morphology of the spray dried and spray freeze-dried microparticles was examined by 
SEM imaging. Images of the Eudragit microparticles produced by spray drying are 
illustrated in Figure 5.5. Microparticles produced with Eudragit L 100 showed a fairly 
spherical and regular shape (Figure 5.5 A and B) and microparticles produced with 
Eudragit S 100 also appeared spherical and were of regular shape (Figure 5.5 C and D). In 
both cases the particle size was generally between 1 and 5 µm in diameter.  
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Figure 5.5. SEM images of Eudragit spray dried microparticles containing HBcAg.  
Eudragit microparticles, containing HBcAg VLP, were produced by spray drying and then 
examined by SEM. (A) and (B) illustrates two SEM images of Eudragit L 100 
microparticles (2000x and 4500x, respectively). (C) and (D) show two SEM images of 
Eudragit S 100 microparticles (2500x and 4000x, respectively). 
 
Eudragit microparticles containing HBcAg produced by spray freeze-drying were also 
examined by SEM, as shown in Figure 5.6. Microparticles produced with Eudragit L 100 
have a spherical shape, however, their size seemed highly irregular (Figure 5.6 A, B and 
C). Furthermore, the microparticles appeared highly porous, showing a spongy structure. 
Microparticles produced with Eudragit S 100 looked similar, though they seemed to have 
slightly more regular spherical shape (Figure 5.6 D, E and F). The microparticles were 
fairly brittle, especially in the case of Eudragit L 100 microparticles, which might be due to 
their high porosity and could explain their irregular shape. The size of Eudragit L 100 and 
Eudragit S 100 microparticles seemed to range from fragments as small as a few microns 
to spherical particles of 100 µm in diameter.  
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Figure 5.6. SEM images of Eudragit spray freeze-dried microparticles containing 
HBcAg. 
Eudragit microparticles, containing HBcAg VLP, were produced by spray freeze-drying 
and then examined by SEM. (A), (B) and (C) illustrates three SEM images of Eudragit L 
100 microparticles (100x, 250x and 1200x, respectively). (C), (D) and (F) show three SEM 
images of Eudragit S 100 microparticles (100x, 500x and 2000x, respectively). 
 
The fact that the microparticles produced by spray drying have a smooth surface, while the 
ones produced by spray freeze-drying are extremely porous, is not surprising. In spray 
drying, the solvent in the atomised droplets is quickly evaporated, while the solute 
migrates to the surface till a point when saturation occurs and a crust of solute forms on the 
surface (Abdul-Fattah et al., 2007). The formation of such crust is likely to confer a smooth 
appearance to the dried microparticle. Instead, in spray freeze-drying the droplets are snap-
frozen into liquid nitrogen maintaining their original shape and size and the water in the 
form of ice is removed by sublimation. In this process, the saturated solutes maintain the 
original droplet frame and the ice water sublimates through the cavities, giving the typical 
“honeycomb” appearance to the final microparticles (Niwa et al., 2009).  
 
5.4.2.4 Encapsulation Efficiency and Gastro-Protective Properties 
Table 5.6 illustrates the results of the HBcAg encapsulation efficiency and gastro-
protection for the Eudragit L 100 and S 100 microparticles, produced by spray drying and 
by spray freeze-drying. The encapsulation efficiency was in all cases > 65%; however, the 
HBcAg release from the formulations after pre-incubation in SGF was < 15% in all the 
formulations. Moreover, it seems that Eudragit spray dried microparticles could elicit 
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better HBcAg protection than those produced by spray-freeze drying and that 
microparticles produced with Eudragit S 100 were more effective than L 100 in preventing 
antigen degradation in SGF. 
 
Table 5.6. Microparticles encapsulation efficiency and gastro-protection (%, mean ± 
SD; n = 3). 
Microparticles type 
 
Encapsulation efficiency (%) Gastro-protection- 
HBcAg Release (%) 
Spray drying 
  
L 100 81.1 (± 4.7) 6.0 (± 1.2) 
S 100 65.5 (± 6.9) 11.3 (± 0.9) 
Spray freeze-drying 
  
L 100 72.9 (± 4.2) 2.7 (± 0.7) 
S 100 76.3 (± 2.4) 4.1 (± 0.5) 
 
The results obtained in terms of encapsulation efficiency suggest that HBcAg VLPs could 
withstand the spray drying and spray freeze-drying process, being effectively entrapped 
within the microparticles and mostly maintaining their native structure. This indicates that 
HBcAg could resist the heat stress, evaporation and atomisation during spray drying and 
the snap-freezing, atomisation and sublimation during the spray freeze-drying. Although 
Eudragit L 100 and S 100 are not commonly used as stabilising excipients in drying 
processes, they proved effective in entrapping the protein in its native form.  
 
Nevertheless, the results relative to the release of HBcAg VLP under more basic pH, after 
2 hours of pre-incubation in SGF, suggested that the enteric formulation offered limited 
gastric protection. The sandwich ELISA used in this assay detects only native HBcAg 
VLPs, therefore, it should be assumed that the circa 90% of HBcAg that was not recovered 
was either degraded or denatured during the SGF pre-incubation. It is probable that despite 
the fact that the microparticles produced remained intact, i.e. undissolved, during the acid 
incubation, they did not succeed in sheltering the inner part of the microparticles. The 
observation that such a high amount of VLP was degraded suggests that not only the 
surface of the microparticles was in contact with the acidic media, but also the internal 
matrix. This hypothesis is strongly supported by a study on Eudragit microparticles, in 
which the gastric burst of different actives from enteric microparticles was evaluated. 
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Small therapeutic molecules with different molecular weight were encapsulated within 
Eudragit S 100 microparticles by a solvent evaporation method and then the release of the 
active from the microparticles in acid media was investigated. Interestingly, a correlation 
between the molecular weight and the release of the active from the microparticles was 
found: generally molecules < 300 Da were subjected to premature release in acid, 
compared to larger molecules, which were retained within the microparticles. It was 
suggested that the microparticles have a network microstructure that allowed molecules 
smaller than < 300 Da to move out from the microparticulate matrix during the incubation 
in acid. This indicated that the acidic media could penetrate inside the microparticles and 
dissolve the small molecules, which were diffused out through the microparticles’ pores 
(Alhnan et al., 2010). Therefore, there is a strong suggestion that Eudragit microparticles, 
although insoluble in acidic media, are not impermeable to them. The Eudragit particles 
are composed of a fine matrix, which can be penetrated by the acidic media. In this regard, 
large molecules are not protected by the acidic media, but they merely remain trapped 
within the microparticles, until these dissolve in alkaline media. Hence, an acid-labile 
product is likely to be degraded even when incorporated in an Eudragit particle. 
 
In such a context, the results of the current study suggest that HBcAg VLPs were 
efficiently encapsulated within the microparticles, however, the acidic medium could 
penetrate the formulation and come into contact with the encapsulated antigens, probably 
allowing its denaturation. As a result, only a reduced amount of native protein could be 
retrieved. The fact that spray dried microparticles could protect the antigen to a higher 
extent than spray freeze-dried microparticles, obviously suggests that the smoother surface 
of the spray dried product (Figure 5.5) was less permeated by the denaturing SGF, 
compared to the “honeycomb”, spongy-like structure of the spray freeze-dried 
microparticles (Figure 5.6). Furthermore, as the Eudragit L 100 polymeric chain contains 
double the amount of carboxylic groups than the S 100, which instead is richer in esters, 
implies that the Eudragit L 100 is more hydrophilic than the S 100. This suggests that 
Eudragit L 100 could induce more water uptake during the incubation in acid and therefore 
could result in greater HBcAg instability than Eudragit S 100.  
 
Nevertheless, the relative low gastric protection achieved must be contextualised to the 
extremely high intrinsic instability of HBcAg in acid gastric fluids. For comparison it can 
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be mentioned that HBcAg, either purified or within the plant leaf, was completely 
degraded when incubated in SGF with or without pepsin (Chapter 4). Thus, the observation 
that circa 10% of native HBcAg VLP within the microparticles could resist degradation 
upon 2 hours incubation in SGF indicates that the formulation could remarkably improve 
the stability of such a sensitive antigen. However, the superior levels of enteric protection 
obtained with the coated tablets in Chapter 4 could not be achieved with the microparticles. 
In this regard, Professor Abdul Basit (University College London) suggested that the 
stabilisation of acid labile proteins in the gastric environment might require a thicker and 
more impermeable layer of protection, than that offered by the microparticlate matrix 
(personal communication).  
 
Overall, it can be concluded that despite the fact that spray drying of Eudragit solutions 
containing HBcAg VLP enabled formation of microparticles containing stable VLPs, such 
microparticles provided only limited gastric protection to the antigen. It was hypothesised 
that the small size of the microparticles, combined with their porosity, allowed contact of 
the acid medium with the VLP during 2 hours incubation in SGF and hence led to the 
major degradation observed. In the case of spray freeze-drying the extremely porous 
structure of the microparticles further reduced HBcAg gastric protection.  
 
5.4.3 Freeze-Drying 
In this study freeze-drying was used for the production of HBcAg solid formulations, 
potentially usable for oral delivery. Four different formulations were tested in order to find 
the most suitable excipient that could stabilise the VLPs during the freeze-drying process 
and also maintain a stable physical state over time upon storage in different conditions. 
The aim was to find a suitable freeze-dried form that could be potentially processed into a 
dosage form for oral delivery (i.e. enteric coated tablets or capsules).  
 
5.4.3.1 Stability of Purified HBcAg upon Freeze-drying with Different Excipients 
Figure 5.7 shows the stability of HBcAg in the re-suspended freeze-dried formulations. 
Figure 5.7 A represents the quantification of HBcAg VLP in the density gradient fractions 
of the re-suspended solid formulations of the antigen in glycine, lactose, mannitol and 
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trehalose. The immunoreactivity was calculated as a percentage ratio to the total HBcAg, 
present in the control and corresponding to the amount of HBcAg in each formulation prior 
to freeze-drying. In the control sample HBcAg VLPs were found mainly in the 30 and 40% 
(w/v) density bands, as typical for native HBcAg VLP (Birnbaum and Nassal, 1990). In the 
case of glycine and mannitol reduced immunoreactivity could be seen in the 30 and 40% 
(w/v) bands compared to the control. Instead in the case of lactose, the overall HBcAg 
detection was similar to that of the control, though more HBcAg was present in the 30% 
(w/v) band and less in the 40% (w/v) fraction. In the case of the trehalose, the presence of 
HBcAg in the density bands corresponding to intact HBcAg seemed intermediate between 
mannitol and lactose. Moreover, the HBcAg yield for each formulation was also calculated 
as the amount of HBcAg VLP present in the 30 and 40% (w/v) density fractions, compared 
to that of the control: 101.7%, 58.8%, 40.9%, 30.4% of HBcAg VLPs could be recovered 
in the lactose, trehalose, mannitol and glycine formulations, respectively.  
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Figure 5.7. Stability of HBcAg freeze-dried with different excipients. 
HBcAg was mixed with separate solutions of glycine, lactose, mannitol and trehalose in 
PBS. The four solutions were freeze-dried. After freeze-drying, the formulations were re-
suspended and either separated by density gradient sedimentation or used for native 
agarose gels. Solutions of HBcAg in PBS were used as controls. (A) illustrates the 
sandwich ELISA quantification of  the density gradients’ fractions relative to the glycine, 
lactose, mannitol and trehalose freeze-dried formulations. HBcAg immunoreactivity is 
calculated as a percentage ratio to the total HBcAg present in the control. (B) shows the 
dot blot (monoclonal antibody) of the density gradients’ fractions relative to the glycine, 
lactose, mannitol and trehalose freeze-dried formulations. (C) illustrates the ethidium 
bromide stained (left) and Coomassie stained (right) native agarose gel of the four re-
suspended formulations.  
 
Figure 5.7 B illustrates the distribution of HBcAg through the gradient, analysed by dot 
blot. This assay clearly shows that most anti-HBcAg immunoreactivity was present in the 
30 and 40% (w/v) bands, corresponding to intact VLPs, in the control, the lactose and the 
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trehalose samples. However, in the case of glycine and mannitol samples, HBcAg could 
also be detected in other fractions of the gradients, corresponding to disassembled form of 
the antigen (supernatant, 10, 20% w/v) and to agglomerates (50 and 60% w/v). Figure 5.7 
C illustrates native agarose gels, ethidium bromide stained and Comassie stained, of the 
four freeze-dried re-suspended formulations. In both gels VLP bands corresponding to that 
of the control, could be seen in both lactose and trehalose formulations. Instead in the case 
of glycine and mannitol the bands seemed more faint and smeared. 
 
The sandwich ELISA assay is specific for native HBcAg VLP, while the monoclonal 
antibody used in dot blot and also used for the Western blot is able to detect denatured 
HBcAg. Therefore, the analysis of the sucrose gradients with both methods is 
complementary. The sandwich ELISA results provide evidence that HBcAg VLPs were 
mostly stable upon freeze-drying using lactose as a stabiliser. Decreasing HBcAg 
stabilisation was obtained, respectively, in the trehalose, mannitol and glycine 
formulations. In addition, the dot blot suggested that HBcAg VLPs were partially 
disassembled and agglomerated in the glycine and mannitol formulations, while HBcAg 
present in the lactose and trehalose formulations was mainly present as VLPs. Finally, the 
native agarose gel, which allows the detection of intact VLP encapsidating nucleic acids, 
confirmed the partial instability of the glycine and mannitol formulations observed in the 
previous assays.  
 
HBcAg is stable upon several freeze-thawing cycles (Nath et al., 1992). Therefore, the 
main stability obstacle during the freeze-drying process of HBcAg remains dehydration. 
Stabilisers that act as lyoprotectants could therefore stabilise HBcAg during this process. 
Lactose and trehalose are two disaccharides often used as lyoprotectants in the freeze-
drying of proteins. Upon freeze-drying these lyoprotectants tend to form an amorphous 
phase, which can act as a “water substitute” during the drying, forming hydrogen bonds 
with the protein and stabilising the protein (Abdul-Fattah et al., 2007; Costantino et al., 
1998; Wang, 2000). Glycine and mannitol are instead often used as freeze-drying 
excipients, mainly as bulking agents, rather than lyoprotectants: this is due to the fact that 
they tend to crystallise upon freeze-drying and therefore dry as a stable crystalline form 
(Pyne et al., 2003). Crystalline components are not available in the glassy state as a 
substitute to the solvate water around the protein, hence they often elicit poorer protein 
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stabilisation than amorphous stabilisers (Wang, 2000). It is therefore not surprising that 
higher HBcAg VLP stability could be achieved using lactose and trehalose, than using 
glycine and mannitol. It can be supposed that the lactose and trehalose formulations 
contained higher amorphous components, thus enabling better VLP stabilisation. In the 
next Paragraph, the thermal analysis of the freeze-dried formulations is described in order 
to better evaluate the effect of the physical state of the lyoprotectant on the HBcAg 
stability upon freeze-drying. Furthermore, the thermal analysis will help to elucidate which 
formulation bears a more stable physical state under different humidity conditions.  
 
5.4.3.2 Thermal Analysis of Freeze-dried Excipients 
The freeze-dried material produced in this study could be further processed into an oral 
dosage form. For this purpose, the freeze-dried material should maintain a stable physical 
form during processing and storage under ambient conditions to prevent denaturation of 
the biopharmaceutical protein (Wang, 2000). Therefore, the evaluation of the stability of 
the physical form of the excipients used in the freeze-dried formulations is particularly 
relevant in this context. Moreover, such a study can also elucidate the relationship between 
HBcAg stabilisation and physical state of the stabiliser in the different formulations. 
 
The surface water loss (assessed by TGA) and the relevant thermal events (extrapolated 
from the MTDSC thermograms) of freeze-dried "placebo" glycine (i.e. without the antigen) 
after storage at the two different humidity conditions are summarised in Table 5.7; the 
MTDSC thermograms are also showed in Figure 5.8. The surface water loss measured was 
similar for the glycine samples stored at 0% RH and 75% RH. Moreover, the MTDSC 
thermograms relative to the glycine samples stored at 0% RH (Figure 5.8 A) and 75% RH 
(Figure 5.8 B) show a weak endothermic phase transition at 166.5 °C and 192.8 °C, 
respectively, and a similar sharp peak at circa 220 °C. This profile is the typical profile of 
γ-crystalline form: this polymorph, being metastable, shows a characteristic phase 
transition that can range between 165 °C and 201 °C from the γ- to the α-form (Perlovich 
et al., 2001). Sublimation and decomposition of the heat induced α-form occurs at 210 to 
250 °C (Yang et al., 2008). These results suggest that the freeze-dried glycine was present 
as γ-form regardless of the storage condition. 
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Table 5.7. Summary of TGA/MTDSC thermograms of freeze-dried glycine (mean ± 
SD, n = 3)  
RH (%) Surface water loss (%) Phase transition (°C) Sublimation and decomposition (°C) 
0%  0.26 (± 0.09) 166.5 (± 0.1) 216.3 (± 0.2) 
75% 0.18 (± 0.05) 192.8 (± 1.2) 220.5 (± 1.9) 
 
 
Figure 5.8. MTDSC thermograms of freeze-dried glycine. 
Freeze-dried glycine was stored at 0% RH or at 75% RH for 5 days and then analysed by 
MTDSC: (A) and (B) show the thermograms relative to 0% RH and 75% RH conditions, 
respectively. 
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Freeze-dried lactose surface water loss and main thermal events after storage at the two 
different humidity conditions are summarised in Table 5.8 and the MTDSC thermograms 
are shown in Figure 5.9. The freeze-dried lactose stored at 0% RH contained 1.74 % (± 
0.31) surface water. Moreover, the sample (Figure 5.9 A) shows a possible glass transition 
at circa 65 °C, but this transition was not clear and hence could not be reliably measured. 
However, for exclusion the freeze-dried lactose was suggested to be amorphous: in fact the 
α-lactose forms are easily recognisable from a dehydration event at circa 135 to 155 °C, 
which is accompanied by water loss (Listiohadi and Hourigan, 2009). The MTDSC 
thermogram and the TGA of the freeze-dried lactose stored at 0% RH did not show such 
thermal event and the related water loss. Moreover, the β-anhydrous form typically 
contains very low surface water (Listiohadi and Hourigan, 2009), far lower than that 
measured for the freeze-dried lactose stored at 0% RH. Hence the latter sample is likely to 
be amorphous lactose. Instead the freeze-dried lactose stored at 75% RH (Figure 5.9 B) 
showed a re-crystallisation peak at 135 °C in the MTDSC thermogram, resulting in 4.65% 
weight loss, measured by TGA. This loss perfectly matches the stoichiometric loss of one 
molecule of water in each molecule of the lactose in the α-monohydrate form, usually 
occurring at circa 135 to 155 °C (Buckton et al., 1998; Listiohadi and Hourigan, 2009). 
Therefore, both TGA and DSC plots strongly suggest that the freeze-dried lactose stored at 
75% RH was the α-monohydrate form.  
 
Table 5.8.  Summary of TGA/MTDSC thermograms of freeze-dried lactose (mean ± 
SD, n = 3). 
RH 
(%) 
Surface water 
loss (%) 
Glass transition 
(°C) 
Dehydration 
(°C) 
Water loss at 
dehydration (%) 
Melting point and 
decomposition (°C) 
0% 1.74 (± 0.31) 67.6 (± 4.2) - - > 185 
75% 0.31 (± 0.62) - 135 (± 0.0) 4.65 (± 0.06) > 185 
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Figure 5.9. MTDSC thermograms of freeze-dried lactose. 
Freeze-dried lactose was stored at 0% RH or at 75% RH for 5 days and then analysed by 
MTDSC: (A) and (B) show the thermograms relative to 0% RH and 75% RH conditions, 
respectively.  
 
It is well documented in the literature that lactose solutions in water or salt mixtures when 
freeze-dried usually result in the formation of amorphous lactose, which is metastable and 
highly hygroscopic. Freeze-dried amorphous lactose tends to absorb moisture when it is 
exposed to humidity; the water acting as a plasticiser lowers the glass transition 
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temperature to a point where it matches the storage temperature. At this point lactose re-
crystallises, losing the sorbed water; this process is temperature, time and water content 
dependent (Fakes et al., 2000; Herrington, 1934; Omar and Roos, 2007a; Roos, 2009). For 
instance, it was demonstrated that different freeze-dried lactose samples re-crystallised 
from the amorphous state at room temperature (22 to 23 °C) within 24 hours: amorphous 
freeze-dried lactose samples recrystallized when stored at RH > 44%, whereas amorphous 
freeze-dried lactose-salt mixtures recrystallized at RH > 54.4%. Moreover, storage at 
76.1% RH resulted in re-crystallisation after only 3 to 4 hours (Omar and Roos, 2007a, 
2007b). This is in accordance with the current study in which the freeze-dried lactose-PBS 
mixture produced by freeze-drying was in the amorphous state when stored at 0% RH and 
in the crystalline state when stored at 75% RH for 5 days, probably due to re-crystallisation 
of the metastable amorphous form. The influence of this phase transition process on the 
stabilisation of protein formulations will be discussed later.  
 
The surface water loss and relevant thermal events of freeze-dried mannitol stored at 0% 
and 75% RH are detailed in Table 5.9 and the MTDSC thermograms are illustrated in 
Figure 5.10. The TGA and MTDSC analysis appeared very similar for the two storage 
conditions, suggesting that the mannitol form produced upon freeze-drying remained stable 
regardless of the storage condition. A first endothermic peak at 145.8 °C and 148.9 °C can 
be visualised for the samples stored at 0% RH and at 75% RH, respectively. Moreover, a 
second endothermic peak is present at 156.6 °C and 155.3 °C for the 0% RH and at 75% 
RH samples, respectively (Figure 5.10 A and B).  
 
Table 5.9. Summary of TGA/MTDSC thermograms of freeze-dried mannitol (mean ± 
SD, n = 3). 
RH (%) Surface water loss (%) 1st Melting point (°C) 2nd Melting point (°C) 
0% 0.29 (± 0.17) 145.8 (± 3.8) 148.9 (± 1.7) 
75% 0.23 (± 0.07) 156.6 (± 1) 155.3 (± 0.1) 
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Figure 5.10. MTDSC thermograms of freeze-dried mannitol. 
Freeze-dried mannitol was stored at 0% RH or at 75% RH for 5 days and then analysed by 
MTDSC: (A) and (B) show the thermograms relative to 0% RH and 75% RH conditions, 
respectively.  
 
There was no loss of water measured by TGA at either of these two temperatures, 
suggesting that these thermal events were not associated with loss of water of 
crystallisation, but corresponded to the melting of anhydrous crystalline forms. 
Specifically, the first melting point could be attributed to the presence of δ-mannitol, while 
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the second peak could correspond to the eutectic melting point of the α- and β-mannitol 
polymorphs (Liao et al., 2007; Telang et al., 2003).The fact that the freeze-drying generally 
results in the formation of α, β and δ-mannitol mixtures has already been reported; 
moreover, extensive thermal analysis studies suggested that the ratio between these three 
polymorphs is highly dependent on the mannitol concentration in the solution and on the 
freezing rate (Kim et al., 1998). 
 
The surface water loss and the most important thermal events of freeze-dried trehalose 
stored at 0% RH and 75% RH are summarised in Table 5.10 and the MTDSC thermograms 
are illustrated in Figure 5.11. The two thermograms of the samples stored at 0% RH 
(Figure 5.11 A) and at 75% RH (Figure 5.11 B) showed very different profiles. The main 
thermal event of freeze-dried trehalose stored at 0% RH is a glass transition observed 
between 56.5 °C and 78.2 °C in the three replicates examined here. The glass transition 
was consistent with the presence of amorphous trehalose. However, based on the data 
included in McGarvey et al. (2003), the glass transition temperature seen here is slightly 
lower than that expected for the water content measured by TGA. This could most likely 
be explained by the presence of PBS in the current formulation, as this buffer has shown to 
lower the trehalose glass transition temperature in a concentration-dependent manner 
(Sitaula and Bhowmick, 2006).  
 
Table 5.10. Summary of TGA/MTDSC thermograms of freeze-dried trehalose (mean 
± SD, n = 3). 
RH 
(%) 
Surface 
water loss 
(%) 
Glass 
transition 
(°C) 
Dehydration 
(°C) 
Water loss at 
dehydration 
(%) 
1st Melting 
point (°C) 
2nd Melting 
point (°C) 
0%  2.03 (± 0.27) 63.8 (± 12.5) -  - - 
75%  0.57 (± 0.3) - 95.4 (± 1.4) 8.94 (± 0.32) 124.6 (± 0.0) 204.5 (± 1.2) 
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Figure 5.11. MTDSC thermograms of freeze-dried trehalose. 
Freeze-dried trehalose was stored at 0% RH or at 75% RH for 5 days and then analysed by 
MTDSC: (A) and (B) show the thermograms relative to 0% RH and 75% RH conditions, 
respectively.  
 
The thermal plot of the trehalose stored at 75% RH (Figure 5.11 B) suggests that trehalose 
was mainly present in a crystalline form. The endothermal peaks seen at 95.4 °C, 124.6 °C 
and 204.5 °C could correspond to the typical plot of the dihydrate trehalose form, as 
proposed in the work of McGarvey et al. (2003). However water loss at dehydration, 
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measured by TGA, was 8.94% (± 0.32) and hence it was slightly lower than the 9.5% 
water loss, theoretically assigned to the loss of two molecules of water for a molecule of 
trehalose in the dihydrate form. This might suggest that a minimal percentage of the 
freeze-dried trehalose was present in a different form. 
 
The main observation from the freeze-dried trehalose study is that, similarly to the lactose, 
the trehalose tended to remain amorphous upon storage at 0% RH, while it was present in a 
crystalline form upon storage at 75% RH. This strongly suggests that re-crystallisation 
occurred upon exposure to high moisture level. This is in accordance with what was 
extensively documented by others: amorphous trehalose has in fact shown to re-crystallise 
in a humidity and time-dependent manner (Fakes et al., 2000; Heljo et al., 2012; Hunter et 
al., 2010; Iglesias et al., 1997), where re-crystallisation of freeze-dried trehalose occurred 
at 43% RH in 500 hours of incubation and in less than 2 hours when the trehalose was 
stored at 60% RH (Heljo et al., 2012).  
 
Overall, the thermal analysis results suggest that freeze-dried lactose and trehalose stored 
at 0% RH were amorphous, while glycine and mannitol, stored at the same conditions were 
present in a crystalline form. These results strongly suggest that the higher stabilisation 
offered by lactose and trehalose in the freeze-dried HBcAg VLP formulations (Paragraph 
5.4.3.1) was due to the lyoprotecting effect of these excipients that freeze-dried as 
amorphous solids. This is in accordance with the principle that such excipients act as a 
“water substitute” for proteins by fulfilling the hydrogen bonding requisites, necessary to 
maintain stability (Carpenter and Crowe, 1989; Wang, 2000). Considering the in-process 
stability, lactose and trehalose might therefore seem ideal protein stabilisers.  
 
Nevertheless, storage of the four excipients at 75% RH resulted in re-crystallisation of the 
metastable lactose and trehalose forms; in contrast both glycine and mannitol seemed to 
maintain their physical form. Re-crystallisation of amorphous excipients is one of the 
biggest complications in protein formulation development. In other words, the use of 
excipients in their amorphous state has been shown to stabilise protein formulations, 
however, crystallisation of the amorphous excipient upon storage can lead to undesirable 
protein aggregation and denaturation (Costantino et al., 1998; Wang, 2000). As the 
crystallisation process is moisture and temperature dependent, this phenomenon can 
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possibly be avoided by storing the formulation at low RH and temperature (i.e. sealed 
vials, storage in the fridge). However, the aim of this Chapter was to produce solid bulk 
materials containing stable forms of HBcAg VLPs that could be further processed into a 
solid dosage form. In this context, excipients that are so susceptible to temperature and 
humidity would not be ideal for further pharmaceutical processing under ambient 
conditions. For this reason crystalline excipients, such as glycine and mannitol probably 
would be more suitable, as they are more stable upon exposure to temperature and 
humidity. Nonetheless, crystalline excipients failed to stabilise HBcAg VLP upon freeze-
drying, when compared to lactose and trehalose (Paragraph 5.4.3.1). It can be proposed 
that the ideal candidate excipients should stabilise the protein during the freeze-drying and 
at the same time maintain a stable physical form upon storage. Therefore, neither the 
amorphous excipients (i.e. lactose and trehalose) nor the crystalline ones (i.e. glycine and 
mannitol), as used in this study, would be real “winners”. 
 
As a final remark it should also be underlined that lactose, being a reducing sugar, has the 
potential to react with primary and secondary amino groups of proteins via the Maillard 
reaction, leading to visible browning of the solid dosage form and to the formation of 
complexes able to destabilise proteins. However, the use of reducing sugars can be 
contemplated when these are the best stabilisers available (Akers, 2002; Wang, 2000). 
Therefore, their use should be assessed on case-by-case, balancing the requirement for 
immediate stabilisation of the protein and long-term product stability. 
 
5.4.4 Contextualisation and Relevance of the Findings 
The conventional drying methods for drying biopharmaceutical proteins are spray drying, 
or more commonly freeze-drying (Abdul-Fattah et al., 2007). However, while there is 
broad research on the processing of proteins into dry formulations to be used for parenteral 
administration (Abdul-Fattah et al., 2007; Vehring, 2008; Wang, 2000), there is much 
narrower knowledge about the production of dry protein formulations for oral use. This is 
probably due to the fact that most protein-based therapeutics are still mainly delivered by 
injection. In this Chapter, the production of an oral dosage form of purified HBcAg VLP 
was investigated. Furthermore, given the high instability of this antigen in the gastric 
condition (Chapter 3), an ideal oral formulation of HBcAg should be gastro-protected. The 
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main hurdles to be overcome seemed the protein stabilisation and processing into a 
pharmaceutically stable dosage form.  
 
Initially, drying by desiccation was attempted, as, despite the possible instability of the 
biopharmaceuticals when drying by desiccation, this risk could be counterbalanced by the 
low cost of such a process (Amorij et al., 2008). Therefore, HBcAg was mixed with the 
binder solution used for the wet granulation of drug-excipients mixtures ultimately used for 
compression. However, 80 to 95% of HBcAg VLPs were unstable upon drying of the wet 
mass in the oven or desiccator. For a term of comparison, it can be mentioned that when an 
engineered Lactobacillus lactis strain was mixed with the binder liquid used for the 
production of pellets by extrusion-spheronisation, 99% of the bacterial viability was lost 
(Huyghebaert et al., 2005b). Therefore, it can be suggested that the stabilisation of large 
biopharmaceutics requires more than a simple granulation process, generally suitable for 
processing of small molecules.  
 
As an alternative approach spray drying, which is often a method of choice for the 
production of therapeutic proteins, was used. Moreover, by spray drying the VLPs with a 
pH responsive polymer, the antigen should be encapsulated into a pH-dependent 
microparticulate carrier. Thus, in a one-step process a gastro-protected formulation of the 
candidate vaccine should be produced. Furthermore, such small particles could be easily 
administered by gavage to small animals in in vivo studies, whereas conventional gastro-
resistant oral dosage form (i.e. tablets or capsules) would be too big to be administered by 
gavage. Eudragit microparticles were successfully produced using this method and 
remarkably high encapsulation efficiency and antigen stability were achieved. However, 
the microparticles did not allow effective gastro-protection in simulated gastric fluid 
(SGF). Similarly, production of microparticles by spray freeze-drying did not enable 
effective gastro-protection. The outcome of these experiments underlines that both spray 
drying and spray freeze-drying techniques and the use of Eudragit are compatible for the 
stabilisation of the HBcAg VLP in the dry state. However, the morphology of the 
microparticles did not allow gastro-protection of such an acid and pepsin labile 
biopharmaceutical. Based on this research and on the evaluation of the morphology and 
functionality of Eudragit microparticles performed by Kendall et al. (2008), it can be 
concluded that pH-responsive particles cannot impede the medium-active contact, when 
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the formulation is incubated in acidic fluids. Hence, it can be suggested that this 
microencapsulation technique is not suitable for the protection of highly labile therapeutics 
from acid or pepsin. However, the pH-responsive microparticles could be used for 
intestinal targeted delivery of molecules, which are intrinsically gastro-stable.  
 
Finally, freeze-drying of glycine, lactose, mannitol and trehalose solutions was used for the 
stabilisation of HBcAg VLP in dry state. In this case it was shown that the lactose and 
trehalose, which freeze-dried in their amorphous form, acted as good lyoprotectants and 
stabilised HBcAg VLP more than glycine and mannitol, which were present as crystalline 
solids. Despite the good in-process stabilisation that lactose and trehalose offered, further 
thermal studies elucidated that these excipients could be subjected to uncontrolled 
crystallisation if exposed to humidity. This would be unacceptable from a regulatory point 
of view as the physical structure of a formulation has to remain mainly unchanged; 
moreover this could cause destabilisation of the protein (i.e. HBcAg VLP) (Costantino et 
al., 1998; Wang, 2000). In case of a formulation for parenteral administration, the use of a 
lyoprotectant, which can be freeze-dried in the amorphous state, could be contemplated, as 
the dry product could be stored inside sealed vials. However, for further processing of the 
solid cake into solid dosage forms, moisture and temperature could become a problem for 
the stability of the biopharmaceutical. For instance, it has been reported that a 
bioengineered Lactobacillus lactis strain was formulated into a freeze-dried formulation, 
using skimmed milk as a lyoprotectant. The freeze-dried product was then compressed into 
mini-tablets. In order to prevent sticking of the dry powder all the handling was carried out 
at 20% RH. Despite this, the bacterial viability was only 15% immediately after the 
production of the tablets and dropped to complete viability loss after 1 week storage at 
60% RH. The authors suggested that coating of a such hygroscopic formulation could have 
been difficult and incompatible with the bacterial viability (Huyghebaert et al., 2005b). 
The same research group obtained better results by using the freeze-dried material for the 
preparation of enteric coated capsules. However, this dosage form was still extremely 
sensitive to moisture and temperature (Huyghebaert et al., 2005a). These studies taken 
together suggest that freeze-dried formulations of labile biopharmaceutics are difficult to 
be processed, due to the intrinsic hygroscopicity and instability of the lyophilised material.  
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It can therefore be concluded that the production of a freeze-dried solid cake of amorphous 
excipients containing HBcAg VLPs can be an excellent approach for the drying of such a 
complex multimeric protein. Moreover, further processing of the lyophilised form into a 
gastro-protected solid dosage form could be contemplated; however, care must be taken in 
processing and storage of the material in controlled humidity and temperature conditions, 
in order to avoid excessive moisture absorption or undesired excipient crystallisation. 
 
5.5 Conclusions 
This Chapter offered an investigative screening into the stability of HBcAg upon drying 
for the potential development of oral formulations of this antigen. Mixing of HBcAg in the 
binder liquid used for the formulation of granules resulted in remarkable loss of 
antigenicity and hence it discouraged using this method for the drying of HBcAg VLPs. As 
an alternative, pH-responsive microparticles containing intact HBcAg VLPs were 
produced by spray drying and spray freeze-drying: the microparticles appeared regular and 
of spherical shape and enabled 65 to 81% encapsulation of native VLPs. However, 
incubation of the microparticles in simulated gastric fluid (SGF) resulted in a major loss of 
antigenicity, suggesting that the microparticles were permeable to the acidic media. 
Finally, HBcAg was freeze-dried using different stabilising excipients. Excipients that 
freeze-dried as glassy solids allowed good stabilisation of the VLP during the 
lyophilisation process. However, thermal studies revealed that, as typical for amorphous 
sugars, such formulations can be subjected to re-crystallisation. Therefore, it was suggested 
that the stability of the freeze-dried cakes upon further processing into oral dosage forms 
would require handling and storage in controlled humidity and temperature conditions.  
 
Overall, the results from this Chapter confirm that in the case of enteric formulations of 
multimeric proteins (i.e. HBcAg VLP), the formulation of the protein into a stable dry 
form is only the initial challenge. Ensuring effective gastro-protection (i.e. in the 
microencapsulation), as well as sufficient stability of the formulation upon further 
processing into oral dosage forms (i.e. in the freeze-drying) can constitute more complex 
downstream hurdles. In this regard, it should be highlighted that film-coated gastro-
resistant tablets using the freeze-dried plant-material expressing HBcAg were more 
effective and convenient formulations, as described in Chapter 4. 
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6 HBcAg Intestinal Permeability - an in vitro and in vivo Approach 
6.1 Introduction 
In the previous Chapters the ability of HBcAg VLP to survive the first gastro-intestinal 
(GI) barrier, i.e. the harsh GI environment, was evaluated. The influence of plant bio-
encapsulation on the oral delivery of the antigen was also assessed. Then the formulation 
of HBcAg VLPs into solid dosage forms usable for oral delivery was investigated, using 
raw plant material expressing the antigen or using the purified antigen. In this Chapter, the 
ability of HBcAg to cross the second GI barrier, commonly considered the intestinal 
impermeability to macromolecules (Park et al., 2011), was evaluated.  
 
VLPs differ from other, more extensively studied nanocarrier antigen-loaded oral vaccine 
candidates, as in VLPs the antigens self-assemble into particles, acting as self-carriers 
(discussed in Chapter 1). This is an obvious advantage in terms of formulation, because it 
eliminates the technological hurdles related to the active encapsulation, release and 
characterisation studies typical of nanoparticulate systems. Furthermore the high density of 
antigen display on the surface of VLPs is very likely to exhibit a more effective interaction 
with the Antigen-presenting cells (APC) and with cells of the immune system (Huang et 
al., 2004; Ludwig and Wagner, 2007; Noad and Roy, 2003; Plummer and Manchester, 
2011). In addition to these unique advantages, VLPs, as all other nanoparticulate 
approaches, are generally subjected to higher absorption than small “soluble” antigens 
(Des Rieux et al., 2006). For these reasons VLPs could represent a promising oral 
candidate vaccine.  
 
In this Chapter, the absorption of HBcAg VLPs in the Gut-associated lymphoid tissue 
(GALT) was investigated and is discussed. Intestinal absorption of various substances can 
be evaluated using cell culture models. In particular, a human colon carcinoma cell line, 
called Caco-2, has been shown to spontaneously differentiate into enterocytes when grown 
in culture; such enterocytes have functional and morphological features similar to those of 
small intestinal enterocytes (Hidalgo et al., 1989; Meunier et al., 1995). Due to these 
unique characteristics, Caco-2 cell mono-layers mounted on inserts’ membranes have been 
extensively used as a model system to study the small intestinal absorption of drugs 
(Artursson, 1990; Hilgers et al., 1990; Yee, 1997). This can be an optimal method for 
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assessing the permeability of small molecules, which are generally well absorbed by the 
conventional absorptive epithelium of the small intestine (Le Ferrec et al., 2001). However, 
macromolecules, such as most vaccines, and nanoparticles are very poorly absorbed orally 
(Donovan et al., 1990). Therefore a model of solely Caco-2 enterocytes presents great 
limitations for the assessment of macromolecules' absorption and it does not offer a 
reliable physiological simulation. In this context a human model that includes the presence 
of M-cells of the Follicle-associated epithelium (FAE) was developed (Gullberg et al., 
2000). M cells physiologically function as specialised transporters of antigens and 
nanoparticulate matters and they strategically overlay the immune system of the gut, 
playing a crucial role in delivering particulate matter for presentation to the underlying 
immune cells. Thus it is evident that a model including the FAE is much more appropriate 
for studies on oral vaccines and particulates (Gamboa and Leong, 2013). 
 
6.1.1 Human FAE Uptake Assay 
The FAE covering the Peyer’s patches (PP) could be exploited by microorganisms and 
therapeutic candidates to breach the otherwise “impermeable” intestinal barrier. Based on 
the observation that M cell formation seems to be regulated by the stimulation of immune 
cells, Kerneis at al. (1997) developed an in vitro model of FAE using cell cultures. This 
model is based on the intercalation of mouse PP lymphocytes into Caco-2 epithelial mono-
layers. Lymphocytes had been shown to induce morphological and functional changes in 
the epithelial cells, consistent with the morphological transformation of undifferentiated 
enterocytes into M cells. This modelled FAE provided enhanced microorganism and 
particle sampling ability, when compared to the enterocytes mono-layer (Kernéis et al., 
1997). In an updated model, the mouse B cells, used in the original model, were substituted 
with human Raji B lymphocytes and the functionality of the system was validated 
(Gullberg et al., 2000). This new version, which relies on an entirely human co-culture 
system, would more closely represent the physiology of human FAE and would therefore 
be more relevant for oral delivery studies. The assay is based on growing Caco-2 cells on 
normally oriented Transwell inserts: upon confluence of the cells into a tight mono-layer, 
Raji B lymphocytes are seeded at the bottom of the wells in a co-culture. The formation of 
M cells is considered to be completed after 4 to 6 days of co-culturing (Gullberg et al., 
2000). 
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6.1.2 In vivo Ligated Intestinal Loop Model 
Before the advent of cell culture systems of the gut epithelium, the main technique to study 
the local intestinal absorption of bacteria, viruses or nanoparticles for oral vaccine 
research, involved direct injection of the formulations into surgically ligated small 
intestinal loops in animal models (Brayden et al., 2005). Several animal species have been 
used for this assay and different surgical procedures have been developed. The main 
advantage of this model over other more conventional oral administration techniques is 
that these intestinal ligated loop experiments can give absorption information, devoid from 
the potential limitation of the upstream GI instability and dilution. Therefore, this assay 
exclusively limits the investigation to the intestinal absorption (Gamboa and Leong, 2013). 
It is however clear that this cannot be considered an administration method, but it can only 
be used as an experimental model.  
 
In this Chapter, the human in vitro cell culture model and a ligated small intestinal loop 
mice model were used in order to evaluate the absorption of the VLPs.  
 
6.2 Materials 
6.2.1 Molecular Biology Media, Buffers and Solutions  
General media, buffers and solutions used in this study for bacterial growth, plant agro-
infiltration and protein analysis are catalogued in Table 2.1 of Chapter 2. 
 
6.2.2 Antibodies and Antigens  
Antibodies and antigens standards used for sandwich and direct ELISA are listed in Table 
2.2 of Chapter 2. Antibodies used for immunohistochemistry (IHC) studies are presented in 
Table 6.1. 
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Table 6.1 Antibodies used for immunohistochemistry (IHC) studies. 
Antibody Antigen Supplier Application 
Polyclonal rabbit 
HBcAg antibody 
HBcAg AbD Serotec, UK IHC: 1:20 in 5% (v/v) FCS in PBS 
Anti-rabbit IgG 
Alexa  Fluor® 488 
Host: Donkey 
Rabbit IgG Invitrogen, UK IHC: 1:250 in 5% (v/v) FCS in PBS 
(Co-incubated with Anti-mouse 
CD11c) 
Anti-rabbit IgG 
Alexa  Fluor® 594 
Host: Donkey 
Rabbit IgG Invitrogen, UK IHC: 1:250 in 5% (v/v) FCS in PBS 
Anti-mouse CD11c 
Alexa Fluor® 647 
Host: Hamster 
Mouse CD11c AbD Serotec, UK IHC: 1:50 in 5% (v/v) FCS in PBS 
(Co-incubated with Anti-rabbit 
Alexa  Fluor® 488) 
 
6.2.3 Human FAE Model Components 
This Paragraph will list the materials used in the cell culture model.  
 
6.2.3.1 Cell Lines 
Human colon carcinoma Caco-2 cells and Human Burkitt’s lymphoma Raji B were 
obtained from the American Type Culture Collection (ATCC). Both cell lines were 
mycoplasma free.  
 
6.2.3.2 Cell Culture Media, Chemicals and Plates 
Dulbecco modified Eagle’s minimal essential medium (DMEM), Roswell Park Memorial 
Institute (RPMI) 1640 medium, L-glutamine, penicillin/streptomycin, non-essential amino-
acids, sodium pyruvate and trypsine/EDTA (0.25% w/v) were purchased from Sigma (UK) 
and used as received. Fetal bovine serum (FBS) was bought from Invitogen Gibco (UK). 
Transwell inserts (6.5 mm diameter, 3.0 µm pore size) were purchased from Corning 
Glass, Costar (UK). 
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6.2.3.3 Experimental Instruments 
The electrical resistance system (Millicell-ERS) was bought from Millipore (UK). 
 
6.2.4 In vivo Loop Study Materials 
Isoflurane (Isoflo) was bought from Abbott Laboratories (UK). Microslides Superforst 
Plus Blue were purchased from VWR International (UK). CelLyticTM MT, Protease 
Inhibitor Cocktail and Anti-rabbit IgG-FITC antibody in goat were purchased from Sigma 
(UK). Silgard 184 silicon elastomer was bought from Dow Corning (Belgium). Saponin (8 
to 25%) was bought from Sigma (UK). All materials were used as received. 
 
6.3 Methods 
This Paragraph briefly describes both the human FAE uptake assay and the in vivo VLP 
uptake assay and the methods used for the quantification of VLP in both models. 
Fluorescent microscopy and immunohistochemistry studies are also described. 
 
6.3.1 Transport of HBcAg VLPs through the Human FAE Model 
6.3.1.1 In vitro Human FAE Culture 
Caco-2 cells were cultivated in 75 mL plastic flasks in a medium composed of DMEM and 
supplemented with 10% (v/v) FBS, 1% (v/v) non-essential amino-acids, 1% (v/v) 
penicillin/streptomycin and 1% (v/v) sodium pyruvate, at a temperature of 37 °C and CO2 
level of 5%. The medium was refreshed every 2 to 3 days. The confluence of the cells at 
the bottom of the flask was monitored using an optical microscope: when circa 80% of 
confluence was reached, Caco-2 cells were subcultured. This cell passage was performed 
every 4 to 5 days: the media was removed and the cells were incubated in 5 mL 
trypsin/EDTA for 5 to 10 minutes for trypsinisation. When the Caco-2 cells were fully 
detached from the bottom of the flask, they were immediately spun on a centrifuge rotor at 
1000 g for 5 minutes and the pellet was then re-suspended in fresh DMEM medium and 
split into four new flasks. Raji B cells were grown in 75 mL plastic flasks in RPMI 
medium supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) 
penicillin/streptomycin at 37 °C and 5% CO2 level. Raji B cells suspensions were 
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subcultured by splitting the cultures at a ratio of 1:10 and replenishing with fresh media 
every 5 to 7 days.  
 
Caco-2 cells were used between the 55th and 63rd passages, following a previously 
described protocol (Des Rieux et al., 2005; Gullberg et al., 2000; Man et al., 2008). Upon 
80% confluence, Caco-2 cells harvested by trypsinisation were re-suspended in fresh 
medium and 5 x 105 cells in 200 µL of medium were seeded onto the upper face of 
Transwell inserts. The cells were cultured on the filters in an incubator at 37 °C and 5% 
CO2 and the medium was changed on alternate days. The formation of a tight cellular 
mono-layer was assessed by monitoring transepithelial electric resistance (TEER) 
throughout this period using Millicell-ERS. After 10-11 days, 1 x 106 Raji B cells in a 
suspension of a total volume of 600 µL were added to the lower chamber of the Transwell 
and incubated at 37 °C and 5% CO2 level. The medium in the co-culture was refreshed 
daily: all the medium was changed in the apical side of the insert, while only half of the 
medium was replenished each time in the basolateral side, taking good care not to remove 
Raji B cells mostly sedimented at the bottom. The co-culture was maintained for 4-5 days 
prior to transport experiments. The maintenance of integrity of the cell mono-layer was 
monitored by TEER measurements. Corresponding Caco-2 mono-cultures were prepared 
identically; however, the Raji B cells were not added. 
 
6.3.1.2 VLP Transport 
HBcAg VLPs were used for this assay: plant expressed HBcAg VLPs were extracted from 
the leaves, purified through sucrose gradient, dialysed against PBS and concentrated into a 
stock suspension (described in Chapter 2). The stock suspension was quantified by ELISA, 
diluted in PBS to the desired concentration and filtered through 0.22 µm membrane filters. 
Finally the VLPs suspension was used for the transport studies. 
 
TEER values of the mono-layers were monitored before and after the experiments. The 
lower compartment of the Transwells containing mono- and co-cultures was washed with 
sterile PBS. After 15 minutes equilibration, the medium from the apical inserts was 
removed and replaced with 100 µL HBcAg suspensions of different concentrations or PBS, 
and 600 µL of fresh PBS were added to the basolateral compartments. Three Transwells 
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were used for each concentration in order to obtain a biological triplicate (n = 3) for both 
the co-culture (FAE mono-layer) and the control mono-culture (conventional absorptive 
epithelium mono-layer). Transwell plates were kept in an incubator at a temperature of 
37 °C and 5% CO2 level. The content of the basal compartments was sampled after three 
hours of incubation. HBcAg content of the samples, collected from the basolateral side, 
was quantified by sandwich ELISA.  
 
Cell culture set-up of the human FAE and its functional relevance for transport studies 
have been summarised in Figure 6.1. 
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Figure 6.1. Representation of the human FAE model. 
The top image illustrates how Caco-2 cell mono-layers were co-cultured with Raji B cells 
to induce the formation of M cells. In parallel, Caco-2 cell mono-cultures were used as a 
control. Transport studies were performed by evaluating the passage of HBcAg VLPs from 
the apical to the basolateral chamber. The bottom image shows the biological significance 
of this model: this fully functional small intestinal epithelium model enables the evaluation 
of both co-culture absorption and mono-culture absorption. The co-culture and the mono-
culture mimic respectively the FAE and the conventional absorptive epithelium, 
respectively.  
 
6.3.1.3 Quantification of Transport and Papp 
The amount of HBcAg VLPs transported through the FAE mono-layer and through the 
undifferentiated epithelium mono-layer was quantified by indirect and sandwich ELISA. 
Results from the same experiments were expressed as amount of the donor solution for 
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each given loaded dose (Des Rieux et al., 2005) and as an apparent permeability (Papp in 
cm/s) (Slütter et al., 2009). Apparent permeability (Papp) is calculated as follows: 
 
P 𝑎𝑝𝑝 =
∆𝑄
∆𝑡𝐴𝐶0
        Eq. (6.1) 
 
Where ∆Q is the amount of HBcAg (µg) present in the basal compartment as a function of 
time (t, in s), A is the area of the Transwell (in cm2), Δt is the time (in s) and C0 is the 
concentration of HBcAg (in µg/mL) in the donor solution. The hypothesis that HBcAg 
transport was concentration-dependent was evaluated by a 2-tailed t-test for the two doses 
used. Statistical significance between results obtained with the FAE mono-layer and those 
obtained with the undifferentiated epithelium mono-layer at different doses was also 
assessed by a 2-tailed a t-test.  
 
6.3.2 In vivo VLP Uptake Assay 
6.3.2.1 VLPs Preparation and Quantification 
Four different formulations were prepared for this study and they include: 
 
 HBcAg VLPs: plant expressed HBcAg was extracted from the leaves, purified 
through a sucrose gradient, dialysed against PBS and concentrated into a stock 
solution by ultrafiltration. The stock solution was then quantified by sandwich 
ELISA, diluted to 5 mg/mL in PBS and filtered through membrane filters. 
 
 Heterotandem cores-GFP (CoHe7e-eGFP): plant expressed CoHe7e-eGFP was 
extracted from the leaves purified through a sucrose gradient and dialysed against 
PBS. Purified VLPs were then layered on the top of a second sucrose gradient in 
order to maximise the concentration of VLPs. CoHe7e-eGFP was then quantified 
by direct ELISA. 
 
 VLP binding Green fluorescent protein (VLP-GFP): an innovative VLP, developed 
by Hadrien Peyret (JIC, unpublished data), was also employed for this study. This 
plant-expressed VLP makes use of the HBcAg amino-acidic sequence as a scaffold 
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to carry antibodies that are specific for GFP. The monomeric protein containing 
HBcAg sequence and the anti-GFP antibody is a 54 kDa protein which assembles 
into circa 30 nm diameter polymeric VLP. This particle was shown to strongly bind 
plant-expressed GFP (Hadrien Peyret lab notebook and personal communication). 
A stock of VLP-GFP, with the VLP already bound to the GFP, was kindly donated 
by Hadrien Peyret (JIC) and the sample was partially purified: upstream pre-
incubation of the VLP with GFP, determined the formation of a particulate antigen-
antibody interaction complex. 
 
 Green fluorescent protein (GFP): GFP was also expressed in plant, using the -HT 
protein expression system (Sainsbury and Lomonossoff, 2008), combined with the 
pEAQ vector system (Sainsbury et al. 2009). GFP was extracted from plant as a 
clarified total protein crude extract and it was not further purified. This sample was 
also kindly donated by Hadrien Peyret (JIC). 
 
The four formulations were analysed by Coomassie stained SDS-PAGE in order to 
evaluate the purity of the samples and to obtain a semi-quantitative estimation of VLP-
GFP and GFP. The VLP suspensions were ultimately used for the transport studies.  
 
6.3.2.2 Small Intestinal Loop Assay 
11 to 12 weeks old c57BL/6 mice (Charles River, Margate, UK), maintained in an access-
restricted room under conventional conditions were used for the study. The experiments 
were conducted under the guidelines of the Scientific Procedures Animal Act (1986) of the 
United Kingdom. Mice were starved overnight, anaesthetised by inhalation of isoflurane 
and kept under anaesthesia for the whole duration of the surgical procedure.  
 
The manual handling of the animals as well as the surgical procedures were kindly carried 
out by Prof. Claudio Nicoletti and Miss Nadezhda Gicheva, in my presence.  
 
Five animals were employed in this study:  
 Mouse 1 was unchallenged (Control).  
 Mouse 2 was challenged with HBcAg VLP for 15 minutes.  
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 Mouse 3 was challenged with HBcAg VLP for 40 minutes.  
 Mouse 4 was challenged with VLP-GFP for 40 minutes. 
 Mouse 5 was challenged with CoHe7e-eGFP and GFP for 40 minutes, whereby 
each formulation was injected into a different ligated loop.  
 
Briefly, the abdomen of the mouse was opened by an incision along the midline, in order to 
expose the small intestine. Once the ileum was identified, small loops of a few centimeters 
in length were isolated by ligation with cotton surgical threads. Generally two or three 
Peyer’s Patches (PPs) were contained within one loop. Different VLP formulations in PBS 
were injected into the loop via a 30 G needle. No more than circa 40 to 50 µL of 
formulation per cm of loop was injected, as injection of higher volumes would have 
excessively distended the intestinal wall, diluting the mucus and possibly altering the 
epithelial barriers. Subsequent to the intra-luminal injection, the intestine was returned into 
the abdominal cavity. Care was taken in order to maintain a normal blood supply and the 
abdominal cavity was frequently moisturised with sterile PBS during the incubation time. 
At the end of the experiments (15 or 40 minutes), the mice were sacrificed by cervical 
dislocation. Immediately after, the tracts of intestine containing the loops were excised and 
removed from the body cavity. Sections of the gut of less than 0.5 cm in length, containing 
single PPs or non-lymphoid tissue, were cut. At this point, the tissues were handed to me 
for the final processing.  
 
PP or non-lymphoid tissues were pinned out in Petri dishes coated with silicone elastomer. 
The luminal side was washed three times with a solution of dithiothreitol (DTT) 0.5 mM in 
PBS, in order to remove unbound protein and loosely adherent mucus. After a final rinse 
with PBS, the PP tissues were placed within two slices of pig liver (forming a “pig liver 
sandwich”) and snap-frozen via an isopentane/dry ice bath. The pig liver sandwiches were 
created in order to maintain the delicate surfaces of the intestinal tissue protected from 
physical damage, during storage and handling (i.e. sectioning). Those samples were 
preserved at -80 ºC until cryo-sectioning. The cryo-sections were used for fluorescent 
microscopy and IHC studies. Loops challenged with HBcAg formulation (mouse 2 and 3) 
were also destined for protein quantification. Two PPs per animal were washed with DTT 
and PBS and directly snap-frozen (without the formation of pig liver sandwich). Pieces of 
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non-lymphoid intestinal tissue from the same loops were also cut, washed with DTT and 
PBS and snap-frozen. Mouse 1, used as a control, was not challenged with any 
formulation. Following sacrifice, the intestinal tissue of the ileum was processed in a 
similar way to the other treated mice.  
 
6.3.2.3 HBcAg Quantification in Intestinal Tissue 
HBcAg was quantified in mouse 1, 2 and 3 following the loop study. Initially, frozen 
tissues were de-frosted. In the case of lymphoid tissues, excisions along the perimeter of 
the PPs were made, in order to isolate them from the remaining intestinal wall. Two PPs 
from the same mouse were pooled and weighed together. In parallel two tracts of non-
lymphoid tissue were also weighed. An extraction buffer composed of 1% (v/v) Protease 
Inhibitor in CelLyticTM MT was freshly prepared. The tissues were homogenised using a 
FastPrep machine (MP Biomedicals) at a setting of 4.0 for 40 seconds. Approximately 20 
µL of extraction buffer per mg of intestinal tissue were used. Each extracted sample was 
used for the quantification of tissue total protein and for HBcAg quantification. Total 
protein content was measured using a NanoDrop Spectrophotometer (Thermo Scientific), 
which automatically calculates the total protein concentration by measuring the UV 
absorbance at 280 nm. HBcAg concentration was measured using the sandwich ELISA 
assay described in Chapter 2. The presence of HBcAg VLPs in the PPs and the non-
lymphoid tissues was calculated as weight of HBcAg in tissue per mg of total protein.  
 
6.3.2.4 Fluorescent Microscopy and Immunohistochemistry  
Frozen pig liver sandwiches were cryo-sectioned using a Leica CM1100 cryostat. Sections 
of 8 µm thickness were captured on microscopy slides. Slides were used for either 
fluorescence microscopy or immunohistochemistry. 
 
For fluorescent microscopy, the slides were initially fixed in acetone at –20 °C for 8 
minutes. Then they were washed three times with PBS and were covered with either 0.5 
µg/mL 4', 6-diamidino-2-phenylindole (DAPI) or 1 µg/mL propidium iodide (PI) nuclear 
staining for subsequent analysis under a Zeiss Axioplan flurescent microscope. 
Alternatively slides were not fixed and were directly stained with DAPI or PI. This was 
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attempted in order to eliminate the possible fluorescence quenching, due to the fixative-
induced denaturation.  
 
For immunohistochemistry studies, the sections were initially fixed and / or permabilised.  
Several fixation approaches have been attempted: 
 Acetone at -20 °C for 8 minutes. 
 Methanol at -20 °C for 8 minutes. 
 Paraformaldehyde (4%) at 4 °C for 10 minutes. 
 Paraformaldehyde (4%) at 4 °C for 10 minutes, followed by methanol at -20 °C for 
8 minutes. 
 Paraformaldehyde (4%) at 4 °C for 10 minutes, followed by two washes with 0.1% 
saponin PBS. 
 No fixation 
 
Slides were then washed three times with PBS and blocked with 10% (v/v) FBS in PBS for 
1 hour. After a further wash with PBS, the sections were incubated with rabbit anti-HBcAg 
antibody 5% FBS in PBS for 1 hour 30 minutes. Following three washes with PBS, the 
sections were incubated with donkey anti-rabbit secondary antibody 5% FBS (v/v) in PBS 
for a further 1 hour. After three washes with PBS, the sections were stained with DAPI and 
the fluorescence was analysed using the microscope. In some sections, the secondary 
antibody was co-incubated with anti CD11c antibody. 
 
In the case of slides fixed with paraformaldehyde and washed with saponin, all washes and 
incubation steps were carried out using 0.1% saponin in PBS, rather than PBS which was 
used in all other cases.  
 
At least two slides of the same tissue were imaged independently to confirm 
reproducibility. 
 
6.4 Results and Discussion 
A qualitative and quantitative investigation of the transport of plant-expressed HBcAg-
derived VLPs in the complex intestinal mucosa is presented in the Paragraph. This 
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investigation has been tackled from two different sides. First, a FAE cell culture model 
provided an entirely human platform for an accurate simulation of the functional intestinal 
epithelium. Second, in vivo transport studies in mice allowed evaluation the transport under 
more physiological conditions.  
 
6.4.1 In vitro Human FAE Culture- Transport of HBcAg VLPs 
HBcAg, used in this study, was expressed in plant, extracted and purified according to the 
methods described in Chapter 2. Three different doses of HBcAg were prepared for the 
transport studies. The presence of HBcAg was quantified by sandwich ELISA. 
 
The absorption of HBcAg VLPs in the GALT of the small intestine was evaluated by a 
human cell culture model, using Transwell plates (Gullberg et al., 2000). Since it was first 
published 13 years ago this entirely human FAE model has earned the reputation of an 
elegant experimental technique and it has been used widely to investigate empty nanobeads 
and loaded nanoparticles absorption (Des Rieux et al., 2007, 2005; Kadiyala et al., 2010; 
Slütter et al., 2009; Yoo et al., 2010).  
 
This study introduces a novel application of the FAE model where it has been exploited to 
evaluate the intestinal absorption of a virus-like, particulate vaccine candidate. In this 
study, the co-culture model was used to simulate the FAE of the GALT, while the mono-
culture, resembling the conventional absorptive epithelium, was kept as a control. The 
insert of the Transwell consists of two compartments separated by a filter, on which a layer 
of epithelial cells constitutes a physical barrier. The integrity of this physical barrier was 
monitored by TEER measurements, with the TEER values being above 200 Ω cm2 for both 
co-cultures and mono-cultures before and after the experiments. Such TEER values are 
compatible with the integrity of mono-layers: it was in fact reported that TEER values of 
more than 175 Ω cm2 represent cell mono-layers of uncompromised integrity (Gullberg, 
2005; Gullberg et al., 2006). HBcAg transport through the mono-layer was measured by 
sandwich ELISA. Control wells where the co-culture and mono-culture were incubated 
with PBS did not show any unspecific immunoreactivity. Dose-dependency of the 
transport and permeability of the co-culture compared to the control mono-cultured were 
evaluated.  
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6.4.1.1 Dose-dependent Transport 
Firstly, the dose dependency of HBcAg transport was calculated. Three different doses of 
HBcAg (i.e. 200 µg, 50 µg and 10 µg) in 0.1 mL aliquots were added at the apical side of 
the inserts and the passage to the basolateral compartments was measured. The graph in 
Figure 6.2 illustrates the quantity of HBcAg measured in the basolateral compartment at 
the end of the experiment at the three different doses, in the FAE and in the control cell 
mono-layer. Within the co-culture model, the transport of HBcAg clearly increased with 
increasing loaded doses: doses of 200 µg demonstrated a 3.7 fold increase in HBcAg 
transported compared to 50 µg doses (P < 0.01), while the latter demonstrated a 2.6 fold 
increase compared to 10 µg doses (P < 0.01). Therefore, the transport proved to be dose-
dependent in the FAE. 
 
Absorption by the conventional epithelium is less relevant for vaccines and nanoparticles 
delivery; however, it was measured for control purposes. In the mono-culture, used as a 
control, doses of 200 µg resulted in a 15.9 fold increase in transport compared to 50 µg 
doses (P < 0.05), while doses of 50 µg resulted in only a 1.1 fold transport increase 
compared to 10 µg doses (P > 0.05). It could therefore be concluded that among the three 
doses used there was a significant difference between the first two highest doses, but not 
between the second and the third. This could be explained by the very low quantities of 
HBcAg transported through the conventional Caco-2 mono-layer. The HBcAg measured 
values were quite close to the lower detection limit of the ELISA assay. In other words, 
extremely low levels of absorption can be difficult to be accurately calculated. Probably for 
the same reason, the evaluation of dose-dependency in the conventional Caco-2 mono-
layer was ignored in a similar research using nanobeads (Des Rieux et al., 2005).  
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Figure 6.2. HBcAg dose-dependent transport. 
Different doses (200 µg, 50 µg, 10 µg) of purified HBcAg in PBS were added to the insert 
above the cell monolayers and incubated for 3 hours. The transport of VLPs was 
significantly higher in the FAE incubated at higher doses. In the control mono-culture the 
transport was significantly higher when the loaded dose was 200 µg, compared to 50 µg, 
while there was no significant difference between loaded doses of 10 µg, compared to 50 
µg. Statistical significance was calculated using a 2-tailed T-test. Significant differences 
values are indicated by * = P < 0.001; ** =P < 0.005 and *** P < 0.05. Error bars indicate 
SD, n = 3. 
 
6.4.1.2 FAE Selective Transport 
This model was most importantly used to assess whether HBcAg VLPs could be 
selectively transported by the FAE, rather than being transported via the conventional 
absorptive epithelium (control). For this purpose the data from the previous experiment 
were also expressed in terms of HBcAg permeability through the co-culture as compared 
to the control mono-culture. To enable Papp to be calculated, as shown in Eq. 6.1, the 
amount of antigen on the donor side was expressed as a concentration (2000, 500 and 100 
µg/mL), rather than as an amount (200, 50 and 10 µg). The results are shown in Figure 6.3.  
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Figure 6.3. HBcAg transport in co-culture and mono-culture.  
HBcAg transport is given as values of apparent permeability (Papp) as a function of 
concentration of HBcAg added. The transport was assessed at three different loaded 
concentrations (2000, 500 and 100 µg/mL) of purified HBcAg VLP in PBS. Statistical 
significance was calculated using a 2-tailed T-test. Significant differences in Papp values 
between FAE and control are indicated by * and ** where P is < 0.05 and < 0.005, 
respectively. Error bars indicate SD, n = 3. 
 
At the three concentrations the permeability and hence the transport was always 
significantly higher in the FAE than in the control (i.e. the conventional absorptive 
epithelium). The permeability in co-culture was 2.4 fold (P < 0.05), 10.2 fold (p < 0.005) 
and 4.2 fold (P < 0.005) higher than that in mono-culture, at concentrations of 2000, 500 
and 100 µg/mL, respectively.  
 
A similar investigation using the FAE model, but on antigen-loaded nanoparticles of larger 
size, gave comparable results in terms of ratio of particles transported in the FAE and in 
the control mono-layer, statistical significance and the order of magnitude of Papp (Slütter 
et al., 2009). Nevertheless, those experimental in vitro models have a certain degree of 
variability and therefore numerical data should be evaluated in terms of order of magnitude 
of transport, rather than as absolute values (Des Rieux et al., 2005). The order of 
magnitude of Papp obtained in this study and stated by others (Slütter et al., 2009) is 
extremely low compared to the typical permeability (Papp) values obtained with small 
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molecules in in vitro Caco-2 cells mono-layers: drugs or peptides with in vitro Papp values 
less than 10-7 cm/s have been correlated to in vivo oral absorption in humans of less than 
1% (Artursson and Karlsson, 1991). In the case of macromolecules and particles of nano-
dimensions, oral absorption of less than 1% is not surprising: it has been shown that 
absorption of PEG of only 2 kDa molecular weight is less than 2% when administered to 
mice via gavage (Donovan et al., 1990). For a size comparison it can be remembered that 
HBcAg VLP are made by the self-assembly of 180 or 240 units of 20 kDa-long proteins. 
The low bioavailability of conventional macromolecular therapeutics via the oral route is 
generally accepted and it is debatable whether oral therapeutic effect will be ever achieved, 
given this limitation (Florence, 2005). However in vaccine delivery, the dose-dependency 
is much less stringent than in therapeutic drug delivery (McConnell et al., 2008b) and 
paradoxically too high doses or too high absorption could induce tolerance (Garside et al., 
1995; Mayer et al., 2001). Therefore, low intestinal absorption might not be as much of an 
issue with vaccines as with therapeutics. Nevertheless case by case considerations must be 
undertaken. 
 
6.4.2 HBcAg VLPs Intestinal Permeability In vivo 
The intestinal uptake of HBcAg VLPs was further studied using the small intestinal loop 
model. This intestinal in vivo in situ model has been used to study the oral delivery of 
nanoparticles (Porta et al., 1992; Primard et al., 2010; Prosser et al., 1998). It is indeed an 
exceptionally useful tool to selectively analyse the small intestinal absorption: the 
inoculation of particles dispersion directly into the animal gut, compared to oral gavage, 
allows the study of oral absorption in vivo, circumventing the risk of excessive dilution and 
/ or degradation of the compound in the upper GI. On the other hand, the invasive surgical 
procedure does not allow the animal to be kept alive for long after the surgery (Gamboa 
and Leong, 2013): it is therefore not possible, in most cases, to collect efficacy data or to 
measure antibodies production for vaccine candidates. 
 
6.4.2.1 Fluorescent VLPs and HBcAg Preparation 
Concentrated HBcAg VLP was quantified by sandwich ELISA and diluted in PBS to a 
final concentration of 5 mg/mL. CoHe7e-eGFP was concentrated by two consecutive 
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sucrose gradients and quantified by direct ELISA. A final concentration of CoHe7e-eGFP 
of 80 µg/mL was measured using HBcAg as a standard. 
 
Furthermore the four formulations used in this Chapter including HBcAg, CoHe7e-eGFP, 
VLP-GFP and GFP (Paragraph 6.4.2.1) had been analysed by Coomassie stained SDS-
PAGE, as shown in Figure 6.4. HBcAg (lane 5) showed a degree of purity comparable to 
the commercially available recombinant HBcAg standards (lanes 2 and 6). CoHe7e-eGFP 
(lane 3) was slightly less pure. VLP-GFP (lane 1) and GFP (lane 4) were not pure; 
however, this experiment did not require highly purified formulations, because of the non-
parenteral route of administration and the short incubation time. In the case of VLP-GFP, 
both the monomer forming the VLP and the bound GFP were distinguishable. By 
comparison with the known concentration of the standards, the concentration of VLP-GFP 
(lane 1) can be visually estimated as circa 0.5 to 1 mg/mL (lanes 2 and 6). Considering the 
complexity of these three-layered particles, i.e. VLP-GFP, it would have been difficult to 
develop a more precise quantification technique. Finally, GFP concentration can be 
estimated as circa 2 mg/mL. 
 
 
Figure 6.4. Coomassie stained SDS-PAGE gel of the formulations administered.  
HBcAg, CoHe7e-eGFP, VLP-GFP and GFP preparations were analysed. Lane 1 = VLP-
GFP; 2 = 0.2 mg/mL yeast HBcAg standard; 3 = CoHe7e-eGFP, 4 = GFP; 5 = HBcAg 
(diluted 1/20) and 6 = 0.5 mg/mL yeast HBcAg standard. Green arrows indicate GFP and 
the red arrow denotes the HBcAg-based monomer containing the anti-GFP antibody. 
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6.4.2.2 Localisation of Fluorescent VLPs in the Ileum 
Ligated intestinal loops of mice 4 and 5 were inoculated with fluorescent VLPs as 
described in Paragraph 6.4.2.2: mouse 4 was inoculated with VLP-GFP, while mouse 5 
was inoculated with CoHe7e-eGFP in one ligated loop and with GFP in the other. 
 
CoHe7e-eGFP was used as a fluorescent-labelled version of the wild-type HBcAg. The 
loop inoculated with CoHe7e-eGFP did not show any more fluorescence than the 
background fluorescence shown in the control mouse. The 80 µg/mL dose inoculated into 
the gut was probably too low for the detection of this construct by fluorescent microscopy. 
However, given the tendency of the tandem VLPs proteins (i.e. CoHe7e-eGFP) to 
aggregate (personal communication with Dr Eva Thuenemann), it could be problematic to 
obtain considerably higher concentrations by means of ultrafiltration.  
 
VLP-GFP is a complex structure, displaying antibodies on the HBcAg moiety that bind 
GFP. By comparing the transport of soluble GFP with that of the VLP-GFP particulate 
complex, it should have been possible to demonstrate whether the HBcAg-based scaffold 
could improve the oral absorption of GFP by the gut. In fact, if the encapsulation of a 
protein into nanoparticles can increase its absorption (Ensign et al., 2011; Kammona and 
Kiparissides, 2012), it is possible that a protein bound to a VLP frame by an antigen-
antibody interaction could similarly increase the protein permeability into the gut. For this 
purpose, HBcAg-based VLP could function as an efficient oral carrier for proteins bound 
to its particulate structure. Unfortunately, intestinal tissues inoculated with GFP or VLP-
GFP did not show any more fluorescence than the background fluorescence observed in 
the control mouse. Several fixation protocols (Paragraph 6.3.2.4) were attempted or 
alternatively the slides were analysed without any fixation, to assess whether the fixation 
methodology was the cause of this "negative" result. However even in the absence of 
fixation, the result was the same, suggesting that the low fluorescence was not due to the 
possible denaturation effect of the fixative on the GFP, which could result in partial or total 
fluorescence quenching.  Figure 6.5 shows fluorescence microscopy images relative to an 
intestinal section of the control mouse and another intestinal section of the mouse 
inoculated with VLP-GFP.  
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Figure 6.5. Fluorescence microscopy.  
Microscopy images (10x), obtained for PPs areas of an untreated intestinal section, control, 
(left side) and of an in vivo ligated ileal loop inoculated with the VLP-GFP preparation and 
incubated 40 minutes (right side). PI (red) shows the tissue structure; GFP (green) shows 
the green fluorescence in the tissue. L = Lumen, PP = Peyer’s patches. The white line 
outlines the interface between the tissue and the lumen. Images obtained without fixation.  
 
The lack of detection of “soluble” GFP is not surprising, as other studies have shown that 
GFP-containing constructs without an appropriate adjuvant vehicle do not elicit detectable 
fluorescence in the ileum of mice, when given by oral gavage or inoculated in ligated 
intestinal loops (Kadaoui and Corthésy, 2007; Limaye et al., 2006). However, one would 
have expected that the binding of GFP to a VLP structure could have increased the 
intestinal penetration of GFP. It is unclear whether this enhanced intestinal penetration did 
not occur at all or whether (perhaps more likely) VLP-GFP particles were simply 
undetectable. The latter suggestion could be possibly related to a certain degree of 
instability of the VLP-GFP complex in the relatively harsh intestinal lumen environment 
that strongly diminished the fluorescence down to undetectable levels. This seems 
particularly probable considering that the GFP is bound to the VLP only through numerous 
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weak Van der Waals interactions. Furthermore, high green auto-fluorescence background 
was noticed in the mice guts and this is also documented by other immunofluorescent 
images of the gut found in the literature (Limaye et al., 2006). Therefore, the fluorescence 
background, probably intrinsic to the tissue, could mask the fluorescence of the GFP, if the 
latter signal was not strong enough. Finally it has been reported that GFP is highly 
degraded when incubated in simulated intestinal fluid (Richards et al., 2003); therefore, it 
is also possible to hypothesise that GFP was partially or totally digested during the 
incubation in the intestinal fluids of the mice gut.  
 
Overall the dose inoculated into the mice loop was considerably high for both GFP and 
VLP-GFP and far higher than potentially therapeutic doses. However searching into 
literature, enormous doses up to almost 5 mg of fluorescent nano-beads have been 
inoculated into loops of just 1.5 cm, in order to study their permeability in mouse intestine 
by fluorescent microscopy (Primard et al., 2010). In this study circa 100-fold fewer 
particles were inoculated into the intestinal loops. Accordingly, a possible approach to 
obtain better results could be to increase the concentration of the formulation of at least 
one order of magnitude, provided that such high concentrations of protein are compatible 
with protein physical stability and do not lead to agglomeration or instability of the VLP 
complex. 
 
6.4.2.3 Immunological Localisation of HBcAg in the Ileum 
HBcAg VLPs can be expressed and purified in high-yield in plants much more efficiently 
than the more complex CoHe7e-eGFP (Chapter 2) and VLP-GFP constructs. However, 
HBcAg VLPs are not fluorescently labelled, and an alternative approach to fluorescent 
microscopy was used to assess their permeability in the gut. Immunohistochemistry (IHC) 
studies as well as tissue homogenisation, followed by VLP quantification were carried out 
(Paragraph 6.4.2.3 and 6.4.2.4), in order to understand the fate of HBcAg VLPs after short-
term intraluminal intestinal incubation.   
 
For the IHC studies, several fixation and permeabilisation combinations were employed on 
the tissue sections. The best compromise between epitopes retrieval and maintenance of 
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integrity of the tissue structure was achieved using acetone for the fixation-
permeabilisation step.  
 
Firstly the fate of HBcAg in the intestinal ileum was assessed by comparing the detection 
of anti-HBcAg antibody in an untreated ileal tissue (control) to that in an ileal tissue 
acquired from a loop, inoculated with a 5 mg/mL dose of HBcAg (40-50 µL/cm of loop) 
for 15 and 40 minutes. HBcAg VLPs were detected by monitoring the fluorescent signals 
emitted from the Alexa 594 secondary antibody, bound to the anti-HBcAg primary 
antibody. DAPI cellular staining was used to outline the section structure. Figure 6.6 shows 
the microscopy image of untreated intestinal sections (control), for the villi (left side) and 
PPs (right side) areas. DAPI (blue) shows the tissue structure (top); Alexa 594 (red) shows 
the HBcAg immunoreactivity (middle) and DAPI + Alexa 594 (red + blue) show the 
merged images (bottom). The absence of red fluorescent signal confirmed the lack of 
unspecific binding or background fluorescence in both the PP and villi areas. 
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Figure 6.6. IHC of intestinal sections (control).  
Microscopy images (10x), obtained for villi (left side) and PPs (right side) areas, of 
untreated (i.e. non-inoculated) intestinal sections (control). DAPI (blue) shows the tissue 
structure; Alexa 594 (red) shows the HBcAg immunoreactivity and DAPI + Alexa 594 (red 
+ blue) show the merged images. L = Lumen, V = Villi; PP = Peyer’s patches. The white 
line outlines the interface between the tissue (i.e. villi or PPs) and the lumen.  
 
On the other hand Figure 6.7 shows intestinal cryosections, following an in vivo ligated 
ileal loop inoculated with 5 mg/mL HBcAg (40-50 µL/cm of loop) and incubated for 15 
minutes. Images were obtained for villi (left side) and PPs (right side) areas. In these 
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images, red fluorescence, corresponding to HBcAg immunoreactivity, was present in the 
mucus of the ileum in both follicular and non-follicular regions. In the follicular region, 
most of the red fluorescence was accumulated mainly at the interface between the 
epithelium of the PP and the lumen and only very few dots were detected inside the PP 
epithelium. At an incubation time of 15 minutes, it could be concluded that some HBcAg 
VLPs could penetrate the first intestinal barrier constituted by the mucus. However, the 
penetration through the second barrier, i.e. the epithelium, seemed minimal in both non-
follicular and follicular (Peyer’s patches) regions. 
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Figure 6.7. IHC of intestinal sections after after 15 minutes incubation with HBcAg.  
Microscopy images (10x), obtained for villi (left side) and PPs (right side) areas, of an in 
vivo ligated ileal loop inoculated with 5 mg/mL HBcAg and incubated for 15 minutes.  
DAPI (blue) shows the tissue structure and Alexa 594 (red) shows the HBcAg 
immunoreactivity. DAPI + Alexa 594 (red+blue) shows the merged images. L = Lumen, V 
= Villi; PP = Peyer’s patches. The white line outlines the interface between the tissue (i.e. 
villi or PPs) and the lumen. Enlarged images of the PP epithelium illustrate HBcAg uptake 
inside the PP, as indicated by the white arrows.  
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The effect of increasing the incubation time of HBcAg in the ileal lumen is illustrated in 
Figure 6.8. The ileal sections, following 40 minutes incubation of HBcAg into the 
intestinal ligated loop, showed much stronger HBcAg immunoreactivity in the mucus than 
that observed after 15 minutes incubation, in both villus and PP areas. Furthermore, red 
fluorescence corresponding to HBcAg immunoreactivity was seen clearly in the PP below 
the epithelial interface with the lumen and a few dots were also present more internally in 
the follicular region. Limited red fluorescence could be also seen on a few villi. Overall, 
the images demonstrate that a longer incubation time favoured the penetration of HBcAg 
VLPs through the mucus barrier and supported a certain internalisation of VLPs 
particularly into the PP.  
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Figure 6.8. IHC of intestinal sections after 40 minutes incubation with HBcAg.  
Microscopy images (10x), obtained for villi (left side) and PPs (right side) areas, of an in 
vivo ligated ileal loop inoculated with 5 mg/mL HBcAg and incubated for 40 minutes. 
DAPI (blue) shows the tissue structure; Alexa 594 (red) shows the HBcAg 
immunoreactivity and DAPI + Alexa 594 (red + blue) show the merged images. L = 
Lumen, V = Villi; PP = Peyer’s patches. The white line outlines the interface between the 
tissue (villi or PP) with the lumen. Enlarged images of the PP epithelium illustrate HBcAg 
uptake inside the PP, as indicated by the white arrows.  
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A further IHC study was undertaken in order to better understand the absorption of HBcAg 
in the FAE covering the PP. In this experiment, HBcAg VLPs were visualised in some of 
the cryosections by the detection of the fluorescent signal emitted by the Alexa 488 
secondary antibody (green fluorescence), bound to the anti-HBcAg primary antibody. At 
the same time, anti-CD11c antibody allowed the recognition of CD11c cells in the sub-
epithelial domain (SED) of the PP (purple fluorescence). As discussed in Chapter 1, 
CD11c cells are a class of dendritic cells (DCs), within the PP, which strategically populate 
the area just underneath the epithelium (SED). Hence their function is that of promptly 
taking up antigens from M cells for presentation to immune cells and further processing 
(Kunisawa et al., 2012). Staining of these cells, together with DAPI cellular staining was 
important, because it enabled the localisation of the FAE within the PP: the DAPI stained 
(blue) region between the lumen and the SED (purple) denoted the FAE. Figure 6.9 
illustrates the penetration of HBcAg VLPs from the lumen to the FAE. Green fluorescence, 
corresponding to the immunoreactivity of HBcAg, can be visualised at the external surface 
of the PP in the tissue in which HBcAg was incubated for 15 minutes. In the tissue 
incubated for 40 minutes, HBcAg some immunoreactivity was also seen inside the FAE. 
The untreated ileal tissue that was not incubated with HBcAg (control) showed a stronger 
green background than the one obtained previously using the red-fluorescent antibody. 
However, this green background of the control can be neglected when compared to the 
much more intense signal elicited by the HBcAg immunoreactivity. Overall, this result 
confirmed the previous finding: HBcAg initially penetrated the mucosal barrier covering 
the PPs and after longer exposure small amounts could also breach the FAE overlying the 
SED. 
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Figure 6.9. IHC of the FAE after incubation with HBcAg.  
Microscopy images (10x), obtained for external PPs areas, of an untreated intestinal 
section, control, (left side) and of an in vivo ligated ileal loop inoculated with 5 mg/mL 
HBcAg and incubated for 15 (centre) and 40 minutes (right side).. DAPI (blue) + Alexa 
647 (purple) show the tissue structure and CD11c immunoreactivity, respectively, and 
Alexa 488 (green) shows HBcAg immunoreactivity. DAPI + Alexa 647 + Alexa 488 show 
the merged blue pink and red fluorescence. FAE = Follicle associated epithelium; SED = 
Sub-epithelial domain. 
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6.4.2.4 Immunological Quantification of HBcAg in the Ileum  
As an alternative approach, ileal tissues recovered from the intestinal loop studies were 
used for protein quantification. Intestinal tissues were accurately cut into PPs and villi 
areas and extensively washed with 0.5 mM DTT solution in PBS. The tissues were then 
snap-frozen. A few days later, the following six different tissues were briefly thawed at 
room temperature and homogenised separately: 
 
 PPs of untreated intestine (control) 
 Villi area tissue of untreated intestine (control) 
 PPs of ileum from loop pre-incubated with HBcAg for 15 minutes 
 Villi area of ileum from loop pre-incubated with HBcAg for 15 minutes 
 PPs of ileum from loop pre-incubated with HBcAg for 40 minutes 
 Villi area of ileum from loop pre-incubated with HBcAg for 40 minutes 
 
For each sample, two pieces of tissue collected from distal parts of the loop were pooled 
and processed together. This was done in order to obtain a sample concentrated enough to 
allow reliable protein detection. Then, HBcAg content was measured by sandwich ELISA 
and the total protein content was measured by Nanodrop. The results are reported as 
HBcAg/total protein content of the tissue. Figure 6.10 illustrates the data for the protein 
quantification. The HBcAg/total protein ratio was higher in the Peyer Patches (PPs) than in 
the villi areas. The ratio was 21.2% and 17.8% higher in the PPs incubated with HBcAg 
for 15 and 40 minutes, respectively. In the untreated intestine used as control no HBcAg 
was found. 
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Figure 6.10. HBcAg quantification in the intestinal tissue. 
HBcAg quantification in the villi and PP given as a ratio between HBcAg content and the 
total protein content of the tissue as a function of the incubation time. In vivo intestinal 
loops incubated with 5 mg/mL HBcAg for 15 and 40 minutes were used. Each value 
results from two tissues of the same loop pooled together.  
 
The fact that a considerable amount of HBcAg was present in the villi area can possibly be 
explained by the inefficiency of the washing step with diluted DTT solutions (0.5 mM) to 
extensively remove the mucus and bound HBcAg. This is also confirmed by the 
microscopy studies clearly showing HBcAg immunoreactivity in the mucosal surfaces 
covering the intestinal epithelium. Furthermore, an interesting study reported that even 
aggressive luminal flushes with 10 mM DTT solution cannot efficiently remove the mucus 
(Sandberg et al., 1994). It is therefore possible that most of the VLPs measured were 
HBcAg embedded into the mucus and not internalised into the gut tissue. This could have 
created a high background concentration and it is possible to speculate that this 
background could have led to underestimation of the ratio between HBcAg measured in 
the PP and in the villi. Furthermore, physiologically the presence of mucus is relatively 
less in the PP than in the villi (Ensign et al., 2011), therefore, this trapping effect of 
HBcAg by the mucus could be less accentuated in the PP tissue. Finally, it is worth 
mentioning that in this experiment HBcAg could be detected by sandwich ELISA, which is 
specific for un-denatured VLPs. This implies that HBcAg was in an intact particulate state 
after being incubated for 15 and 40 minutes in the mouse intestinal lumen.  
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6.4.3 Contextualisation and Relevance of the Findings 
The aim of this study was to evaluate whether HBcAg VLPs could be absorbed in the 
intestine, overcoming the two mucosal barriers constituted by mucus and the epithelial 
barrier. Interestingly, previous research on the penetration of mucus by macromolecules 
showed that some VLPs of viruses, which infect the mucosal surfaces, can diffuse rapidly 
through explanted human cervical mucus. In contrast, polystyrene nanoparticles (59 to 
1000 nm), unmodified or functionalised with carboxylate, epoxy, or amino groups did not 
cross the mucus at all (Olmsted et al., 2001). This result was regarded as a “lesson from 
nature”; the intrinsic properties of microorganisms, which have evolutionally adapted to 
infect mucosal tissues, could explain this result and they include: (1) the small size, (2) the 
net neutral, yet hydrophilic surface (typical of many proteins) and (3) the lack of 
superficial hydrophobic area (Olmsted et al., 2001). These properties were thought to 
provide the VLPs with the perfect characteristics to penetrate low viscosity pores in the 
mucus. Nevertheless, not all VLPs could penetrate efficiently this cervical gel, probably 
due to the larger size and the presence of exposed hydrophobic patches, which were able to 
interact with the mucus (Cone, 2009; Lai et al., 2009). Based on this work, it is possible to 
hypothesise that HBcAg VLPs, bearing small size and being made of amphiphilic 
monomers, could also penetrate the intestinal mucus in the current study. In agreement, 
using the IHC approach in this work, HBcAg VLPs were found to be able to diffuse into 
the ileal mucus in vivo. The fact that HBcAg VLPs were found in direct contact with the 
intestinal epithelial surfaces even after 15 minutes of incubation clearly shows deep and 
fast penetration of the mucus. This result is particularly relevant as the loop was not “filled 
up” with non-physiological volumes of formulation and thus excessive dilution of the 
mucus barrier and consequent facilitated penetration was minimised.  
 
However the second mucosal barrier, i.e. the epithelial layer, seemed to create a greater 
obstacle to particle penetration: in fact only small traces of HBcAg could be detected in the 
intestinal tissue, mainly in the FAE epithelium (Figure 6.7, 6.8 and 6.9). This result is in 
accordance with the quantitative in vitro experiment illustrated in Paragraph 6.5.1.2, which 
demonstrated that the loaded doses of HBcAg can cross the epithelial barrier at an order of 
magnitude of 0.001%. This ratio supports the in vivo results where a potent HBcAg signal 
was detected on the mucus at the luminal interface of the epithelial barrier, acting as a 
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highly concentrated reservoir of VLPs. However, only a minute amount of the particles 
could cross the epithelium, giving rise to limited patches of signal, particularly in the FAE 
of the PPs. As discussed in Paragraph 6.4.1, only small amounts of macromolecules can be 
absorbed orally; however, this might not be a problem in case of oral vaccines, whose 
efficacy is generally not strictly dose-dependent.  
 
The fact that HBcAg VLPs could breach the gut epithelium covering the PP, even if in 
small quantities, could have significant implications in oral vaccine delivery. It has already 
been shown that Cowpea Mosaic Virus (CPMV), a virus infecting plants, can be 
internalised inside PPs in vivo (Gonzalez et al., 2009). This current work suggests that 
HBcAg, a VLP derived from human infectious pathogens, can also be internalised inside 
the PPs of the ileum, intriguingly being a non-enteric pathogen. Enteric pathogens, 
normally infective through the oral route, have developed complex and often elegant 
evolutionary mechanisms to invade the gut over thousands of years (Brayden et al., 2005). 
However, the epithelial absorption of HBcAg, which is not an enteric pathogen, is likely to 
be merely due to the physical particulate structure which could favour M cells-mediated 
transport (Florence et al., 2000). This can suggest that the non-enteric nature of HBcAg 
VLP can also count for the relatively low amount of transport. It can therefore be easily 
proposed that by decorating the VLP with adjuvant sequences to target M cells, higher 
absorption might be achieved (Azizi et al., 2010; Brayden et al., 2005). Recombinant 
biology techniques or chemically coupling could be used to modify the VLP for this 
purpose. 
 
6.4.4 Conclusions 
The GALT is an organised apparatus which finely regulates foreign antigen sampling and 
immunogenic responses. The presence of such a functional immune machinery makes the 
gut a possible target for mucosal vaccine delivery. 
 
In this Chapter the permeability of HBcAg VLP in the GALT was evaluated both in vitro 
and in vivo. As a first approach an entirely human cell culture model of functional FAE 
was grown on Transwells inserts in order to quantify the VLP permeability of this barrier: 
plant-expressed HBcAg, extracted and purified, was shown to cross the epithelial barrier of 
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the intestinal cell mono-layer in a concentration-dependent manner. More importantly it 
was shown that, at the three different doses used, the permeability through the FAE was 
always significantly higher than the permeability through the conventional absorptive 
epithelium, suggesting selective absorption of these VLP in the PPs. Nevertheless, the 
magnitude of all the permeability values obtained clearly showed very low absorption. 
These quantitative results were confirmed by in vivo experiments in mice: HBcAg 
inoculated into ligated intestinal loops and incubated for 15 and 40 minutes, was shown to 
be absorbed after 40 minutes in the FAE of the PPs. Moreover mucus constitutes a further 
physiological barrier to the intestinal absorption of large molecules; the ligated loop study 
showed that HBcAg VLPs deeply penetrate the mucus and accumulate at the interface 
between the mucus and the epithelial barrier. Quantitative studies on the HBcAg presence 
in the lymphoid and non-lymphoid tissue of the inoculated intestinal loops suggested again 
the selective presence of HBcAg in the PP. However, HBcAg entrapment in the mucus 
constitutes background interference in the quantification which renders precise absorption 
measurement in vivo elusive. Overall in this Chapter it was shown that HBcAg can 
penetrate the mucus and can be poorly, yet selectively absorbed by the FAE of the PPs. 
The results obtained are in line with the general trend of absorption of nanoparticles and 
they suggests that in the research towards the development of oral vaccines, the VLP 
approach could flank more “traditional” nanoparticulate methods. 
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7 Outlook and Future Work 
 
The aim of this thesis was to investigate the potential use of a recombinant protein 
expressed in plants as an oral vaccine. The antigen chosen was Hepatitis B core antigen 
(HBcAg) virus-like particle (VLP) and the plant used as an expression host was Nicotiana 
benthamiana. More specifically, the main objectives of this research were to determine if 
and to what extent HBcAg VLP could withstand and overcome some of the gastro-
intestinal (GI) barriers and to evaluate whether the compartmentalisation of the antigen in 
the plant material in which it is expressed could offer some aid to the oral delivery of 
HBcAg VLPs. The final objective was that of producing an oral formulation of HBcAg, 
exploiting its expression in plant.  
 
It was previously reported that HBcAg is highly immunogenic when administered 
parenterally, but only poorly immunogenic when given orally (Huang et al., 2006; Milich 
et al., 1987b). In this context, a novel investigative approach was undertaken, where the 
instability in the GI fluid and the low gut permeability, both possibly responsible for the 
poor antigen immunogenicity, were analysed separately, in order to understand the cause 
of the poor oral response. For this purpose, scientific methods usually utilised in drug 
delivery studies of small molecules, and more recently nanoparticles, were employed. This 
represents a novelty in the field, as previously used candidate VLP vaccines, transiently 
expressed in plants, were directly administered to laboratory animals by gavage. The oral 
administration to animals offers the possibility of evaluating the immune response to the 
given antigen (Huang et al., 2006, 2005; Nuzzaci et al., 2010; Santi et al., 2008). However, 
the real “bottle-neck” of the delivery of antigens with poor oral immunogenicity cannot be 
identified, because such an approach, i.e. gastro-gavage, does not allow the independent 
analysis of the impact of each gastro-intestinal barrier to the given antigen. Hence, the 
research presented here suggests that drug delivery studies could fill a gap of knowledge in 
a research area traditionally confined at the interface between biotechnology and 
immunology. 
 
In this scenario, the first technological hurdle to overcome was to establish a production, 
extraction and purification protocol, which could routinely produce considerable quantities 
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of purified or unpurified HBcAg VLPs from plants to be used in further drug delivery 
studies. Sainsbury and Lomonossoff (2008) showed that high-yield transient expression of 
HBcAg VLPs in plant could be achieved using the –HT system. The exploitation of this 
method for the production of HBcAg offered a unique opportunity to produce milligram 
quantities of this complex biopharmaceutical protein at bench scale. Chapter 2 described 
the development of a robust method for routine production, extraction and purification of 
HBcAg in plant. This method allowed the generation of several milligrams of purified 
HBcAg stock on a fortnight-base by a single operator. This constituted the bulk material 
used for the pharmaceutical research described in this study. Moreover in Chapter 2, 
characterisation and quantification techniques for HBcAg VLP were described. Virology 
(i.e. sucrose gradient and native agarose gel), immunology (immunodection methods) and 
imaging (TEM) techniques were the ones chosen. Interestingly, the combination of the 
various techniques enabled a thorough characterisation of the complex chemical and three-
dimensional structure of HBcAg. It was also shown, as a proof of concept, that HBcAg 
could be also expressed in edible plants such as lettuce. 
 
In Chapter 3, it was demonstrated that HBcAg VLPs were highly physically and 
chemically unstable in simulated human gastric media. For this purpose different bio-
relevant gastric conditions were used in order to account for the extremely high variation in 
acid and enzymatic composition observed in the human stomach in vivo (Efentakis and 
Dressman, 1990; Gomes et al., 2003). Moreover, it was shown that HBcAg is digested in 
simulated human intestinal fluid (SIF) and ex-vivo pig intestinal fluids, but surprisingly the 
main digested form of HBcAg maintained the particulate three-dimensional structure and 
the most antigenic epitopes. This Chapter offered an important prediction about the 
stability of HBcAg administered orally. Additionally, the fact that intestinal digestion did 
not lead to physical instability suggested that physical and chemical stability should be 
always analysed separately when evaluating the stability of such complex 
biopharmaceuticals in bio-relevant media. The methodology used in the Chapter could be 
also put forward as a potential approach to investigate the stability of other VLPs in bio-
relevant media. 
 
In Chapter 4, it was shown that leaves expressing HBcAg can be efficiently dried by oven- 
or freeze-drying and that the physical and chemical stability of HBcAg were significantly 
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maintained upon drying processes. Further studies suggested that HBcAg VLPs within the 
leaves were strongly digested by the simulated human GI fluids. Nevertheless, the 
unpurified plant material containing the antigen was exploited for the formulation of 
“green” tablets. Such tablets were then film-coated with a pH-dependent polymer. The 
resulting formulation showed effective in vitro HBcAg gastro-protection and enabled the 
antigen to be released in simulated intestinal fluid (SIF). Potentially, this formulation could 
enable the delivery of HBcAg undigested to the small intestine where absorption could 
take place.  
 
Plant vaccine enthusiasts suggest that plant-bioencapsulation can provide additional 
protection of the labile antigen from GI degradation (Walmsley and Arntzen, 2000). This 
hypothesis did not prove correct in the current study. However, the plant tissue acted as a 
natural lyoprotectant, maintaining the VLP stability when the leaves were dried. Moreover, 
the homogeneity of HBcAg content within the tablets suggested that such an alternative 
formulation could overcome the poor homogeneity issues typical of low dose active oral 
formulations (i.e. a suggested dose of HBcAg could be in the range of tens of micrograms). 
It was previously speculated that plant-made vaccines, in particular if orally delivered, 
could produce an improvement in global health, by reducing the incidence of major 
infectious diseases, particularly in developing countries (Penney et al., 2011). The current 
study suggests that plant-expressed vaccines could be processed into an oral dosage form, 
potentially cheap and easy to produce. Moreover, application of gastro-protective coating 
could overcome one of the major GI barriers (i.e. the gastric instability of the antigen), 
hence enhancing the chances of efficacy of the oral dosage form.  
 
In Chapter 5, the development of solid dosage forms of purified HBcAg VLPs potentially 
usable for oral delivery was described. The drying of the antigen from the liquid state, 
following extraction and purification from the leaf material, was an initial challenge: 
desiccation of granules containing HBcAg VLPs in the binder solutions resulted in low 
antigen stability. Instead, HBcAg VLPs could be effectively encapsulated within spray 
dried or spray freeze-dried microparticles of a pH-dependent polymer. However, such 
microparticles could not offer efficient gastro-protection. Finally, purified HBcAg was 
freeze-dried using different stabiliser excipients. Interestingly, excipients which freeze-
dried as amorphous solids offered good HBcAg VLP stability, while excipients which 
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freeze-dried as crystalline solids led to greater antigen instability. However, thermal 
analysis studies revealed that freeze-dried amorphous excipients were metastable upon 
exposure to high relative humidity, while crystalline ones maintained their physical form. 
Freeze-dried solids which are metastable are not preferred dosage forms, particularly 
when, as in the case of this project, the final aim is that of further processing of the solid 
material into an oral dosage form which will be stored under ambient conditions 
(Costantino et al., 1998; Wang, 2000). In conclusion, amorphous excipients, which could 
offer higher in-process HBcAg VLP stability than crystalline ones upon freeze-drying, 
could not however be used for processing or storage at ambient conditions.  
 
Even though a final dosage form which was effectively gastro-protective could not be 
produced, important considerations could be drawn. The screening of different drying 
methods suggested that HBcAg VLP can be dried efficiently by spray-, freeze- and spray 
freeze-drying, using amorphous excipients. However, desiccation and freeze-drying using 
stabilisers which dry as crystalline solids were not compatible with the antigen stability. 
Moreover, the lack of gastro-protection obtained with the microencapsulation, compared to 
the efficient gastro-protection obtained with the film-coated “green” tablets (in Chapter 4), 
suggests that the protection of highly gastro-labile biopharmaceuticals requires a certain 
coating thickness to enable effective gastro-resistance. Finally, the freeze-drying 
experiment re-proposed a very recurrent problem in protein formulations: excipients which 
freeze-dry as amorphous are excellent protein stabilisers. However, amorphous solids can 
absorb moisture, which could act as a plasticiser and reduce the glass transition 
temperature to a point where re-crystallisation occurs. This phenomenon can often 
jeopardise proteins’ stability upon storage (Costantino et al., 1998; Wang, 2000). A 
possible option to overcome this problem could be that of using lyoprotectant excipients 
that freeze-dry as amorphous solids, but have a high glass transition temperature. However, 
the moisture absorbed acts as a plasticiser on amorphous solids, lowering their glass 
transition temperatures. This phenomenon could be further reduced, if the amorphous solid 
is non-hygroscopic. For example, it has been shown that freeze-dried inulin has a higher 
glass transition temperature and much lower tendency to re-crystallise than trehalose 
(Hinrichs et al., 2001). Another alternative approach could be that of freeze-drying the 
stabiliser (i.e. trehalose) with excipients that have higher glass transition temperatures and 
with excipients which could absorb moisture after freeze-drying. For instance, it has been 
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reported that a low glass transition substance (simvastatin) could be spray dried together 
with PVP and Aerosil 200. Such excipients inhibited the tendency of spray dried 
simvastatin to re-crystallise upon storage. This was mainly due the increase of glass 
transition temperature, mediated by the PVP and to the selective absorption of the moisture 
onto the Aerosil, which functioned as a “buffer” for the spray dried system (Ambike et al., 
2005). This knowledge could be also extrapolated to freeze-drying: for instance the re-
crystallisation tendency of stabilisers, whose glass transition temperature is low or tends to 
be lowered by the moisture absorption, could be prevented by addition of PVP (for 
elevation of glass transition temperature) and Aerosil 200 (as adsorbent) in the solution to 
be freeze-dried. Moreover, other excipients with similar properties could be used.  
 
In future work it could be suggested to freeze-dry HBcAg VLPs using inulin as a stabiliser, 
as the freeze-dried material could be further processed into a final dosage form (i.e. enteric 
coated capsules or tablets), if good in-process stabilisation could be achieved. 
Alternatively, a mixture of trehalose, PVP and Aerosil could be taken forward to further 
processing of the freeze-dried solid material into an oral formulation, if these excipients 
proved to be effective in stabilising HBcAg VLP upon freeze-drying and if the resulting 
solid exhibited low tendency to re-crystallise.  
 
In Chapter 6 the intestinal permeability of HBcAg VLPs was evaluated. Selective 
absorption of the antigen through the Follicle-associated epithelium (FAE) could be 
assessed using an in vitro human cell culture model. Moreover, in vivo mouse intestinal 
loop studies confirmed that HBcAg VLPs could cross easily the mucus barrier and that 
small amounts of HBcAg VLPs could breach the intestinal epithelial barrier, in particular 
through the epithelium covering the Peyer’s patches (PPs). However, the results obtained 
both in vitro and in vivo suggested that HBcAg VLPs, as most macromolecules, were very 
poorly absorbed.  
 
Nevertheless, immunogenic responses are not strictly dose-dependent (McConnell et al., 
2008b): the influence of the extent of antigen absorption on the induction of tolerance or 
immunogenic response is extremely complicated and not fully understood yet. Therefore, it 
is not possible to predict whether such low absorption could mediate tolerance or immunity 
and this can be determined only experimentally. Unfortunately, when performing loop 
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studies it is advisable to sacrifice the animal soon after the invasive procedure. As a result, 
the animals are not kept alive long enough to measure the immunogenic response to the 
antigen. Thus, this study could have been alternatively performed administering HBcAg 
VLP by oral gavage if the immunogenic response is to be determined. However, the results 
in Chapter 3 discourage this approach, because the antigen is likely to be extensively 
degraded in the animal’s stomach upon gavage. Hence, a gastro-protected formulation 
should have been used. This would have presented a major obstacle, as mice are too small 
for the administration of conventional tablets or even mini-tablets or mini-capsules. The 
use of Eudragit pH-responsive microparticles, containing HBcAg VLPs, would have been 
an elegant way to obviate this problem. This formulation was therefore developed, as 
described in Chapter 5. However, the limited gastro-protection of such formulation 
discouraged from taking it further to the animal studies. Moreover, it has been reported that 
the GI pH of Balb/c mice greatly differs from that of humans: the pH measured in the 
mouse fasted stomach and fasted intestine was circa 3 and 5, respectively (McConnell et 
al., 2008a). In humans, the pH in the stomach generally ranges from pH 1 to 2.5 in normal 
fasted state conditions, while it generally ranges from pH 6.3 to 7.5 in the intestine (Evans 
et al., 1988). It is therefore evident that pH-dependent polymers, whereby the delivery 
pattern is totally dependent on the environmental pH, should not be tested in mice if the 
intention is to relate the results to the human situation. For instance, formulations of 
Eudragit L 100 or S 100 with a threshold of dissolution of pH 6 and 7, respectively, are 
unlikely to dissolve in the gut of mice. For this purpose it could be advisable to use animal 
models, whose GI physiology can be better correlated to that of the humans GI [i.e. rats or 
even better, rabbits (McConnell et al., 2008a; Merchant et al., 2011)]. In this regard, a 
possible suggestion for future work could be that of preparing film-coated mini-capsules or 
mini-tablets containing HBcAg VLP and to gavage them to rabbits. HBcAg VLP could be 
either formulated as unpurified plant material (“green tablets”) or could be extracted, 
purified and then formulated.  
 
A final suggestion for future work can be proposed: it has been demonstrated that the 
administration of vaccines to the large intestine can elicit stronger local immunity at rectal 
and genital mucosal sites, compared to the oral administration to the small intestine 
(McConnell et al., 2008c; Zhu et al., 2008). Therefore, the delivery of vaccines to the colon 
could offer an effective way of protection against sexually transmitted infections, including 
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Hepatitis B. Hence it could interesting to evaluate the absorption of HBcAg VLP in the 
large intestine: the particulate nature, the intrinsic strong immunogenicity and the relatively 
high stability of VLP combined with the low enzymatic environment and long residence 
time in the colon could offer an effective and novel approach for delivering vaccines. 
Studies of colonic delivery of vaccines have been mainly performed by intracolorectal 
administration; however colonic delivery of vaccines was recently achieved using oral pH-
dependent formulations for targeted delivery to the colon (Zhu et al., 2012). Therefore oral 
formulations of HBcAg VLPs for targeted colonic delivery could be investigated.  
 
The first objective of this thesis was to have a better understanding about the oral delivery 
of HBcAg VLPs: Huang et al. (2006) showed that HBcAg VLPs elicit only a poor 
immunogenic response when administered orally to mice. However, a question remained 
as to what could be the cause of the poor immunogenicity. In other words, it was not clear 
whether the poor immunogenicity was mainly due to the GI instability or to the lack of 
absorption. The results from this thesis suggest that an evident limitation to the oral 
delivery of this antigen is the very high gastric instability. As the stomach is the first 
physico-chemical barrier, such an upstream obstacle could have influenced the 
downstream delivery of the antigen, i.e. crossing the intestinal fluids, crossing the 
epithelium and eventually eliciting an immunogenic response. Nevertheless, the intestinal 
digestion itself, devoid from the upstream gastric instability, was shown to be compatible 
with the maintenance of HBcAg particulate structure and immunogenicity. Finally, it was 
shown that when the GI instability was overcome and the absorption was evaluated 
independently, small amounts of HBcAg could be absorbed by the FAE of the PPs. As PPs 
are thought to be a major site for the induction of immunogenic response in the gut (Neutra 
et al., 2001), this finding suggested that undigested HBcAg VLPs can be delivered to the 
gut immune machinery. However, from the current work it is not known whether such low 
levels of absorption could trigger tolerance or elicit strong immune responses. The findings 
of this research taken together suggest that HBcAg could be delivered orally, definitely 
within a gastro-protected formulation. However, co-administration of mucosal adjuvants 
that are able to improve the oral adsorption might be needed to induce strong immunogenic 
responses.  
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Another important question that was answered in this thesis was that regarding the claimed 
possibility of protecting labile antigens from the harsh GI environment, by delivering the 
antigen within the plant material in which it is expressed as a recombinant protein. In the 
case of HBcAg VLP and Nicotiana benthamiana, plant bio-encaspulation could not protect 
the labile antigen from the simulated GI media and hence could not substitute the use of 
polymer-based pH-dependent formulations. However, the expression in plant offered the 
novel possibility of preparing “green” tablets, which were subsequently film-coated. This 
approach exploited the fact that the antigen would be expected to be reasonably well 
distributed in the leaf material and hence would mitigate against homogeneity issues 
commonly observed in low dose formulations. These results also highlighted that high 
antigen stability can be maintained upon drying, simply by oven drying or freeze-drying 
the leaves. 
 
Finally, the formulation studies on purified HBcAg VLPs offered a good insight into the 
options available for the development of stable HBcAg VLP solid dosage forms. The 
preparation techniques of choice should be either spray drying, spray freeze-drying or 
freeze-drying and the excipients chosen should preferentially dry as amorphous solids. 
However, it is advisable to choose excipients or combinations of excipients that could 
withstand processing at ambient conditions without the risk of excessive moisture 
absorption or re-crystallisation. Moreover, it can be suggested that when gastro-labile 
antigens, such as HBcAg, have to be included within a gastro-resistant formulation, the 
choice of the formulation should not fall on micron-sized dosage forms, such as 
microspheres, as, based on the current results, these are unlikely to offer the same level of 
protection as more conventional, monolithic gastro-resistant formulations, such as tablets.  
 
The work described in this thesis constitutes a distinctive investigation at the interface 
between the drug delivery and plant biotechnology fields. The fact that such research could 
be successfully carried out, obtaining these interesting results, suggests that the two 
scientific fields could work alongside each other: pharmaceutical research could enable a 
better understanding of novel biotechnological discoveries and could elucidate their 
potential applications. More specifically, this research provided important information 
about the use of plant-expressed HBcAg VLP as an oral candidate vaccine, evaluating the 
delivery and formulation of the antigen and also exploiting its expression in plant. 
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Overall the current study suggest that HBcAg VLP expressed in plant could not be used as 
such, as an effective vaccine candidate for oral delivery, mainly due to the high intrinsic 
instability in the simulated gastric environment. Moreover the very low intestinal 
absorption might represent a futher limitation to the vaccine effectivity. It is therefore 
possible that the efficacy of this plant VLP vaccine approach could be enhanced by 
protecting the antigen within a gastro-resistant oral formulation (as described in Chapter 4) 
and by adding in the formulation an adjuvant which could improve the intestinal 
absorption. A similar approach of an HBV vaccine should be first tested in animal models 
and then it could be potentially brought to clinic.   
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